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Abstract	  
Sepsis	   consists	   of	   both	   the	   systemic	   inflammatory	   response	   syndrome	   (SIRS)	   and	   the	  
compensatory	   anti-­‐inflammatory	   response	   syndrome	   (CARS).	   How	   these	   differential	  
response	   states	   are	   regulated	   is	   yet	   to	   be	   fully	   elucidated.	   Tumour	   necrosis	   factor-­‐alpha	  
(TNF)	  is	  one	  of	  the	  principal	  cytokines	  involved	  in	  mediating	  SIRS.	  TNF	  is	  released	  from	  cells	  
by	   tumour	  necrosis	   factor-­‐alpha	   converting	   enzyme	   (TACE),	   this	   enzyme	   is	   responsible	   for	  
the	  ectodomain	  cleavage	  of	  a	  number	  of	  other	  substrates	  relevant	  to	  inflammation	  including	  
both	   TNF	   receptors	   and	   the	   adhesion	  molecule	   L-­‐selectin.	   How	   TACE	   contributes	   to,	   and	  
functions	  in,	  SIRS	  and	  CARS	  is	  not	  yet	  known.	  
My	   objective	   was	   to	   investigate	   TACE	   activity	   and	   associated	   substrate	   shedding	   in	  
monocytes,	   specifically	   how	   the	   enzyme	   behaved	   in	   the	   context	   of	   in	   vitro	  models	   that	   I	  
designed	   to	   induce	   states	   of	   priming	   and	   tolerance.	   I	   then	   obtained	   in	   vivo	   samples	   from	  
critically	  ill	  patients	  to	  determine	  whether	  there	  were	  similarities	  between	  the	  TACE	  activity	  
profiles	  found	  in	  patient	  cells,	  and	  volunteer	  cells	  placed	  in	  the	  in	  vitro	  models.	  
My	   aims	   were:	   1)	   Determine	   how	   TACE	   activity	   profiles	   were	   altered	   when	   sequential	  
inflammatory	  stimuli	  were	  utilised	  in	  a	  two-­‐hit	  model	  of	  sepsis	  designed	  to	  induce	  states	  of	  
priming	  and	  tolerance	  and	  2)	  To	  perform	  a	  clinical	  study	  to	  investigate	  TACE	  behaviour	  in	  the	  
context	  of	  critical	  illness.	  
I	  successfully	  refined	  a	  method	  of	  isolating	  primary	  monocytes	  from	  healthy	  volunteers	  and	  
patients	  that	  allowed	  determination	  of	  TACE	  activity	  profiles.	  Furthermore,	  I	  demonstrated	  
that	  the	  LPS-­‐TACE	  axis	  was	  reset	  in	  the	  context	  of	  a	  two-­‐hit	  LPS	  model	  and	  in	  sepsis.	  I	  found	  
evidence	   of	   differential	   signalling	   pathway	   reprogramming	   in	   monocytes	   taken	   from	  
patients	  with	  infectious	  and	  non-­‐infectious	  SIRS.	  Finally,	  I	  demonstrated	  that	  the	  monocyte	  
TACE	   response	   to	   LPS	   is	   dependent	   on	   cell	   contact.	   These	   data	   provide	   new	   insights	   into	  
monocyte	  inflammatory	  function	  during	  the	  immune	  response.	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1.1	  Sepsis	  –	  the	  current	  paradigm	  
The	   greatest	   advance	   in	   the	   battle	   against	   infection	   occurred	   in	   London	   at	   St	   Mary’s	  
Hospital,	   Paddington	   when	   Sir	   Alexander	   Fleming	   discovered	   Penicillin	   [1].	   This	   discovery	  
heralded	  the	  start	  of	   the	  modern	  antibiotic	  era	  that	  now	   is	   reaching,	   if	  not	   its	  end,	   then	  a	  
significant	   juncture.	   Liberal	   prescription	   practices	   together	  with	   partial	   course	   completion	  
have	   led	   to	   the	   emergence	  of	   resistant	   organisms	   [2,	   3].	   These	  organisms,	  most	   famously	  
methicillin	   resistant	   Staphylococcus	   aureus	   (MRSA)	   [4],	   have	   become	   a	   byword	   for	   poor	  
healthcare	   practices	   and	   have	   seen	   renewed	   public	   focus	   on	   infection	   control	   issues	   and	  
prescription	  practices	  [5].	  
Although	   this	   renewed	   focus	   on	   infection	   control	   is	   welcome,	   the	   problems	   caused	   by	  
infection	  are	  far	  from	  solved.	  Sepsis	  accounts	  for	  more	  than	  31,000	  ICU	  admissions	  per	  year	  
in	   the	  United	   Kingdom	   (UK)	   and	   results	   in	  more	   than	   14,000	   deaths	   [6].	   The	   incidence	   of	  
more	  severe	   forms	  of	   infection	   (severe	  sepsis)	   is	   increasing	  and	  mortality	   rates,	  which	  can	  
approach	   50%,	   have	   remained	   comparatively	   static.	   In	   the	   UK,	   the	   percentage	   of	   ICU	  
admissions	  with	   severe	   sepsis	   rose	   from	  23.5%	   in	   1994	   to	   28.7%	   in	   2004	   [7],	  with	   similar	  
patterns	  reported	  in	  other	  areas	  such	  as	  North	  America	  [8,	  9].	  As	  the	  population	  ages,	  these	  
conditions	  will	  manifest	  themselves	  in	  those	  who	  already	  have	  organ	  dysfunction	  as	  a	  result	  
of	  chronic	  illnesses	  [9],	  and	  this	  is	   likely	  to	  result	   in	  a	  greater	  demand	  for	  ICU	  services.	  The	  
associated	   costs	   to	  healthcare	  providers	   as	   a	   result	  of	   these	   facts	   are	  enormous.	   In	  North	  
America	   it	   is	   estimated	   that	   each	   case	  of	   sepsis	   costs	   an	  average	  of	   $22,100	  and	   that	   the	  
total	  annual	  cost	  of	  treating	  patients	  with	  sepsis	  is	  $16.7	  billion	  [9].	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The	   facts	   and	   figures	   outlined	   above	   formed	   the	   basis	   on	   which	   the	   surviving	   sepsis	  
campaign	  was	   founded	  [10].	  This	  multi-­‐national	  healthcare	   initiative	  aimed	  to	   improve	  the	  
recognition	   and	   early	   management	   of	   sepsis,	   with	   the	   aim	   of	   reducing	   morbidity	   and	  
mortality.	  Although	  early	  results	  have	  been	  encouraging,	  and	  demonstrated	  some	  success	  in	  
achieving	  these	  aims	  [11],	  more	  treatment	  options	  are	  needed.	  
The	   issues	   with	   resistant	   organisms	   outlined	   above	   and	   a	   reliance	   on	   a	   single	   treatment	  
strategy	  (antibiotics)	  means	  that	  pharmaceutical	  companies	  must	  continue	  to	  produce	  new	  
antibiotics	   that	   work	   in	   different	   ways	   to	   stay	   ahead	   of	   emerging	   resistance	   patterns.	  
Unfortunately	   this	   is	   not	   the	   case	   [12]	   as	   in	   comparison	   to	   other	   drugs	   antibiotics	   are	  
difficult	   to	   develop,	   yet	   even	  with	   appropriate	   antibiotics	   some	   patients	   still	   die.	   This	   has	  
driven	  research	  into	  the	  inflammatory	  cascade	  generated	  as	  a	  response	  to	  infection,	  in	  order	  
that	  new	  therapeutic	  targets	  can	  be	  identified.	  
There	  have	  been	  some	  attempts	  over	  the	  years	  to	  introduce	  alternative	  treatments.	  As	  will	  
be	  outlined	  in	  more	  detail	  later,	  researchers	  have	  targeted	  specific	  elements	  of	  the	  cytokine	  
response	   by	   seeking	   to	   negate	   the	   effects	   of	   inflammatory	   cytokines.	   This	   approach	   has	  
often	  led	  to	  success	  in	  animal	  models	  but	  has	  failed	  to	  translate	  into	  specific	  clinical	  benefit,	  
often	  exposing	   the	   limitations	  of	  animal	  modelling	  and	   lack	  of	   caution	   in	   interpretation	  of	  
their	   data.	   Indeed	   until	   recently	   there	   was	   only	   one	   drug	   available	   that	   was	   specifically	  
licenced	   for	   the	   treatment	   of	   severe	   sepsis,	   activated	   protein	   C.	   The	   use	   of	   this	   serine	  
protease	  was	  always	  controversial,	  with	  questions	  about	   its	  efficacy	  and	  side	  effect	  profile	  
raised	   throughout	   the	   duration	   of	   its	   use.	   The	   recent	   PROWESS-­‐SHOCK	   trial	   [13]	   failed	   to	  
show	  a	   survival	   benefit	   and	   subsequently	   the	  manufacturer	   has	  withdrawn	   the	  drug	   from	  
the	  market	  after	  a	  huge	  investment.	  There	  is	  therefore	  no	  specific	  therapy	  licenced	  for	  the	  
treatment	   of	   severe	   sepsis,	   a	   condition	   that	   is	   the	   single	   most	   common	   cause	   of	   ICU	  
admission.	  There	   is	  clearly	  a	  need	  for	   further	  treatment	  strategies	   in	  sepsis	  to	  help	  reduce	  
the	  significant	  morbidity	  and	  mortality	  that	  it	  causes;	  hence	  research	  in	  this	  area	  in	  order	  to	  
identify	  potential	  therapeutic	  targets	  is	  warranted.	  
In	   an	   attempt	   to	   better	   understand	   the	   pathophysiology	   of	   sepsis	   and	   identify	   novel	  
therapeutic	   targets	   and	   diagnostic	   strategies,	   in	   this	   project	  we	   studied	   the	   inflammatory	  
pathway	  responsible	  for	  the	  production	  of	  the	  pro-­‐inflammatory	  cytokine	  Tumour	  Necrosis	  
Factor-­‐alpha	  (TNF),	  focusing	  on	  the	  regulation	  and	  function	  of	  TNF-­‐alpha	  converting	  enzyme	  
(TACE),	  which	  is	  responsible	  for	  the	  release	  of	  soluble	  TNF,	  and	  a	  number	  of	  other	  proteins,	  
from	  the	  cell	  surface.	  In	  the	  remainder	  of	  the	  introduction	  I	  will	  expand	  on	  the	  current	  state	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of	  knowledge	  in	  sepsis	  before	  focusing	  in	  on	  the	  innate	  immune	  response	  and	  TNF	  biology	  
during	  the	  evolution	  of	  sepsis.	  Finally	   the	  hypothesis	  and	  aims	  on	  which	  this	   thesis	   is	  built	  
will	  be	  presented.	  
	  	  
1.2	  Sepsis	  and	  the	  systemic	  inflammatory	  response	  syndrome	  
Part	  of	  the	  difficulty	  in	  the	  early	  stages	  of	  research	  into	  sepsis	  stemmed	  from	  a	  lack	  of	  clarity	  
in	  definitions.	  These	  were	  agreed	  at	  a	  consensus	  conference	  in	  1992	  and	  a	  new	  concept,	  the	  
systemic	   inflammatory	   response	   syndrome	   (SIRS),	   was	   introduced	   [14].	   SIRS	   is	   a	   pro-­‐
inflammatory	  state	   that	  was	  diagnosed	  when	   two	  or	  more	  of	   the	   following	  clinical	   criteria	  
were	  present:	  
1. A	  temperature	  of	  less	  than	  36	  or	  greater	  than	  38	  degrees	  Celsius;	  
2. A	  heart	  rate	  of	  greater	  than	  90	  beats	  per	  minute;	  
3. A	   respiratory	   rate	   of	   greater	   than	   20	   breaths	   per	   minute	   or	   an	   arterial	   partial	  
pressure	  of	   carbon	  dioxide	  of	   less	   than	  4.3	   kilopascals	  or	   the	  need	   for	  mechanical	  
ventilation;	  
4. A	  white	  blood	  cell	  count	  of	  less	  than	  4x109	  or	  greater	  than	  12	  x	  109	  per	  litre	  or	  >10%	  
immature	  (band)	  forms;	  
	  
Sepsis	   was	   then	   defined	   as	   the	   co-­‐existence	   of	   SIRS	   and	   the	   suspicion,	   or	   confirmed	  
presence	   of	   infection	   [14].	   Severe	   sepsis	   was	   defined	   as	   being	   present	   when	   there	   was	  
evidence	   of	   acute	   organ	   dysfunction	   or	   hypo-­‐perfusion	   and	   septic	   shock	   as	   being	  
hypotension	  resulting	  from	  sepsis	  that	  was	  refractory	  to	  fluid	  therapy	  [14].	  Each	  category	  is	  
associated	   with	   a	   stepwise	   increase	   in	   mortality	   [15,	   16].	   In	   addition	   the	   multiple	   organ	  
dysfunction	   syndrome	   (MODS)	   was	   defined	   as	   being	   impairment	   of	   two	   or	   more	   organ	  
systems,	   in	   an	   acutely	   unwell	   patient,	   where	   homeostasis	   cannot	   be	  maintained	   without	  
therapeutic	  intervention.	  Overall	  the	  SIRS	  response	  describes	  widespread	  inflammation	  and	  
this	   reponse	   is	   produced	   and	   maintained	   by	   the	   release	   of	   inflammatory	   cytokines.	  
Cytokines	  are	  molecules	  that	  can	  be	  considered	  the	  messengers	  that	  coordinate	  the	  immune	  
response	  [17].	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Lewis	  Thomas	  -­‐	  uncontrolled	  inflammation	  
In	   1972	   in	   an	   article	   entitled	   Germs	   [18]	   the	   dean	   of	   Yale	  Medical	   School,	   Lewis	   Thomas	  
wrote	  the	  following,	  “The	  microorganisms	  that	  seem	  to	  have	  it	   in	  for	  us	  in	  the	  worst	  way	  -­‐	  
the	  ones	  that	  really	  appear	  to	  wish	  us	  ill	  -­‐	  turn	  out	  on	  close	  examination	  to	  be	  rather	  more	  
like	  bystanders,	  strays,	  strangers	  in	  from	  the	  cold.	  They	  will	  invade	  and	  replicate	  if	  given	  the	  
chance,	  and	  some	  of	  them	  will	  get	  into	  our	  deepest	  tissues	  and	  set	  forth	  in	  the	  blood,	  but	  it	  
is	   our	   response	   to	   their	   presence	   that	   makes	   the	   disease.	   Our	   arsenals	   for	   fighting	   off	  
bacteria	  are	  so	  powerful,	  and	  involve	  so	  many	  different	  defence	  mechanisms,	  that	  we	  are	  in	  
more	  danger	  from	  them	  than	  from	  the	  invaders.	  We	  live	   in	  the	  midst	  of	  explosive	  devices;	  
we	   are	   mined.”	   This	   idea	   of	   an	   over	   stimulated	   immune	   system	   producing	   organ	  
dysfunction/failure	   was	   widely	   accepted	   [19,	   20]	   and	   was	   labelled	   the	   Lewis	   Thomas	  
hypothesis	   [21].	   In	   this,	   uncontrolled	   inflammation	   manifests	   itself	   as	   organ	   dysfunction	  
and/or	   failure	   though	   a	   combination	   of	   endothelial	   dysfunction	   [22,	   23]	   and	   coagulation	  
activation	  [24]	  producing	  tissue	  hypo-­‐perfusion.	  
Much	   scientific	   interest	  was	   initially	   focused	   on	   the	   inflammatory	   cytokine	   TNF	   as	   clinical	  
studies	   demonstrated	   elevated	   circulating	   levels	   [25]	   that	   were	   shown	   to	   correlate	   with	  
mortality	   [26-­‐28].	   Animal	  models	   revealed	   that	   injection	   of	   sol-­‐TNF	   produced	   a	   syndrome	  
similar	  to	  sepsis,	  with	  both	  hypotension	  and	  vascular	  leak,	  [29]	  and	  demonstrated	  a	  survival	  
benefit	  if	  anti-­‐TNF	  treatments	  were	  used	  [30-­‐33].	  These	  findings	  lent	  sufficient	  credence	  to	  
anti-­‐TNF	   therapy	   that	   clinical	   trials	   were	   instigated	   to	   investigate	   its	   efficacy	   in	   the	  
treatment	  of	   sepsis.	  However	   these	  produced	  only	   limited	  success	  with	   studies	   suggesting	  
that	  anti-­‐inflammatory	  treatments	  may	  be	  of	  benefit	  in	  only	  in	  a	  small	  (app.	  10%)	  subgroup	  
of	  patients	  with	  sepsis	  [34,	  35]	  and,	  in	  some	  situations,	  might	  even	  lead	  to	  harm	  [36].	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Roger	  Bone	  -­‐	  the	  compensatory	  anti-­‐inflammatory	  response	  syndrome	  
It	  was	  this	  lack	  of	  clinical	  benefit	  provided	  by	  anti-­‐TNF	  treatments	  that	  led	  to	  a	  reappraisal	  of	  
our	   understanding	   of	   sepsis	   pathophysiology.	   This	   resulted	   in	   a	   new	   concept,	   the	  
compensatory	  anti-­‐inflammatory	   response	  syndrome	   (CARS).	  This	   idea	  of	  a	  CARS	   response	  
was	  first	  proposed	  by	  Roger	  Bone	  in	  1996	  to	  denote	  the	  mechanism	  that	  prevents	  systemic	  
dissemination	  of	  inflammation	  [37].	  In	  his	  article	  he	  quoted	  a	  maxim	  from	  Sir	  Isaac	  Newton’s	  
Philosophiae	  Naturalis	  Principia	  Mathematica	  [38],	  “To	  every	  action	  there	  is	  always	  opposed	  
an	  equal	   reaction:	  or,	   the	  mutual	  action	  of	   two	  bodies	  upon	  each	  other	  are	  always	  equal,	  
and	  directed	  to	  contrary	  parts.”	  By	  doing	  so	  he	  was	  outlining	  his	  hypothesis	   that	   the	  body	  
mounts	   an	   anti-­‐inflammatory	   response	   to	   infection	   and	   that,	   at	   times,	   this	   may	   be	  
dominant.	   Furthermore	   the	   importance	  of	   the	  CARS	   response	  might	   explain	   the	   failure	  of	  
therapeutic	  strategies	  aimed	  solely	  at	  attenuating	  the	  pro-­‐inflammatory	  response.	  
Bone’s	  work	  was	  prescient	  and	   the	   idea	  of	  a	  counteractive	  or	  balancing	  anti-­‐inflammatory	  
response	  in	  sepsis	  is	  now	  widely	  accepted,	  if	  not	  yet	  fully	  elucidated.	  His	  hypothesis	  explains	  
the	   alterations	   in	   immune	   function	   that	   are	   seen	   in	   patients	   exposed	   to	   severe	  
inflammation.	   Patients	  who	   have	   sepsis	   display	   anergy	   to	   skin	   test	   allergens	   [39,	   40]	   and	  
have	   an	   increased	   susceptibility	   to	   infection	   [41,	   42].	   Their	   plasma	   can	   be	   seen	   as	   an	  
immunosuppressive	   milieu	   [43]	   as	   it	   induces	   anti-­‐inflammatory	   changes	   in	   cells	   bathed	  
within	   it	   [44-­‐46].	   It	   is	   well	   documented	   that	   leukocytes	   taken	   from	   patients	   with	   sepsis	  
display	   a	   reduced	   release	   of	   some	   pro-­‐inflammatory	   cytokines	   (such	   as	   TNF)	   on	   ex	   vivo	  
stimulation	   [47].	   There	   are	   also	   non-­‐septic	   inflammatory	   conditions	   where	   an	   anti-­‐
inflammatory	   response	   unexpectedly	   predominates,	   such	   as	   the	   release	   of	   anti-­‐
inflammatory	   cytokines	   after	   the	   aorta	   is	   unclamped	   in	   bypass	   surgery	   [48]	   and	   after	  
resuscitation	  from	  cardiac	  arrest	  [49].	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Several	   putative	   mechanisms	   have	   been	   proposed	   as	   to	   how	   this	   anti-­‐inflammatory	  
response	   is	   generated	   with	   changes	   described	   in	   both	   innate	   and	   acquired	   immune	   cell	  
function.	   Monocytes	   taken	   from	   patients	   with	   sepsis	   display	   alterations	   in	   both	   their	  
oxidative	   burst	   and	   cytokine	   production	   pattern	   on	   ex	   vivo	   stimulation	   [50].	   Monocytes	  
taken	  from	  patients	  with	  both	  sterile	  inflammation	  and	  sepsis	  display	  reduced	  expression	  of	  
the	  MHC	   class	   II	   antigen-­‐presenting	  molecule	  HLA-­‐DR	   [51-­‐53]	   and	   this	   has	   been	   linked	   to	  
both	  outcome	  and	  infective	  complications	  [54,	  55].	  This	  may	  also	  result	  in	  reduced	  activation	  
of	   lymphocytes,	  which	   themselves	  change	   from	  a	  pro-­‐inflammatory	  Th1	  profile	   to	  an	  anti-­‐
inflammatory	  Th2	  profile	  [56].	  
	  
The	  dynamics	  of	  SIRS	  and	  CARS	  
Although	   there	   is	   agreement	   that	   both	   inflammatory	   and	   anti-­‐inflammatory	   response	   can	  
dominate	   in	   sepsis,	   the	   factors	   governing	   this	   and	   the	   interplay	   between	   them	   is	   not	   yet	  
clear.	   In	   2003	   Hotchkiss	   and	   Karl	   presented	   their	   hypothesis	   as	   to	   how	   these	   might	   be	  
related	   and	   termed	   them	   the	   hyper-­‐immune	   and	   hypo-­‐immune	   response	   [21].	   They	  
described	  a	  temporally	  separated	  response	  in	  which	  an	  initial	  hyper-­‐immune	  response	  was	  
followed	  by	  a	  hypo-­‐immune	  response.	  They	  hypothesised	  that	  the	  size	  and	  duration	  of	  each	  
response	  is	  most	  likely	  determined	  by	  a	  combination	  of	  factors	  which	  include,	  “the	  virulence	  
of	  the	  organism,	  the	  size	  of	  the	  inoculum,	  and	  the	  patient’s	  coexisting	  conditions,	  nutritional	  
status,	   age,	   and	   polymorphisms	   in	   cytokine	   genes	   or	   other	   immune-­‐effector	  molecules	   or	  
their	   receptors.”	   Thus	   a	   patient	   with	   numerous	   comorbidities	   may	   display	   a	   protracted	  
hypo-­‐immune	  period	  following	  their	  initial	  presentation	  with	  an	  infective	  pathology.	  During	  
this	  period	  of	  hypo-­‐immunity	  they	  are	  vulnerable	  to	  nosocomial	   infection.	  This	  is	  similar	  to	  
clinical	  reality,	  most	  patients	  who	  succumb	  to	  severe	  sepsis	  survive	  their	  initial	  infection	  but	  
die	   later	   in	  the	  course	  of	  their	   ICU	  stay	  with	  signs	  of	  organ	  failure	  and	  secondary	   infection	  
[57].	  Roger	  Bone	  himself	   [57]	  envisaged	  a	   situation	   in	  which	  either	   SIRS	  or	  CARS	   could	  be	  
dominant	  in	  a	  similar	  fashion	  to	  that	  described	  by	  Hotchkiss	  and	  Karl.	  An	  illustration	  of	  this	  
relationship	  is	  outlined	  in	  figure	  1.1.	   	  




Figure	  1.1:	  Graphical	  illustration	  of	  the	  possible	  relationships	  between	  SIRS	  and	  CARS.	  	  
The	  green	   line	   illustrates	  the	   inflammatory	  balance	  seen	   in	  a	  person	  with	   local	  sepsis	   -­‐	   this	  
may	   oscillate	   between	   net	   pro	   or	   anti-­‐inflammatory	   effects.	   Systemic	   dissemination	   of	  
infection	  produces	  a	  cytokine	  storm	  and	  a	  SIRS	  response	  that	   is	  characterised	  by	  a	  net	  pro-­‐
inflammatory	   response	   and	   early	   organ	   dysfunction.	   This	   is	   followed	   by	   a	   period	   in	  which	  
there	   is	   a	   net	   anti-­‐inflammatory	   response,	   where	   late	   organ	   dysfunction	   and	   immune	  
suppression	  is	  seen.	  Here	  there	  may	  be	  an	  increased	  risk	  of	  nosocomial	  infection	  and	  viral	  re-­‐
activation.	  A	  person	  may	  recover	  (as	  illustrated	  above)	  but	  can	  die	  during	  either	  the	  net	  SIRS	  
or	  net	  CARS	  periods.	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Other	   authors	   have	   argued	   that	   the	   two	   processes	   occur	   simultaneously	   but	   are	  
compartmentalised;	   inflammation	   is	   spatially	   limited	   to	   the	   affected	   extra-­‐vascular	   site	   or	  
compartment	   with	   a	   systemic	   anti-­‐inflammatory	   response	   occurring	   to	   prevent	  
dissemination	  [50,	  58].	  This	  hypothesis	  may	  explain	  why	  the	  anti-­‐inflammatory	  mediators	  IL-­‐
10	   and	   IL-­‐1	   receptor	   antagonist	   are	   detected	   as	   early	   as	   one	   hour	   after	   the	   aorta	   is	  
unclamped	  during	  cardiac	  bypass	  surgery	  [48].	  It	  also	  explains	  why	  there	  are	  higher	  levels	  of	  
pro-­‐inflammatory	  mediators	  and	   lower	   levels	  of	  anti-­‐inflammatory	  mediators	  at	  the	  site	  of	  
inflammation	  when	  compared	  to	  those	  seen	  systemically	  [59-­‐61].	  
There	   is	   a	   direct	   body	   of	   evidence	   to	   support	   the	   compartmentalisation	   theory	   of	   the	  
immune	  response	  in	  sepsis.	  It	  has	  been	  reported	  that,	  in	  response	  to	  sepsis,	  gene	  expression	  
profiles	   are	   organ	   specific	   [62]	   and	   there	   is	   evidence	   for	   heterogeneity	   between	   different	  
macrophage	   populations.	   In	   the	   lung	   the	   alveolar	   macrophage	   will	   encounter	   antigenic	  
material	  on	  a	  more	  frequent	  basis	  than	  many	  other	  cells.	   It	   is	  of	  note	  then	  that	  these	  cells	  
seem	  resistant	  to	  the	  induction	  of	  LPS	  tolerance	  that	  is	  seen	  in	  other	  cells	  of	  the	  monocyte-­‐
macrophage	  lineage	  [63].	  Further	  evidence	  of	  organ	  specific	  alterations	  in	  immunity	  can	  be	  
seen	   in	   the	   liver.	   Kuppfer	   cells	   that	   are	   stimulated	  ex-­‐vivo	   in	   arginine	   free	  media	  produce	  
less	   TNF	   than	   those	   stimulated	   in	  media	   containing	   arginine	   [64].	  Arginine	   free	   conditions	  
are	   similar	   to	   those	   found	   normally	  within	   the	   liver	  where	   high	   levels	   of	   hepatic	   arginase	  
activity	  prevent	   its	  accumulation	  [64].	  The	  study	  authors	  argue	  this	  represents	  an	  adaptive	  
evolution	  of	  these	  cells	  that	  prevents	  them	  generating	  excessive	  cytokine	  responses	  despite	  
their	  proximity	   to	  gut	  derived	  LPS.	  Such	  alterations	   in	  macrophage	   function	  are	   in	  keeping	  
with	  the	  adaptive	  nature	  of	  cells	  of	  the	  monocyte	  macrophage	  lineage.	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Enhanced	   levels	   of	   pro-­‐inflammatory	   cytokines	   have	   been	   repeatedly	   demonstrated	   in	  
broncho-­‐alveolar	   lavage	   fluid	   (BALF)	   samples	   taken	   in	   the	   context	  of	   chest	   injury	   [59]	   and	  
ventilator	   associated	   pneumonia	   [65],	   yet	   the	   same	   patterns	   were	   not	   seen	   systemically.	  
Enhanced	  levels	  of	  pro-­‐inflammatory	  BALF	  cytokines	  have	  also	  been	  described	  in	  the	  acute	  
respiratory	  distress	  syndrome	  (ARDS)	  [66-­‐70].	  In	  bacterial	  pneumonia	  it	  has	  been	  shown	  that	  
there	  are	  higher	   levels	  of	  pro-­‐inflammatory	  cytokines	   in	  BALF	  recovered	  from	  the	   involved	  
lung	  when	   compared	   to	   the	  non-­‐involved,	   contralateral	   lung	   [71].	   Increased	   levels	   of	   pro-­‐
inflammatory	  cytokines	  have	  also	  been	  shown	  in	  fluid	  retrieved	  from	  skin	  wounds	  [72],	  the	  
cerebrospinal	   fluid	  of	  patients	  with	  bacterial	  meningitis	   [73],	   pancreatic	   ascites	   [74],	   urine	  
from	  those	  with	  urosepsis	  [75]	  as	  well	  as	  in	  peritoneal	  fluid	  from	  patients	  with	  appendicitis	  
[76]	  and	  peritonitis	  [77].	  
The	  most	  developed	  argument	  for	  spatial	  regulation	  of	  the	  immune	  response	  was	  made	  by	  
Pugin	   and	  Munford	  who	   hypothesised	   that	   the	   body’s	   normal	   response	   to	   tissue	   injury	   is	  
both	   systemic	   and	   anti-­‐inflammatory	   [58].	   They	   suggested	   that	   in	   some	   situations	   this	  
response	  could	  be	  over	  zealous	  in	  nature	  resulting	  in	  an	  immune-­‐suppressed	  phenotype	  that	  
rendered	   patients	   vulnerable	   to	   further	   infection	   [58].	   Although	   the	   relationship	   between	  
SIRS	  and	  CARS	  is	  not	  yet	  known,	  it	  is	  clear	  that	  any	  immune	  modulating	  therapy	  would	  need	  
to	  be	   introduced	  at	   an	  appropriate	   time	   in	  order	   to	  benefit	  patients.	   Thus	   further	  work	   is	  
required	   to	   delineate	   the	   regulation	   of	   these	   inflammatory	   and	   anti-­‐inflammatory	  
responses.	  
Compartmentalisation	   of	   inflammation	   in	   sepsis	   raises	   the	   possibility	   that	   circulating	  
inflammatory	   cells	   (e.g.	   monocytes	   and	   neutrophils)	   would	   be	   required	   to	   switch	   from	   a	  
relatively	  passive	   to	  more	  pro-­‐inflammatory	   state	  while	  migrating	   into	   the	   inflamed	   tissue	  
via	   the	   vascular	   endothelium.	   	   Consistent	  with	   such	   environmental	   triggers,	   non-­‐adherent	  
versus	   adherent	   conditions	   have	   been	   shown	   to	   alter	   the	   mode	   of	   leukocyte	   response	  
elicited	   by	   stimuli	   such	   as	   complement	   and	   IL-­‐10	   [78,	   79].	   This	   raises	   the	   possibility	   that	  
circulating	   cells	   assessed	   in	  ex	  vivo	   studies	  might	  be	  unrepresentative	  of	   cells	   adherent	   to	  
the	  endothelium.	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It	  is	  clear	  from	  the	  literature	  that	  there	  is	  an	  un-­‐met	  need,	  in	  both	  basic	  science	  and	  clinical	  
medicine,	   for	   an	   improved	   understanding	   of	   inflammation	   and	   robust	   biomarkers	   of	  
SIRS/CARS	  in	  order	  that	  therapies	  can	  be	  guided	  rather	  than	  instigated	  blindly.	  	  
Roger	   Bone	   identified	   four	   groups	   of	   patients	   [55]	   who	   have	   been	   exposed	   to	   an	  
inflammatory	  stimulus:	  
1. “Patients	  who	  show	  little	  evidence	  of	  a	  systemic	  reaction.	  Although	  recovery	  may	  be	  
protracted	  because	  of	  the	  severity	  of	  the	  underlying	  illness,	  organ	  dysfunction	  rarely	  
develops.	  
2. Patients	  who	  develop	  a	  mild	  form	  of	  SIRS	  with	  some	  evidence	  of	  organ	  dysfunction.	  
Dysfunction	  is	  usually	  limited	  to	  one	  or	  two	  organs	  and	  resolves	  rapidly.	  
3. Patients	   in	  whom	  a	  massive	   systemic	   inflammatory	   reaction	  develops	   rapidly	  after	  
the	  initial	  insult.	  These	  patients	  often	  die	  of	  profound	  shock	  within	  a	  few	  days.	  
4. Patients	  who	  have	   a	   less	   severe	   initial	   course	  of	   disease	  but	  deteriorate	  markedly	  
several	   days	   or	   more	   after	   the	   original	   insult.	   Failure	   of	   one	   or	   more	   organs	   is	  
common,	  and	  many	  of	  these	  patients	  die.”	  
What	  we	   require	   is	   the	   ability	   to	   identify	   a	   pathological	   response	   (groups	   three	   and	   four)	  
from	   those	   having	   a	   normal	   response	   (groups	   one	   and	   two),	   as	   well	   as	   a	   capacity	   to	  
determine	   whether	   that	   pathological	   response	   is	   characterised	   by	   an	   excessive	  
inflammatory	   or	   anti-­‐inflammatory	   processes.	   If	   we	   can	   do	   this,	   it	   may	   be	   possible	   to	  
instigate	   future	   inflammatory/anti-­‐inflammatory	   therapies	   having	   appropriately	   targeted	  
those	  who	  will	  receive	  maximum	  benefit.	  
	  
1.3	  Innate	  immunity	  and	  inflammation	  
Innate	   immunity	   refers	   to	   a	   co-­‐ordinated,	   non-­‐specific	   response	   that	   is	   generated	   rapidly	  
after	   microbial	   invasion,	   confers	   no	   long	   lasting	   immunity	   to	   a	   specific	   pathogen	   and	   is	  
considered	   to	   be	   the	   most	   primitive	   form	   of	   immunity	   [80].	   Whilst	   the	   innate	   immune	  
response	   has	   a	   number	   of	   different	   constituent	   parts	   it	   is	   difficult	   to	   consider	   them	  
individually	  due	  to	  the	  continuous	  and	  complex	  interplay	  that	  occurs	  between	  them.	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Whilst,	   in	  strict	  terms,	  barriers	  such	  as	  the	  skin	  and	  mucosal	  defence	  mechanisms	   like	  cilia	  
form	  part	  of	  the	  innate	  immune	  system,	  the	  response	  element	  of	  the	  system	  can	  be	  broken	  
down	  into	  cellular	  and	  humoural	  components.	  The	  cellular	  response	  consists	  of	  neutrophils,	  
monocytes/dendritic	   cells	   and	   NK	   cells	   [80],	   whereas	   the	   humoural	   response	   consists	   of	  
complement	   [81].	   Given	   that	   the	   hallmark	   of	   the	   innate	   immune	   response	   is	   a	   lack	   of	  
specificity,	   the	   first,	   and	  most	   fundamental	   question,	   is	   how	   the	   system	  distinguishes	   self	  
from	  non-­‐self.	  
	  
PAMPS,	  PRRs	  and	  self-­‐discrimination	  
The	   ability	   to	   discriminate	   self	   from	   non-­‐self	   prevents	   the	   innate	   immune	   response	   from	  
being	  inappropriately	  triggered.	  This	  discriminatory	  capacity	  is	  provided	  through	  a	  series	  of	  
pattern	  recognition	  receptors	   (PRR)	   found	  on	  monocytes,	  neutrophils	  and	  endothelial	  cells	  
that	   recognise	   microbial	   molecules	   known	   as	   pathogen	   associated	   molecular	   patterns	  
(PAMPS).	   These	  PAMPS	   are	   conserved	   across	   broad	   groups	  of	  microbes	   [82,	   83],	   the	  best	  
characterised	   being	   lipopolysaccharide	   (LPS)	   or	   endotoxin.	   This	   component	   of	   the	   gram-­‐
negative	  bacterial	  cell	  wall	  has	  been	  subjected	  to	  considerable	  scientific	  interest	  since	  it	  was	  
first	   characterised	   and	   subsequently	   synthesised	   [84].	   It	   is	   bound	   by	   the	   PRR	   toll-­‐like	  
receptor	  (TLR)-­‐4	  [85,	  86]	  but	  in	  order	  to	  do	  so	  it	  first	  must	  form	  a	  complex	  with	  LPS	  binding	  
protein	  [87]	  and	  requires	  the	  presence	  of	  the	  co-­‐receptors	  CD14	  [88]	  (which	  can	  be	  soluble)	  
and	  MD2	  [89].	  TLR-­‐4	   is	  one	  of	  a	  series	  of	  ten	  TLRs	  that	  are	  currently	  described	   in	  humans,	  
each	  of	  which	  binds	   to	   a	   specific	   ligand/ligands	   [90].	   For	   example	  TLR-­‐2	  binds	   lipoteichoic	  
acid,	   peptidoglycan	   and	   bacterial	   lipopeptides	   [80],	   whereas	   TLR-­‐3	   binds	   viral	   double	  
stranded	   RNA	   [91].	   In	   addition	   to	   the	   TLR	   family	   that	   bind	   extracellular	   or	   endocytosed	  
PAMPS,	  there	  are	  other	  PRR	  which	  are	  cytosolic	  and	  bind	  invasive	  pathogens.	  These	  include	  
the	  nucleotide	  oligomerisation	  domain	   leucine-­‐rich	   repeat	   (NOD-­‐LRR)	   receptors	   (detecting	  
bacteria)	  and	  the	  cytoplasmic	  caspase	  activation	  and	  recruiting	  domain	  helicases	  (thought	  to	  
be	  anti-­‐viral)	  that	  make	  up	  the	  rest	  of	  the	  PRR	  family	  [92].	  Binding	  of	  PAMP	  to	  PRR	  produces	  
cellular	  activation	  through	  the	  recruitment	  of	  intra-­‐cellular	  proteins	  that	  serve	  to	  amplify	  the	  
inflammatory	  signal.	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Sterile	   inflammation,	  as	  may	  result	   from	  trauma,	   is	  mediated	  through	  similar	  mechanisms.	  
However,	  rather	  than	  responding	  to	  PAMPs,	  cells	  respond	  to	  damage	  associated	  molecular	  
patterns	   (DAMPs)	   that	   are	   released	   from	   damaged	   tissues	   [93].	   These	   molecules	   are	  
released	  by	  necrotic	  (but	  not	  apoptotic)	  cells	  in	  response	  to	  tissue	  injury	  and	  are	  bound	  by	  
PRRs	  generating	  an	  inflammatory	  signal	  as	  outlined	  above.	  Substances	  identified	  as	  DAMPS	  
include	  high	  mobility	  group	  box	  1	  (HMGB-­‐1),	  heparan-­‐sulphate	  (HS)	  and	  heat	  shock	  proteins	  
[93,	   94].	   HMGB-­‐1	   is	   a	   non-­‐histone,	   nuclear	   DNA	   binding	   protein	   which	   has	   roles	   in	   in	  
nucleosome	   stabilisation	   and	   gene	   transcription	   [93].	   When	   passively	   released	   in	   large	  
amounts	   by	   necrotic	   cells,	   it	   can	   become	   a	   mediator	   of	   severe	   inflammation	   [95].	   HS	   is	  
found	   on	   the	   cell	   surface	   and	   extra-­‐cellular	   matrix,	   thus	   is	   released	   by	   tissue	   injury	   and	  
subsequently	   recognised	   by	   TLR-­‐4	   [94],	   producing	   inflammation	   [96].	   An	   important	  
difference	   between	   PAMPS	   and	   DAMPS	  may	   be	   the	   higher	   potency	   of	   the	   former,	   which	  
could	  explain	  why	  SIRS	  tends	  only	  to	  develop	  in	  the	  most	  severely	  affected	  trauma	  patients.	  
Alternatively,	   it	   is	   argued	   that	  a	   significant	  number	  of	  DAMPS	   identified	   in	   the	   laboratory,	  
acquire	   their	   activity	   through	   trace	   contamination	   with	   potent	   PAMPs	   such	   as	   endotoxin	  
during	  isolation	  and	  handling	  procedures.	  
	  
Signal	  amplification	  and	  NFκB	  activation	  
Activated	   TLRs	   induce	   signalling	   through	   a	   total	   of	   five	   cytoplasmic	   adapter	   proteins:	  
myeloid	   differentiation	   protein	   (MyD)	   88;	   Toll/IL-­‐1	   receptor	   homology	   domain-­‐containing	  
adapter	   protein	   (TIRAP);	   TLR	   domain	   containing	   adaptor	   inducing	   interferon	   β	   (TRIF);	  
MyD88-­‐4	  and	  MyD88-­‐5	   [80].	  These	  adapter	  proteins	  all	   serve	   to	  amplify	   the	   inflammatory	  
signal,	   but	   the	   core	   transduction	   element	   is	   the	   recruitment	   of	   interleukin-­‐1	   receptor	  
associated	  kinase	  (IRAK)-­‐4	  by	  MyD88.	  This	  induces	  and	  recruits	  IRAK-­‐1	  and	  2,	  which	  form	  a	  
scaffold	   with	   TNF-­‐receptor	   associated	   factor	   (TRAF)-­‐6,	   eventually	   producing	   an	   activated	  
signalosome.	  This	  causes	  phosphorylation	  and	  degradation	  of	  I-­‐kappa	  B	  kinase,	  the	  negative	  
regulator	   of	   the	   key	   inflammatory	   transcription	   factor:	   nuclear	   factor	   kappa	   (NFκ)	   B	   [80].	  
This	   loss	   of	   negative	   regulation	   results	   in	   nuclear	   translocation	  of	  NFκB	   and	   a	   subsequent	  
transcription	   of	   more	   than	   150	   genes	   of	   which	   a	   significant	   number	   have	   inflammatory	  
properties	   [97].	   The	   signal	   amplification	   that	   occurs	   intra-­‐cellularly	   in	   response	   to	   TLR	  
activation	   occurs	   through	   two	   key	  molecules,	   reactive	   oxygen	   species	   (ROS)	   and	  mitogen	  
activated	  protein	  kinases	  (MAPK).	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Signal	  amplification	  -­‐	  ROS	  	  
Historically,	  ROS	  were	   thought	   to	  be	  harmful	   and	   confined	   to	  phagocytic	   cells	  where	   they	  
were	  produced	  by	  enzymes	  responsible	  for	  generating	  the	  oxidative	  burst	  [98].	  However,	  it	  
is	  now	  known	  that	  enzymes	  such	  as	  NADPH	  oxidases	  are	  widely	  expressed	  and	  provide	  an	  
important	  source	  of	  ROS	  [99,	  100].	  Mitochondria	  represent	  another	  key	  source	  of	  ROS	  and	  
are	   able	   to	   directly	   produce	   hydrogen	   peroxide,	   potentially	   as	   a	   means	   of	   triggering	  
apoptosis	   [101].	   Although	   these	   represent	   the	   two	   major	   sources	   of	   ROS,	   there	   are	   a	  
number	  of	  other	  enzymes,	  such	  as	  cyclooxygenases	  and	  cytochromes,	  that	  produce	  oxidants	  
[98].	  Studies	  have	  demonstrated	  that	  receptor-­‐ligand	  binding	  (such	  as	  that	  between	  LPS	  and	  
TLR-­‐4)	  produces	  ROS	   [102,	  103].	   It	  has	  become	  well	   established	   that	   the	   targets	   for	   these	  
molecules	  are	  phosphatase	  enzymes	  and	  that	   these	  are	  activated	  by	  oxidative	  stress	   [104,	  
105]	  establishing	  a	  role	  for	  ROS	  in	  signal	  transduction.	  ROS	  are	  now	  known	  to	  regulate	  MAPK	  
[106-­‐109],	  NFκB	  [110]	  and	  cytoskeletal	  proteins	  [111].	  
Several	   species	   of	   ROS	   are	   generated;	  membrane	   bound	  NADPH	   oxidase	   utilises	   cytosolic	  
NADPH	   in	   order	   that	   extracellular	   O2	   is	   reduced	   to	   superoxide	   (O2-­‐).	   There	   is	   also	   a	  
production	  of	  reactive	  nitrogen	  species	  through	  the	  action	  of	  constitutive	  and/or	   inducible	  
nitric	  oxide	  synthase	  (NOS)	  that	  oxidate	  L-­‐arginine	  producing	  nitric	  oxide	  (NO)	  [112].	  Whilst	  
neither	   superoxide	   nor	   NO	   is	   especially	   reactive	   they	   can	   combine	   to	   produce	   the	  
peroxynitrate	  ion	  (ONOO-­‐)	  that	  is	  highly	  reactive.	  Alternatively	  superoxide	  can	  be	  dismuted	  
through	  the	  action	  of	  superoxide	  dismutase	  to	  produce	  hydrogen	  peroxide	  (H2O2),	  a	  process	  
that	   occurs	   readily	   in	   aqueous	   environments.	   This	   uncharged	  molecule	   can	   readily	   diffuse	  
across	   cell	  membranes	   but	   can	  be	   reduced	  by	   transition	  metals	   in	   the	   Fenton	   reaction	   to	  
produce	  the	  reactive	  hydroxyl	  radical	  (OH-­‐).	  
ROS	   are	   widely	   generated,	   highly	   reactive	   molecules	   and	   must	   be	   tightly	   regulated;	  
therefore	  the	  mechanisms	  that	  control	  this	  are	  of	  considerable	  scientific	   interest.	  Potential	  
mechanisms	   include	  co-­‐localisation	  of	   target	  molecules	  and	  ROS	  generating	  enzymes	  [113]	  
and	  the	  formation	  of	  an	  intracellular	  ROS	  gradient	  [114].	  A	  further	  mechanism	  for	  conferring	  
a	  degree	  of	   specificity	   in	   signalling	  exists,	   and	   functions	  by	   channelling	  hydrogen	  peroxide	  
through	   membrane	   expressed	   aquaporin	   channels	   that	   regulate	   its	   entry	   [115,	   116].	   A	  
number	   of	   scavenging	   systems	   exist	   to	   limit	   the	   activity	   of	   ROS.	   These	   include	   catalase,	  
which	   catalyses	   the	   decomposition	   of	   hydrogen	   peroxide	   to	  water,	   as	  well	   as	   thioredoxin	  
and	  glutathione	  peroxidase.	  These	  latter	  two	  enzymes	  play	  a	  key	  role	   in	  maintaining	  redox	  
homeostasis	  through	  reducing	  sulphide	  bridges	  in	  target	  proteins	  [98].	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Signal	  amplification	  -­‐	  MAPKs	  
MAPKs	  are	  a	  series	  of	  highly	  conserved	  and	  widely	  expressed	  intracellular	  enzymes	  that	  are	  
responsible	  for	  converting	  external	  stimuli	  into	  cellular	  responses	  [117].	  In	  humans	  there	  are	  
five	  MAPKs:	  p38;	  extracellular-­‐regulated	  kinase	  (ERK);	  Jun	  N-­‐terminal	  kinase	  (JNK);	  ERK	  3/4	  
and	  the	  big	  mitogen-­‐activated	  protein	  kinase	  (BMK1)	  [107].	  Conventional	  MAPK	  consists	  of	  a	  
set	   of	   three,	   sequentially	   acting	   kinases:	   a	  MAPK,	   a	  MAPK	   kinase	   (MAPKK)	   and	   a	  MAPKK	  
kinase	   (MAPKKK).	  Activation	  of	  MAPKKK	  can	  occur	   through	  phosphorylation	  or	   interaction	  
with	  a	  GTP	  binding	  protein	  and	  results	   in	  phosphorylation	  of	  a	  MAPKK	  at	  Ser/Thr	   residues	  
that	   in	   turn	   results	   in	  MAPK	  activation	   [117].	  MAPK	  activation	  requires	  phosphorylation	  at	  
two	   residues:	   Thr	   and	   Tyr.	   These	   sequences	   are	   contained	   within	   a	   conserved	   activation	  
loop	  and	  this	  dual	  phosphorylation	  process	  was	  first	  demonstrated	  for	  ERK	  [118].	  Much	  less	  
detail	   is	   known	   about	   the	   activation	   of	   atypical	  MAPKS	   such	   as	   ERK	   3/4	   but	   they	   are	   not	  
thought	  to	  function	  through	  the	  same	  three-­‐tiered	  cascade	  as	  conventional	  MAPKs	  [117].	  
MAPKs	   mediate	   a	   broad	   range	   of	   functions	   through	   phosphorylation	   of	   downstream	  
molecules,	  notably	  members	  of	  the	  MAPK	  activated	  protein	  kinases	  (MAPKAPKs)	  [119,	  120].	  
These	   consist	   of	   p90	   ribosomal	   S6	   kinases	   9	   (RSKs)	   [121],	   mitogen	   and	   stress	   activated	  
kinases	   (MSKs)	   [122],	   MAPK-­‐interacting	   kinases	   (MNKs)	   [123],	   MAPK-­‐activated	   protein	  
kinase	  2/3	  (MK2/3)	  [124]	  and	  MK5	  [124].	  These	  MAPKAPKs	  serve	  to	  amplify	  the	  signal	  and	  
generate	  a	  signalling	  cascade.	  
P38MAPK	   is	   activated	   by	   the	   MAPKKs	   MKK3	   and	   MKK6	   [125],	   which	   are	   themselves	  
activated	   by	   a	   stimulus	   specific	   MAPKKK.	   In	   the	   case	   of	   upstream	   signalling	   by	   ROS	   this	  
MAPKKK	  is	  thought	  to	  be	  apoptosis	  signal-­‐regulating	  kinase	  1	  (ASK-­‐1).	  ASK-­‐1	  is	  maintained	  as	  
an	   inactive	  homodimer	  through	  the	  action	  of	  reduced	  thioredoxin	   [108,	  109].	  ROS	  oxidises	  
the	   thioredoxin	   catalytic	   disulphide,	   liberating	   ASK-­‐1,	   which	   is	   subsequently	   auto-­‐
phosphorylated,	   activating	   the	   p38	   pathway.	   As	   p38MAPK	   is	   a	   stress	   induced	   kinase	   it	   is	  
particularly	   susceptible	   to	   activation	   by	   ROS	   and	   can	   be	   activated	   by	   superoxide	   [126],	  
hydrogen	  peroxide	  [127],	  NO	  [128]	  and	  peroxynitrate	  [129].	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P38	  is	  activated	  through	  cell	  stressors	  such	  as	  PAMPs,	  hyperosmolar	  states	  and	  stretch	  [130-­‐
132].	  This	  activation	  is	  rapid	  but	  it	  is	  also	  rapidly	  reduced.	  In	  response	  to	  an	  LPS	  stimulus	  in	  
primary	   human	   monocytes,	   we	   observed	   increased	   levels	   of	   activated	   (phosphorylated)	  
p38MAPK	   15	   minutes	   after	   stimulation	   that	   were	   falling	   again	   at	   30	   minutes	   post-­‐
stimulation	  [133].	  This	   rapid	  down	  regulation	  of	  activity	  occurs	  through	  dephosphorylation	  
at	  the	  Tyr	  or	  Thr	  residues	  through	  the	  action	  of	  the	  MAPK	  phosphatases	  (MKPs),	  a	  family	  of	  
dual	   specificity	   phosphatases	   [134].	   The	   p38	   pathway	   is	   key	   to	   modulating	   the	   cellular	  
inflammatory	  response	  and	  has	  been	  implicated	  in	  the	  regulation	  of	  a	  number	  of	  cytokines	  
including	  TNF,	  IL1-­‐β,	  IL-­‐6,	  IL-­‐8	  and	  INF-­‐γ	  [135-­‐138].	  The	  main	  target	  of	  p38	  is	  MK2	  and	  these	  
molecules	  exist	  as	  a	  pre-­‐formed	  complex	  that	  regulates	  gene	  transcription	  [139].	  
	   	  




















Figure	  1.2:	  Schematic	  illustrating	  ROS/p38	  MAPK	  activation	  pathway	  
ROS	  are	   produced	   in	   response	   external	   signals,	   such	   as	   LPS	   binding	   to	   TLR-­‐4,	   and	  activate	  
ASK-­‐1.	   In	   turn	  this	  activates	  MKK3/6	  through	  phosphorylation	  at	  Ser	  and	  Thr	   residues.	  This	  
then	  phosphorylates	  p38MAPK	  at	  Thr	  and	  Tyr	  resulting	  in	  sequential	  activation	  of	  MK2.	  This	  
process	  produces	  an	  increase	  in	  the	  transcription	  of	  a	  number	  of	  mediators	  that	  determines	  
the	  cellular	  inflammatory	  response.	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Evolution	  of	  the	  innate	  immune	  response	  
The	  sentinel	  cell	  in	  the	  evolution	  of	  the	  immune	  response	  is	  the	  resident	  tissue	  macrophage.	  
These	  cells	  are	  thought	  to	  be	  derived	  from	  circulating	  monocytes	  but	  also	  proliferate	  in	  situ	  
[140]	  and	  have	  roles	  in	  microbial	  clearance	  and	  the	  maintenance	  of	  local	  homeostasis	  [141,	  
142].	   Once	   activated	   by	   PAMPS/DAMPS	   these	   cells	   recognise	   antigenic	   material	   and	   can	  
relay	  this	  information	  to	  neutrophils	  and	  other	  monocytes	  though	  the	  release	  of	  cytokines.	  
Activation	  of	   these	  cells,	  and	  also	  of	  surrounding	  endothelial	  and	  epithelial	  cells,	   results	   in	  
the	  transcription	  of	  numerous	   inflammatory	  signalling	  molecules	  that	  produce	  vasodilation	  
and	   increased	   vessel	   permeability	   [93,	   143],	   as	   well	   as	   enhanced	   neutrophil	   recruitment	  
[144].	   This	   process	   can	   trigger	   secondary	   cascades,	  which	   augment	   the	   cytokine	   response	  
and	  up-­‐regulate	  cell	  adhesion	  molecules,	  further	  facilitating	  chemotaxis	  [145].	  The	  net	  result	  
of	   this	  process	   is	   that	   cells	   are	   recruited	   to	  a	   cytokine	   rich	   local	   environment	   through	   the	  
action	  of	  chemokines.	  Any	  pathogen	  is	  then	  engulfed	  (phagocytosis)	  and	  subsequently	  killed	  
through	  the	  action	  of	   lysosymes	  containing	  reactive	  oxygen	  or	  nitrogen	  species	  (ROS/RNS).	  
Cells	   responsible	   for	   phagocytosis	   are	   recruited	   and	   tissue	   macrophages	   or	   recruited	  
neutrophils.	  As	  previously	  discussed,	  different	   tissue	  macrophages	  may	  display	   a	  modified	  
response.	   For	   example,	   the	   alveolar	   macrophage	   will	   regularly	   be	   exposed	   to	   antigenic	  
material	   that	   passes	   into	   the	   airway.	   This	   will	   not	   always	   result	   in	   the	   creation	   of	   an	  
inflammatory	   focus;	   often	   the	   cell	   will	   be	   capable	   of	   disposing	   of	   this	   material	   by	  
phagocytosis.	   However,	   once	   the	   amount	   of	   antigenic	  material	   exceeds	   a	   threshold	   value	  
the	   macrophage	   will	   release	   sufficient	   chemokines	   and	   cytokines	   to	   recruit	   and	   activate	  
systemic	  cells.	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1.4	  Soluble	  mediators	  of	  inflammation	  -­‐	  cytokines	  
These	  are	  a	  series	  of	  small,	   soluble,	   signalling	  molecules	   that	  effect	  nearly	  every	  biological	  
process	  but	  play	  a	  key	  role	   in	  determining	  the	   immune	  response	  [17].	  They	  are	  capable	  of	  
acting	   in	   an	   autocrine,	   endocrine	   and	   paracrine	   fashion	   and	   can	   be	   divided	   into	   those	  
exerting	  a	  net	  inflammatory	  effect	  and	  those	  exerting	  a	  net	  anti-­‐inflammatory	  effect.	  Initially	  
there	  was	  some	  effort	  made	  to	  restrict	  their	  nomenclature	  based	  on	  the	  cells	  that	  produced	  
them	  but	   their	  pleiotropic	  nature	  meant	   that	   this	  was	   rapidly	  dropped.	  The	   term	  cytokine	  
now	  refers	  to	  interferons,	  interleukins,	  the	  chemokine	  family,	  mesenchymal	  growth	  factors,	  
the	   tumour	   necrosis	   factor	   family	   and	   adipokines	   [17].	   Although	   cytokines	   are	   considered	  
pro	  or	   anti-­‐inflammatory	   in	  nature,	   their	   net	   effect	   is	   often	  more	  difficult	   to	  quantify	   and	  
depends	  on	  both	  local	  and	  systemic	  factors.	  
	  
Pro-­‐inflammatory	  cytokines	  
Pro-­‐inflammatory	   cytokines,	  whose	   function	   is	   to	  amplify	   the	   response	   to	  DAMPS/PAMPS,	  
include	   TNF,	   IL-­‐1,	   IL-­‐6	   and	   INF-­‐γ.	   The	   coordinated	   release	   of	   these	   molecules	   results	   in	  
vasodilation	   (meaning	   more	   leukocytes	   are	   diverted	   to	   the	   area),	   adhesion	   molecule	   up-­‐
regulation	   (producing	   leukocyte	   arrest	   that	   facilitates	   further	   recruitment)	   and	   enhanced	  
killing	  of	  any	  pathogenic	  organism	  that	  may	  be	  present.	  The	  production	  of	  these	  cytokines	  
occurs	  concurrently	  with	   the	  acute	  phase	  response	  [143]	  and	  serves	   to	   further	  augment	   it	  
[80].	  The	  acute	  phase	  response	  is	  characterised	  by	  the	  generation	  of	  fever,	  a	  fall	   in	  plasma	  
iron	  and	  albumin,	  and	  the	  increased	  production	  of	  a	  series	  of	  proteins,	  some	  of	  which	  have	  
well-­‐described	  defensive	  functions.	  Increased	  fibrinogen	  may	  help	  to	  wall	  off	  infected	  areas,	  
LBP	  binds	   LPS	  whereas	   c-­‐reactive	  protein	   (CRP)	  binds	   to	   streptococci	   and	  may	   signal	   their	  
presence	   [80].	   Fever	   itself	   enhances	   immunological	   functions	   such	   as	   the	   bacteriocidal	  
effects	  of	  neutrophils,	  the	  anti-­‐viral	  effects	  of	   interferon	  and	  the	  proliferative	  responses	  of	  
lymphocytes.	   In	  addition	   to	   the	  major	  pro-­‐inflammatory	   cytokines	  mentioned	  above	   there	  
are	  a	  number	  of	  other	  cytokines	  that	  may	  be	  of	  importance	  in	  sepsis.	  These	  include	  IL-­‐4,	  IL-­‐
8,	  IL-­‐9,	  IL-­‐12,	  IL-­‐13,	  macrophage	  inhibitory	  factor	  and	  HMGB-­‐1	  [146].	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TNF	  activates	  and	   induces	  margination	   in	  neutrophils	  and	  monocytes,	  as	  well	  as	  producing	  
fever,	   gluconeogenesis	   and	  protein	   synthesis	   [146].	   The	   Lewis-­‐Thomas	  hypothesis	   focused	  
attention	   on	   circulating	   levels	   of	   TNF,	   as	   clinical	   studies	   had	   demonstrated	   these	   to	   be	  
elevated	   [25]	   and	  administration	  of	   endotoxin	   to	  human	  volunteers	   elicited	  a	   TNF	   release	  
that	   mimicked	   the	   cardiovascular	   and	   metabolic	   changes	   seen	   in	   sepsis	   [147-­‐149].	  
Unfortunately,	   treatments	   based	   on	   blocking	   TNF	   through	   the	   use	   of	   either	   TNF	   receptor	  
proteins	  or	  anti-­‐TNF	  antibodies	  had	  little	  success	  except	  in	  a	  small	  sub-­‐group	  of	  patients	  [34,	  
35],	  and	  in	  some	  may	  patients	  may	  be	  harmful	  [36].	  At	  present	  the	  successful	  use	  of	  these	  
therapies	   are	   limited	   to	   the	   treatment	   of	   chronic	   inflammatory	   conditions	   such	   as	  
rheumatoid	  arthritis	  [150]	  and	  inflammatory	  bowel	  disease	  [151].	  
The	  IL-­‐1	  superfamily	  originally	  consisted	  of	  IL-­‐1β,	  IL-­‐1α	  and	  the	  IL-­‐1	  receptor	  antagonist	  (IL-­‐
1ra)	  although	   these	  have	  subsequently	  been	  added	   to.	  Both	  mononuclear	  phagocytes	  and	  
neutrophils	  produce	   IL-­‐1β.	   It	  enhances	   leukocyte	  bacterial	  killing,	  enhances	  the	  production	  
of	   other	   pro-­‐inflammatory	   cytokines	   and	   mediates	   biological	   changes	   similar	   to	   those	  
produced	  by	  TNF	   [152,	  153].	   IL-­‐1α	   is	  a	   related	  cytokine	  with	  a	   similar	   spectrum	  of	  activity	  
whereas	   IL-­‐1ra	   is	   a	   soluble	   inhibitor	  of	   IL-­‐1β	   that	   is	  produced	  by	  mononuclear	  phagocytes	  
and	  neutrophils	  and	  binds	  to	  cell	  surface	  receptors	  to	  block	  the	  action	  of	  IL-­‐1β	  [146].	  When	  
IL-­‐1β	   levels	  are	   found	   to	  be	  elevated	   in	   the	  context	  of	   septic	   shock	   they	  correlate	  with	  an	  
increased	  risk	  of	  mortality	  [26].	  
Activated	   monocytes,	   endothelial	   cells,	   fibroblasts	   and	   lymphocytes	   release	   IL-­‐6.	   This	  
cytokine	  produces	  an	  activation	  of	  coagulation	  and	  induces	  the	  production	  of	  hepatic	  acute	  
phase	  proteins	  [146].	  As	  will	  be	  discussed	  in	  more	  detail	  later	  it	  correlates	  with	  the	  severity	  
of	  sepsis	  and	  may	  have	  a	  role	  as	  a	  clinical	  marker	  of	  such	  [26].	  
INF-­‐ϒ	  is	  released	  by	  lymphocytes,	  specifically	  activated	  natural	  killer	  cells,	  helper	  T-­‐cells	  and	  
cytotoxic	  T-­‐cells.	  It	  induces	  expression	  of	  the	  major	  histocompatibility	  complex	  antigen	  and	  
classically	  activates	  macrophages.	  It	  is	  thought	  to	  act	  synergistically	  with	  other	  cytokines	  in	  a	  
manner	  that	  may	  contribute	  to	  adverse	  outcomes	  in	  sepsis	  yet	  is	  not	  consistently	  elevated	  in	  
this	   state	   [26].	   Recombinant	   INF-­‐ϒ	   has	   been	   used	   as	   an	   immune-­‐stimulatory	   therapy	   in	  
patients	  thought	  to	  have	  sepsis	  induced	  immune-­‐suppression	  [154].	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Anti-­‐inflammatory	  cytokines	  
The	  major	  anti-­‐inflammatory	  cytokines	  are	  IL-­‐10	  and	  transforming	  growth	  factor-­‐β	  (TGF-­‐β).	  
IL-­‐10	  is	  released	  by	  lymphocytes	  and	  mononuclear	  phagocytes	  and	  acts	  to	  reduce	  both	  the	  
release	   of	   pro-­‐inflammatory	   cytokines	   and	   expression	  of	  MHC	  molecules	   [146].	   It	   reduces	  
the	   killing	   function	   of	   mononuclear	   phagocytes,	   inhibits	   coagulation	   activation	   and	  
stimulates	   lymphocytes	   [155].	   TGF-­‐β	   acts	   to	   antagonise	   the	   action	   of	   both	   TNF	   and	   IL-­‐1β	  
through	   a	   reduction	   in	   their	   secretion	   and	   a	   stimulation	   of	   their	   antagonists	   (soluble	   TNF	  
receptors	  [TNFR]	  and	  IL-­‐1ra)	  [156,	  157].	  In	  the	  case	  of	  soluble	  TNFR	  1	  and	  2	  these	  molecules	  
are	   released	   rapidly	   through	   the	   cleavage	   of	   membrane-­‐expressed	   proteins	   in	   a	   process	  
termed	   ectodomain	   shedding	   [158-­‐160].	   The	   net	   effect	   of	   this	   process	   is	   variable;	   soluble	  
receptors	  can	  act	  to	  “soak	  up”	  cytokines	  thus	  limiting	  their	  bioactivity	  [161]	  yet	  can	  also	  act	  
as	  a	  “sump”	  resulting	  in	  their	  slow	  release	  [162,	  163].	  
	  
Soluble	  mediators	  of	  inflammation	  –	  chemokines	  
These	  molecules	  are	  small	  (8-­‐10kDa)	  proteins	  that	  are	  able	  to	  induce	  chemotaxis	  in	  nearby	  
cells	   and	   hence	   guide	   migration	   of	   these	   cells	   toward	   an	   inflammatory	   focus.	   They	   are	  
divided	  up	  into	  four	  groups	  based	  on	  the	  structural	  homology	  of	  cysteine	  residues:	  
1. CC	   chemokines:	   this	   group	   induces	   the	   migration	   of	   monocytes,	   NK	   cells	   and	  
dendritic	  cells.	  Monocyte	  chemo-­‐attractant	  protein-­‐1	  (MCP-­‐1)	  belongs	  to	  this	  group	  
and	   induces	   the	   recruitment	   of	   monocytes	   from	   the	   bloodstream	   into	   the	   tissue	  
compartment,	   whereas	   CC	   ligand-­‐5	   (CCL5)	   induces	   similar	   movements	   in	  
lymphocytes.	   Investigators	   have	   attempted	   blockade	   of	   receptors	   to	   MCP-­‐1	   in	  
animal	   models	   of	   sepsis	   but	   have	   found	   this	   reduces	   bacterial	   clearance	   and	  
increases	  kidney	  injury	  [164].	  
2. CXC	  chemokines:	  IL-­‐8	  belongs	  to	  this	  category	  and	  induces	  migration	  of	  neutrophils.	  
Expression	  of	  the	  CXC	  receptor	  2	  (CXCR2)	  is	  elevated	  on	  neutrophils	  in	  septic	  shock	  
[165]	  whereas	  mice	  deficient	  in	  this	  receptor	  are	  protected	  from	  septic	  shock	  [166].	  
3. C	  chemokines:	   this	  group	  contains	   the	   lymphotactins	   that	  are	  partially	   responsible	  
for	  lymphocyte	  recruitment.	  
4. CX3C	  chemokines:	   this	  group	  contains	  only	  one	  molecule,	   fractalkine	  which	  as	  well	  
as	  acting	  as	  a	  chemokine	  also	  functions	  as	  an	  adhesion	  molecule.	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Prostanoids	  
This	  group	  of	  signalling	  molecules	  consists	  of	  prostaglandins	  and	  thromboxanes.	  These	  are	  
molecules	   that	   are	   formed	   when	   arachidonic	   acid	   is	   metabolised	   through	   the	   action	   of	  
prostaglandin	   synthase	   or	   cyclooxygenase	   enzymes	   [167].	   They	   sustain	   homeostatic	  
functions	  and	  yet	  also	  mediate	  pathogenic	  mechanisms	  such	  as	  the	  inflammatory	  response	  
[167].	   There	   are	   four	   principal	   prostaglandins	   (PGs)	   synthesized	   in	   vivo:	   prostaglandin-­‐D2	  
(PGD2),	  prostaglandin-­‐E2	  (PGE2),	  prostaglandin-­‐F2	  (PGF2)	  and	  prostacyclin	  (PGI2).	  Together	  
with	  thromboxane	  A2	  these	  molecules	  are	  locally	  produced	  in	  inflamed	  tissues	  prior	  to	  the	  
recruitment	   of	   leukocytes	   and	   mediate	   their	   actions	   through	   a	   family	   of	   prostanoid	  
receptors.	  PGD2	  has	  been	  associated	  with	  inflammatory	  and	  atopic	  conditions	  [167]	  and	   is	  
thought	   to	   mediate	   leukocyte	   trafficking	   to	   the	   lung,	   a	   feature	   of	   asthma	   [168].	   PGE2	  
mediates	  the	  general	  vasodilation	  and	   increased	  microvascular	  permeability	  that	  facilitates	  
leukocyte	   recruitment	   during	   the	   inflammatory	   response	   [169].	   Whilst	   the	   exact	   role	   of	  
PGF2	   is	   not	   precisely	   defined	   its	   administration	   produces	   inflammation	   whereas	   its	  
inhibition	   may	   have	   a	   role	   in	   attenuating	   pulmonary	   fibrosis	   [170].	   PGI2	   is	   a	   potent	  
vasodilator	   and	   inhibits	   platelet	   aggregation,	   leukocyte	   adhesion	   and	   vascular	   smooth	  
muscle	   cell	   proliferation	   [171].	   TXA2	  mediates	   platelet	   adhesion	   and	   aggregation,	   smooth	  
muscle	   contraction	   and	   proliferation	   as	   well	   as	   activation	   of	   endothelial	   inflammatory	  
responses	  [172].	  
There	   have	   been	   a	   number	   of	   studies	   investigating	   the	   clinical	   utility	   of	   targeting	  
prostaglandin	   synthesis	   as	   a	   means	   of	   improving	   outcomes	   from	   sepsis.	   Several	   have	  
targeted	   the	   initial	   reaction	  mediated	   by	   the	   cyclooxygenase	   enzymes	   in	   order	   to	   reduce	  
inflammation	   [173,	   174].	   Despite	   success	   in	   animal	   models,	   these	   findings	   are	   yet	   to	   be	  
reproduced	  in	  clinical	  studies.	  
	  
Nitric	  oxide	  
Nitric	   oxide	   (NO)	   is	   another	  mediator	   of	   inflammation	   that	   has	   been	   implicated	   in	   sepsis	  
pathophysiology.	   It	   is	   synthesized	   from	   L-­‐arginine	   through	   the	   action	   of	   the	   nitric	   oxide	  
synthase	  (NOS)	  family	  of	  enzymes.	  These	  consist	  of	  a	  calcium	  dependent	  constitutive	  (cNOS)	  
isoform,	  an	  endothelial	  (eNOS)	  isoform,	  a	  calcium	  independent	  inducible	  (iNOS)	  isoform	  and	  
a	   constitutive	   neuronal	   (nNOS)	   isoform	   [175].	   NO	   derived	   from	   nNOS	   acts	   as	   a	  
neurotransmitter	   and	   has	   a	   role	   in	   mediating	   the	   cardiovascular	   autonomic	   outflow.	   NO	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from	  eNOS	  has	  a	  key	  role	  in	  determining	  vascular	  tone	  and	  regional	  blood	  flow	  whereas	  that	  
from	   iNOS	   is	   expressed	   in	   leukocytes,	   erythrocytes,	   vascular	   smooth	   muscle,	   kidney	  
pancreas	   liver	  and	   lung	  [176].	  The	  constitutive	   isoforms	  are	  responsible	   for	  a	  constant	   low	  
production	  of	  NO	  that	  can	  be	  increased	  acutely	  when	  required	  (as	  in	  inflammation)	  only	  for	  
short	  periods	  of	  time	  [175].	  The	  inducible	  isoform	  however	  can	  be	  increased	  over	  a	  period	  of	  
hours	  thus	  allowing	  NO	  levels	  to	  rise	  from	  the	  nanomolar	  to	  the	  micromolar	  range.	  NO	  has	  a	  
short	  half-­‐life	  (8-­‐9	  seconds)	  and	  is	  degraded	  to	  nitrite.	  It	  has	  been	  of	  interest	  to	  researchers	  
in	  sepsis	  as	   it	  mediates	   the	   reduction	   in	  vascular	   tone	  seen	   in	   response	   to	  LPS,	  with	  some	  
investigators	   describing	   the	   molecule	   as	   the	   final	   mediator	   of	   sepsis	   [177].	   NO	   is	   also	  
thought	   to	   play	   a	   role	   in	   the	   pathophysiology	   of	   myocardial	   dysfunction	   in	   sepsis	   [178].	  
Research	  into	  this	  field	  continues,	  but	  at	  present	  it	  would	  seem	  that	  some	  NO	  is	  required	  for	  
optimal	  cardiac	  function	  but	  excessive	  amounts	  (as	  are	  seen	  in	  septic	  shock)	  are	  undesirable	  
as	   they	   result	   in	   excessive	   vasodilation.	   It	  would	   appear	   that	   non-­‐selective	  NOS	   inhibition	  
produces	  myocardial	  depression	  and	  does	  not	   improve	  outcomes	   in	   sepsis	   [179],	  whereas	  
selective	   iNOS	   inhibition	  may	   have	   some	   beneficial	   effects	   on	   cardiac	   function	   [178].	   This	  
difference	   may	   be	   due	   to	   issues	   of	   dose	   and	   timing,	   but	   also	   because	   targeting	   a	   single	  
molecule	  may	  not	  be	  sufficient	  given	  the	  complexity	  of	  the	  immune	  response	  [175].	  
	  
1.5	  Leukocyte	  recruitment	  and	  the	  humoural	  response	  
Selectins	  and	  integrins	  
The	   vasodilation	   that	   is	  mediated	   through	   cytokines,	   prostanoids	   and	  nitric	   oxide	  has	   two	  
main	   functions.	   It	   ensures	   that	  more	  blood	   is	   diverted	   to	   the	  affected	  area	   and	   slows	   the	  
velocity	  of	  cells	  flowing	  through	  these	  vessels	  [80].	  This	  reduction	  in	  leukocyte	  velocity	  is	  an	  
important	   step	   as	   it	   facilitates	   leukocyte	   recruitment	   through	   the	   mechanisms	   of	   rolling,	  
adhesion	  and	  transmigration	  [180].	  Selectins	  (sugar	  binding	  adhesion	  molecules)	  are	  found	  
on	   both	   leukocytes	   (L-­‐selectin)	   and	   inflamed	   endothelial	   cells	   (P-­‐selectin	   and	   E-­‐selectin)	  
[181],	   the	   reduction	   in	   leukocyte	   rolling	   velocity	   produced	   by	   vasodilation	   allows	   these	  
molecules	   to	   interact	   with	   their	   glycoprotein	   counterparts	   [182],	   a	   process	   that	   further	  
slows	  the	  cell.	  Selectin	  binding	  induces	  signalling	  in	  both	  leukocyte	  and	  endothelial	  cell	  [183-­‐
185];	   in	   neutrophils	   this	   results	   in	   activation	   of	   p38MAPK	   to	   produce	   integrin	   activation	  
[185].	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Integrins	  are	  a	  family	  of	  ligands	  that	  are	  responsible	  for	  mediating	  leukocyte	  adhesion	  [180].	  
As	   leukocytes	   roll	   along	   the	   endothelium	   they	  may	   encounter	   endothelial	  molecules	   that	  
activate	   integrins.	   These	   include	   members	   of	   the	   immunoglobulin	   superfamily,	   the	  
intercellular	   adhesion	   molecule	   (ICAM)-­‐1	   and	   vascular	   cell	   adhesion	   molecule	   (VCAM)-­‐1	  
[186,	  187].	  Integrins	  are	  also	  activated	  by	  endothelial	  surface-­‐bound	  chemokines,	  produced	  
as	  part	  of	  the	  inflammatory	  response,	  transported	  from	  the	  abluminal	  to	  the	  luminal	  surface	  
of	  the	  endothelial	  cell	  [188]	  and	  supplemented	  by	  other	  chemokines	  produced	  by	  mast	  cells	  
and	  platelets	  [189,	  190].	  Integrin	  activation	  occurs	  quickly,	  almost	  instantaneously,	  through	  
either	   process	   [191]	   and	   leukocyte	   arrest	   then	   follows.	   The	   activation	   process	   involves	   a	  
change	   in	   confirmation	   as	   a	   result	   of	   inside-­‐out	   signalling	   that	   produces	   a	   high	   affinity	  
binding	   confirmation	   [192]	   that	   further	   strengthens	   adhesion	   [180].	   Once	   this	   process	   is	  
complete,	   transmigration	   follows	   and	   can	   occur	   through	   either	   the	   trans	   or	   para-­‐cellular	  
routes,	   meaning	   that	   recruited	   leukocytes	   can	   access	   the	   inflammatory	   focus.	   The	   net	  
results	  are	  the	  four	  signs	  of	  inflammation,	  as	  recorded	  in	  the	  first	  century	  AD	  by	  the	  Roman	  
encyclopaedist	   Aulus	   Cornelius	   Celsus:	   calor	   (heat);	   dolor	   (pain);	   rubor	   (erythema)	   and	  
tumor	  (swelling).	  
In	  health	  there	   is	  a	  resident	  population	  of	  neutrophils	  and	  monocytes	  that	  are	  marginated	  
(sitting	  on	  vessel	  walls	  but	  not	  invading	  the	  organ)	  within	  the	  lung	  microcirculation	  [193].	  In	  
sepsis	  there	  is	  an	  enhanced	  propensity	  for	  these	  cells	  to	  accumulate	  and	  it	  is	  thought	  that	  a	  
release	   of	   inflammatory	   products	   by	   these	   marginated	   leukocytes	   may	   explain	   why	  
pulmonary	  dysfunction	  is	  so	  common	  in	  this	  setting,	  potentially	  contributing	  to	  dysfunction	  
in	  other	  organs	  [193-­‐195].	  
	  
Recruited	  cells	  –	  neutrophils	  
Neutrophils	   are	   the	   most	   abundant	   leukocyte	   in	   humans	   and	   it	   is	   estimated	   that	   their	  
precursor	  cells	  constitute	  60%	  of	  nucleated	  cells	  within	  the	  bone	  marrow	  [196].	  As	  a	  result	  
they	  are	   found	   in	  high	  numbers	   in	   the	  blood	  and	  at	  any	  site	  of	   inflammation.	  The	  primary	  
neutrophil	   function	   is	   phagocytosis,	   triggered	   through	   the	   recognition	   of	   PAMPs	   by	   PRRs	  
found	   on	   the	   neutrophil	   surface	   [197-­‐199]	   or	   via	   complement	   opsonisation	   [200].	   This	  
process	   is	   aided	  by	   the	   fact	   that	  neutrophils	   are	   “primed”	   for	   enhanced	  phagocytosis	   and	  
bactericidal	   activity	   by	   a	   number	   of	   different	   cytokines	   and	   chemokines	   they	   encounter.	  
Phagocytosis	   triggers	   both	   ROS	   production	   and	   fusion	   of	   cytoplasmic	   granules	   with	  
pathogen	  containing	  vacuoles.	  ROS	  are	  produced	  through	  the	  action	  of	  a	  membrane	  bound,	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nicotinamide	  adenine	  dinucleotide	  phosphate	  (NADPH)	  oxidase	  enzyme,	  that	  generates	  high	  
levels	  of	  superoxide	  in	  a	  process	  known	  as	  the	  respiratory	  burst	  [201-­‐203].	  As	  cells	  have	  such	  
a	  high	  destructive	  capacity	  they	  are	  tightly	  regulated	  and	  undergo	  apoptosis	   (programmed	  
cell	   death)	   rapidly	   after	   phagocytosis	   [204,	   205],	   a	   process	   that	   aids	   in	   tissue	   repair.	   Both	  
inflammatory	  cytokines	  such	  as	  TNF	  and	  bacterial	  toxins	  delay	  this	  apoptosis	  [206,	  207],	  this	  
may	  be	  biologically	  useful	  and	  facilitate	  rapid	  bacterial	  clearance	   [208].	  Neutrophil	  granule	  
proteins,	   such	  as	  secretory	  vesicles	  and	  azurocidin,	  are	   left	  on	   the	  endothelium	  as	   the	  cell	  
migrates,	   a	   process	   thought	   to	   aid	   monocytes	   chemotaxis	   [144,	   209,	   210].	   Similarly	   the	  
release	   of	   substances	   such	   as	   proteinase	   3	   induces	   chemokine	   secretion	   in	   surrounding	  
endothelial	  cells	  that	  causes	  a	  further	  recruitment	  of	  cells.	  The	   interplay	   in	  this	  situation	   is	  
refined;	  chemokines	  are	  rendered	  up	  to	  1000	  fold	  more	  potent	  when	  they	  are	  released	  into	  
a	  milieu	  containing	  neutrophil	  products	  [211].	  Neutrophils	  recruited	  to	  the	  tissues	  undergo	  a	  
transcriptional	  burst	  [212]	  which	  may	  alter	  the	  local	  environment	  and	  help	  recruit/augment	  
responses	  in	  other	  cells	  such	  as	  monocytes.	  
Host	   tissue	   damage	   can	   arise	   in	   sepsis	   through	   several	   mechanisms;	   these	   include	  
premature	  neutrophil	  activation	  (seen	   in	  the	  migration	  stage),	  an	  extra-­‐cellular	  “spill	  over”	  
of	   cytotoxic	   material	   during	   the	   microbial	   killing	   phase	   or	   through	   a	   failure	   to	   terminate	  
inflammatory	   responses	   [93,	   213].	   Neutrophils	   release	   elastase,	   a	   substance	   with	   potent	  
bacteriocidal	   activity	   that	   also	   can	   destroy	   host	   tissue	   [214].	   An	   excessive	   release	   of	   this	  
enzyme	   has	   been	   implicated	   in	   pulmonary	   diseases	   that	   may	   result	   from	   chronic	  
inflammation	   such	   as	   emphysema	   [215],	   pulmonary	   fibrosis	   [216]	   and	   acute	   lung	   injury	  
[217].	  Neutrophil-­‐derived	  heparin	  binding	  protein	  is	  a	  potent	  mediator	  of	  increased	  vascular	  
permeability	   and	  has	   been	   implicated	   in	   the	   pathogenesis	   of	   oedema	   resulting	   from	  burn	  
injury	  [218].	  
	  
Recruited	  cells	  –	  monocytes	  
Human	  monocytes	   are	   divided	   into	   subsets:	   classical	   and	  non-­‐classical	   (see	   later	   for	  more	  
detail).	   The	   exact	   role	   of	   each	   subset	   is	   not	   yet	   clear	   but	   there	  may	   be	   different	   roles	   in	  
normal	  homeostasis	  when	  compared	  to	  inflammation	  [144].	  Current	  research	  [219]	  supports	  
the	  idea	  that	  non-­‐classical	  monocytes	  have	  a	  patrolling	  function,	  crawling	  along	  the	  luminal	  
aspect	  of	  the	  vessel	  wall	  and	  monitoring	  the	  tissues.	  In	  response	  to	  inflammation	  these	  cells	  
are	   then	   rapidly	   recruited	   to	   the	   affected	   tissues	   where	   they	   augment	   the	   local	   cytokine	  
response	   and	   recruit	   both	   neutrophils	   and	   classical	   monocytes	   [144].	   The	   classical	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monocytes	   arrive	   later	   than	   neutrophils	   and	   then	   rapidly	   supersede	   their	   non-­‐classical	  
counterparts	   [144,	   210].	   On	   arrival	   in	   the	   tissues	  monocytes	   can	   differentiate	   to	   become	  
macrophages;	  collectively	  these	  cells	  are	  referred	  to	  as	  the	  mononuclear	  phagocyte	  system	  
[220]	   and	   can	   be	   activated	   through	   classical	   or	   alternative	   pathways.	   Classical	   activation	  
occurs	  through	  the	  products	  of	  TH1	  T-­‐cells	  (mainly	  interferon-­‐γ,	  IL-­‐12	  and	  IL-­‐18)	  resulting	  in	  
phagocytosis	   and	   cytokine	   production.	   Monocytes	   also	   present	   antigens	   to	   lymphocytes,	  
bridging	   the	  gap	  between	   the	   innate	  and	   the	  acquired	   immune	  systems	  and	   thus	  must	  be	  
considered	  “key	  players”	  in	  the	  immune	  response.	  These	  mononuclear	  phagocytes	  produce	  
large	  amounts	  of	   TNF	  as	  well	   as	  other	  pro-­‐inflammatory	  mediators	   such	  as	   IL-­‐1,	   IL-­‐6,	   IL-­‐8,	  
eucosinoids,	  ROS,	  platelet	  activating	  factor	  and	  nitric	  oxide.	  This	  role	  means	  they	  co-­‐ordinate	  
the	   immune	   response	   ensuring	   that	   the	   correct	   local	  milieu	   has	   been	   generated	   and	   the	  
appropriate	  cells	  recruited.	  
In	  contrast	   to	  neutrophils,	  whose	   function	   is	   limited	   to	   the	   initial	  pro-­‐inflammatory	  phase,	  
mononuclear	  phagocytes	  display	  a	  plasticity	  of	   function	   that	   allows	   them	   to	  play	  a	   role	   in	  
tissue	   repair	  and	   regeneration.	  This	   is	   initiated	   through	   the	  alternative	  activation	  pathway	  
triggered	  via	  the	  products	  of	  TH2	  T-­‐cells,	  IL-­‐4	  and	  IL-­‐13	  [221]	  and	  switches	  the	  cells	  function	  
so	  that	  they	  orchestrate	  the	  repair	  process.	  A	  major	  component	  of	  this	  is	  efferocytosis,	  the	  
process	   through	   which	   they	   phagocytose	   dead	   and	   dying	   cells	   but,	   in	   addition,	   these	  
alternatively	  activated	  macrophages	   release	  WNT-­‐ligands,	   secreted	  glycoproteins	   that	  may	  
play	  a	  key	  role	  in	  the	  regenerative	  process	  [222].	  
In	   sepsis	   there	   is	   a	   change	   in	   monocyte	   behaviour.	   Cells	   display	   a	   reduced	   capacity	   to	  
present	   antigens	   as	   well	   as	   reduced	   production	   of	   TNF,	   IL-­‐1,	   IL-­‐6	   and	   IL-­‐8	   on	   ex-­‐vivo	  
stimulation,	   a	   state	   that	   is	   thought	   to	   be	   induced	   by	   IL-­‐10	   [223]	   and	   has	   been	   termed	  
monocyte	  deactivation	   [224].	  Deactivation	  has	  been	   seen	  by	  many	  as	   reflecting	  a	   state	  of	  
systemic	   immunosuppression	   [224]	   and	   a	   pathological	   exaggeration	  of	   the	  CARS	   response	  
which	  may	  then	   leave	  a	  patient	  exquisitely	  vulnerable	  to	  secondary	   infections	  [225].	  Some	  
investigators	   have	   attempted	   to	   reverse	   these	   changes	   through	   the	   use	   of	   immune-­‐
stimulatory	   therapies	   [154,	   224,	   226]	   but	   this	   has	   yet	   to	   translate	   into	   a	   direct	   clinical	  
benefit.	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The	  humoural	  response	  –	  coagulation	  and	  complement	  
In	  tandem	  to	  the	  activation	  of	  the	  cellular	  response	  outlined	  above,	  there	  is	  also	  humoural	  
activation	   in	   response	   to	   infection	   or	   tissue	   injury.	   This	   results	   in	   activation	   of	   the	  
coagulation	   cascade	   to	   seal	  off	   the	   site,	   complement	  activation	   to	  directly	   kill	   or	  opsonize	  
the	   pathogen,	   and	   release	   of	   soluble	   products	   that	   augment	   leukocyte	   chemotaxis,	  
vasodilation	  and	  vascular	  permeability	  [143].	  The	  coagulation	  system	  is	  mainly	  activated	  by	  
tissue	   factor	   [227,	   228]	   a	   substance	   expressed	  on	   activated	  monocytes	   or	   sub-­‐endothelial	  
cells	  [229].	  The	  end	  product	  of	  this	  process	  is	  the	  conversion	  of	  fibrinogen	  to	  fibrin	  with	  the	  
formation	  of	  thrombi	  that	  are	  deposited	  within	  the	  microcirculation	  and	  can	  amplify	  tissue	  
injury	   [230].	   In	   conjunction	   with	   this,	   there	   is	   a	   reduction	   in	   fibrinolysis	   [231]	   through	  
alteration	   of	   the	   levels	   and	   activity	   of	   anticoagulant	   factors	   such	   as	   protein	   C,	   protein	   S,	  
antithrombin	  III	  and	  tissue	  factor	  pathway	  inhibitor.	  In	  health,	  protein	  C	  is	  activated	  through	  
thrombin-­‐α	  binding	  to	  thrombomodulin	  and	  subsequently	  binding	  to	  the	  endothelial	  protein	  
C	   receptor	   [232].	   This	   activated	   form	  of	   protein	   C	   exerts	   its	   anticoagulant	   effects	   through	  
inactivating	  clotting	  factors	  Va	  and	  VIIIa	  [233,	  234]	  as	  well	  as	  through	  inhibiting	  the	  synthesis	  
of	  plasminogen	  activator	  inhibitor	  [235].	  The	  protein	  has	  effects	  outside	  of	  the	  coagulation	  
cascade	  that	  are	  relevant	  to	  the	  inflammatory	  process.	  It	  reduces	  apoptosis	  [236],	  leukocyte	  
adhesion	  and	  further	  cytokine	  production	  [237].	  
The	  complement	  cascade	  is	  also	  activated	  through	  a	  number	  of	  stimuli	  that	  include	  amongst	  
others,	   bacterial	   components,	   acute	   phase	   proteins	   and	   immune	   complexes	   [238].	  
Activation	  results	  in	  construction	  of	  the	  membrane	  attack	  complex	  that	  subsequently	  forms	  
pores	   in	   pathogenic	   organisms	   resulting	   in	   their	   lysis.	   The	   complement	   product	   C5	   has	   a	  
number	  of	  pro-­‐inflammatory	  effects	  [238]	  such	  as	  inducing	  neutrophil	  chemotaxis	  [239]	  and	  
superoxide	  production	  [240],	  as	  well	  as	   inducing	  granular	  enzyme	  release	  from	  phagocytes	  
[241].	   These	   latter	  points	   serve	   to	   illustrate	   the	   constant	   interplay	  between	   the	  humoural	  
and	  cellular	  constituents	  of	  innate	  immunity.	  
In	   sepsis	   there	   are	   reduced	   levels	   of	   anticoagulants	   such	   as	   protein	   C	   [242].	   LPS	   and	   TNF	  
attenuate	   production	   of	   thrombomodulin	   and	   the	   endothelial	   protein	   C	   receptor;	   hence	  
protein	   C	   activation	   is	   impaired	   [243].	   They	   also	   increase	   production	   of	   plasminogen	  
activator	   inhibitor	   1	   (PAI-­‐1),	   further	   inhibiting	   fibrinolysis	   [243].	   These	   processes	   are	  
compounded	   by	   secondary	   insults	   such	   as	   ischemia	   and	   hypoxia	   (both	   common	   in	   the	  
context	  of	  critical	  illness)	  that	  result	  in	  a	  further	  release	  of	  both	  tissue	  factor	  and	  PAI-­‐1	  [244].	  
	   36	  
Similar	  to	  these	  changes	  in	  coagulation,	  a	  dysregulation	  of	  the	  complement	  system	  can	  also	  
occur	   in	  sepsis	   [245].	  A	  deficiency	  of	  C3	  results	   in	  a	   lack	  of	  complement	  effector	   functions	  
and	   increases	   mortality	   from	   sepsis	   in	   animal	   models	   [246-­‐248].	   This	   reinforces	   the	  
importance	   of	   complement	   as	   a	   component	   of	   the	   immune	   response.	   Inhibition	   of	   C5	  
signalling	   may	   improve	   outcomes	   in	   animal	   models	   [249].	   Although	   this	   may	   seem	  
counterintuitive,	   given	   that	   complement	   is	   protective,	   it	   may	   reflect	   a	   diversity	   of	  
complement	   functions	   during	   the	   development	   of	   sepsis	   [245].	   Some	   bacterial	   infections	  
such	   as	   those	   produced	   by	   Haemophilus	   influenza	   and	   Streptococcus	   pneumonia	   cause	  
defects	   in	   the	  opsonisation	  process	   that	   facilitate	  bacterial	   killing	   [250],	   compromising	   the	  
host	  immune	  response.	  
	  
The	  link	  to	  acquired	  immunity	  
Both	  dendritic	  cells	  and	  tissue	  macrophages	  perform	  antigen	  presentation	  functions	  through	  
the	   action	  of	   the	  major	   histocompatibility	   complex	   (MHC)	   class	   II	  molecules	   they	   express.	  
These	  are	  required	  in	  order	  for	  a	  functional	  adaptive	  immune	  response	  to	  be	  induced	  [251,	  
252].	  However,	  whilst	   the	  MHC	  molecules	   themselves	  are	  necessary	   for	  successful	  antigen	  
presentation,	  alone	  they	  are	  insufficient.	  An	  up-­‐regulation	  of	  other	  surface	  markers	  such	  as	  
CD40,	   CD80	   and	   CD86	   are	   required	   [80].	  Monocytes	   stimulated	   by	   LPS	   up-­‐regulate	   CD86	  
expression	   [253],	   meaning	   that	   antigen	   presentation	   is	   enhanced	   by	   TLR	   stimulation.	  
Therefore	   the	   responsiveness	   of	   the	   TLR	   system	   may	   have	   an	   influence	   on	   the	   adaptive	  
system’s	   response	   capability	   in	   sepsis.	   Models	   of	   endotoxin	   tolerance	   in	   which	   the	   TLR	  
responsiveness	   of	   monocyte	   is	   reduced	   by	   exposure	   to	   large	   amounts	   of	   LPS	   have	  
demonstrated	   reduced	   antigen	   presentation	   capabilities	   [254].	   In	   sepsis	   the	   antigen	  
presenting	  capabilities	  of	  monocytes	  are	  diminished	  and	  there	  is	  an	  increased	  apoptosis	  of	  
dendritic	  cells	  [224,	  255].	  
Antigen	   presenting	   cells	   acquire	   and	   process	   the	   antigen	   in	   the	   tissues,	   but	   migrate	   to	  
secondary	  lymphoid	  tissues	  such	  as	  lymph	  nodes	  in	  order	  to	  present	  them	  to	  naïve	  CD4+	  T-­‐
lymphocytes.	   This	   process	   results	   in	   the	   lymph	   node	   swelling	   that	   is	   characteristic	   of	  
infection.	   CD4+	   lymphocytes	   are	   known	   as	   helper	   T-­‐cells	   and	   become	   activated	   by	   this	  
process	   of	   antigen	   presentation.	   This	   activation	   induces	   differentiation	   with	   at	   least	   four	  
pathways	   available	   to	   the	   naïve	   T-­‐cell	   [256].	   These	   include	   TH1,	   TH2,	   TH17	   and	   induced	  
regulatory	   (iTreg)	   cells	   [256,	   257].	   TH1	   cells	   produce	   IFN-­‐ϒ,	   IL-­‐2	   and	   lymphotoxin-­‐α	   and	  
favour	   cell-­‐mediated	   immune	   responses	   (although	   they	   facilitate	   the	   production	   of	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opsonising	  antibodies)	  by	  maximising	   the	  bacteriocidal	  phagocytic	  activity	  of	  macrophages	  
and	  producing	  activation	  and	  growth	  of	  cytotoxic	  T-­‐cells	  that	  kill	  damaged	  or	  infected	  cells.	  
TH2	  cells	  produce	  IL-­‐4,	  IL-­‐5,	  IL-­‐6,	  IL-­‐10	  and	  IL-­‐13	  and	  are	  primarily	  involved	  in	  optimising	  the	  
humoural	   immune	   system	   by	   stimulating	   B-­‐lymphocytes	   to	   produce	   antibodies	   directed	  
against	   the	   pathogenic	   organism.	   TH1	   cells	   mediate	   the	   immune	   responses	   against	  
intracellular	   pathogens	  whereas	   TH2	   cells	  mediate	   immunity	   directed	   against	   extracellular	  
parasites	  [256].	  TH17	  cells	  do	  not	  produce	  classical	  TH1	  or	  TH2	  cytokines	  and	  are	  involved	  in	  
mediating	   immunity	   against	   extracellular	   bacteria	   and	   fungi	   as	  well	   as	   in	   the	   induction	   of	  
autoimmune	   tissue	   injury	   [258].	   Similar	   to	   other	   regulatory	   T-­‐lymphocytes	   the	   iTreg	   cells	  
function	   to	   regulate	   both	   the	   immune	   response	   itself	   and	   self-­‐tolerance,	   the	   process	   that	  
prevents	  B-­‐lymphocytes	  from	  producing	  self-­‐directed	  antibodies	  [259].	  
B-­‐lymphocytes	   comprise	   the	   other	   arm	   of	   the	   acquired	   immune	   system;	   their	   major	  
functions	   are	   antibody	   production	   and	   the	   formation	   of	   memory	   cells.	   Activated	   B-­‐cells	  
differentiate	  to	  become	  either	  antibody	  secreting	  plasma	  cells	  or	  to	  become	  memory	  cells.	  
Plasma	  cells	  produce	  antibodies	  that	  are	  specific	  to	  the	  pathogenic	  organism	  triggering	  the	  
immune	   response	   and	   facilitate	   immunity	   by	   binding	   to	   the	   pathogen.	   This	   prevents	   the	  
pathogen	  entering	  or	  damaging	  cells	  and	  stimulates	  both	  their	  uptake	  by	  macrophages	  and	  
the	  complement	  pathway	  [260].	  Memory	  B-­‐cells	  remain	  quiescent,	  yet	  are	  able	  to	  produce	  
antibodies	  to	  the	  original	  antigen	  when	  the	  same	  antigenic	  material	  is	  encountered.	  
Similar	   to	   the	   alterations	   seen	   in	   innate	   immunity,	   sepsis	   also	   produces	   alterations	   in	  
acquired	  immunity.	  These	  changes	  may	  be	  consistent	  with	  an	  exaggerated	  CARS	  response,	  a	  
link	  between	  the	  reduced	  delayed-­‐type	  hypersensitivity	   reactions	  seen	   in	   ICU	  patients	  and	  
their	  increased	  risk	  of	  nosocomial	  infections	  was	  described	  in	  the	  1970’s	  [39].	  Sepsis	  induces	  
a	  lymphopenia	  that	  is	  seen	  across	  all	  lymphocyte	  subsets	  which	  is	  characterised	  by	  increased	  
levels	   of	   apoptosis	   [261].	   It	   also	   produces	   functional	   alterations	   in	   lymphocyte	   behaviour	  
such	   as	   reduced	  proliferation	   and	   reduced	   cytokine	  production	   in	   response	   to	   stimulation	  
[262].	  Cells	  display	  reduced	  expression	  of	  co-­‐stimulatory	  molecules	  as	  well	  as	  changes	  in	  the	  
circulating	   regulatory	   T-­‐lymphocyte	   makeup	   [263].	   These	   lymphocyte	   dysfunctions	   are	  
accompanied	  by	  viral	  reactivation	  and	  deleterious	  outcome	  after	  septic	  shock	  [264,	  265]	  and	  
some	  authors	  have	  described	  lymphocytes	  in	  this	  context	  as	  being	  exhausted	  [262].	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1.5	  Indicators	  of	  innate	  immune	  status	  in	  sepsis	  
Cytokines,	  surface	  markers	  and	  even	  leukocyte	  subsets	  have	  all	  been	  used	  in	  attempting	  to	  
determine	   the	  nature	  and	   severity	  of	   the	  patient’s	   immune	   response.	   In	   this	   section	   I	  will	  
focus	  attention	  on	  some	  of	  the	  most	  pertinent.	  
	  
Determining	  the	  severity	  of	  the	  SIRS	  response	  
Over	   the	   years	   a	   number	   of	   cytokines	   have	   been	   investigated	   as	   potential	   markers	   of	  
severity.	   The	   difficulty	   of	   this	   approach	   is	   that	   circulating	   levels	   can	   be	   considered	   to	  
represent	   only	   the	   tip	   of	   the	   “inflammatory	   iceberg”	   and	   cell	   associated	   cytokines	   can	   be	  
demonstrated	  even	  in	  the	  context	  of	  undetectable	  plasma	  levels	  [266]	  meaning	  it	  is	  unlikely	  
that	  any	  single	  cytokine	  will	  provide	  us	  with	  the	  perfect	  marker.	  Current	  evidence	  suggests	  
that	   IL-­‐6	   may	   be	   the	   most	   effective	   marker	   of	   the	   severity	   of	   both	   infectious	   and	   non-­‐
infectious	   stress	   [266]	   but	   Is	   not	   in	  widespread	   clinical	   use.	   IL-­‐6	   levels	   are	  higher	   in	   those	  
patients	  who	  die	   from	  SIRS	  and	  correlate	  with	   illness	  severity	  scores	   [267].	  They	  may	  help	  
predict	   outcomes	   in	   severe	   pancreatitis	   [268]	   as	   well	   as	   the	   onset	   of	   infectious	  
complications	  in	  the	  post-­‐operative	  patient	  [269].	  It	  is	  thought	  that	  IL-­‐6	  levels	  are	  correlated	  
with	  injury	  severity	  scores	  in	  trauma	  [270].	  Some	  researchers	  have	  explored	  the	  circulating	  
ratio	  of	   IL-­‐6	   to	   IL-­‐10	  and	  have	   found	  an	   increase	   in	   this	   ratio	   to	  be	  correlated	  with	  a	  poor	  
outcome	  in	  SIRS	  [271]	  	  as	  well	  as	  the	  severity	  of	  traumatic	  injury	  [272].	  
	  
Differentiating	  infectious	  from	  non-­‐infectious	  SIRS	  	  
The	  ACCP	  definitions	  themselves	  give	  an	  idea	  of	  some	  of	  the	  problems	  facing	  clinicians	  in	  the	  
ICU.	  Unsurprisingly	  a	  high	  proportion	  of	  critical	  care	  patients	  have	  SIRS	  and	  it	  can	  be	  difficult	  
to	   determine	  whether	   this	   has	   arisen	   as	   a	   result	   of	   infectious	   or	   non-­‐infectious	   aetiology.	  
The	  sepsis	  definition	  originally	  referred	  to	  “SIRS	   in	  response	  to	   infection”	  [14]	  but	  this	  was	  
refined	   in	  2001	   to	   SIRS	   arising	   in	   response	   to	   “documented	  or	   suspected	   infection”	   [273].	  
This	   change	   recognised	   the	   limitations	   of	   the	   accepted	   gold	   standard	   for	   demonstrating	  
infection,	   positive	  microbiology.	  Not	   all	   patients	  with	   bacterial	   infection	  will	   have	   positive	  
cultures	  and	  there	  is	  a	  lag	  time	  between	  the	  sample	  being	  obtained	  and	  any	  positive	  culture	  
evidence	  being	  produced.	  This	  means	  that	  clinical	  decisions	  about	  starting	  antibiotics	  cannot	  
always	   be	   based	   on	   positive	   microbiology.	   A	   number	   of	   markers	   suggesting	   an	   active	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immune	  response	   to	   infection	  have	  been	  proposed	  as	  being	  useful	   in	   this	  context:	   several	  
interleukins	   [274];	   triggering	   receptor	   expressed	   on	   myeloid	   cells	   1	   (TREM-­‐1)	   [275];	   pro-­‐
vasopressin	  [276];	  interferon-­‐γ	  [275];	  atrial	  natriuretic	  peptide	  (ANP)	  [277]	  and	  resistin	  [278]	  
have	  all	  been	  investigated.	  However,	  much	  clinical	  focus	  recently	  has	  surrounded	  the	  use	  of	  
procalcitonin	   (PCT)	   in	   this	   context	   [279]	   and	   some	   countries	   have	   incorporated	   PCT	   into	  
clinical	  guidelines	  [280].	  PCT	  is	  a	  precursor	  of	  calcitonin	  produced	  physiologically	  by	  thyroid	  
C	  cells	  but	  also	  in	  neuro-­‐endocrine	  tissues	  in	  response	  to	  bacterial	  infections.	  Hence	  it	  may	  
be	  useful	  in	  both	  diagnosing	  infection	  and	  directing	  antibiotic	  therapy	  [279].	  
	  
Differentiating	  between	  SIRS	  and	  CARS	  
Delineating	  sepsis	  from	  non-­‐infectious	  SIRS	  has	  important	  implications	  for	  dictating	  patient	  
treatments	   such	  as	  antibiotics.	   Similarly	  delineating	  where	  a	  patient	   lies	  on	   the	  SIRS/CARS	  
continuum	  may	  also	  help	  guide	  therapy.	  For	  instance	  those	  patients	  suffering	  from	  extreme	  
pro-­‐inflammatory	  conditions	  may	  benefit	  from	  therapies	  to	  reduce	  them.	  It	  may	  be	  that	  this	  
category	   of	   patient	   represents	   those	   that	   will	   derive	   benefit	   from	   anti-­‐inflammatory	  
therapies	  [35,	  281].	  In	  direct	  contrast,	  those	  patients	  suffering	  from	  CARS	  may	  benefit	  from	  
immune	  stimulating	  therapies.	  Immune	  stimulating	  trials	  that	  have	  been	  performed	  without	  
biomarkers	   have	   been	   unsuccessful	   in	   demonstrating	   clinical	   benefit,	   this	   resulted	   in	   the	  
authors	   of	   a	   recent	   meta-­‐analysis	   concluding	   that	   future	   trials	   should	   be	   biomarker	   led	  
[282].	  
Interest	   has	   focused	   on	   numerous	   biomarkers	   from	   cytokines	   to	   cell	   surface	   markers.	  
Systemic	  cytokines	  have	  been	  used	  with	  investigators	  focusing	  on	  the	  use	  of	  TNF	  [26-­‐28],	  IL-­‐
6	  [267]	  and	  IL-­‐10	  [283-­‐285].	  All	  of	  these	  are	  elevated	  in	  SIRS	  and	  correlate	  with	  mortality	  but	  
as	   previously	   discussed	   the	  use	  of	   systemic	   cytokine	  profiles	  may	  not	   tell	   the	  whole	   story	  
and	  the	  systemic	  circulation	  may	  not	  accurately	  represent	  the	  affected	  tissue	  compartment.	  
Some	  investigators	  have	  argued	  that	  the	  systemic	  response	  is	  by	  default	  anti-­‐inflammatory	  
[58].	  Prins	  et	  al	  successfully	  demonstrated	  that	  serum	  from	  septic	  patients	  had	  the	  ability	  to	  
down	   regulate	  ex	   vivo	  TNF	  production	  by	  monocytes	   taken	   from	  healthy	   controls	   [44].	  As	  
discussed	   in	   detail	   later,	   a	   cellular	   immune-­‐responsive	   phenotype	   may	   provide	   a	   better	  
indication	  of	  the	  patient’s	  net	  inflammatory	  status	  over	  time	  than	  plasma-­‐based	  assays	  and	  
measurements.	  The	  major	  cell	  type	  used	  for	  assessment	  of	  sepsis	  and	  SIRS	  patient	  status	  has	  
been	  monocytes.	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Monocytes	  as	  indicators	  of	  immune	  status:	  HLA-­‐DR	  
A	   reduction	   in	   circulating	   monocyte	   surface	   expression	   of	   HLA-­‐DR	   in	   sepsis	   has	   been	  
reported	  by	  numerous	  investigators	  [224,	  286].	  It	  has	  been	  proposed	  that	  measuring	  surface	  
markers	  rather	  than	  circulating	  mediators	  may	  be	  advantageous	  as	  it	  reflects	  the	  net	  result	  
that	  the	  systemic	  response	  has	  on	  the	  cell	  [287].	  It	  is	  known	  that	  expression	  levels	  of	  HLA-­‐DR	  
are	   regulated	  both	  positively	   and	  negatively	   through	   the	   action	  of	   cytokines	   such	   as	   IL-­‐10	  
and	   IFN-­‐γ,	   but	   also	   through	   glucocorticoids	   and	   catecholamines	   [288-­‐291],	   therefore	  
measuring	   expression	   levels	   reflects	   these	   processes.	   There	   is	   now	   an	   acceptance	   that	  
reduced	  HLA-­‐DR	  expression	   levels	  may	  reliably	   indicate	   immune-­‐depression	  [287,	  292]	  and	  
hence	  CARS.	  Reduced	  expression	  levels	  have	  functional	  relevance	  as	  they	  reflect	  a	  reduced	  
capacity	  to	  present	  antigens	  to	  lymphocytes	  [293].	  
One	   group	   found	   persistently	   low	   monocyte	   HLA-­‐DR	   expression	   to	   be	   an	   independent	  
marker	  of	  mortality	  in	  septic	  shock	  patients	  [286],	  another	  reported	  that	  survivors	  could	  be	  
delineated	  from	  non-­‐survivors	  by	  permanently	  suppressed	  or	  late	  falling	  levels	  [294].	  Others	  
have	  found	  it	  to	  be	  a	  potentially	  useful	  marker	  for	  the	  development	  of	  secondary	  infection	  
[54].	  Despite	  some	  efforts	  to	  standardise	  practice	  [295],	  there	   is	  currently	  no	  consensus	  as	  
to	   how	   HLA-­‐DR	   should	   be	   measured	   and	   what	   levels	   constitute	   pathologically	   low	  
expression.	   Some	   investigators	   have	   termed	   those	  patients	  who	  have	  <30%	  of	  monocytes	  
expressing	   HLA-­‐DR	   (it	   is	   normally	   >80%)	   as	   having	   a	   state	   of	   “immune-­‐paralysis”	   and	  
suggested	   these	   patients	   are	   suitable	   for	   immune	   stimulating	   therapies	   [224].	   One	   group	  
used	   this	   cut-­‐off	   to	   guide	   immune-­‐stimulating	   therapy	   in	   the	   form	   of	   granulocyte-­‐
macrophage	   colony-­‐stimulating	   factor	   (GMCSF)	   in	   patients	   with	   severe	   sepsis	   and	   septic	  
shock.	   They	   found	   that	   patients	   receiving	   GMCSF	   spent	   less	   time	   ventilated	   and	   had	   a	  
shortened	  ICU	  and	  hospital	  stay	  than	  those	  who	  did	  not	  [226].	  Once	  again	  there	  appears	  to	  
be	  no	  consensus	  as	  to	  exactly	  how	  HLA-­‐DR	  levels	  should	  be	  used	   in	  clinical	  practice.	  There	  
are	   also	   uncertainties	   as	   to	   how	   to	   standardise	   flow	   cytometry	   methodologies	   including	  
problems	   in	   evaluating	   positive	   cells	   and	   variability	   in	   measured	   values	   across	   different	  
laboratories.	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Monocytes	  as	  indicators	  of	  immune	  status:	  subset	  dynamics	  
Human	  monocytes	   have	   classically	   been	   divided	   into	   two	   distinct	   subsets	   on	   the	   basis	   of	  
their	  surface	  expression	  of	  the	  pattern	  recognition	  receptor	  CD14	  and	  the	  antibody	  binding	  
Fc	   receptor	   CD16	   [296].	   These	   consist	   of	   a	   classical	   CD14++CD16-­‐	   population	   and	   a	   non-­‐
classical	   CD14-­‐CD16+	   population	   with	   the	   vast	   majority	   (approx.	   90%)	   of	   circulating	   cells	  
belonging	   to	   the	   former	   group.	   Other	   investigators	   have	   argued	   that	   there	   is	   a	   third	  
population,	   splitting	   the	   CD16+	   population	   into	   both	   a	   mature	   (CD14-­‐CD16+)	   and	   an	  
intermediate	   (CD14+CD16+)	  population	   [297-­‐299].	   Recently	   it	   has	  been	  proposed	   that	   the	  
classical	  CD14++CD16-­‐	  cells	  represent	  a	  pro-­‐inflammatory	  subset	  whereas	  the	  CD14-­‐CD16+	  
cells	   play	   a	   role	   in	  patrolling	  blood	  vessels	   to	  detect	   virally	   infected	  and/or	  damaged	   cells	  
[297].	   However	   a	   general	   consensus	   on	   this	   has	   not	   been	   reached	   with	   other	   authors	  
reporting	  that	  the	  CD14+CD16+	  population	  are	  the	  more	  pro-­‐inflammatory	  subset	  based	  on	  
their	  increased	  expression	  of	  pro-­‐inflammatory	  cytokines	  on	  ex	  vivo	  stimulation	  [300,	  301].	  
Investigators	   have	   reported	   an	   expansion	   of	   the	   CD16+	   (intermediate	   and	   mature)	   cell	  
population	   in	   several	   conditions	   including	   acquired	   immunodeficiency	   [302],	   asthma	   [303]	  
and	  some	  forms	  of	  chronic	  infections	  [304].	  A	  substantial	  expansion	  of	  this	  subset	  has	  been	  
reported	   by	   several	   investigators	   in	   sepsis	   [305-­‐307]	  where	   the	   percentage	   of	  monocytes	  
expressing	  CD16	  may	  increase	  markedly	  from	  10%	  to	  50%	  [308].	  This	  expansion	  occurs	  with	  
the	   onset	   of	   bacteraemia	   and	   is	   preceded	   by	   cytokine	   production	   [306].	   Because	   of	   this,	  
such	  changes	  have	  been	  suggested	  as	  a	  useful	  monitoring	  tool	  in	  those	  patients	  at	  high	  risk	  
of	  sepsis	  [309].	  The	  proportion	  of	  CD14+CD16+	  cells	  has	  been	  shown	  to	  correlate	  with	  both	  
body	  temperature	  [305]	  and	  APACHE	  II	  score	  [310]	  in	  the	  context	  of	  surgical	  intervention.	  At	  
present,	  a	  lack	  of	  consensus	  in	  terms	  of	  both	  nomenclature	  and	  identification	  of	  the	  various	  
monocyte	  populations,	  combined	  with	  the	  limitations	  of	  using	  flow	  cytometry	  in	  the	  clinical	  
setting	  (cost,	  access	  and	  variation	   in	  gating	  strategies)	  have	  precluded	  their	  wider	  use	  as	  a	  
biomarker.	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Monocytes	  as	  indicators	  of	  immune	  status:	  priming	  and	  tolerance	  
If	  one	  can	  make	   the	  argument	   that	   cellular	  expression	  of	  markers	   reflects	   the	  effects	  of	  a	  
multitude	   of	  mediators,	   the	   next	   logical	   step	   is	   to	   examine	   the	   response	   of	   the	   cell	   as	   a	  
whole.	   Innate	   cell	   immune	   status	   can	   be	   considered	   pivotal	   to	   both	   immunity	   and	  
inflammation	   and,	   whereas	   neutrophils	   are	   capable	   only	   of	   displaying	   varying	   degrees	   of	  
priming,	  monocytes	   can	   display	   differential	   responses	   to	   an	   inflammatory	   stimulus.	   These	  
states	   are	   termed	   priming	   and	   tolerance	   and	   these	   may	   reflect,	   on	   a	   cellular	   level,	   the	  
dominant	   systemic	  process	  occurring	   in	  SIRS	  and	  CARS.	  Hence	   it	  may	  be	   the	  case	   that	   the	  
monocyte	  represents	  an	  appropriate	  gauge	  of	  the	  status	  of	  the	  innate	  immune	  system.	  
	  
Priming	  
Priming	   refers	   to	   an	   increased	   response	   after	   previous	   low	   dose	   exposure	   and	   has	   been	  
extensively	   described	   in	   neutrophils	   in	   response	   to	   numerous	   stimuli	   [311,	   312].	   A	  
Shwartzman-­‐like	  reaction	  has	  been	  repeatedly	  reported	  in	  which	  repeated	  exposure	  to	  two	  
low	  doses	  of	  LPS	  is	  then	  manifest	  as	  a	  shock	  syndrome	  [313,	  314].	  This	  reaction	  is	  mediated	  
through	  TNF,	  and	   IL-­‐1	  with	  monocytes	  and	  macrophages	   implicated	  as	  the	  cell	   responsible	  
for	   their	   release	   in	   response	   to	   the	   second	   LPS	   stimulus,	   although	   INF-­‐ϒ	   is	   also	   involved	  
[315].	   Such	   “two-­‐hit”	  models	   seek	   to	   reflect	   the	   normal	   or	   latent	   inflammatory	   response	  
that	  can	  become	  pathophysiological	  when	  a	  second	  insult	  is	  applied.	  Animal	  work	  [316]	  has	  
demonstrated	  that	  a	  “two	  hit”	  LPS	  model,	  when	  a	  sub-­‐clinical	  dose	  of	  LPS	   is	   followed	  by	  a	  
further	   dose	   at	   clinical	   levels,	   produces	   a	   substantial	   increase	   in	   monocyte	   membrane	  
(mem)-­‐TNF	  expression,	  indicative	  of	  priming.	  In	  terms	  of	  immunology,	  priming	  is	  an	  adaptive	  
response	   to	   enhance	   the	   host	   response	   preparedness	   following	   a	   low-­‐grade	   stimulus.	  
However,	   it	  would	  appear	  that	  this	  protective	  mechanism	  could	  malfunction,	  reflecting	  the	  
unpredictability	  of	  sepsis.	  
In	   vivo,	   adherence	   of	   cells	   to	   the	   endothelium	   may	   represent	   a	   form	   of	   spatial	   or	   cell	  
interaction	  dependent	  priming,	  whereby	  cells	  become	  more	  responsive	  once	  in	  contact	  with	  
the	   vascular	   endothelium.	   This	   process,	   involving	   sequestration	   of	   cells	   in	   capillaries,	   is	  
probably	  critical	  in	  neutrophil	  mediated	  ALI,	  where	  they	  remain	  in	  pulmonary	  capillaries	  in	  a	  
latent	  activation	  state	  but	  not	  migrating.	  In	  keeping	  with	  this	  picture	  investigators	  seeking	  to	  
model	   priming	   in	  monocytes	  have	  either	   found	  adherence	   to	  be	   key	  or	   used	   an	   adherent	  
system	   [317-­‐320]	   with	   the	   p38MAPK	   enzyme	   found	   to	   be	   a	   critical	   determinant	   of	   the	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primed	   TNF	   response	   to	   LPS.	   Schaeffer	   et	   al	   found	   that	   the	   complement	   component	   C5a	  
primed	  both	  IL-­‐6	  and	  TNF	  production	  by	  monocytes	  through	  p38MAPK	  [319].	  However	  they	  
isolated	  monocytes	  by	  adherence	  culture	  and	  thus	  only	  examined	  cells	  that	  may	  have	  been	  
primed	  by	   adherence	   [319].	   Cuschieri	   and	   co-­‐workers	   found	   that	   platelet-­‐activating	   factor	  
(PAF)	   primed	   mononuclear	   cell	   production	   of,	   amongst	   others,	   IL-­‐6	   and	   TNF	   through	  
enhanced	  TLR	  signalling	  but	  only	  under	  adherent	  conditions	  [318].	  Another	  group	  examined	  
the	   LPS	   priming	   of	   alveolar	   macrophages	   and	   again	   found	   that	   the	   MAPK	   pathway	   was	  
implicated	   [320]	   however,	   these	   cells	   may	   be	   non-­‐representative	   of	   other	   mononuclear	  
phagocytes	  due	  to	  their	  altered	  regulation	  [63,	  321].	  
	  
Tolerance	  
Endotoxin	  tolerance	  was	  first	  described	  in	  1946	  [322]	  and	  refers	  to	  reduced	  responsiveness	  
to	   an	   LPS	   challenge	   following	  previous	  exposure	   to	  high	   levels	   of	   the	  molecule	   [323].	   It	   is	  
well	  recognised	  in	  innate	  immune	  cells	  such	  as	  monocytes	  and	  macrophages	  [324].	  The	  key	  
readout	  of	  endotoxin	   tolerance	   is	  a	   reduced	   release	  of	   soluble	   (sol)-­‐TNF	  on	  secondary	  LPS	  
exposure	  [324].	  There	  are	  clear	  parallels	  between	  this	  and	  clinical	  reality.	  Monocytes	  taken	  
from	  patients	  with	  a	  variety	  of	  pathologies,	  in	  addition	  to	  expressing	  reduced	  levels	  of	  HLA-­‐
DR,	   also	   display	   reduced	   cytokine	   release	   on	   ex	   vivo	   LPS	   stimulation	   [224,	   287,	   325].	   The	  
clinical	   literature	   often	   refers	   to	   this	   state	   of	   reduced	   HLA-­‐DR	   expression	   and	   LPS	  
responsiveness	   as	   monocyte	   deactivation	   [224].	   Numerous	   negative	   regulators	   of	  
inflammatory	   signalling	   have	   been	   reported	   as	   being	   up-­‐regulated	   in	   tolerance	   although	  
only	   one,	   interleukin-­‐1-­‐receptor	   associated	   kinase-­‐M,	   has	   been	   confirmed	   in	   both	  murine	  
and	   human	   models	   [326-­‐328].	   Interestingly	   MAPKs	   have	   been	   implicated	   in	   the	  
development	  of	  tolerance.	  Attenuation	  of	  MAPK	  phosphorylation	  has	  been	  demonstrated	  in	  
models	  of	   tolerance	  created	  using	  both	  murine	  macrophages	   [329]	  and	  the	  pro-­‐monocytic	  
human	   cell	   line	   THP-­‐1	   [330].	   In	   humans	   it	   is	   thought	   that	   this	   occurs	   through	   an	   up-­‐
regulation	  in	  the	  activity	  of	  phosphatase	  enzymes	  such	  as	  MKP-­‐1	  [331].	  Detecting	  cells	  that	  
display	  this	  phenotype	  may	  help	  guide	  the	  use	  of	  immune-­‐stimulatory	  therapies.	  
We	   made	   the	   argument	   earlier	   that	   the	   monocyte	   could	   be	   used	   as	   a	   gauge	   of	   innate	  
immune	   status	   as	   it	   is	   capable	   of	   both	   priming	   and	   tolerance.	   Therefore	   detecting	   these	  
states	  is	  of	  key	  importance	  and	  could	  direct	  immune	  modulating	  therapies.	  Detecting	  a	  cell	  
in	  a	  primed	  state	  could	  be	  predictive	  of	  both	  immune	  competence	  and	  of	  a	  potential	  risk	  of	  
excessive	   inflammation;	   hence	   immune	   suppressant	   therapies	   may	   be	   warranted.	   In	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contrast,	   detecting	   a	   tolerant	   cell	  may	   indicate	   both	   immune	   suppression	   and	   a	   potential	  
risk	  of	  nosocomial	  infection;	  hence	  immune	  stimulatory	  therapies	  may	  be	  required.	  In	  order	  
that	   the	   primed	   and	   tolerant	   phenotypes	   can	   be	   accurately	   detected	   and	   characterised,	  
there	   is	   a	   need	   for	   in	   vitro	  models	   of	   these	   states	   to	  be	   created,	   a	   process	   that	  may	   also	  
identify	  new	  targets	  for	  immune	  modulating	  therapies.	  
	  
1.6	  Regulation	  and	  role	  of	  TNF	  in	  sepsis	  
Tumour	  Necrosis	  Factor	  and	  its	  receptors	  
Despite	   the	   lack	   of	   success	   in	   sepsis	   clinical	   trials,	   targeting	   TNF	   successfully	   led	   to	  
treatments	   used	   in	   other	   inflammatory	   conditions	   [150,	   151]	   and	   this	   cytokine	   is	   still	  
considered	  a	  primary	  regulator	  of	  systemic	   inflammation.	  TNF	   levels	   increase	  before	  those	  
of	  other	  cytokines	  in	  response	  to	  systemic	  or	  local	  inflammatory	  stimuli	  and	  it	  has	  been	  the	  
subject	  of	  enormous	  body	  of	  work	  since	  it	  was	  first	  identified	  [332]	  and	  subsequently	  cloned	  
[333].	  Whilst	  it	  was	  initially	  characterised	  by	  its	  ability	  to	  produce	  cachexia	  and	  tumour	  cell	  
apoptosis,	  it	  is	  now	  known	  to	  mediate	  a	  considerable	  degree	  of	  pleiotropy	  [334]	  and	  signals	  
through	  two	  distinct	  cell	  surface	  receptors,	  TNF	  receptor	  1	  and	  2	  (TNFR-­‐1	  [p55]	  and	  TNFR-­‐2	  
[p75])	   [335].	   The	   trimeric	   TNF	  molecule	   itself	   exists	   in	   two	   separate	   forms,	   a	   26kDa	   non-­‐
glycosylated	  membrane	  protein	   (mem-­‐TNF)	  and	  a	  17kDa	  soluble	  protein	   (sol-­‐TNF)	  which	   is	  
produced	  by	  cleavage	  of	  mem-­‐TNF	  [336].	  Similar	  to	  its	  soluble	  counterpart,	  mem-­‐TNF	  levels	  
have	  been	  implicated	  in	  both	  chronic	  inflammatory	  disorders	  such	  as	  hepatitis	  [337]	  as	  well	  
as	   infective	  pathology.	   It	  has	  been	  suggested	  that	  mem-­‐TNF	  plays	  a	  role	   in	  host	  protection	  
from	   bacterial	   infection	   [338]	   and	   levels	   have	   been	   shown	   to	   correlate	   with	   the	  
development	   of	   MODS	   [339].	   Although	   in	   recent	   years	   attention	   has	   been	   drawn	   to	   the	  
potentially	  unique	   functions	  of	  memTNF	   in	   cell-­‐cell	   signalling,	   the	   soluble	   form	   remains	  of	  
primary	  importance	  as	  the	  mediator	  of	  the	  majority	  of	  TNF	  functions.	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Tumour	  necrosis	  factor-­‐alpha	  converting	  enzyme	  
Tumour	  necrosis	  factor-­‐alpha	  converting	  enzyme	  (TACE,	  CD156b)	  is	  a	  widely	  expressed	  type	  
1	   trans-­‐membrane	   multi-­‐domain	   enzyme	   that	   belongs	   to	   the	   ADAM	   (a	   disintegrin	   and	  
metalloprotease)	  family	  of	  proteases	  (ADAM-­‐17).	  It	  was	  first	  discovered	  in	  1997	  [340]	  and	  is	  
fundamental	   to	   TNF	   regulation	   as	   it	   cleaves	   up	   to	   90%	   of	   mem-­‐TNF	   to	   sol-­‐TNF,	   the	  
remaining	  10%	  being	  accounted	  for	  by	  the	  action	  of	  other	  cell	  surface	  sheddases	  [341].	  TACE	  
is	   responsible	   for	   the	   shedding	  of	  nearly	   40	  proteins	   [342]	   rendering	   it	   a	   key	  enzyme	   in	   a	  
wide	  array	  of	  physiological	  functions.	  These	  can	  be	  grouped	  into	  those	  involved	  in	  regulating	  
the	   immune	   response	   and	   those	   that	   influence	   cell	   fate,	   such	   as	   cell	   proliferation	   and	  
angiogenesis	   [343].	  Only	  nine	  of	   these	   substrates	  have	  been	  confirmed	   in	  vivo	   [344];	  TNF,	  
TNFR-­‐1	   [158],	   TNFR-­‐2	   [345],	   transforming	   growth	   factor	   alpha,	   L-­‐selectin	   [158],	   heparin-­‐
binding	   epidermal	   growth	   factor,	   platelet	   glycoprotein	   1b	   and	   Fms-­‐like	   tyrosine	   kinase	  
ligand	  3L	  [344].	  
In	   addition	   to	   its	   function	   in	  health,	   it	   is	   important	   to	  appreciate	   the	  wider	   importance	  of	  
TACE	   in	   pathophysiology,	   as	   it	   is	   vital	   for	   normal	  mammalian	   development.	  Mice	   that	   are	  
deficient	  in	  the	  enzyme	  cannot	  survive	  and	  die	  shortly	  before	  birth	  [158];	  this	  is	  thought	  to	  
be	  due	  to	  deficient	  shedding	  of	  transforming	  growth	  factor	  alpha.	   In	  addition	  to	  this,	  TACE	  
has	   been	   implicated	   in	   numerous	   conditions	   such	   as	   acute	   lung	   injury	   [346,	   347],	  
Alzheimer’s	   disease	   [348],	   cancer	   [349-­‐352],	   inflammatory	  bowel	   disease	   [353],	   some	   skin	  
diseases	  [354]	  and	  sepsis	  [355].	  
In	  common	  with	  other	  ADAMs,	  TACE	  is	  initially	  synthesised	  as	  a	  zymogen	  with	  a	  pro-­‐domain	  
(fig	  1.2)	  that	  serves	  as	  an	  inhibitor	  during	  translation	  by	  maintaining	  the	  zinc	  ion	  within	  the	  
catalytic	   domain	   in	   an	   inactive	   state	   [356].	   This	   pro-­‐domain	   is	   subsequently	   cleaved	   [357]	  
and	  the	  enzyme	   is	   transported	  to	   the	  cell	  membrane	  where	   it	   is	   located	   in	  micro-­‐domains	  
called	   lipid	  rafts	   [358].	   In	  addition	  to	  the	  pro-­‐domain	  TACE	  contains	  multiple	  other	  regions	  
(fig.	   1.2).	  Despite	   there	  being	  21	  other	  human	  ADAMs	  TACE	  has	   little	   sequence	  homology	  
with	   any	   of	   them.	   It	   most	   closely	   resembles	   ADAM	   10,	   but	   despite	   this	   the	   sequence	  
homology	  between	  them	  is	  only	  30%	  [343].	  
	   	  


















Figure	  1.3:	  The	  structure	  of	  TACE	   (Adapted	   from	  Black	  et	  al	  2002,	   Int	   J	  Biochem	  Cell	  Biol	  
[341]).	  
Pro	   stands	   for	   prodomain;	   Dis	   for	   disintegrin;	   Cys-­‐rich	   for	   cysteine	   rich;	   TM	   for	  
transmembrane	   and	   Cyto	   for	   cytoplasmic.	   Consistent	   with	   other	   zinc	   dependent	  
metalloprotease	  enzymes	  there	  is	  a	  Zn	  ion	  within	  the	  catalytic	  domain.	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The	  potential	  consequences	  of	  TACE	  shedding	  are	  multiple	  and	  depend	  on	  the	  nature	  of	  the	  
shed	  molecule.	  Shedding	  of	  a	  receptor	  from	  the	  cell	  may	  shut	  down	  the	  activity	  that	  would	  
normally	   be	   induced	   by	   ligand	   binding.	   However,	   the	   shed	  molecule	   could	   also	   act	   as	   an	  
antagonist,	  competing	  with	  cells	  for	  available	  ligands.	  This	  is	  of	  key	  importance	  with	  regard	  
to	  TNF	  biology	  given	  that	  both	  the	  molecule	  and	   its	   receptors	  are	  shed	  by	  TACE.	  Thus	   it	   is	  
plausible	   that	   the	   enzyme	   could	   have	  both	  pro-­‐inflammatory	   (shedding	   sol-­‐TNF)	   and	   anti-­‐
inflammatory	  (shedding	  TNFRs)	  effects.	  Pellegrini	  et	  al	  examined	  both	  monocyte	  mem-­‐TNF	  
and	  shed	  TNFR2	  levels	  in	  ICU	  patients.	  There	  was	  a	  correlation	  between	  increased	  mem-­‐TNF	  
and	  reduced	  shedding	  with	  increased	  multiple	  organ	  dysfunction	  score	  [339].	  Although	  this	  
initially	   lacked	  specificity,	   if	   the	  two	  parameters	  were	  combined	  as	  a	  mem-­‐TNF/TNFR	  ratio	  
they	   became	   a	   highly	   specific	   correlate	   for	   the	   development	   of	   organ	   failure	   [339],	  
implicating	  TACE	  in	  sepsis	  pathophysiology.	  
	  
TACE	  regulation	  
A	  range	  of	  stimuli	  can	  induce	  TACE	  activation	  and	  substrate	  shedding.	  These	  include	  LPS,	  the	  
protein	   kinase	   C	   activator	   phorbol	   12-­‐myristate	   13-­‐acetate	   (PMA),	   hydrogen	   peroxide,	  
growth	  factors	  and	  cytokines.	  In	  addition	  to	  stimulation	  induced	  shedding,	  there	  appears	  to	  
be	   a	   degree	   of	   constitutive	   shedding	   with	   some	   substrates	   such	   as	   L-­‐selectin	   and	   TNFRs	  
being	  shed	  in	  the	  absence	  of	  an	  inflammatory	  stimulus.	  The	  relevance	  of	  this	  latter	  process	  
is	  unclear.	  
Previously,	  work	  in	  cell	  lines	  demonstrated	  that	  TACE	  was	  directly	  activated	  through	  reactive	  
oxygen	  and	  nitrogen	  species,	  which	  produced	  this	  through	  nullification	  of	  the	  inhibitory	  pro-­‐
domain	   [359-­‐361].	   In	   contrast,	   in	   primary	   human	   cells,	   all	   cell	   surface	   TACE	   is	   in	   the	  
mature/active	   form	  [340]	  as	   the	  pro-­‐domain	   is	   removed	   intra-­‐cellularly	   [362,	  363],	  making	  
nullification	   or	   removal	   of	   this	   region	   an	   unlikely	   regulatory	   mechanism	   in	   vivo.	   In	   our	  
laboratory	  we	  dissected	  the	  mechanism	  of	  TACE	  activation	  in	  primary	  monocytes	  and	  found	  
activation	  of	  TACE	  occurred	  indirectly,	  through	  intracellular	  ROS	  acting	  on	  p38MAPK,	  which	  
in	   turn	   produced	   TACE	   activation	   [133].	   Furthermore,	   no	   role	  was	   found	   for	   RNS	   and	   the	  
increase	  in	  TACE	  activity	  was	  independent	  of	  gene	  expression	  [133],	  meaning	  that	  the	  rapid	  
activity	   increases	   seen	   in	   response	   to	   LPS	   and	   INF-­‐ϒ	   [133,	   364]	   are	   consistent	   with	   post-­‐
translational	  modification	   of	   the	   enzyme.	  We	   recently	   suggested	   that	   this	   occurs	   through	  
modification	   of	   TACE	   structure	   (and	   thereby	   activity)	   by	   disulfide	   exchange	   through	   the	  
action	  of	   an	  exogenous	   cell	   surface	  oxidoreductase	   such	   as	  protein	  disulfide	   isomerase	  or	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thioredoxin	  [133].	  A	  recent	  study	  by	  Xu	  et	  al	  offers	  an	  alternative	  explanation	  as	  to	  how	  this	  
structural	  modification	  may	  occur	  [365].	  They	  demonstrated	  in	  a	  breast	  cancer	  cell	  line	  that	  
inactive	  TACE	  is	  present	  as	  a	  dimeric	  compound,	  in	  close	  association	  with	  its	  known	  inhibitor	  
[366],	   the	   tissue	   inhibitor	   of	   metalloprotease	   (TIMP)-­‐3	   [367].	   TACE	   activation	   results	   in	   a	  
shift	   from	   dimeric	   to	   monomeric	   compounds	   with	   a	   concomitant	   reduction	   in	   TIMP-­‐3	  
association	  and	  increased	  cell	  surface	  presentation	  of	  TACE	  [365].	  TNF	  itself	  has	  been	  shown	  
to	   increase	   TACE	   transcription,	   expression	   and	   catalytic	   activity	   [133,	   368]	   and	  may	   signal	  
through	   the	  p38MAPK	  pathway	  outlined	  above.	  This	   is	  unlikely	   to	   represent	   the	   complete	  
story	   however,	   as	   other	   investigators	   have	   described	   a	   reduction	   in	   TACE	   expression	   in	  
response	  to	  alternate	  stimuli	  [369,	  370].	  Such	  stimulation	  induced	  down	  regulation	  has	  been	  
suggested	   as	   another	   means	   of	   regulating	   activity	   levels.	   In	   addition,	   IL-­‐10	   inhibits	   TACE	  
through	  both	  TIMP-­‐3	  dependent	  and	  independent	  pathways	  [364,	  366].	  
Leukocyte	   adhesion	   and	  migration	  may	   have	   an	   effect	   on	   the	   enzyme.	   TACE	   is	   known	   to	  
interact	  with	  both	  the	  actin	  cytoskeleton	  [371]	  and	  the	  integrin	  receptors	  that	  mediate	  cell-­‐
cell	   interaction	  [372].	  In	  addition	  the	  integrin	  activation	  process	  has	  been	  shown	  to	  involve	  
p38MAPK	   [373]	  and	  TACE	  expressed	  by	  kidney	  mesangial	   cells	   is	   regulated	  by	  β-­‐1	   integrin	  
[374].	  These	  factors	  are	  suggestive	  of	  a	  common	  pathway	  linking	  both	  TACE	  activation	  and	  
the	  integrin	  mediated	  adhesion	  process.	  
	  
Substrate	  specificity	  
Given	   its	   numerous	   substrates	   it	  would	   seem	   that	   TACE	  must	   have	   a	   degree	   of	   substrate	  
specificity,	   yet	   how	   this	   is	   regulated	   is	   unknown.	   Some	   investigators	   have	   suggested	   the	  
enzyme	   acts	   as	   a	   “lawn-­‐mower	   sheddase”	   where	   it	   is	   continuously	   switched	   on	   but	   held	  
separately	   from	   the	   substrates	   it	   cleaves	   [375].	   Analysis	   of	   substrates	   other	   than	   TNF	  
provide	  few	  clues	  as	  there	  are	  no	  consensus	  sequences,	  and	  mutations	  around	  the	  cleavage	  
sites	   do	   not	   always	   prevent	   shedding	   [376].	   TNF	   is	   unique	   as	   it	   is	   the	   only	   substrate	   that	  
TACE	  will	  cleave	  as	  an	  isolated	  peptide	  [375].	  This	  has	  enabled	  investigators	  to	  analyse	  TACE	  
activity	  using	  fluorescence	  resonance	  energy	  transfer	  assays	  that	  are	  based	  on	  TNF	  cleavage	  
[133].	   It	   has	  been	   suggested	   that,	   in	   a	   similar	  manner	   to	   the	  mechanisms	  outlined	  above,	  
post-­‐translational	   modification	  may	   play	   a	   role	   in	   determining	   substrate	   specificity	   [343].	  
Killock	  and	  co-­‐workers	  demonstrated	  that	  the	  cytoplasmic	  domains	  of	  TACE	  are	  differentially	  
regulated	   by	   p38	   MAPK	   and	   PKC	   to	   induce	   shedding	   [377].	   Thus	   different	   stimuli	   could	  
induce	  differential	  regulation	  of	  the	  enzyme	  that	  may,	   in	  turn,	   induce	  changes	  in	  substrate	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specificity	  and	  shedding.	   It	   is	  also	  possible	   that	  TACE	  does	  not	  have	  as	  many	  substrates	  as	  
are	   currently	   attributed	   to	   it,	   but	   that	   shedding	   of	   one	   substrate	   (e.g.	   TNF)	   results	   in	   a	  
cascade	  in	  which	  numerous	  other	  sheddases	  are	  activated.	  
	  
TACE	  in	  priming	  and	  tolerance	  
Given	   that	   leukocyte	   adhesion	  may	   impact	   on	   TACE	   there	   is	   a	   possibility	   that	   the	   enzyme	  
may	  be	  spatially	  regulated	  through	  this	  process.	  This	   is	   intriguing	  given	  that	  the	  SIRS/CARS	  
response	  may	  be	  similarly	  regulated	  and	  mononuclear	  phagocytes	  are	  the	  biggest	  producers	  
of	   TNF.	   It	   is	   also	   of	   note	   that	   monocytes	   can	   display	   primed	   or	   tolerant	   phenotypes	   in	  
response	   to	   LPS	   with	   evidence	   for	   the	   involvement	   of	   p38MAPK	   and	   TACE	   in	   the	  
development	   of	   both	   of	   these	   states.	   Cell-­‐cell	   adhesion	   interactions,	   such	   as	   the	   β-­‐2	  
integrin-­‐ICAM-­‐1	  interaction,	  are	  known	  to	  enhance	  the	  inflammatory	  response	  in	  monocytes	  
[378]	   in	   a	   process	   analogous	   to	   priming.	   Furthermore,	   it	   has	   been	   demonstrated	   that	  
adherent	  monocytes	  are	  primed	  to	  produce	  more	  TNF	  than	  their	  non-­‐adherent	  counterparts	  
in	  response	  to	  an	  LPS	  challenge	  [379]	  meaning	  that	  TACE	  activity/regulation	  may	  be	  altered	  
in	  this	  context.	  Sol-­‐TNF	  is	  generally	  considered	  to	  be	  the	  best	  marker	  of	  endotoxin	  tolerance	  
due	   to	   its	   markedly	   reduced	   production	   in	   tolerant	   cells	   [323],	   implicating	   TACE	   in	   this	  
response	  state.	  Attenuation	  of	  MAPK	  phosphorylation	  has	  been	  demonstrated	  in	  models	  of	  
tolerance	  created	  using	  murine	  macrophages	   [329]	  and	  the	  pro-­‐monocytic	  human	  cell	   line	  
THP-­‐1	  [330].	  
Having	  established	  earlier	  that	  there	  is	  clear	  benefit	   in	  determining	  whether	  a	  monocyte	  is	  
primed	  or	  tolerant,	  the	  data	  outlined	  above	  implicate	  TACE	  in	  both	  states.	  TACE	  responds	  to	  
both	  TNF	  [133,	  368]	  and	   IL-­‐10	   [366],	  and	  regulates	   the	  release	  of	  sol-­‐TNF	  [340]	  and	  hence	  
may	  determine,	  or	  reflect,	  monocyte	  inflammatory	  status.	  Whilst	  TACE	  has	  previously	  been	  
investigated	  in	  both	  cell	  lines	  [360,	  361,	  365,	  369,	  377,	  380]	  and	  human	  cells	  [133,	  340,	  364,	  
366,	   370],	   it	   is	   yet	   to	   be	   directly	   measured	   in	   critical	   illness.	   The	   requirement	   to	   further	  
investigate	   TACE	   is	   made	   even	   more	   paramount	   by	   the	   fact	   that	   the	   enzyme	   appears	  
sensitive	  to	  the	  adherence	  state	  of	  the	  monocytes	  and	  can	  have	  potentially	  opposing	  effects	  
on	   TNF	   signalling	   through	   differential	   shedding	   of	   TNF	   and	   TNFRs.	   Therefore,	   any	   in	   vitro	  
model	   of	   the	   primed	   and	   tolerant	   states	   should	   include	   determination	   of	   cellular	   TACE	  
activity	  profiles	  and	  associated	  substrate	  shedding.	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1.7	  Hypothesis	  and	  aims	  
We	  hypothesised	  that	  inducing	  states	  of	  priming	  and	  tolerance	  in	  monocytes	  would	  result	  in	  
changes	   in	  TACE	  activity	  and	  associated	  substrate	  behaviour,	  meaning	   that	   these	  could	  be	  
used	  as	   indicators	  of	   cellular	   inflammatory	  phenotype,	  potentially	   reflecting	   the	  dominant	  
systemic	  SIRS/CARS	  response.	  As	  established	  earlier	  in	  this	  chapter,	  there	  is	  clear	  benefit	  in	  
knowing	   where	   patients	   lie	   on	   this	   SIRS/CARS	   continuum	   as	   it	   may	   help	   guide	   immune	  
modulating	   therapies.	   It	   is	   possible	   that	   such	   future	   therapies	   could	   be	   targeted	   against	  
TACE	  if	  enzyme	  behaviour	  in	  both	  primed	  and	  tolerant	  monocytes	  could	  be	  determined	  and	  
conclusively	  be	  shown	  to	  mirror	  clinical	  reality.	  
In	  order	  to	  test	  our	  hypothesis	  we	  attempted	  to	  induce	  priming	  and	  tolerance	  in	  monocytes	  
using	   in	   vitro	  models,	   and	   then	  measure	   both	   their	   TACE	   activity	   profiles	   and	   associated	  
shedding	   behaviour.	   To	   determine	   whether	   these	   models	   mirrored	   clinical	   reality	   we	  
obtained	   monocytes	   from	   critically	   unwell	   patients	   and	   determined	   their	   inflammatory	  
phenotype	  using	  a	  standard	  measure	  of	  immune	  status,	  HLA-­‐DR	  expression.	  
Our	  primary	  aims	  were	  as	  follows:	  
1. To	  create	   in	  vitro	  models	  of	  priming	  and	   tolerance	  and	  determine	  monocyte	  TACE	  
activity	  profiles	  and	  associated	  substrate	  behaviour	  therein.	  
2. To	  perform	  a	  clinical	  study	  in	  which	  monocytes	  were	  obtained	  from	  critically	  unwell	  
patients	   and	   determine	   their	   TACE	   activity	   profiles	   and	   associated	   shedding	  
behaviour.	  
	  
To	  address	  these	  aims:	  
We	   first	   assessed	   the	   relative	  advantages	  of	  using	  a	  human	  pro-­‐monocytic	   cell	   line	  versus	  
primary	  human	  monocytes	  for	  studying	  TACE	  biology.	  This	  work	  is	  detailed	  in	  Chapter	  Three.	  
Using	   this	   information,	   we	   then	   investigated	   the	   dynamics	   of	   primary	   monocyte	   TACE	  
activation	   responses	   in	   relation	   to	   sequential	   septic	   stimuli	   of	   different	   intensities	   under	  
minimally	  adherent	  in	  vitro	  conditions	  as	  detailed	  in	  Chapter	  Four.	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Based	  on	   the	  approaches	  developed	   in	   the	   in	  vitro	  models,	  we	  carried	  out	  a	   clinical	   study	  
using	  patient	  peripheral	  blood	  monocytes.	   Standard	  monocyte-­‐related	   soluble	  and	  cellular	  
markers	   of	   sepsis	   inflammatory	   status	   were	   compared	   to	   monocyte	   TACE	   expression,	  
activity	  and	  related	  responses,	  in	  patients	  with	  sepsis	  and	  non-­‐infectious	  SIRS	  with	  this	  work	  
detailed	  in	  Chapter	  Five.	  
We	   concluded	   the	   project	   by	   extending	   our	   previous	   work	   on	   the	   signalling	   mechanisms	  
responsible	   for	   TACE	   catalytic	   activation,	   investigating	   the	   regulation	   of	   such	   responses	  
under	   conditions	   that	   aimed	   to	   simulate	   the	   contrasting	   systemic	   non-­‐adherent	   and	   local	  
adherent	   environments	   that	   monocytes	   will	   encounter	   during	   sepsis	   and	   the	   results	   we	  
obtained	  from	  this	  make	  up	  Chapter	  Six.	  
	   	  







Materials	  and	  methods	  
	   	  




General	   laboratory	   reagents	   were	   purchased	   from	   either	   Invitrogen	   (Renfrewshire	   UK)	   or	  
Sigma	   (Dorset,	   UK).	   Invitrogen	   supplied	   Dulbecco’s	   Phosphate	   Buffered	   Saline	   (DPBSS),	  
Foetal	   Calf	   Solution	   (FCS),	  Hank’s	   Balanced	   Salt	   Solution	   (HBSS)	   and	  distilled	  water.	   Sigma	  
were	   used	   to	   purchase	   Bovine	   Serum	   Albumin	   (BSA),	   Dimethylsulfoxide	   (DMSO),	  
ethylenediaminetetraacetic	  acid	  (EDTA),	  hydrogen	  peroxide	  and	  sodium	  azide.	  
	  
Pharmacologically	  active	  agents:	  
Adenosine	   tri-­‐phosphate	   (ATP)	  disodium	  salt	  was	  purchased	   from	  TOCRIS	  bioscience	   (R&D	  
systems,	  Abingdon	  UK),	   as	  were	   the	   inhibitors	   Suramin	  hexasodium	   (a	  purinergic	   receptor	  
antagonist)	  and	  A74003	  (an	  inhibitor	  of	  the	  P2X7	  receptor).	  Recombinant	  Human	  INF-­‐ϒ	  and	  
monocyte	  chemotactic	  protein	  (MCP)-­‐1	  were	  purchased	  from	  R&D;	  LPS	  E.coli	  ultra-­‐pure	  was	  
obtained	   from	   InvivoGen	   (San	   Diego	   USA).	   Super-­‐oxide	   dismutase	   and	   catalase	   were	  
purchased	  from	  Sigma.	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Antibodies:	  




Antibodies	   were	   fluorophore	   conjugated	   and	   anti-­‐human.	   Where	   used	   for	   measurement	  
purposes	  (as	  opposed	  to	  gating),	  the	  relevant	  isotype	  control	  antibody	  recommended	  by	  the	  
manufacturer	   was	   purchased.	   Table	   2.1	   contains	   details	   of	   the	   antigen,	   fluorophore	   and	  
manufacturer	  for	  each	  antibody.	  
	   	  
	   55	  




Alexa	  Fluor	  780	  
Biolegend	  (California,	  USA)	  
eBioscience	  
CD14	   PerCP	   BD	  Biosciences	  (Oxfordshire	  UK)	  
CD16	   FITC	   Biolegend	  	  
CD56	   PE-­‐Cy7	   Biolegend	  
CD64	   PE-­‐Cy7	   BD	  
CCR2	   Alexa-­‐Fluor	  647	   BD	  
HLA-­‐DR	   APC	   Biolegend	  
L-­‐selectin	   PE	   eBioscience	  
Phospho-­‐ERK	   Alexa-­‐Fluor	  647	   Cell	  Signalling	  (Massachusetts,	  USA)	  
Phospho-­‐MK2	   Alexa-­‐Fluor	  647	   Cell	  Signalling	  
Phospho-­‐p38	   PE	   Cell	  Signalling	  
TACE	   PE	   R&D	  Systems	  (Oxfordshire,	  UK)	  
TNFR-­‐1	   PE	   R&D	  
TNFR-­‐2	   PE	   R&D	  
IgG1	  isotype	  
control	  
PE	   R&D	  
Isotype	  for	  TACE	  and	  TNFR-­‐1	  
IgG2A	  isotype	  
control	  
PE	   R&D	  
Isotype	  for	  TNFR-­‐2	  
IgG2aκ	  isotype	  
control	  
APC	   Biolegend	  
Isotype	  for	  HLA-­‐DR	  
IgG1κ	  isotype	  
control	  
PE	   eBioscience	  
Isotype	  for	  L-­‐selectin	  
	  
	  
Table	  2.1:	   Details	  of	  flow	  cytometry	  antibodies:	  
Specific	   information	   about	   antigen,	   fluorophore	   and	   manufacturer	   is	   provided.	   PE	   –	  
phycoerythrin,	  PerCP	  –	  perinidin	  chlorophyll	  protein,	  FITC	  –	  fluorescein	  isothiocyanate,	  APC	  –	  
allophycocyanin.	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Blocking	  antibodies:	  
Details	   of	   blocking	   antibodies	   used	   are	   shown	   in	   table	   2.3.	   All	   were	   anti-­‐human	  with	   the	  
exception	  of	   the	   Integrin	  αL/M/X/β2	  antibody,	  which	  was	  anti-­‐mouse.	  Where	  possible	   low	  
endotoxin	   and	   azide	   (LEAF)	   preparations	   were	   purchased.	   Cells	   were	   incubated	   with	  




Target	  Integrin	   Manufacturer	  
CD11b	   eBioscience	  
CD18	   Biolegend	  
CD29	   Biolegend	  
Integrin	  αL/M/X/β2	   Santa	   Cruz	   Biotechnology	  
(Heidelberg,	  Germany)	  
	  
Table	  2.3:	  	   Details	  of	  blocking	  antibodies:	  
Specific	  details	  about	  antibody	  target	  and	  manufacturer	  are	  provided.	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2.2	  Monocyte	  isolation	  
PBMCs	   were	   isolated	   from	   healthy	   donor	   blood	   using	   Histopaque	   -­‐1077	   (Sigma)	   in	  
conjunction	   with	   Leucosep	   tubes	   (Greiner,	   Stonehouse,	   UK)	   and	   by	   following	   the	  
manufacturers	   instructions.	  PBMCs	  were	   re-­‐suspended	   in	  cell	   separation	  buffer	  –0.1%	  BSA	  
(Sigma)	   and	   2mM	   EDTA	   (Sigma)	   in	   HBSS.	   PBMC	   numbers	   were	   then	   assessed	   by	   flow	  
cytometry	  (below).	  
CD14+	  monocytes	  were	  purified	   from	  PBMCs	  by	  positive	   immune-­‐magnetic	  bead	  selection	  
(MACS®	  –	  Miltenyi	  Biotech,	  Surrey,	  UK).	  Cells	  were	  incubated	  for	  15	  minutes	  with	  anti-­‐CD14	  
antibodies	  that	  were	  directly	  labelled	  with	  magnetic	  beads	  and	  an	  FcR	  blocking	  agent	  (both	  
Miltenyi	   Biotech)	   that	   blocked	   unwanted	   binding	   of	   antibodies	   to	   human	   Fc	   receptor-­‐
expressing	  cells	  (such	  as	  B	  cells,	  monocytes,	  and	  macrophages).	  Cells	  were	  then	  applied	  to	  a	  
magnetic	   separation	   column	   (LS,	   Miltenyi	   Biotech)	   to	   deplete	   non-­‐labelled	   cells.	   Purified	  
monocytes	   were	   collected	   from	   the	   column	   and	   passed	   through	   a	   second	   column	   (MS,	  
Miltenyi	  Biotech)	  to	  both	  reduce	  platelet	  contamination	  and	  increase	  cell	  purity.	  	  
Where	   a	   negative	   selection	   protocol	   was	   run	   for	   comparison,	   this	   was	   done	   using	   the	  
monocyte	   isolation	   II	   kit	   (Miltenyi).	   This	   contained	   a	   cocktail	   of	   biotinylated	   antibodies	  
designed	  to	  deplete	  T-­‐lymphocytes	  (CD3&7),	  natural	  killer	  (NK)	  cells	  (CD7,	  CD16	  &	  CD56),	  B-­‐
lymphocytes	   (CD19),	   erythrocytes	   (CD235a)	   and	   a	   combination	   of	   dendritic	   cells,	  myeloid	  
precursors,	  macrophages,	  mast	  cells,	  basophils	  and	  megakaryocytes	  (all	  CD123).	  A	  separate	  
biotinylated	  anti-­‐CD41	  antibody	  (Serotec	  Oxford,	  UK)	  was	  used	  for	  platelet	  depletion.	  Cells	  
were	   incubated	   with	   this	   cocktail	   before	   anti-­‐biotin	   micro-­‐beads	   were	   added	   and	   non-­‐
monocytic	  cells	  were	  retained	  in	  the	  magnetic	  column,	  hence	  depleted.	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2.3	  Cell	  culture:	  
THP-­‐1	  cells	  (European	  Collection	  of	  Animal	  Cells)	  were	  cultured	  in	  suspension	  culture	  37°C	  in	  
95%	  air/5%	  CO2	  for	  16	  hours	   in	  RPMI-­‐1640	  containing	  10%	  FCS,	  2mM	  glutamine,	  10	  µg/ml	  
streptomycin	  and	  10	  U/ml	  penicillin-­‐G	  (all	  from	  Invitrogen,	  Paisley,	  UK).	  Cells	  were	  cultured	  
in	  50-­‐600ml	  tissue	  culture	  flasks	  (Becton	  Dickinson)	  with	  media	  changed	  every	  48	  hours	  by	  
spinning	  cells	  down.	  As	  per	  our	   laboratory	  protocols	  each	  media	  change	  was	  counted	  as	  a	  
single	  passage	  with	  cells	  used	  between	  passage	  four	  and	  fifteen.	  
Isolated	  monocytes	   were	   cultured	   at	   37°C	   in	   95%	   air/5%	   CO2	   for	   16	   hours	   in	   RPMI-­‐1640	  
containing	   10%	   FCS,	   2	   mM	   glutamine,	   10	   µg/ml	   streptomycin	   and	   10	   U/ml	   penicillin-­‐G	  
(Invitrogen).	   Cells	   were	   cultured	   in	   12	   or	   24	   tissue	   culture	   plates	   (Becton	   Dickinson,	   New	  
Jersey,	   USA)	   at	   a	   density	   of	   3x106/ml	   within	   non-­‐adherent	   polytetrafluoroethylene	   (PTFE,	  
Teflon®)	   cell	   inserts	   (Millipore,	   Carrigtwohill,	   Ireland).	   Also	   added	   to	   culture	   media	   were	  
ultra-­‐pure	   E.	   Coli	   LPS	   or	   recombinant	   Human	   INF-­‐γ.	   Retrieval	   from	   overnight	   culture	   was	  
performed	  on	   ice	  and	  by	  washing	   inserts	  with	  cold	  HBSS	  supplemented	  with	  5%	  FCS.	  Cells	  
were	   then	   centrifuged	   at	   1400rpm	   for	   10	  minutes	   and	   suspended	   in	   HBSS	   supplemented	  
with	  5%	  FCS	  prior	  to	  stimulation.	  
	  
2.4	  Cell	  stimulation:	  
After	   culture	   or	   isolation	   cells	   were	   counted	   by	   flow	   cytometry	   (below)	   before	   being	  
suspended	   in	  HBSS	   containing	  5%	  FCS	  at	   a	  density	  of	  2x106	   to	  5x106	  CD14+	  cells/ml.	  Cells	  
were	  then	  placed	  in	  1.5ml	  Eppendorf	  tubes	  before	  being	  stimulated	  at	  37°C.	  Inhibitors	  and	  
blocking	  antibodies	  were	  incubated	  with	  cells	  for	  15	  minutes	  prior	  to	  stimulation.	  Where	  no	  
inhibitor	   was	   used	   cells	   and	   stimulant	   were	   added	   to	   Eppendorfs	   simultaneously.	   The	  
concentrations	  of	   inhibitors	  and	  stimulants	  used	  were	  saturating	  doses	  based	  on	  review	  of	  
the	  literature/previous	  laboratory	  experience	  within	  our	  group.	  
After	   stimulation	   cells	   were	   washed	   in	   HBSS	   (x4	   excess)	   prior	   to	   having	   TACE	   activity	  
determined	  or	  flow	  cytometric	  analysis	  performed	  (below).	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2.5	  Flow	  cytometry:	  
Cells	   were	   incubated	   with	   the	   relevant	   antibodies	   (table	   2.1)	   for	   30	  minutes	   at	   4°C	   then	  
washed	  in	  2ml	  of	  wash	  buffer	  (WB	  –	  2%	  FCS,	  5	  mM	  EDTA	  [Sigma]	  and	  0.01%	  sodium	  azide	  in	  
PBS)	   before	   being	   centrifuged	   (5	  minutes	   at	   2000rpm).	   Cells	  were	   then	   suspended	   in	  WB	  
and	   flow	  cytometric	  acquisition	  of	   samples	  was	  performed	  using	  a	  Cyan	  ADP	   fluorescence	  
activated	   cell	   sorter	   (Dako,	  Denmark)	  with	   Summit	  Version	  4.3.02	   (Beckman	  Coulter,	  High	  
Wycombe	  UK).	  Accucheck	  fluorescent	  counting	  beads	  (Invitrogen)	  were	  used	  to	  perform	  cell	  
counts	   before	   and	   after	   magnetic	   separation.	   By	   comparing	   numbers	   of	   cells	   expressing	  
CD14	  before	  and	  after	  separation	  both	  purity	  and	  yield	  could	  be	  determined.	  Representative	  
flow	  cytometry	  plots	  for	  monocytes	  post	  separation	  are	  shown	  below	  (fig	  2.1)	  
Viability	  was	  determined	  using	  propidium	  iodide	  (PI).	  This	  penetrates	  the	  membrane	  of	  non-­‐
viable	   cells	   and	   binds	   to	   DNA,	   producing	   a	   fluorescent	   signal	   that	   is	   detected	   via	   flow	  
cytometry.	  
	  





Figure	   2.1:	   Representative	   dot	   plots	   of	  monocytes	   isolated	   using	   CD14	   positive	   selection	  
protocol.	  
A:	  	   Plot	  obtained	  after	  PBMCs	  exposed	  to	  monocyte	   isolation	  protocol.	   In	  keeping	  with	  
expectations	   a	   single	   cell	   population	   with	   forward	   scatter	   (FSC)	   and	   side	   scatter	   (SSC)	  
characteristics	   consistent	   with	  monocytes	  was	   obtained.	   A	   single	   gate	  was	   placed	   around	  
these	  cells.	  
B:	   Gated	  cells	  expressed	  CD14	  as	  expected	  and	  consistent	  with	  monocytes.	  These	  cells	  
were	  then	  used	  to	  determine	  cell	  surface	  marker	  expression.	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Determination	  of	  intracellular	  MAPK	  levels	  (p38,	  MK-­‐2,	  ERK):	  
To	  determine	  MAPK	  levels	  cells	  were	  placed	   in	  Eppendorfs	  and	   incubated	  with	  LPS	  1μg/ml	  
for	  15	  and	  30	  minutes	  at	  37°C	  along	  with	  un-­‐stimulated	  controls.	  Post	  stimulation	  cells	  had	  
Cytofix/Cytoperm™	   (Becton	   Dickinson)	   x4	   excess	   added	   (in	   order	   to	   both	   fix	   and	  
permeabilise	  the	  cells)	  and	  were	  incubated	  for	  a	  further	  five	  minutes.	  500μl	  of	  wash	  buffer	  
(PBS	   supplemented	   with	   2%	   FCS,	   sodium	   azide	   and	   saponin)	   was	   then	   added	   and	   cells	  
centrifuged	  at	  400G.	  Supernatants	  were	  removed	  and	  cells	  suspended	  in	  1ml	  of	  wash	  buffer.	  
Centrifugation	  was	  repeated	  and	  cells	  dissolved	  in	  50μl	  of	  PWB	  before	  being	  incubated	  with	  
antibodies	   (table	   2.1)	   for	   30	  minutes	   in	   the	   dark	   at	   room	   temperature	   before	   undergoing	  
washing	   and	   flow	   cytometric	   acquisition	   as	   outlined	   above.	   In	   order	   to	   control	   for	   non-­‐
specific	  staining,	  non-­‐activated	  cells	  were	  used	  as	  the	  control	  population	  (fig	  2.2C).	  Levels	  of	  
MAPK	   phosphorylation	   in	   these	   non-­‐activated	   cells	   were	   subtracted	   from	   those	   in	   LPS	  
activated	  cells	  to	  determine	  the	  MAPK	  response.	  
Representative	   dot	   plots	   and	   a	   histogram	   demonstrating	   p38	   MAPK	   activation	  
(phosphorylation)	  after	  LPS	  treatment	  is	  shown	  in	  figure	  2.2.	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Figure	  2.2:	  Flow	  cytometry	  protocol	  for	  determination	  of	  MAPK	  phosphorylation	  
A:	   Representative	   flow	   cytometry	   plot	   of	   forward	   scatter	   (FSC)	   and	   side	   scatter	   (SSC)	  
obtained	  after	  PBMC	  were	  exposed	  to	  the	  MAPK	  protocol	  and	  LPS	  LPS	  1μg/ml	  for	  15	  minutes	  
at	  37°C.	  Cells	  were	  stimulated	  at	  5x106	  monocytes/ml	  in	  static	  Eppendorf	  culture.	  A	  gate	  was	  
drawn	  around	  cells	  with	  characteristics	  consistent	  with	  monocytes.	  
B:	   A	  further	  gate	  was	  then	  made	  on	  cells	  expressing	  high	  levels	  of	  CD14	  and	  MAPK	  (p38	  
MAPK	  shown	  in	  this	  example).	  
C:	   Representative	   histogram	   of	   p38	   MAPK	   phosphorylation	   in	   monocytes	   after	   LPS	  
stimulation.	   Grey	   curve	   represents	   non-­‐stimulated	   controls	   whereas	   black	   represents	   cells	  
exposed	  to	  LPS	  in	  static	  Eppendorf	  culture.	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Flow	  cytometry	  data	  analysis:	  
Acquisition	  analysis	  was	  performed	  using	  Flowjo	  V.7.5.	   (Tree	  Star	   Inc.,	  Oregon).	  Expression	  
levels	  are	  given	  as	  the	  geometric	  mean	  of	  fluorescence	  intensity	  (MFI)	  emitted	  by	  cells,	  with	  
the	  isotype	  control	  value	  subtracted.	  Results	  are	  reported	  as	  mean	  of	  repeated	  experiments	  
±	  the	  SD	  of	  the	  mean.	  
	  
2.6	  Fluorescence	  resonance	  energy	  transfer	  (FRET)	  assay	  to	  determine	  TACE	  activity:	  
The	  assay	  utilises	  fluorescence	  resonance	  energy	  transfer	  in	  order	  to	  give	  a	  read	  out	  of	  TACE	  
catalytic	  activity	  in	  live	  cells.	  Isolated	  monocytes	  were	  incubated	  with	  a	  peptide	  consisting	  of	  
two	  donor	  fluorophores	  conjugated	  by	  a	  TACE	  sensitive	  13	  amino	  acid	  mem-­‐TNF	  sequence.	  
One	   fluorophore	   acts	   as	   a	   donor	   (fluorescein	   (FAM))	   and	   the	   other	   as	   an	   acceptor	  
(tetramethylrhodamine	   (TAMRA)).	   Cleavage	   of	   the	   peptide	   at	   the	   alanine-­‐valine	   bond	  
contained	  within	   the	  peptide	  by	  TACE	   results	   in	  an	   increase	   in	   fluorescence	  due	   to	   loss	  of	  
internal	   quenching	   (fig	   2.3).	  Measurement	   of	   this	   fluorescence	   allows	   TACE	   activity	   to	   be	  
ascertained	  as	  described	  in	  detail	  below.	  
	  
Protocol	  
Following	   incubation	   and	   stimulation	   (above),	   cells	   were	   washed	   and	   suspended	   in	   assay	  
media–1%	   bovine	   serum	   albumin	   (Sigma)	   in	   HBSS.	   Cell	   counts	   were	   performed	   by	   flow	  
cytometry	  and	  cells	  were	  plated	  at	  a	  density	  of	  1x105	   cells	  per	  well	  or	  2.5x104	  per	  well	   in	  
either	   96	   or	   384	   well	   plates	   (Corning	   Incorporated,	   Surrey,	   UK)	   in	   triplicate	   or	   greater	  
wherever	  possible.	  Each	  well	  totalled	  100µL	  in	  96	  well	  plates	  or	  25μl	  in	  384	  well	  plates	  and	  
this	   consisted	   of	   5µM	   fluorescein-­‐tetramethylrhodamine	   (FAM-­‐TAMRA,	   GlaxoSmithKline,	  
Stevenage,	   UK)	   peptide	   and	   an	   appropriate	   volume	   of	   assay	   media.	   TACE	   activity	   was	  
determined	  via	  measurement	  of	   fluorescence	   intensity	  using	  a	  microplate	   fluorimeter	   (Flx-­‐
800,	   Bio-­‐tek	   Instruments	   Inc.,	   UK)	   in	   conjunction	  with	   KC4	   data	   analysis	   software	   (Bio-­‐tek	  
Instruments	  Inc.).	  Assays	  were	  run	  at	  37oC	  using	  an	  excitation	  wavelength	  of	  485nm	  and	  an	  
emitted	   wavelength	   of	   535nm.	   The	   methodology	   outlined	   above	   is	   consistent	   with	   a	  
published	  protocol	  generated	  within	  our	  laboratory	  [381].	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FRET	  assay	  data	  analysis:	  
Data	   were	   exported	   and	   subsequently	   analysed	   using	   Microsoft	   Excel.	   TACE	   activity	   was	  
calculated	  by	  determining	   the	  gradient	  of	   the	   curve	   (fluorescence	  vs.	   time)	  obtained	   from	  
the	   FRET	   assay	   over	   a	   10	   minute	   time	   period.	   For	   each	   experiment	   activity	   has	   been	  
calculated	  by	  determining	   the	  mean	  of	  experimental	   replicates	  and	  values	  are	   reported	  as	  
mean	  of	  separate	  experiments	  ±SD	  in	  fluorescence	  units	  per	  minute	  (FU/min).	  
	   	  













Figure	  2.3:	  Illustration	  of	  FRET	  assay:	  	  
Peptide	  containing	  13	  amino	  acid	  sequences	  conjugated	  to	  donor	  and	  acceptor	  fluorophore.	  
TACE	   cleaves	   the	   peptide	   at	   the	   alanine-­‐valine	   (AV)	   bond,	   resulting	   in	   fluorescence	   from	  
donor	   fluorophore	  as	  a	   result	  of	   loss	  of	   internal	  quenching.	  Fluorescence	   is	  proportional	   to	  
TACE	   catalytic	   activity	   hence	   activity	   can	   be	   calculated	   by	   the	   rate	   of	   increase	   in	   the	  
fluorescent	  signal	  per	  unit	  time.	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2.7	  Enzyme-­‐linked	  immunosorbent	  assay	  (ELISA):	  
This	  was	  performed	  using	  our	   in-­‐house	  assay	  with	   reagents	  purchased	   from	  R&D	  systems.	  
ELISA	  plates	  (Nunc,	  Roskilde,	  Denmark)	  were	  coated	  with	  capture	  antibody	  (R&D)	  at	  2μg/ml	  
and	   left	   at	  4°C	   for	  16	  hours.	   Each	  well	  was	   then	  washed	  x	  4	  with	  PBS	   supplemented	  with	  
0.05%	  Tween-­‐20	  (Sigma),	  this	  washing	  protocol	  was	  automated	  as	  standardised	  throughout	  
the	  protocol.	  Wells	  were	  then	  blocked	  for	  an	  hour	  using	  a	  PBS	  supplemented	  with	  1%	  BSA	  
(Sigma)	   and	   0.05%	   Tween-­‐20	   (Sigma).	   The	   washing	   step	   was	   repeated	   before	   standards	  
consisting	   of	   rhTNF	   (R&D)	   were	   added.	   Samples	   were	   added	   and	   diluted	   in	   block	   buffer	  
where	   appropriate.	   Plates	   were	   left	   for	   two	   hours	   before	   being	   washed	   and	   having	  
detection	  antibody	   (R&D)	  added	  at	  100ng/ml	  and	   then	   left	   for	  a	   further	   two	  hours.	  Plates	  
were	  washed	  once	  again	  and	  streptavidin-­‐HRP	  (R&D)	  was	  added	  at	  a	  1/200	  dilution	  and	  left	  
for	  20	  minutes.	  Substrate	  solution	   (R&D)	  was	  added	  and	  plates	   incubated	   for	  a	   further	  20	  
minutes	   before	   10M	   hydrochloric	   acid	   (VWR,	   Leicestershire	   UK)	   was	   added	   as	   a	   stop	  
solution.	  
Plates	  were	  read	  using	  a	  Dynex	  MRX	  II	  plate	  reader	  (Dynex	  Technologies	  LTD,	  Worthing	  UK)	  
in	  conjunction	  with	  RevelationTM	  (version	  4.22,	  Dynex).	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2.8	  Statistics	  
Results	   for	   each	   experiment	   are	   reported	   as	   the	  mean	   of	   repeated	   experiments	   ±SD.	   For	  
non-­‐parametric	   data	  medians	   and	   inter-­‐quartile	   ranges	   are	   provided.	   For	   parametric	   data	  
with	   two	   variables	   a	   t-­‐test	  was	   used,	   for	   those	  with	   three	   or	  more	   a	   one-­‐way	   analysis	   of	  
variance	   (ANOVA)	   was	   used	   with	   Bonferroni	   correction	   for	   multiple	   comparisons.	   A	  
corrected	  p-­‐value	  of	  <0.05	  was	  considered	  to	  be	  statistically	  significant.	  
For	  categorical	  data	  chi-­‐squared	  analysis	  was	  used.	  Mann-­‐Whitney	  U	  test	  or	  Kruskal	  Wallis	  
testing	  was	  used	  for	  non-­‐parametric	  data.	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Summary	  
Sepsis	   is	   comprised	   of	   both	   the	   systemic	   inflammatory	   response	   syndrome	   and	   the	  
compensatory	  anti-­‐inflammatory	   response	  syndrome.	  There	  are	  similarities	  between	  these	  
systemic	   processes	   and	   the	   primed	   vs.	   tolerant	   states	   that	   monocytes	   can	   display	   in	  
response	  to	  an	   in	  vitro	   inflammatory	  stimulus	  such	  as	  LPS.	  Previously	  we	  have	  shown	  that	  
primary	   human	   monocytes	   up-­‐regulate	   their	   TACE	   activity	   in	   response	   to	   LPS.	   Before	  
generating	   primed	   and	   tolerant	   cells	   it	   was	   crucial	   to	   reproduce	   these	   findings	   and	   to	  
develop	  a	   reliable	  means	  of	  providing	  monocytes.	   In	  an	  attempt	   to	  address	   these	   two	  key	  
areas	  I	  performed	  a	  series	  of	  pilot	  experiments	  in	  the	  human	  pro-­‐monocytic	  cell	  line	  THP-­‐1.	  
We	   hypothesised	   that	   cells	   would	   display	   a	   >3	   fold	   increase	   in	   their	   TACE	   activity	   when	  
challenged	  with	  LPS	  in	  accordance	  with	  our	  previous	  findings.	  
Undifferentiated	  THP-­‐1	  cells	  displayed	  no	  up-­‐regulation	  of	  TACE	  activity	  in	  response	  to	  LPS.	  
This	   hypo-­‐responsive	   state	   persisted	   despite	   efforts	   to	   induce	   differentiation	   toward	   a	  
monocyte	   phenotype	   using	   vitamin-­‐D3	   (VD3).	   A	   partial	   response	   to	   LPS	   appeared	   to	   be	  
induced	  by	  a	  16-­‐hour	  IFN-­‐ϒ	  treatment	  also	  designed	  to	  induce	  differentiation.	  However,	  this	  
response	  was	  small	  and	  did	  not	  reach	  statistical	  significance.	  
The	   project	  was	   then	   re-­‐appraised	   and	   an	   alternative	  means	   of	   providing	  monocytes	  was	  
found	  by	  employing	  density	  gradient	  centrifugation	  followed	  by	  immune-­‐magnetic	  activated	  
cell	  sorting	  together	  with	  a	  CD14	  positive	  selection	  strategy.	  The	  kinetics	  of	  the	  acute	  TACE	  
response	  in	  cells	  isolated	  using	  this	  protocol	  were	  determined	  and	  found	  to	  be	  suitable	  for	  
our	  needs.	  Finally	  an	  optimised	  flow	  cytometry	  protocol	  to	  detect	  activated	  MAPK	  levels	  in	  
response	  to	  LPS	  was	  created.	  
In	   conclusion,	   I	   ascertained	   the	   limitations	   of	   using	   cell	   lines	   when	   examining	   the	   TACE	  
response.	   I	   then	   determined	   a	  means	   of	   rapidly	   isolating	   primary	   human	  monocytes	   that	  
forms	  one	  of	  the	  core	  pieces	  of	  methodology	  contained	  within	  this	  thesis.	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Chapter	  3.1	  Background	  
	  
Previously	  within	  our	  group	  we	  have	  demonstrated	  that,	  in	  response	  to	  LPS,	  TACE	  activity	  is	  
rapidly	  up	  regulated	  [133,	  381].	  This	   response	   is	  sufficiently	   rapid	   (x2-­‐5	   fold,	  present	  at	  30	  
minutes)	   to	   be	   consistent	   with	   post-­‐translational	   modification	   of	   the	   enzyme	   and	   is	  
mediated	   indirectly	   through	   intra-­‐cellular	   ROS	   activating	   and	   phosphorylating	   p38MAPK	  
[133].	   Before	   measuring	   monocyte	   TACE	   activity	   in	   models,	   designed	   to	   induce	   states	   of	  
priming	  and	  tolerance,	   it	  was	  necessary	  to	  reaffirm	  TACE	  behaviour	   in	  single	  hit	  conditions	  
as	  this	  would	  form	  the	  basis	  for	  any	  comparison	  between	  cell	  states.	  TACE	  catalytic	  activity	  
was	   measured	   using	   a	   fluorescence	   resonance	   energy	   transfer	   (FRET)	   assay	   that	   was	  
developed	  and	  refined	  by	  our	  group	  [381].	  This	  assay	  represents	  a	  significant	  improvement	  
on	   previous	  methods	   of	   quantifying	   TACE	   activity	  where	   activity	  was	   calculated	   indirectly	  
through	  derived	   indices,	  differential	   inhibition	  or	   inferred	   indirectly	   from	  expression	   levels	  
[355,	  364,	  369].	  However,	  the	  FRET	  assay	   is	   incapable	  of	  distinguishing	  between	  cell	  types,	  
and	  as	  TACE	  is	  widely	  expressed	  [340],	  it	  is	  necessary	  to	  perform	  experiments	  in	  a	  single	  cell	  
line/isolated	  cells	  for	  accurate	  interpretation	  of	  results.	  
Previously	   [133],	  within	   our	   laboratory	  we	   had	   used	   both	   primary	   human	  monocytes	   and	  
human	  cell	   lines	  with	  both	  approaches	  having	  advantages	  and	  disadvantages.	  Primary	  cells	  
have	   obvious	   biological	   relevance	   but	   the	   isolation	   process	   [133]	   is	   expensive	   and	  
incorporates	   density	   gradient	   centrifugation	   followed	   by	   magnetic	   activated	   cell	   isolation	  
employing	   a	   negative	   selection	   protocol.	   In	   this	   process	   non-­‐monocyte	   populations	   are	  
labelled	  with	  antibodies	  attached	  to	  magnetic	  beads	  meaning	  they	  are	  retained	  in	  a	  column	  
placed	  in	  a	  magnetic	  field	  and	  pure	  monocyte	  preparations	  can	  be	  obtained.	  
When	  validating	  the	  FRET	  assay	  both	  MonoMac-­‐6	  (an	  alternate	  human	  monocyte	  cell	   line)	  
and	  THP-­‐1	  cell	   lines	  were	  used	  [381]	  and	  two	  populations	  of	  MonoMac-­‐6	  cells	  were	  found,	  
one	   expressed	   high	   levels	   of	   TACE	   and	   another	   that	   expressed	   negligible	   amounts.	   It	  was	  
noted	   that	   the	   relative	  proportions	  of	   these	  groups	   changed	  with	   time,	   rendering	   this	   cell	  
line	   sub-­‐optimal	   for	   use	   in	   investigating	   the	   acute	   TACE	   response	   to	   LPS.	   The	   THP-­‐1	   cells	  
appeared	  to	  present	  no	  such	  problem	  and	  displayed	  a	  significant	  (x3.3	  fold)	  increase	  in	  TACE	  
activity	   after	   a	   three	   hour	   LPS	   stimulation.	   Hence,	   in	   order	   try	   and	   minimise	   resources	  
required	  related	  to	  material	  (human	  blood),	  cost,	  speed,	  productivity	  and	  reproducibility,	  we	  
decided	  to	  use	  the	  THP-­‐1	  cell	  line	  and	  investigate	  the	  TACE	  response	  to	  a	  single	  LPS	  stimulus.	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In	   addition	   to	   studying	   the	   TACE	   response	   we	   sought	   to	   determine	   a	   rapid	   and	   reliable	  




The	  specific	  aims	  of	  this	  chapter	  were	  to:	  
1. Determine	  a	  suitable	  method	  of	  providing	  monocytes	   in	  order	  that	  the	  acute	  TACE	  
response	  could	  be	  determined	  in	  single	  hit	  conditions.	  





THP-­‐1	  cells	  were	  cultured	  as	  outlined	  in	  Chapter	  Two	  (methods).	  
	  
THP-­‐1	  cell	  stimulation	  
On	   the	   day	   that	   cells	   were	   removed	   from	   suspension	   culture	   conditions	   they	   were	  
centrifuged	  before	  being	   re-­‐suspended	   in	  HBSS	  with	  5%	  FCS	   at	   a	   cell	   density	  of	   5x106/ml.	  
Stimulation	   was	   performed	   in	   1.5ml	   Eppendorfs	   using	   LPS	   at	   concentrations	   of	   1pg	   to	  
10µg/ml	  for	  time	  periods	  of	  1.5	  to	  3	  hours	  at	  37°C.	  
	  
Blood	  collection	  
30	  ml	  of	  donor	  blood	  was	  obtained	  by	  venesection	  from	  healthy	  volunteers	  who	  had	  given	  
informed	  consent.	  Exclusion	  criteria	  were	   inter-­‐current	   illness	  or	  any	   immune-­‐suppression.	  
Blood	  was	  extracted	  directly	  into	  vacutainers	  containing	  EDTA.	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Monocyte	  stimulation	  
Monocytes	  were	   isolated	   from	  whole	   blood	   using	   differential	   centrifugation	   and	   a	   CD14+	  
bead	  selection	  strategy	  as	  outlined	  in	  Chapter	  Two	  (methods).	  Cells	  were	  then	  re-­‐suspended	  
at	   a	   concentration	   of	   5x106/ml	   in	   HBSS	   with	   5%	   FCS	   and	   stimulated	   using	   LPS	   at	  
concentrations	  of	  1pg	  to	  10µg/ml	  for	  time	  periods	  of	  1.5	  to	  3	  hours	  at	  37°C.	  
	  
Quantification	  of	  MAPK	  response	  
This	   was	   performed	   as	   outlined	   in	   Chapter	   Two	   (methods).	   Briefly,	   cells	   were	   fixed	   and	  
permeated	  before	  being	  stained	  with	  antibodies	  specific	  for	  the	  activated	  form	  of	  the	  MAPK	  
enzyme.	  Cell	  stimulation	  was	  performed	  at	  the	  same	  density	  and	  conditions	  as	  outlined	  for	  
the	   TACE	   response.	   An	   LPS	   concentration	   of	   1µg/ml	  was	   used	  with	   PBMCs	   stimulated	   for	  
either	  15	  or	  30	  minutes.	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3.3 Results	  
	  
The	  FRET	  assay	  is	  quantitative	  for	  TACE	  activity:	  
In	   order	   to	   demonstrate	   the	   quantitative	   nature	   of	   the	   FRET	   assay	   untreated	   THP-­‐1	   cells	  
were	   plated	   at	   varying	   densities	   and	   introduced	   into	   FRET	   assay	   conditions.	   Cells	   were	  
incubated	  with	  the	  FAM-­‐TAMRA	  peptide	  at	  a	  concentration	  of	  5µM	  and	  their	   fluorescence	  
intensity	  measured	  every	  minute	  for	  an	  hour	  (fig	  3.1A	  &	  B).	  
The	  system	  was	  then	  allowed	  to	  equilibrate	  for	  a	  20-­‐minute	  period	  after	  which	  TACE	  activity	  
was	  calculated	  by	  ascertaining	  the	  average	  rate	  of	   increase	  in	  the	  fluorescent	  signal	  over	  a	  
ten-­‐minute	  window.	  The	  curves	  obtained	  from	  the	  assay	  (fig	  3.1A)	  are	  linear	  after	  the	  initial	  
equilibration	   period	   indicating	   a	   constant	   rate	   of	   substrate	   hydrolysis.	   The	   results	  
demonstrate	   that	   TACE	   activity	  was	   directly	   proportional	   to	   cell	   density	   as	   expected.	   The	  
FRET	  assay	  has	  previously	  been	  validated	  for	  the	  THP-­‐1	  cell	  line	  by	  our	  laboratory	  [381].	  The	  
data	  (fig	  3.1B)	  shown	  is	  for	  a	  single	  experiment	  in	  unstimulated	  THP-­‐1	  cells	  that	  was	  in	  line	  
with	  our	  previous	  work	   [381],	  hence	   they	  were	  not	   immediately	   repeated	  and	   I	  moved	   to	  
determine	  the	  TACE	  response	  of	  these	  cells	  to	  LPS.	  
Although	  using	  high	   cell	   densities	   in	   the	  assay	   (e.g.	   1x106,	   fig	   3.1A)	  produced	  a	  high	  TACE	  
signal,	   previous	   published	   protocols	   from	  within	   our	   laboratory	   (including	   for	   THP-­‐1	   cells)	  
have	   been	   standardised	   to	   a	   cell	   density	   of	   either	   1	   or	   2x105	   per	   well	   [133,	   381].	   Such	  
densities	  have	  previously	  produced	  a	  robust	  TACE	  signal	  whilst	  preventing	  excessive	  use	  of	  
resources	  such	  as	  would	  be	  required	  at	  higher	  cell	  densities.	  Hence	  a	  concentration	  of	  1x105	  
cells/well	  was	   initially	  used	  when	  cells	  were	  placed	   in	   FRET	  assay	   conditions	   to	  determine	  
their	  TACE	  activity.	  
	   	  











Fig	  3.1:	  The	  FRET	  assay	  is	  quantitative	  for	  unstimulated	  THP-­‐1	  cells.	  
	  A	   Data	   obtained	   from	   FRET	   assay	   for	   unstimulated	   THP-­‐1	   cells	   plated	   at	   different	  
densities	  and	  left	  for	  60	  minutes.	  B	   TACE	   activity	   calculated	   from	   fluorescence	   curves	  
seen	   in	   figure	   3.1A.	   Activity	   is	   calculated	   as	  mean	   increase	   in	   FU	   over	   a	   ten	  minute	   time	  
period.	  Bars	  demonstrate	  that	  activity	  is	  directly	  proportional	  to	  cell	  density	  (n=1).	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Undifferentiated	  THP-­‐1	  cells	  do	  not	  acutely	  up-­‐regulate	  their	  TACE	  activity	  in	  response	  to	  
an	  LPS	  stimulus:	  
In	  order	  to	  determine	  the	  kinetics	  of	  TACE	  activity	  in	  response	  to	  an	  inflammatory	  stimulus,	  
THP-­‐1	  cells	  were	  stimulated	  with	  LPS.	  Previously	  in	  THP-­‐1	  cells	  [381]	  an	  LPS	  induced	  increase	  
in	  TACE	  activity	  has	  been	  shown	  to	  occur	  by	  three	  hours.	  TACE	  activation	  in	  primary	  cells	  has	  
been	  shown	  to	  occur	  as	  early	  as	  30	  minutes	  [133].	  Hence	  cells	  were	  removed	  from	  culture	  
and	   stimulated	   for	   time	   periods	   that	   varied	   from	   15	   minutes	   to	   three	   hours	   using	   a	  
saturating	  concentration	  of	  LPS	  (1µg/ml).	  
No	  consistent	  pattern	  of	  TACE	  activity	  up-­‐regulation	  was	  seen	  in	  response	  to	  LPS	  (fig	  3.2).	  A	  
trend	   toward	   increased	  activity	  was	   seen	  only	   at	   the	  30-­‐minute	   time	  point	   (un-­‐stimulated	  
379.9	   ±101.68FU/min	   vs.	   stimulated	   454.4	   ±41.58FU/min;	   non-­‐significant).	   Baseline	   THP-­‐1	  
cell	  TACE	  activity	  increased	  from	  0.25	  hours	  (un-­‐stimulated	  577.5	  ±34.79FU.min)	  through	  to	  
three	  hours	  (un-­‐stimulated	  1470.3	  ±24.18FU/min;	  p<0.001).	  
	   	  




Figure	  3.2:	  Undifferentiated	  THP-­‐1	  cells	  did	  not	  up-­‐regulate	  their	  TACE	  activity	  in	  response	  
to	  a	  LPS	  stimulus	  applied	  between	  0.25	  and	  three	  hours.	  
THP-­‐1	  cell	  time	  course	  in	  response	  to	  LPS	  stimulation	  at	  a	  concentration	  of	  1µg/ml	  (n=3).	  
No	  consistent	  increase	  in	  TACE	  activity	  in	  response	  to	  LPS	  seen	  
*	  Indicates	  significant	  difference	  to	  baseline	  un-­‐stimulated	  value	  (p<0.001)	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No	   acute	   up-­‐regulation	   of	   TACE	   activity	  was	   seen	   in	   undifferentiated	   THP-­‐1	   cells	   over	   a	  
range	  of	  LPS	  concentrations:	  
In	   order	   to	   further	   determine	   whether	   THP-­‐1	   cells	   displayed	   any	   alteration	   in	   their	   TACE	  
response,	  a	  range	  of	  LPS	  concentrations	  were	  used.	  In	  keeping	  with	  both	  previous	  laboratory	  
protocols	   and	   our	   focus	   on	   cellular	   acute	   inflammatory	   signalling	   characteristics	   a	   three-­‐
hour	  time	  point	  was	  used.	  LPS	  concentration	  ranged	  from	  1pg/ml	  through	  to	  10µg/ml.	  
In	  keeping	  with	  the	  results	  of	  the	  previous	  time	  course	  experiment,	  no	  up-­‐regulation	  of	  THP-­‐
1	  cell	  TACE	  activity	  was	  seen	  over	  a	  range	  of	  concentrations	  of	  LPS	  (fig	  3.3	  A).	  Untreated	  cell	  
TACE	   activity	  was	   similar	   to	   that	   obtained	  with	   the	   highest	   LPS	   concentration	   of	   10µg/ml	  
(untreated	   121.2	   ±35.25FU/min	   vs.	   LPS	   10µg/ml	   118.1	   ±39.87FU/min;	   non-­‐significant).	  
There	  were	  also	  no	  differences	  in	  cell	  surface	  TACE	  expression	  (untreated	  MFI	  145.61	  ±21.33	  
vs.	  LPS	  10μg/ml	  MFI	  127.31	  ±25.6;	  non-­‐significant,	  fig	  3.3B).	  
	   	  






Figure	   3.3:	   	   Undifferentiated	   THP-­‐1	   cells	   displayed	   no	   changes	   in	   their	   TACE	   activity	   or	  
expression	  profiles	  in	  response	  to	  a	  range	  of	  LPS	  concentrations.	  
A	   Undifferentiated	  THP-­‐1	  cells	  displayed	  no	   increase	   in	  TACE	  activity	   in	   response	  to	  a	  
range	  of	  LPS	  doses	  (n=4)	  
B	   No	  changes	  in	  surface	  expression	  of	  TACE	  were	  seen	  (n=3).	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THP-­‐1	   cell	   TACE	   activity	   remained	   refractory	   to	   LPS	   despite	   the	   use	   of	   1,25-­‐
dihydroxyvitamin	  D3	  (VD3)	  to	  induce	  differentiation:	  
The	   THP-­‐1	   cell	   line	   is	   pro-­‐monocytic	   (i.e.	   an	   undifferentiated	   monocyte	   precursor).	   It	   is	  
possible	  that	  the	  lack	  of	  response	  seen	  to	  LPS	  described	  above	  reflects	  this	  [382],	  and	  cells	  
require	   differentiation	   to	   generate	   full	   inflammatory	   signalling.	   Our	   group	   had	   previously	  
used	  the	  cytokine	  INF-­‐ϒ	  to	  induce	  this	  process	  but	  we	  were	  concerned	  this	  may	  have	  other,	  
unrecognised,	  actions	  that	  might	  impact	  on	  my	  results.	  
Efforts	  were	  made	  to	  induce	  differentiation	  in	  the	  THP-­‐1	  cells	  toward	  a	  monocyte	  phenotype	  
using	  vitamin	  D3	  (VD3).	  In	  accordance	  with	  a	  previously	  published	  protocol	  [383]	  cells	  were	  
treated	  for	  72	  hours	  with	  VD3	  at	  a	  concentration	  of	  10-­‐7M	  then	  stimulated	  with	  LPS	  1μg/ml	  
for	  three	  hours	  (fig	  3.6).	  There	  were	  no	  significant	  differences	  in	  THP-­‐1	  cell	  TACE	  activity	  in	  
response	  to	  LPS	  after	  72-­‐hour	  culture	  (untreated	  400.55	  ±69.9FU/min	  vs.	  LPS	  1μg/ml	  462.24	  
±77.18FU/min;	  non-­‐significant).	   There	  were	  also	  no	  differences	  between	  VD3	   treated	  cells	  
(VD3	   only	   457.58	   ±69.04FU/min	   vs.	   VD3	   and	   LPS	   μg/ml	   583.14	   ±100.81FU/min;	   non-­‐
significant).	   Similar	   TACE	   activity	   results	   were	   obtained	   for	   72-­‐hour	   VD3	   treatment	   at	   a	  
higher	   concentration	   of	   10-­‐6M	   (VD3	   only	   544.04	   ±165.18FU/min	   vs.	   VD3	   and	   LPS	   1μg/ml	  
695.77	  ±122.3FU/min;	  non-­‐significant).	  
	   	  










Figure	  3.6:	  THP-­‐1	  cells	  exposed	  to	  72-­‐hour	  VD3	  culture	  and	  subsequently	  stimulated	  with	  
LPS	  displayed	  no	  TACE	  activation.	  
THP-­‐1	  cells	  cultured	  with	  VD3	  10-­‐7M	  then	  stimulated	  with	  LPS	  1μg/ml	  for	  3	  hours	  displayed	  
no	  significant	  increase	  in	  their	  TACE	  activity	  levels	  (n=3).	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THP-­‐1	   cells	   remained	   relatively	   refractory	   to	   LPS	   despite	   culture	   with	   interferon-­‐ϒ	  
designed	  to	  induce	  differentiation:	  
THP-­‐1	  cells	  were	  used	  when	  developing	  the	  FRET	  assay	  and	  demonstrated	  a	  3.3	  fold	  increase	  
in	  activity	  in	  response	  to	  a	  three	  hour	  LPS	  stimulus.	  However,	  prior	  to	  this,	  they	  were	  treated	  
for	   16-­‐hours	   with	   INF-­‐ϒ	   100ng/ml	   [381].	   Hence	   we	   developed	   a	   similar	   protocol	   using	   a	  
range	  of	  INF-­‐ϒ	  doses	  in	  an	  effort	  to	  induce	  a	  TACE	  response	  to	  LPS.	  
Cells	   placed	   in	   16-­‐hour	   culture	   ±INF-­‐ϒ	   prior	   to	   LPS	   stimulation	   displayed	   a	   non-­‐significant	  
trend	  toward	  increased	  TACE	  activity	  in	  response	  to	  a	  three	  hour	  LPS	  stimulus	  (fig	  3.4A).	  This	  
ranged	  in	  size	  from	  a	  maximal	  value	  of	  a	  1.65	  fold	  increase	  (untreated	  244.8	  ±80.3FU/min	  vs.	  
LPS	  404	  ±8.89FU/min;	  non-­‐significant)	  in	  those	  cells	  exposed	  to	  LPS	  but	  no	  INF-­‐ϒ	  (untreated	  
244.8	  ±80.3FU/min	  vs.	  LPS	  404	  ±8.89FU/min;	  non-­‐significant)	  through	  to	  a	  1.14	  fold	  increase	  
to	   those	   cells	   exposed	   to	   LPS	   after	   16-­‐hour	   culture	   with	   INF-­‐ϒ	   1μg/ml	   (INF-­‐ϒ	   313.87	  
±14.94FU/min	   vs.	   INF-­‐ϒ	   and	   LPS	   358.4	   ±57.98FU/min;	   non-­‐significant).	   At	   no	   point	   was	  
statistical	  significance	  achieved	  or	  was	  an	  increase	  close	  to	  the	  3.3	  fold	  previously	  reported	  
seen.	  This	  trend	  was	  not	  present	   in	  cells	  exposed	  to	  LPS	  for	  only	  90	  minutes	  after	  16-­‐hour	  
INF-­‐ϒ	  culture	  (fig	  3.4B).	  
	   	  








Figure	  3.4:	   The	   effect	   of	   16	   hour	   INF-­‐ϒ	   pre-­‐treatment	   on	   THP-­‐1	   cell	   TACE	   catalytic	  
activity	  at	  baseline	  and	  in	  response	  to	  LPS	  stimulation.	  
A:	   Three	  hour	  LPS	  stimulation	  1μg/ml	  (n=3)	  
B:	   Ninety	  minute	  LPS	  stimulation	  1μg/ml	  (n=2)	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48-­‐hour	  INF-­‐ϒ	  treatment	  increased	  baseline	  TACE	  activity	  levels:	  
A	  further	  INF-­‐ϒ	  treatment	  of	  48	  hours	  was	  used,	  as	  it	  was	  possible	  that	  the	  16-­‐hour	  culture	  
previously	   used	   was	   insufficient	   to	   induce	   differentiation	   in	   the	   THP-­‐1	   cells.	   As	   the	   90-­‐
minute	   LPS	   stimulation	   used	   in	   the	   16-­‐hour	   interferon	   pre-­‐treatment	   had	   shown	   no	  
additional	  effect,	  the	  new	  (48-­‐hour)	  protocol	   incorporated	  only	  a	  three-­‐hour	  LPS	  exposure.	  
INF-­‐ϒ	   treatment	   for	   period	   of	   48-­‐hours	   induced	   significant	   elevation	   of	   baseline	   (p<0.01)	  
THP-­‐1	   cell	   TACE	   activity	   (fig	   3.5A).	   As	   shown	   in	   Figure	   3.4B	   secondary	   LPS	   stimulation	  
induced	  only	  small	  increases	  of	  TACE	  activity	  that	  ranged	  from	  a	  1.02	  fold	  increase	  in	  those	  
cells	  cultured	  with	  INF-­‐ϒ	  10ng/ml	  (INF-­‐ϒ	  only	  695.13	  ±44.69FU/min	  vs.	  INF-­‐ϒ	  and	  LPS	  768.53	  
±66FU/min;	  non-­‐significant)	  to	  a	  1.44	  fold	  increase	  in	  those	  cultured	  with	  INF-­‐ϒ	  1ng/ml	  (INF-­‐
ϒ	   only	   491.83	   ±40.1FU/min	   vs.	   INF-­‐ϒ	   and	   LPS	   708.1	   ±40.95FU/min;	   p<0.01).	  No	   significant	  
differences	  in	  TACE	  expression	  levels	  were	  seen	  for	  either	  the	  16-­‐hour	  (untreated	  MFI	  97.42	  
±18.25	   vs.	   INF-­‐ϒ	   1μg/ml	   86.94	   ±4.05;	   non-­‐significant)	   or	   48	   hour	   (untreated	   MFI	   76.82	  
±14.42	  vs.	  INF-­‐ϒ	  1μg/ml	  96.57	  ±36.32;	  non-­‐significant)	  treatments.	  
As	  no	  TACE	  response	   to	  LPS	  was	  seen,	   I	  did	  not	  examine	  surface	  expression	  of	  markers	  of	  
monocyte	   differentiation	   but	   rather	   sought	   to	   stimulate	   the	   THP-­‐1	   cells	   using	   a	   protein	  
kinase	   c	   agonist.	  On	   the	  basis	  of	   the	  data	  presented	   it	   is	  not	  possible	   to	   speculate	  on	   the	  
phenotype	  of	  the	  INF-­‐ϒ	  treated	  cells.	  
	   	  















Figure	  3.5:	   Effects	  of	  48	  hour	  INF-­‐ϒ	  treatment	  on	  THP-­‐1	  cell	  TACE	  catalytic	  activity.	  
A:	   THP-­‐1	  cells	  with	  no	  LPS	  stimulation	  (n=3,	  *	  p<0.01	  vs.	  untreated	  control)	  
B:	   THP-­‐1	  cells	  after	  secondary	  LPS	  stimulation	  1μg/ml	  for	  three	  hours	  (n=3)	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THP-­‐1	  cells	  were	  refractory	  to	  stimulation	  with	  phorbol-­‐12-­‐myristate-­‐13-­‐acetate	  (PMA):	  
The	  potent	  protein	  kinase	  c	  agonist	  PMA	  is	  known	  to	  produce	  TNF	  release	  from	  THP-­‐1	  cells	  
[384,	  385].	  It	  has	  also	  been	  shown	  to	  generate	  intra-­‐cellular	  ROS	  and	  induce	  TACE	  substrate	  
shedding	  [380].	  Doses	  as	  low	  as	  30ng/ml	  of	  PMA	  have	  been	  shown	  to	  induce	  an	  increase	  in	  
TACE	  catalytic	  activity	  as	  rapidly	  as	  10-­‐15	  minutes	  [381].	  Hence	  cells	  were	  directly	  stimulated	  
with	  PMA	  to	  determine	  whether	  any	  increase	  in	  TACE	  activity	  could	  be	  elicited.	  
Undifferentiated	  THP-­‐1	  cells	  were	  incubated	  with	  PMA	  1μg/ml	  for	  0.5,	  1	  and	  2	  hours,	  before	  
being	   removed	   from	  culture	   conditions	  and	  entered	   into	   the	  FRET	  assay.	  PMA	  stimulation	  
had	   no	   effect	   on	   cellular	   TACE	   activity	   at	   the	   0.5	   hour	   (untreated	   175.95FU/min	   vs.	   PMA	  
186.95FU/min),	  one	  hour	   (untreated	  226.43	  ±79.94FU/min	  vs.	  PMA	  251.86	  ±74.52FU/min)	  
or	   two	   hour	   (untreated	   148.33	   ±15.17FU/min	   vs.	   PMA	   134.57	   ±10.83FU/min)	   time	   points	  
studied	  (fig	  3.7).	  TACE	  expression	  levels	  were	  not	  measured.	  
	   	  












Figure	  3.7:	  Undifferentiated	  THP-­‐1	  cells	  did	  not	  increase	  TACE	  activity	  in	  response	  to	  a	  PMA	  
stimulus.	  	  
THP-­‐1	  cells	   stimulated	  with	  PMA	  1μg/ml	   for	  either	  0.5	  or	  1H	  displayed	  no	  up-­‐regulation	  of	  
TACE	  activity	  (n=1	  for	  0.5H,	  n=2	  for	  1H	  &	  2H).	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CD14	  positive	  bead	  selection	  strategy	  produced	  satisfactory	  cell	  yields	  and	  viability	  whilst	  
platelet	  contamination	  was	  minimised	  by	  utilising	  a	  two-­‐column	  separation	  strategy:	  
Purified	  monocytes	  were	  obtained	  from	  PBMCs	  by	  the	  use	  of	  differential	  centrifugation	  and	  
immune-­‐magnetic	  bead	  selection	  (fig	  3.8	  A&B).	  The	  use	  of	  a	  second	  column	  with	  a	  smaller	  
surface	   area	   was	   shown	   to	   reduce	   platelet	   contamination	   to	   acceptable	   levels	   (platelet:	  
monocyte	  ratio	  reduced	  from	  5:1	  to	  0.5:1)	  and	  increase	  purity	  of	  the	  eluted	  fraction	  without	  
prohibitively	  reducing	  cell	   retrieval.	  This	   is	   important	  as	  platelets	  express	  TACE	  and	  reduce	  
the	  signal	  to	  noise	  ratio	  of	  the	  FRET	  assay.	  Purity	  of	  the	  cell	  preparation	  was	  determined	  by	  
percentage	  of	  CD14+	  cells	  as	  a	  proportion	  of	  all	   intact	  cells	  and	  was	  routinely	  greater	  than	  
90%.	  Typically	   cell	   yield	  was	  60%	  as	   calculated	  by	   comparing	  CD14+	  cell	   numbers	  pre	  and	  
post	  separation.	  Viability	  was	  greater	  than	  90%.	  
	  
Positively	   selected	   monocytes	   produced	   an	   expression	   independent	   increase	   in	   TACE	  
activity	  in	  response	  to	  LPS:	  
Similar	   to	   previous	   data	   obtained	   using	   a	   negative	   selection	   strategy,	   positively	   selected	  
monocytes	   produced	   an	   acute	   up-­‐regulation	   of	   TACE	   activity	   when	   stimulated	   with	   LPS	  
1μg/ml	  for	  one	  hour	  (untreated	  44.02	  ±16.58FU/min	  vs.	  LPS	  103.84	  ±42.03FU/min;	  p<0.01,	  
fig	   3.9	   A).	   TACE	   activity	   increases	   seen	   on	   LPS	   stimulation	   ranged	   from	   a	   1.75	   -­‐	   3.54	   fold	  
increase	  with	  a	  mean	  value	  of	  2.4.	  These	  increases	  in	  enzyme	  activity	  were	  accompanied	  by	  
a	  consistent,	  but	  non-­‐significant,	   reduction	   in	  cell	   surface	  expression	   (untreated	  MFI	  57.34	  
±24.98	  vs.	  LPS	  MFI	  51.76	  ±17.02	  stimulated;	  fig	  3.9	  B).	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A	   	   	   	   	   	   	   	   B	  
	  
Figure	   3.8:	   Immune-­‐magnetic	   bead	   separation	   using	   a	   CD14	   positive	   selection	   strategy	  
produced	  monocyte	  preparations	  of	  high	  purity.	  
Representative	  flow	  cytometer	  plot	  for	  PBMCs	  with	  forward	  scatter	  (FSC-­‐H)	  and	  side	  scatter	  
(SSC-­‐H)	  labelled	  axis:	  
A	  -­‐	  Cells	  pre	  separation	  procedure	  	  
B	  -­‐	  Cells	  post	  separation	  procedure	  (two	  column).	  
The	  unlabelled	  population	  of	   cells	   circled	   in	  purple	  was	  occasionally	  present	  but	  was	  not	  a	  
consistent	  feature.	  These	  may	  be	  artefacts	  related	  to	  the	  isolation	  procedure.	  
	   	  


















Figure	   3.9:	   Isolated	  monocytes	  display	  an	   expression	   independent	  up-­‐regulation	  of	   TACE	  
activity	  in	  response	  to	  LPS.	  
Positively	  selected,	  isolated	  monocytes	  incubated	  with	  LPS	  1μg/ml	  for	  one	  hour	  display:	  
A:	   Increased	  TACE	  catalytic	  activity	  (n=5,	  *p<0.01)	  
B:	   A	  trend	  toward	  reduced	  surface	  TACE	  expression	  (n=5,	  p=	  0.2)	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Monocytes	   isolated	   by	   a	   positive	   selection	   strategy	   display	   increased	   TACE	   activity	   in	  
response	  to	  an	  LPS	  stimulus	  of	  one	  hour	  but	  not	  30	  minutes:	  
In	   order	   to	   compare	   the	   kinetics	   of	   the	   TACE	   activity	   increase	   using	   this	   new	   isolation	  
strategy,	   negatively	   selected	   and	   positively	   selected	  monocytes	  were	   stimulated	  with	   LPS	  
and	   placed	   in	   the	   FRET	   assay.	   Positive	   selection	   produced	   an	   attenuated	   TACE	   activity	  
increase	   at	   30	   minutes	   (untreated	   18.4FU/min	   vs.	   LPS	   22.2FU/min)	   but	   not	   at	   one	   hour	  
(untreated	  20.8FU/min	  vs.	  LPS	  53.4FU/min).	  This	  was	  in	  contrast	  to	  the	  negatively	  selected	  
monocytes	  where	  the	  activity	  increase	  was	  seen	  at	  30	  minutes	  (untreated	  67.63FU/min	  vs.	  
LPS	  109.8FU/min)	  as	  well	  as	  at	  one	  hour	  (untreated	  62.1FU/min	  vs.	  LPS	  123.6FU/min).	  
Hence	  LPS	  stimulations	  performed	  with	  positively	  selected	  monocytes	  were	  standardised	  to	  
one	  hour.	  
	  
LPS	  induced	  TACE	  up-­‐regulation	  is	  mediated	  in	  part	  through	  p38MAPK:	  
The	   rapid	   increase	   in	   TACE	   activity	   that	   is	   seen	   in	   response	   to	   an	   LPS	   stimulus	   has	   been	  
shown	  to	  be	  mediated,	  at	  least	  in	  part,	  through	  p38MAPK	  [133].	  To	  confirm	  this	  within	  the	  
paradigm	   of	   our	   model,	   PBMCs	   were	   stimulated	   with	   LPS	   (1µg/ml)	   and	   subjected	   to	   the	  
intra-­‐cellular	   staining	   protocol.	   Markers	   stained	   for,	   and	   measured	   using	   flow	   cytometry,	  
were:	  phosphorylated	  (phospho)-­‐p38MAPK,	  MK-­‐2	  and	  ERK.	  As	  can	  be	  seen	  from	  the	  results	  
(fig	   3.10)	   a	   signal	   was	   seen	   across	   all	   three	   markers.	   This	   signal	   reached	   significance	   for	  
phospho-­‐p38MAPK	   at	   15	   minutes	   (451	   ±128	   vs.	   145	   ±85	   at	   baseline,	   p<0.05).	   This	   was	  
repeated	   with	   freshly	   isolated	   monocytes	   and	   similar	   results	   obtained	   reinforcing	   our	  
previous	  data	   [133]	   that,	   in	  single	  hit	  conditions	  using	  static	  Eppendorf	   tubes,	  LPS	   induced	  
TACE	  up-­‐regulation	  is	  mediated,	  in	  part,	  through	  p38MAPK.	  
	   	  
















Figure	  3.10:	  PBMCs	  stimulated	  with	  LPS	  produced	  measurable	  increases	  in	  activated	  MAPK	  
levels.	  
Markers	  of	  intracellular	  activation	  in	  response	  to	  LPS	  1μg/ml	  for	  0,	  15	  and	  30-­‐minutes.	  
Figures	  are	  for	  PBMCs	  gated	  on	  CD14+	  population.	  For	  all	  three	  markers	  LPS	  15	  minutes	  
produces	  measurable	  increases	  in	  activated	  levels	  with	  reduction	  towards	  baseline	  by	  30	  
minutes	  
N=3	  for	  all,	  *p<0.05	  vs.	  control	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3.5	   Discussion	  
For	  the	  project	  to	  progress	  it	  was	  fundamentally	  important	  to	  be	  able	  to	  generate	  a	  reliable	  
and	   viable	   supply	   of	   monocytes.	   Previously	   in	   the	   laboratory	   both	   primary	   human	  
monocytes	   and	   human	   cell	   lines	   have	   been	   used	   to	   provide	   this.	   Due	   to	   the	   expense	  
associated	  with	  previous	  methods	  of	  monocyte	  isolation	  [133],	  and	  because	  the	  FRET	  assay	  
had	  previously	  been	  partially	  validated	  with	  them,	  the	  pro-­‐monocytic	  human	  cell	  line	  THP-­‐1	  
was	  initially	  chosen	  as	  the	  cell	  source.	  
	  
Undifferentiated	  THP-­‐1	  cells	  did	  not	  produce	  a	  TACE	  response	  to	  LPS	  
In	   primary	   human	   monocytes	   we	   have	   shown	   that	   the	   acute	   TACE	   response	   to	   LPS	   is	  
mediated	   through	   the	   CD14-­‐TLR4	   complex,	   intra-­‐cellular	   ROS	   and	   p38MAPK	   [133].	   It	   is	  
known	   that	   the	   THP-­‐1	   cell	   line	   in	   their	   undifferentiated	   form	   express	   low	   levels	   of	   CD14	  
[386]	  whilst	   it	  has	  also	  been	  noted	  that	  relatively	  high	  concentrations	  of	  LPS	  (≥1μg/ml)	  are	  
required	  to	  elicit	  a	  sol-­‐TNF	  response	  in	  undifferentiated	  cells	  [387],	  possibly	  as	  a	  result	  of	  the	  
lower	   CD14	   levels.	   However,	   despite	   this,	   some	   groups	   using	   undifferentiated	   THP-­‐1	   cells	  
have	   reported	   LPS	   induced	   ROS	   production	   [388]	   and	   phosphorylation	   of	  MAPK	   (p38	   and	  
JNK)	  [389].	  
Previously	   within	   our	   lab	   we	   have	   used	   the	   cytokine	   INF-­‐ϒ	   in	   these	   cells	   to	   induce	  
differentiation.	  This	  cytokine	  is	  likely	  to	  have	  multiple	  effects	  and	  can	  be	  considered	  “dirty”.	  
Encouraged	  by	   reports	  of	   LPS	   induced	  activation	   in	  THP-­‐1	  cells,	  despite	   the	   reports	  of	   low	  
CD14	  levels,	  we	  decided	  initially	  to	  avoid	  using	  INF-­‐ϒ	  and	  work	  with	  undifferentiated	  THP-­‐1	  
cells.	   Unfortunately	   it	   rapidly	   became	   apparent	   that	   the	   acute	   TACE	   response	   to	   LPS	  was	  
lacking	   in	   these	   cells	   and	   we	   saw	   no	   response	   even	   at	   very	   high	   (10μg/ml)	   LPS	  
concentrations.	   There	   were	   however,	   some	   time	   dependent	   increases	   in	   non-­‐stimulated	  
THP-­‐1	  cell	  TACE	  activity	  that	  presumably	  reflects	  some	  activation	  of	  the	  cells	  as	  a	  result	  of	  
the	  incubation	  process.	  A	  lack	  of	  responsiveness	  to	  LPS	  has	  previously	  been	  attributed	  to	  a	  
relative	   immaturity	   of	   the	   THP-­‐1	   cell	   [387].	   Thus	   the	   next	   step	   was	   to	   try	   and	   induce	  
differentiation	  in	  the	  cells.	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Differentiated	  THP-­‐1	  cells	  did	  not	  produce	  a	  consistent	  response	  to	  LPS	  
In	  a	  continued	  effort	  to	  avoid	  using	  INF-­‐ϒ	  due	  to	  the	  concerns	  outlined	  above	  we	  considered	  
alternative	  methods	   of	   inducing	   differentiation.	   Previously	   both	   PMA	   and	   VD3	   have	   been	  
used	  [383]	   to	  differentiate	  THP-­‐1	  cells.	  PMA	  activates	  protein	  kinase	  C	   [390]	  and	  has	  been	  
shown	   itself	   to	   activate	  both	  TACE	   [381]	   and	   induce	  TNF	   shedding	   [392]	   in	   cell	   lines,	   thus	  
may	  not	  be	  appropriate	  as	  an	  agent	  of	  differentiation	  in	  studying	  TACE	  biology.	  
VD3	   acts	   via	   the	   vitamin	  D	   receptor	   [393]	   and	   has	   been	   used	   to	   induce	   differentiation	   of	  
THP-­‐1	   cells.	   It	   therefore	   seemed	   a	   rational	   agent	   to	   use	   in	   this	   context.	   We	   followed	   a	  
published	   protocol	   [383]	   that	   involved	   a	   72-­‐hour	   incubation	   with	   VD3.	   Cells	   were	   then	  
stimulated	  with	  LPS	   in	  an	  effort	   to	   induce	  an	  acute	  TACE	  response.	  No	  response	  was	  seen	  
which	   could	   reflect	   either	   a	   failure	   of	   the	   differentiation	   process	   or	   cellular	   hypo-­‐
responsiveness	   due	   to	   contamination.	   Contamination	   of	   cells	   with	   LPS	   would	   produce	   a	  
“tolerant”	   cell	   phenotype	   that	   would	   be	   refractory	   to	   further	   LPS	   stimulation	   [322].	   In	  
addition	   Mycoplasma	   contamination	   of	   THP-­‐1	   cells	   is	   known	   to	   attenuate	   TLR	   responses	  
[394]	  and	   is	   a	  plausible	  explanation	   for	   their	   lack	  of	   response	   to	   LPS,	   although	   the	   lack	  of	  
response	  to	  a	  non-­‐TLR	  stimulus	  (PMA)	  is	  not	  in	  keeping	  with	  this	  last	  point.	  
We	  then	  employed	  an	  INF-­‐ϒ	  differentiation	  protocol	  that	  had	  previously	  been	  successful	  at	  
inducing	   an	   acute	   TACE	   response	   in	   THP-­‐1	   cells	   [381].	   This	   incorporated	   a	   16-­‐hour	   INF-­‐ϒ	  
treatment	   followed	   by	   a	   secondary	   LPS	   stimulation.	   This	   protocol	   resulted	   in	   a	   small	   but	  
consistent	  TACE	  response	  to	  LPS.	  However	  this	  response	  did	  not	  reach	  statistical	  significance	  
nor	  approach	  the	  x3.3	  fold	  activity	  increase	  that	  had	  been	  seen	  previously.	  It	  is	  possible	  that	  
the	  cells	  were	  not	   fully	  differentiated	  by	  the	  16-­‐hour	  time	  point	  so	  we	  extended	  the	   INF-­‐ϒ	  
treatment	   to	   48-­‐hours.	   However,	   this	   treatment	   increased	   basal	   TACE	   activity	   further	  
reinforcing	  our	  concerns	  about	  “off	  target”	  inflammatory	  effects	  of	  INF-­‐ϒ.	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CD14	  positive	  bead	  selection	  allows	  isolation	  of	  monocytes	  without	  attenuating	  their	  TACE	  
response	  to	  LPS	  
At	  this	  point	  the	  project	  was	  reappraised	  and	  we	  decided	  that	  an	  alternative	  source	  of	  cells	  
should	   be	   investigated.	   We	   had	   previously	   discovered	   limitations	   when	   examining	   TACE	  
biology	  in	  another	  cell	  line	  (MonoMac	  6)	  so	  decided	  to	  identify	  a	  viable	  method	  of	  isolating	  
primary	  monocytes	  [381].	  
Previously	   within	   the	   group	   we	   had	   isolated	   monocytes	   using	   a	   magnetic	   activated	   cell	  
separation	   technique	   employing	   a	   negative	   selection	   strategy.	   In	   this	   technique	   non-­‐
monocyte	   populations	   are	   labelled	   with	   antibodies	   attached	   to	   magnetic	   beads.	   The	   cell	  
mixture	   is	   then	   placed	  within	   a	   column	   that	   is	  within	   a	  magnetic	   field	   and	   labelled	   (non-­‐
monocyte)	   cells	   are	   retained	   within	   the	   column	   and	   unlabelled	   cells	   (monocytes)	   pass	  
through.	   As	   the	   monocytes	   are	   unlabelled	   this	   technique	   may	   not	   alter	   their	   response	  
characteristics.	   However,	   this	   technique	   requires	   a	   number	   of	   different	   antibody-­‐bead	  
combinations,	   is	   expensive	   and	   thus	  was	   not	   a	   plausible	   option	   for	   this	   project.	   A	   further	  
disadvantage	  of	   this	   technique	   is	   the	  presence	  of	  platelets	  as	  a	  contaminant	  of	   the	  eluted	  
fraction.	  Platelets	  express	  low	  levels	  of	  TACE	  meaning	  that	  the	  signal:	  noise	  ratio	  in	  the	  FRET	  
assay	   is	   reduced.	   Previously	   we	   had	  modified	   the	   isolation	   protocol	   to	   include	   anti-­‐CD61	  
microbeads	  [133],	  further	  increasing	  the	  cost.	  
An	  alternative	  to	  the	  negative	  selection	  procedure	  outlined	  above	  is	  to	  positively	  select	  cells.	  
In	   this	   protocol	   the	   desired	   cells	   (in	   this	   case	   monocytes)	   are	   themselves	   labelled	   with	  
magnetic	  beads.	  Thus	  when	  placed	  within	  the	  column	  within	  a	  magnetic	  field	  the	  monocytes	  
are	   retained	   within	   a	   column	   and	   can	   be	   retrieved.	   As	   only	   one	   set	   of	   antibody	   labelled	  
beads	  is	  required	  this	  technique	  is	  cheaper	  but	  as	  the	  monocytes	  are	  labelled	  their	  response	  
characteristics	  may	  be	  affected.	  Nevertheless	  we	  decided	  to	  investigate	  this	  as	  an	  option	  for	  
isolating	  cells	  using	  an	  anti-­‐CD14	  antibody.	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We	  rapidly	  established	  that	  this	  was	  an	  effective	  way	  of	  producing	  monocyte	  suspensions	  of	  
high	  purity	  (fig	  3.8)	  and	  viability.	  By	  modifying	  the	  protocol	  so	  that	  two	  columns	  were	  used	  
in	   series,	   platelet	   contamination	  was	   reduced	   substantially	   providing	  optimised	   conditions	  
to	   detect	   the	   TACE	   response.	   I	   then	   demonstrated	   that	   cells	   isolated	   in	   this	   manner	  
produced	   an	   up-­‐regulation	   of	   TACE	   activity	   in	   response	   to	   an	   LPS	   stimulus	   applied	   for	   an	  
hour.	   To	   ensure	   that	   the	   use	   of	   a	   CD14	   binding	   antibody	   did	   not	   substantially	   alter	   the	  
response	   to	   LPS	   (mediated	   through	   CD14)	   we	   compared	   the	   TACE	   response	   to	   LPS	   in	  
negatively	   and	  positively	   selected	   cells.	  Although	   the	  activity	   increase	   seen	   in	   response	   to	  
LPS	  was	  apparent	  in	  both	  at	  one	  hour,	  it	  was	  apparent	  in	  only	  the	  negatively	  selected	  cells	  at	  
30	   minutes.	   Hence	   all	   stimulations	   performed	   with	   positively	   isolated	   monocytes	   were	  
standardised	  to	  one	  hour.	  
Although	   non-­‐significant,	   this	   TACE	   activation	   in	   the	   positively	   selected	   cells	   was	  
accompanied	  by	  a	  down-­‐regulation	  in	  cell	  surface	  expression	  of	  the	  enzyme.	  Previously	  with	  
the	  negative	  selection	   technique	  we	  had	  not	  seen	   this.	  We	  hypothesise	   that	   this	   is	  due	   to	  
either	  shedding	  or	  stimulation	  induced	  down-­‐regulation	  both	  of	  which	  have	  been	  described	  
in	  relation	  to	  TACE	  [369].	  The	  fact	  that	  this	  was	  not	  seen	  in	  our	  previous	  work	  on	  the	  acute	  
TACE	   response	   [133]	   presumably	   reflects	   the	   difference	   in	   the	   duration	   of	   the	   LPS	  
stimulation	  (30	  minutes	  vs.	  one	  hour),	  the	  different	  methods	  of	  monocyte	  isolation	  or	  both.	  
Thus,	  despite	  the	  importance	  of	  CD14	  in	  LPS	  recognition	  and	  TLR-­‐4	  signalling,	  we	  observed	  
no	  obvious	  deficit	   in	  LPS-­‐induced	  TACE	  activation	  at	  the	  one	  hour	  time	  point,	  compared	  to	  
the	   previously	   used	   negative	   selection	   method.	   This	   apparent	   lack	   of	   interference	  
presumably	   reflects	   the	  epitope	  specificity	  of	   the	  CD14	  monoclonal	  antibody	  and	  the	  non-­‐
saturating	   antibody	   concentrations	   recommended	   by	   the	   manufacturer	   (Miltenyi,	   UK).	   In	  
combination	  these	  two	  factors	  should	  ensure	  that	  any	  effects	  of	  the	  CD14	  antibody	  on	  the	  
CD14-­‐LPS	  signalling	  complex	  are	  minimised.	  
	  
Isolated	  monocytes	  stimulated	  with	  LPS	  contained	  increased	  levels	  of	  activated	  MAPKs	  
The	   final	   part	   of	   work	   in	   this	   chapter	   was	   to	   provide	   a	   method	   for	   determining	   MAPK	  
responses.	  MAPKs	   exist	   in	   two	   isoforms,	   un-­‐phosphorylated	   and	   phosphorylated	  with	   the	  
latter	   representing	   the	   activated	   isoform	   that	   is	   generated	   in	   response	   to	   LPS	   [133].	  
Previously	  we	  have	  used	  materials	  to	  fix	  and	  make	  permeable	  the	  cells,	  antibodies	  specific	  
for	   the	   phosphorylated	   MAPK	   isoform,	   and	   flow	   cytometry,	   to	   detect	   changes	   in	   MAPK	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activation	  status.	  We	  modified	  and	  optimised	  this	  protocol	  in	  which	  PBMCs	  were	  fixed	  and	  
made	   permeable	   before	   being	   incubated	   with	   antibodies	   specific	   to	   the	   phosphorylated	  
forms	  of	  these	  enzymes.	  We	  were	  successful	  in	  identifying	  a	  signal	  across	  all	  three	  markers	  
(p38,	  MK-­‐2,	  ERK)	  with	   significantly	  elevated	   levels	  of	   activated	  p38MAPK	  15	  minutes	  after	  
LPS	  stimulation.	  These	  results	  were	   in	   line	  with	  our	  previous	  findings	  [133]	  on	  LPS	   induced	  
signalling	  in	  static	  Eppendorfs.	  
	  
Conclusions	  
In	  summary,	  in	  this	  chapter	  I	  successfully	  identified	  and	  optimised	  a	  viable	  and	  reproducible	  
method	   of	   providing	   sufficient	   quantities	   of	   monocytes	   to	   proceed	   with	   the	   project.	   I	  
outlined	  the	  kinetics	  of	  the	  acute	  TACE	  response	  and	  its	  upstream	  signalling	  in	  the	  form	  of	  
MAPK	  activation	  in	  these	  cells,	  and	  found	  them	  to	  be	  broadly	  in	  keeping	  with	  our	  previous	  
work	   in	   this	  area.	  This	  work	  was	  of	   fundamental	   importance	  to	   the	  project	  as	   the	  method	  
developed	  here	  underpins	  every	  subsequent	  piece	  of	  work	  contained	  within	  this	  thesis.	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Summary	  
Having	   established	   a	   suitable	  method	   of	   isolating	  monocytes,	   I	   next	   sought	   to	   determine	  
how	  the	  TACE	  activity	  profiles	  were	  altered	  by	  continuous	  exposure	  to	  a	  septic	  stimulus	  such	  
as	  LPS	  in	  vitro.	  
Monocytes	  are	  known	  to	  become	  tolerant	  to	  a	  second	  inflammatory	  stimulus	  when	  they	  are	  
exposed	   to	   a	   large	   initial	   stimulus.	   They	   can	   also	   be	   primed	   to	   subsequent	   inflammatory	  
stimuli	  by	  a	  prior	  low-­‐dose	  stimulus.	  Such	  states	  may	  be	  considered	  similar	  to	  CARS	  and	  SIRS	  
respectively	   yet	   TACE	   activity	   has	   not	   been	   evaluated	   in	   tolerant	   or	   primed	   monocytes.	  
Changes	  in	  TACE	  activity	  due	  to	  priming	  or	  tolerance	  may	  impact	  on	  the	  levels	  and	  activity	  of	  
its	  membrane	  substrates	  and	  their	  soluble	  cleavage	  products.	  
I	   created	  a	   two-­‐hit	  model	  using	  a	   culture	   insert	  made	  of	  polytetrafluoroethylene	   (PTFE),	   a	  
minimally	  adherent	  material,	   in	  order	  to	  prevent	  any	  spontaneous	  in-­‐situ	  differentiation	  of	  
monocytes	  during	   the	  extended	   in	  vitro	   incubations.	  Monocyte	  TACE	  activity	  profiles	  were	  
determined	   over	   a	   range	   of	   different	   LPS	   treatments	   that	   were	   intended	   to	   induce	  
differential	   states	  of	  priming	  and	  tolerance.	  Soluble	  TNF	   levels	  were	  quantified	   in	  order	   to	  
definitively	   determine	   how	   these	   activity	   profiles	   related	   to	   monocyte	   inflammatory	  
balance/output.	  We	  found	  that	  a	  state	  of	  net	  tolerance	  was	  induced	  by	  16-­‐hour	  PTFE	  culture	  
with	  LPS	  at	  a	  concentration	  of	  1μg/ml.	  Tolerant	  cells	  displayed	  elevated	  baseline	  activity	  and	  
an	   attenuated	   response	   to	   further	   LPS	   stimulation.	   However,	   we	   found	   no	   evidence	   of	  
priming	  with	   this	   in	   vitro	  model.	  We	   next	   sought	   to	   determine	   the	   kinetics	   of	   the	  MAPK	  
response	   to	   LPS	   within	   cells	   rendered	   tolerant	   by	   LPS,	   but	   found	   that	   untreated	   16-­‐hour	  
PTFE	   culture	   alone	   attenuated	   this	   response.	   This	   meant	   that	   the	   MAPK	   response	   was	  
directly	   affected	  by	  non-­‐adherent	   culture.	   This	  prevented	  us	   from	   further	   analysing	  MAPK	  
responses	  in	  the	  two-­‐hit	  model.	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Finally	  we	  examined	  the	  behaviour	  of	  known	  TACE	  substrates	  within	  the	  model	  and	  found	  
that	   they	  were	  differentially	  affected.	  Consistent	  with	  a	   tolerant	  state,	  TNFR	  shedding	  was	  
reduced	  by	  LPS	  pre-­‐exposure.	   In	  contrast,	  L-­‐selectin	  shedding	  was	  reduced	  by	  PTFE	  culture	  
alone.	  Although	  we	  were	  successful	  in	  producing	  a	  net	  state	  of	  tolerance	  in	  cells,	  the	  clinical	  
relevance	  of	  these	  results	  is	  uncertain.	  
	  
4.1	   Background	  
We	  hypothesised	  that	  TACE	  plays	  a	  key	  role	  in	  determining	  monocyte	  inflammatory	  balance,	  
and	   therefore	   is	   a	   central	   regulator	   of	   both	   the	   hyper	   and	   hypo-­‐responsive	   states	   that	  
determine	  sepsis	  pathophysiology	  [37].	  Monocytes	  can	  become	  tolerant	  to	  an	  inflammatory	  
stimulus	   after	   large	   dose	   exposure	   and	   this	   can	   be	   considered	   hypo-­‐responsive.	   Similarly	  
monocytes	   can	  be	  primed	   to	   an	   inflammatory	   stimulus	   and	   this	   can	  be	   considered	  hyper-­‐
responsive.	   We	   attempted	   to	   induce	   these	   states	   (tolerance	   and	   priming)	   in	   monocytes	  
before	   measuring	   their	   TACE	   activity	   and	   substrate	   behaviour	   to	   determine	   whether	   the	  
enzyme	  was	  acting	  as	  an	  inflammatory	  regulator.	  
To	   try	   and	   induce	   the	   primed	   and	   tolerant	   phenotypes	   we	   decided	   to	   use	   a	   “two-­‐hit”	  
strategy	   in	   which	   cells	   were	   exposed	   to	   two	   inflammatory	   stimuli.	   The	   first	   of	   these	   was	  
intended	  as	  a	  conditioning	  stimulus	  (of	  varying	  doses)	  designed	  to	  induce	  a	  state	  of	  priming	  
or	   a	   state	   of	   tolerance.	   The	   second	   was	   a	   standardised	   stimulus	   designed	   to	   reveal	   the	  
underlying	  response	  phenotype.	  LPS	  was	  used	  for	  both	  hits	  as	  it	  is	  the	  classical	  agent	  used	  to	  
induce	   tolerance	   [322]	   and	   has	   also	   been	   used	   to	   prime	   cells	   [316,	   395,	   396].	   Other	  
investigators	  had	   induced	  priming	  and	   tolerance	  using	  protocols	   in	  which	   the	   two	  LPS	  hits	  
were	   20-­‐24	   hours	   apart	   [315,	   397].	   In	   the	   first	   of	   these	   papers,	   Heremans	   et	   al	  
demonstrated	  priming	   in	   a	  murine	  model	   in	  which	  a	   footpad	   injection	  of	   LPS	   generated	  a	  
supra-­‐normal	   response	   to	   a	   secondary	   LPS	   stimulus	   administered	   24	   hours	   later.	   In	   the	  
second,	   Porta	   et	   al	   generated	   an	   in-­‐vitro	   model	   of	   tolerance	   in	   which	   monocytes	   were	  
incubated	   with	   LPS	   for	   20	   hours	   before	   being	   re-­‐challenged	   with	   LPS.	   Given	   these	   two	  
studies	  we	   set	   the	  duration	  of	   the	   initial	   LPS	   culture	  at	  16	  hours	  and,	   in	   keeping	  with	   the	  
work	   detailed	   in	   Chapter	   Three,	   the	   duration	   of	   the	   second	   hit	   was	   standardised	   to	   one	  
hour.	  We	  also	  quantified	  soluble	  TNF	  release	  in	  response	  to	  a	  second	  LPS	  hit	  to	  allow	  us	  to	  
relate	   enzyme	   activity	   profiles	   to	   monocyte	   inflammatory	   output.	   As	   addressed	   in	   the	  
introduction,	  monocyte	  response	  states	  could	  be	  modulated	  through	  the	  release	  of	  TNFR-­‐1	  
and	  2.	  For	  example,	  shedding	  of	  TNFRs	  could	  bind	  any	   locally	   released	  sol-­‐TNF,	  potentially	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resulting	   in	   a	   tolerant	   state.	   The	   reverse	   process	  may	   increase	   local	   levels	   of	   sol-­‐TNF	   and	  
result	   in	   a	   primed	   state.	   Therefore,	   I	   measured	   both	   the	   expression	   and	   LPS	   induced	  
shedding	   of	   TNFR-­‐1	   and	   TNFR-­‐2.	   I	   also	   chose	   to	  measure	   the	   expression	   and	   LPS	   induced	  
shedding	  of	  the	  adhesion	  molecule	  L-­‐selectin	  as	  adherence	  has	  been	  specifically	  implicated	  
in	  priming	  [378].	  
Previous	   methods	   of	   modelling	   tolerance	   and	   priming	   have	   used	   an	   adherence	   step	   to	  
isolate	  monocytes	  from	  PBMC	  populations	  [326],	  cultured	  bone	  marrow	  derived	  progenitors	  
[398]	  or	  cell	  lines	  [399].	  Adherence	  has	  been	  demonstrated	  to	  induce	  differential	  effects	  of	  
IL-­‐10	  in	  monocytes	  [400]	  as	  well	  as	  enhancing	  TNF	  production	  [378,	  401].	  Therefore	  we	  had	  
significant	   concerns	   that	   placing	   monocytes	   in	   an	   adherent	   environment	   could	   induce	  
spontaneous	  activation/maturation	  and	  result	  in	  a	  change	  in	  their	  response	  phenotype.	  
In	  order	  to	  prevent	  any	  such	  change	  occurring	  and	  also	  to	  facilitate	  a	  gentle	  non-­‐activating	  
cell	  retrieval	  process	  we	  used	  a	  minimally	  adherent	  material,	  polytetrafluoroethylene	  (PTFE),	  
a	  form	  of	  Teflon®.	  Teflon®	  has	  been	  used	  in	  the	  suspension	  culture	  of	  monocytes	  [402]	  with	  
PTFE	  though	  to	  adhere	  and	  activate	  the	  lowest	  numbers	  of	  monocytes	  [403].	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4.2	   Aims	  
	  
The	  specific	  aims	  of	  this	  chapter	  were:	  
1. To	  quantify	  monocyte	  TACE	  activity	  profiles	  within	  a	  two-­‐hit	  LPS	  model	  
2. Then	   determine	   whether	   response	   characteristics	   were	   consistent	   with	  
differential	  states	  of	  priming	  and	  tolerance	  
	  
4.3	   Protocols	  
	  
Blood	  collection	  
30	  ml	  of	  donor	  blood	  was	  obtained	  by	  venesection	  from	  healthy	  volunteers	  who	  had	  given	  
informed	   consent.	   Exclusion	   criteria	   were	   inter-­‐current	   illness	   or	   immune-­‐suppression.	  
Blood	  was	  extracted	  directly	  into	  vacutainers	  containing	  EDTA.	  
	  
Monocyte	  stimulation	  for	  first	  LPS	  hit	  
Monocytes	   were	   isolated	   from	   whole	   blood	   using	   differential	   centrifugation	   followed	   by	  
magnetic	  activated	  cell	  sorting	  utilising	  a	  CD14	  positive	  bead	  selection	  strategy	  as	  outlined	  in	  
detail	  in	  Chapter	  Two.	  Monocytes	  were	  then	  placed	  in	  PTFE	  inserts	  within	  12	  well	  plates	  at	  a	  
density	  of	  3x106/ml	  for	  16-­‐hours	  with	  or	  without	  LPS	  (1ρg/ml	  -­‐	  1μg/ml).	  For	  determination	  
of	   TNFR-­‐1	   &	   2,	   L-­‐selectin	   and	   HLA-­‐DR	   expression,	   PBMC,	   isolated	   from	   whole	   blood	   and	  
plated	  using	  the	  same	  protocol	  at	  3x106	  CD14+	  cells	  per	  ml,	  were	  used.	  
Where	  TACE	  activity	  was	  determined	  this	  was	  done	  as	  outlined	  in	  detail	  in	  Chapter	  Two.	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Monocyte	  stimulation	  for	  second	  LPS	  hit	  
Cells	  were	  retrieved	  from	  culture	  and	  re-­‐suspended	  at	  a	  density	  of	  2x106/ml	  in	  HBSS	  with	  5%	  
FCS.	   They	   were	   subsequently	   placed	   in	   1.5ml	   polypropylene	   Eppendorfs	   and	   stimulated	  
using	  LPS	  at	  a	  concentration	  of	  1µg/ml	  for	  one	  hour	  at	  37°C.	  Polypropylene	  Eppendorfs	  were	  
used	  as	  monocytes	  were	  LPS	  stimulated	  in	  these	  tubes	  during	  the	  work	  presented	  in	  Chapter	  
Three.	   For	   determination	   of	   TNFR-­‐1	   &	   2,	   L-­‐selectin	   and	   HLA-­‐DR	   expression	   the	   same	  
protocol	  was	  used	  but	  with	  PBMCs	  at	  a	  density	  of	  2x106	  CD14+	  cells	  per	  ml.	  These	  densities	  
were	   lower	  than	  those	  used	  previously	  but	  were	  required	  to	  mitigate	  against	  volume	  (and	  
hence	  cell)	  losses	  during	  the	  protocol.	  
	  
Interferon	  stimulation	  
Monocytes	   were	   placed	   in	   16-­‐hour	   PTFE	   culture	   with	   human	   INF-­‐ϒ	   at	   different	  
concentrations.	   Cells	   were	   retrieved	   and	   their	   TACE	   activity	   determined.	   Where	   cellular	  
response	   to	   a	   subsequent	   LPS	   stimulation	   was	   determined,	   monocytes	   were	   placed	   in	  
culture	  conditions	  identical	  to	  those	  used	  for	  the	  second	  LPS	  hit	  (outlined	  above).	  
	  
Soluble	  TNF	  quantification	  
Monocytes	  were	  stimulated	  for	  the	  first	  hit	  as	  above.	  Cells	  were	  subsequently	  retrieved	  and	  
re-­‐suspended	  and	  left	  for	  an	  hour	  to	  allow	  release	  of	  any	  cell	  associated	  soluble	  mediators	  
(including	   TNF)	   that	   might	   have	   been	   carried	   over	   from	   the	   previous	   culture.	   They	   then	  
received	  an	  additional	   rinse	  before	  being	  re-­‐suspended	  and	  stimulated	  with	  LPS	  1μg/ml	  at	  
37°C	   for	   second	  LPS	  hit.	  Supernatants	  were	  collected	  at	  one,	   three	  and	  six	  hours	  with	  sol-­‐
TNF	  levels	  determined	  by	  ELISA.	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Quantification	  of	  MAPK	  response	  
This	   was	   performed	   as	   outlined	   in	   detail	   in	   Chapter	   Two.	   Briefly,	   cells	   were	   fixed	   and	  
permeabilised	   before	   being	   stained	   with	   antibodies	   specific	   for	   the	   activated	  
phosphorylated	   form	   of	   the	   MAPK	   enzyme.	   Cell	   stimulation	   was	   performed	   at	   the	   same	  
density	  and	  conditions	  as	  outlined	   for	   the	  TACE	  response.	  An	  LPS	  concentration	  of	  1µg/ml	  
was	  used	  with	  monocytes	  stimulated	  for	  either	  15	  or	  30	  minutes.	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4.4	   Results	  
	  
Evaluation	  of	  cell	  recovery	  and	  viability	  in	  16-­‐hour	  PTFE	  culture	  
After	  16-­‐hour	  PTFE	  culture,	  monocytes	  were	  retrieved	  by	  performing	  three	  rinses	  with	  cold	  
HBSS	   supplemented	   with	   5%	   FCS.	   Gentle	   pipetting	   was	   employed	   to	   ensure	   minimal	  
activation	   during	   recovery	   of	   non-­‐adherent	   cells.	   This	   process	   resulted	   in	   mean	   retrieval	  
rates	  of	  53.12	  ±8.95%	  of	  the	  total	  number	  of	  monocytes	  placed	  into	  16-­‐hour	  culture	  (both	  
for	  untreated	  and	  LPS-­‐treated).	  Total	  retrieved	  cell	  viability	  was	  73.68	  ±7.08%.	  
After	   the	   second	   LPS	  hit	   in	   Eppendorfs,	   total	   retrieval	   rates	   fell	   further	   and	   typically	  were	  
between	   20-­‐30%	   of	   those	   placed	   in	   overnight	   culture.	   To	   avoid	   the	   requirement	   for	  
additional	  donor	  monocyte	  collection,	   the	  FRET	  assay	  was	  miniaturised	  by	  a	   factor	  of	   four	  
with	  cell	  density	  reduced	  four	  fold,	  compared	  to	  our	  previously	  published	  protocol	  [381].	  A	  
series	   of	   internal	   validation	   experiments	   were	   performed	   to	   ensure	   that	   accuracy	   was	  
maintained.	   In	   these	  experiments	  monocytes	  were	   stimulated	  with	   LPS	   then	  TACE	  activity	  
values	  determined	  by	  both	   the	  old	   assay	  protocol	   (96	  well	   plate	  with	  100μl	   total	   volume)	  
and	   the	   new,	  miniaturised	   protocol	   (384	  well	   plate	  with	   25μl	   total	   volume).	   Results	  were	  
then	  compared	  with	  a	  variation	  of	  less	  than	  10%	  seen	  across	  the	  protocols	  (figure	  4.1).	  
	   	  














Figure	   4.1:	  Monocyte	   TACE	   activity	   as	   determined	   by	   the	   FRET	   assay	   was	   similar	   when	  
assessed	  using	  the	  non-­‐miniaturised	  and	  miniaturised	  protocols.	  
	  
Data	   for	   monocyte	   TACE	   activity	   assessed	   using	   non-­‐miniaturised	   (96	   well	   plate,	   1x105	  
monocytes/well,	   100μl	   final	   volume)	   and	   miniaturised	   (384	   well	   plate,	   2.5x104	  
monocytes/well,	  25μl	  final	  volume).	  
All	  experiments	  performed	  at	  37°C	  
N=5	  for	  all.	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Monocytes	  in	  16-­‐hour	  PTFE	  culture	  had	  increased	  baseline	  TACE	  activity	  but	  no	  changes	  in	  
expression:	  
Having	  established	  that	  cells	  could	  be	  placed	  in	  PTFE	  culture	  and	  retrieved,	  we	  next	  sought	  
to	   establish	   the	   effect	   of	   this	   culture	   on	   their	   TACE	   activity.	   We	   found	   that	   untreated	  
monocytes	   after	   16-­‐hour	   PTFE	   culture	   displayed	   increased	   basal	   TACE	   activity	   when	  
compared	   to	   freshly	   isolated	   cells	   (44.02	   ±16.58	   FU/min	   freshly	   isolated	   vs.	   82.64	   ±18.82	  
FU/min	   after	   16-­‐hour	   culture,	   p<0.01	   fig	   4.2A).	   There	   were	   no	   differences	   in	   cell	   surface	  
expression	  of	  the	  enzyme	  (MFI	  57.34	  ±24.97	  freshly	  isolated	  vs.	  44.85	  ±11.53	  after	  16-­‐hour	  
culture,	  non-­‐significant	  fig	  4.2B).	  
	   	  



















Fig	  4.2:	  Monocytes	  placed	  in	  untreated	  PTFE	  culture	  for	  16-­‐hours	  have	  an	  expression	  
independent	  increase	  in	  TACE	  activity.	  
A	   Monocyte	  TACE	  activity	  was	  higher	  in	  monocytes	  placed	  in	  16-­‐hour	  PTFE	  culture	  than	  
in	  freshly	  isolated	  cells	  	  (n=5	  freshly	  isolated	  n=9	  untreated	  culture,	  *p<0.01)	  
B	   There	  were	  no-­‐significant	  changes	  in	  TACE	  expression	  (n=5)
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Evidence	  for	  monocyte	  LPS-­‐induced	  tolerance	  but	  not	  priming	  was	  seen	  in	  the	  two	  hit	  LPS	  
model	  
1. TACE	  response	  to	  primary	  LPS	  treatment.	  
We	  next	  moved	  to	  determine	  the	  effect	  of	  adding	  LPS	  to	  the	  PTFE	  culture.	  Monocytes	  were	  
placed	   in	   16-­‐hour	   PTFE	   culture	  with/without	   LPS	   at	   three	   different	   concentrations.	   These	  
were	   designed	   at	   a	   range	   of	   concentrations	   in	   order	   to	   explore	   sensitisation	   (low	  
concentrations)	  and	  de-­‐sensitisation	  (high	  concentrations)	  of	  the	  secondary	  TACE	  response.	  
These	  concentrations,	  determined	  based	  on	  previous	  dose	  response	  experiments	  performed	  
within	  our	  laboratory	  [133],	  are	  listed	  below:	  
1. LPS	  1pg/ml:	  low	  concentration	  
2. LPS	  1ng/ml:	  intermediate	  concentration	  
3. LPS	  1μg/ml:	  high	  (saturating)	  concentration	  
TACE	   activity	   after	   16-­‐hour	   culture	   with	   LPS	   at	   1pg/ml	   was	   not	   different	   to	   that	   after	  
untreated	   culture	   (82.64	   ±18.82	   FU/min	   untreated	   vs.	   74.62	   ±24.29	   FU/min	   LPS	   treated;	  
non-­‐significant).	   The	   intermediate	   LPS	   concentration	   of	   1ng/ml	   also	   had	   no	   effect	   (82.64	  
±18.82	   FU/min	  untreated	   vs.	   66.5	  ±21.68	   FU/min	   LPS	   treated;	  non-­‐significant).	   In	   contrast	  
the	   high	   concentration	   of	   LPS	   1μg/ml	   produced	   a	   significant	   increase	   in	   enzyme	   activity	  
(82.64	  ±18.82	  FU/min	  untreated	  vs.	  137.17	  ±62.97	  FU/min	  LPS	  treated;	  p<0.05;	  fig	  4.3A).	  
There	  were	   no	   significant	   differences	   in	   TACE	   expression	   between	   the	   groups	   (MFI	   44.85	  
±11.53	   untreated,	   MFI	   48.34	   ±0.26	   LPS	   1pg/ml,	   MFI	   52.43	   ±6.34	   LPS	   1ng/ml,	   MFI	   42.16	  
±19.44	  LPS	  1μg/ml;	  non-­‐significant,	  fig	  4.3B).	  
	   	  



















Figure	  4.3:	   TACE	   activity	   was	   increased	   after	   16-­‐hour	   culture	   with	   LPS	   1μg/ml	   but	  
TACE	  expression	  was	  not	  affected.	  
	  
A	   TACE	  activity	  after	  16-­‐hour	  PTFE	  culture	  (n=3-­‐9,	  *p<0.05)	  
B	   TACE	  expression	  after	  16-­‐hour	  PTFE	  culture	  (n=3-­‐9,	  non	  significant)	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2. TACE	  response	  to	  secondary	  LPS	  treatment.	  
TACE	   activity	   profiles	   after	   secondary	   LPS	   stimulation	   were	   altered	   by	   16-­‐hour	   culture	  
conditions:	  
After	  16-­‐hour	  PTFE	  culture	  cells	  were	  exposed	  to	  a	  standardised	  secondary	  LPS	  stimulation	  
of	  LPS	  1μg/ml	  for	  one	  hour.	  For	  the	  purposes	  of	  clarity	  the	  abbreviations	  below	  will	  be	  used	  
to	  describe	  culture	  conditions	  within	  the	  model.	  The	  concentration	  of	  the	  first	  LPS	  treatment	  
will	  be	  specified	  each	  time:	  
CC=	  Untreated	  16h	  culture	  (C)	  +	  no	  secondary	  1h	  treatment	  (C)	  	  
CL	  =Untreated	  16h	  culture	  (C)	  +	  secondary	  1h	  LPS	  treatment	  (L)	  	  
LC	  =LPS	  16h	  culture	  (L)	  +	  no	  secondary	  1h	  treatment	  (C)	  	  
LL=	  LPS	  16h	  culture	  (L)	  +	  secondary	  1h	  LPS	  treatment	  (L)	  	  
As	  might	  be	  expected,	  untreated	  monocytes	  left	  in	  PTFE	  for	  16	  hours	  significantly	  increased	  
their	   TACE	   activity	   (x1.58	   fold)	   when	   exposed	   to	   secondary	   LPS	   stimulation	   (82.64	  
±18.82FU/min	   CC	   vs.	   130.29	   ±34.25FU/min	   CL,	   p<0.01).	   Addition	   of	   LPS	   to	   the	   16-­‐hour	  
culture	  resulted	  in	  a	  slight	  attenuation	  of	  this	  secondary	  response	  at	  both	  the	  low	  (x1.49	  fold	  
increase	   in	   LL	   cells	   compared	   to	   LC	   cells)	   and	   intermediate	   (x1.51	   fold	   increase	   in	   LL	   cells	  
compared	  with	  LC	  cells)	  concentrations	  (fig	  4.4A).	  There	  was	  however,	  a	  marked	  attenuation	  
of	  this	  response	  in	  cells	  cultured	  for	  16-­‐hours	  with	  LPS	  at	  the	  high	  concentration.	  These	  cells	  
displayed	   no	   further	   TACE	   activity	   increase	   on	   secondary	   LPS	   exposure	   (137.17	  
±62.97FU/min	   LC	   vs.	   137.05	   ±60.53FU/min	   LL;	   non-­‐significant,	   fig	   4.4A).	   These	   results	   are	  
consistent	   with	   previous	   LPS	   exposure	   attenuating	   the	   TACE	   response	   to	   subsequent	   LPS	  
exposure.	  This	  could	  be	  considered	  as	  consistent	  with	  a	  state	  of	  tolerance.	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Monocytes	   exposed	   to	   the	   two-­‐hit	   LPS	   model	   had	   their	   membrane	   TACE	   expression	  
measured.	   There	   were	   no	   significant	   changes	   seen	   between	   any	   of	   the	   different	   culture	  
conditions.	  However,	  after	  the	  second	  LPS	  hit	  there	  was	  a	  consistent	  trend	  toward	  reduced	  
expression	   (untreated,	   CC	  MFI	   44.85	   ±11.53	   vs.	   CL	   MFI	   38.09	   ±4.67;	   LPS	   1pg/ml,	   LC	  MFI	  
48.34	  ±0.26	  vs.	  LL	  MFI	  40.8	  ±3;	  LPS	  1ng/ml,	  LC	  MFI	  52.43	  ±6.34	  vs.	  LL	  MFI	  39.26	  ±8.66;	  LPS	  
1μg/ml,	  LC	  MFI	  42.16	  ±19.44	  vs.	  LL	  MFI	  29.35	  ±9.79;	  non-­‐significant,	  fig	  4.4B).	  
	   	  















Figure	  4.4:	   TACE	   activity	   and	   expression	   profiles	   in	   response	   to	   a	   secondary	   LPS	  
stimulus	  were	  altered	  by	  prior	  16-­‐hour	  PTFE	  culture	  with	  LPS	  
Grey	  bars	   represent	   values	  after	  16-­‐hour	  PTFE	  culture,	  black	  bars	   that	  after	   secondary	   LPS	  
stimulus	  applied.	  
A	   TACE	   activity	   profiles	   (n=9	   unstimulated,	   n=3	   1pg/ml,	   n=5	   1ng/ml,	   n=7	   1μg/ml,	  
*p=<0.01)	  
B	   TACE	  expression	  profiles	  (n=4	  unstimulated,	  n=3	  for	  all	  other	  LPS	  concentrations)	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Similar	  activity	  profiles	  were	  exhibited	  with	  additional	  intermediate	  LPS	  concentrations	  
As	   we	   saw	   no	   evidence	   of	   in	   vitro	   priming	   with	   the	   low,	   intermediate	   and	   high	  
concentrations	  of	  LPS	  used	   in	  the	  16	  hour	  PTFE	  culture,	  we	  expanded	  them	  in	  an	  effort	  to	  
generate	   conditions	   that	   may	   result	   in	   the	   primed	   phenotype.	   Additional	   intermediate	  
concentrations	  of	  10pg/ml,	  100pg/ml	  and	  10ng/ml	  were	  used	  during	  16-­‐hour	  PTFE	  culture;	  
there	  were	  no	  significant	  differences	  in	  enzyme	  activity	   levels	  seen	  in	  LC	  monocytes	  (other	  
than	  the	  previously	  described	  increase	  seen	  at	  1μg/ml).	  
All	  LPS	  culture	  conditions	  attenuated	  the	  response	  to	  the	  secondary	  LPS	  stimulus	  (table	  4.1	  
and	  fig	  4.5).	  
Thus	  within	  the	  model	  we	  found	  no	  evidence	  for	  priming	  of	  the	  TACE	  response	  by	  prior	  LPS	  
exposure.	   High	   concentration	   (1μg/ml)	   exposure	   appeared	   to	   exhaust	   the	   TACE	   pathway,	  
significantly	  attenuating	  the	  response	  to	  secondary	  LPS	  stimulation	   in	  a	  manner	  that	  could	  
be	  in	  keeping	  with	  a	  state	  of	  tolerance.	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Table	  4.1:	   TACE	  activity	  profiles	  from	  two-­‐hit	  LPS	  model:	  
	  
Data	  displayed	  as	  mean	  ±SD	  
TACE	  activity	  values	  refer	  to	  FU/min	  
	   	  
LPS	  concentration	  per	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Figure	  4.5	   TACE	  activity	  profiles	  from	  2	  hit	  LPS	  model	  
	  
Complete	  TACE	  activity	  profiles	  for	  two-­‐hit	  LPS	  model.	  Grey	  bars	  represent	  activity	  after	  16-­‐
hour	  PTFE	  culture,	  black	  bars	  that	  after	  secondary	  LPS	  stimulus	  applied.	  
N=9	  un-­‐stimulated	  
N=3	  LPS	  1pg/ml	  
N=2	  for	  LPS	  10pg/ml,	  100pg/ml	  and	  10ng/ml	  
N=5	  LPS	  1ng/ml	  
N=7	  LPS	  1μg/ml	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Evaluation	  of	  monocyte	  surface	  marker	  alterations	  after	  model	  conditions:	  
Human	  monocytes	  mature	  from	  a	  CD14++CD16-­‐	  (immature)	  toward	  a	  CD14-­‐CD16+	  (mature)	  
phenotype	  during	  in	  vivo	  and	  vitro	  adherence	  culture	  [404].	  In	  order	  to	  determine	  whether	  
monocytes	  were	  maturing	  during	  the	  16-­‐hour	  culture	  period	  we	  stained	  for	  both	  CD14	  and	  
CD16.	  Results	  may	   show	  some	  evidence	  of	  maturation.	  Although	  CD14	   levels	  were	   similar	  
between	  freshly	  isolated	  and	  CC	  cells	  (MFI	  136±31	  and	  200±72	  respectively;	  non-­‐significant,	  
n=5)	  there	  was	  a	  non-­‐significant	  trend	  toward	  higher	  CD16	  levels	  in	  CC	  cells	  (MFI	  35±14.6	  in	  
freshly	  isolated	  cells	  vs.	  MFI	  76±40	  in	  CC	  cells;	  p=0.09).	  However,	  this	  increase	  in	  CD16	  levels	  
did	   not	   reach	   the	   ten	   fold	   difference	   that	   has	   previously	   been	   reported	  when	   comparing	  
subsets	  [405].	  There	  was	  a	  tendency	  toward	  elevated	  CD14	  levels	  and	  reduced	  CD16	  levels	  
in	  cells	  exposed	  to	  LPS	  (both	  LC	  and	  LL).	  
We	  also	   investigated	   the	  behaviour	  of	   the	  MHC	  class	   II	   antigen	  presenting	  molecule,	  HLA-­‐
DR,	  which	  has	  been	  suggested	  as	  a	  clinically	  useful	  marker	  of	  tolerance	  in	  patients	  [224].	  Its	  
expression	  levels	  are	  reduced	  on	  deactivated/tolerant	  cells	  [224]	  and	  have	  been	  suggested	  
as	   a	  means	   of	   stratifying	   risk	   in	   some	  patient	   groups	   [54,	   225,	   286,	   295].	   Freshly	   isolated	  
cells	   expressed	  detectable	   amounts	  of	  HLA-­‐DR	   (MFI	   484.43	  ±99.98,	   fig	   4.9D).	  As	   shown	   in	  
figure	  4.6	  HLA-­‐DR	  expression	  was	   increased	  dramatically	  by	  16-­‐hour	   culture	   (baseline	  MFI	  
484.43	  ±99.98	  vs.	  untreated	  16-­‐hour	  culture	  MFI	  5807.33	  ±217.89).	  Expression	   levels	  were	  
reduced	  only	  marginally	  by	  the	  addition	  of	  LPS	  to	  the	  PTFE	  culture	  (LPS	  1μg/ml	  MFI	  4122.33	  
±819.38).	  These	  results	  are	  in	  keeping	  with	  other	  in	  vitro	  studies	  that	  have	  reported	  an	  initial	  
increase	  in	  HLA-­‐DR	  expression	  levels	  followed	  by	  a	  fall	  [254,	  406,	  407].	  
	   	  














Figure	  4.6	   Monocyte	  HLA-­‐DR	  expression	  profiles	  before	  and	  after	  model	  conditions	  	  
	  
N=3,	  *p<0.0001,	  **p<0.01	  
	  
‘Freshly	  isolated’	  refers	  to	  cells	  evaluated	  prior	  to	  PTFE	  culture	  Untreated	  culture	  to	  those	  
cultured	  in	  PTFE	  alone	  for	  16-­‐hours	  and	  LPS	  culture	  to	  those	  when	  LPS	  1μg/ml	  was	  added	  to	  
PTFE	  inserts.	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LPS	   pre-­‐treatment,	   in	   keeping	   with	   a	   state	   of	   tolerance,	   suppressed	   sol-­‐TNF	   levels	   in	  
response	  to	  the	  secondary	  LPS	  stimulation	  
In	  order	  to	  determine	  whether	  the	  TACE	  activity	  changes	  seen	  in	  the	  two-­‐hit	  model	  mirrored	  
the	  overall	  changes	  in	  monocyte	  responsiveness,	  sol-­‐TNF	  production	  was	  determined	  under	  
the	   different	   stimulation	   conditions.	   Firstly	   sol-­‐TNF	   production	   was	   determined	   after	   16-­‐
hour	  PTFE	  culture	  only.	  Monocytes	  placed	   in	  untreated	  16-­‐hour	  culture	  (CC)	  produced	   less	  
sol-­‐TNF	  than	  those	  that	  were	  cultured	  with	  LPS	  (78.0	  ±30.27ρg/ml	  CC;	  142.11	  ±35.65ρg/ml	  
LC	  LPS	  1pg/ml;	  2610.67	  ±406.73ρg/ml	  LC	  LPS	  1ng/ml;	  5041.63	  ±2400.6ρg/ml	  LC	  LPS	  1μg/ml;	  
fig	  4.7A).	  
CL	  monocytes	  produced	  sol-­‐TNF	  on	  secondary	  LPS	  stimulation	  (564.36	  ±272.71pg/ml	  at	  six	  
hours).	   Previous	   exposure	   to	   LPS	   (LL	   cells)	   resulted	   in	   reduced	   responsiveness	   to	   LPS	  
stimulation	   for	  6	  hours	   in	  a	  dose	  dependent	  manner.	  This	  was	  most	  marked	   in	   those	  cells	  
exposed	   to	   LPS	   in	   PTFE	   culture	   at	   the	   intermediate	   concentration	   of	   1ng/ml	   and	   the	   high	  
concentration	   of	   1μg/ml	   (1ng/ml	   70.81	   ±24.68;	   1μg/ml	   undetectable	   all	   at	   six	   hours;	   fig	  
4.7B).	  
	   	  













Figure	  4.7:	   Monocytes	  in	  16-­‐hour	  PTFE	  culture	  with	  LPS	  produced	  sol-­‐TNF	  but	  not	  
when	  exposed	  to	  a	  secondary	  LPS	  stimulus	  
A	   Sol-­‐TNF	  levels	  after	  16-­‐hour	  PTFE	  culture	  (n=3,	  *p<0.01	  vs.	  control)	  
B	   Sol-­‐TNF	  levels	  after	  secondary	  LPS	  stimulation	  (n=3,	  p<	  0.05	  control	  vs.	  LPS	  1ng/ml	  
and	  1μg/ml)
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Monocytes	  in	  untreated	  16-­‐hour	  PTFE	  culture	  have	  an	  attenuated	  MAPK	  response	  to	  LPS:	  
To	   further	   understand	   the	   altered	   TACE	   activation	   and	   TNF	   production	   responses	   in	   PTFE	  
culture,	  and	  gain	   insight	   into	   the	  upstream	  signalling	  pathways	  affected,	  we	  evaluated	   the	  
MAPK	  pathway	  activation.	  
Cells	  were	  placed	  in	  untreated	  16-­‐hour	  culture	  conditions	  within	  PTFE	  inserts	  then	  removed,	  
centrifuged,	   re-­‐suspended	   in	   Eppendorfs	   and	   stimulated	   with	   LPS	   1	   μg/ml.	   Activated	  
phosphorylated	  kinase	  levels	  were	  measured	  at	  baseline,	  15	  and	  30	  minutes	  by	  intracellular	  
flow	  cytometry.	  As	  can	  be	  seen	  (fig	  4.8A)	  the	  up-­‐regulation	  of	  phospho-­‐p38MAPK	  expected	  
at	  15	  minutes	  was	  lost.	  A	  similar	  loss	  of	  up-­‐regulation	  at	  all	  time	  points	  was	  seen	  on	  staining	  
for	  both	  phospho-­‐MK2	  and	  phospho-­‐ERK	  (fig	  4.8B	  &C).	  
These	   results	   were	   in	   keeping	   with	   an	   overall	   depression	   of	   the	   LPS	   inducible	   pathways	  
related	  to	  TACE	  activation	  and	  TNF	  expression.	  
	   	  















Figure	  4.8:	   Monocyte	  MAPK	  response	  is	  attenuated	  by	  untreated	  16-­‐hour	  PTFE	  culture	  
	  
Markers	  of	  intracellular	  activation	  in	  response	  to	  LPS	  1μg/ml	  for	  0,	  15	  and	  30	  minutes.	  
All	  three	  markers	  displayed	  an	  attenuated	  response	  across	  the	  time	  points	  examined.	  
N=3	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Using	  INF-­‐ϒ	  in	  16-­‐hour	  culture	  produced	  no	  evidence	  of	  a	  primed	  phenotype:	  
Given	   that	  we	   found	  no	  evidence	  of	   a	  primed	  phenotype	  using	   the	   two	  hit	   LPS	  model	  we	  
then	  altered	  the	  stimulus	  used	  in	  the	  16-­‐hour	  culture	  period.	  INF-­‐ϒ	  is	  an	  immune-­‐stimulatory	  
cytokine	  that	  is	  known	  to	  prime	  cells	  and	  reverse	  tolerance	  [408-­‐410].	  Hence	  this	  was	  added	  
to	  PTFE	  culture	  in	  place	  of	  LPS	  to	  induce	  the	  primed	  phenotype.	  
As	  shown	  in	  figure	  4.9A	  the	  addition	  of	  INF-­‐ϒ	  to	  the	  culture	  conditions	  increased	  monocyte	  
TACE	   activity	   (untreated	   88.68	   ±7.58FU/min;	   INF-­‐ϒ	   1ng/ml	   186.54	   ±4.12FU/min;	   INF-­‐ϒ	  
100ng/ml	  265.06	  ±51.8FU/min).	  This	  was	  in	  keeping	  with	  our	  findings	  in	  the	  THP-­‐1	  cell	   line	  
(Chapter	   Three).	   There	   was	   no	   further	   increase	   in	   activity	   if	   monocytes	   were	   further	  
stimulated	   with	   LPS	   1μg/ml	   (INF-­‐ϒ	   1ng/ml	   207.45FU/min;	   INF-­‐ϒ	   100ng/ml	   176.1FU/min)	  
meaning	  that,	  similarly	  to	  LPS,	  INF-­‐ϒ	  did	  not	  produce	  priming.	  
There	  were	  no	  changes	  in	  TACE	  expression	  in	  the	  INF-­‐ϒ	  treated	  cells	  (untreated	  control	  MFI	  
28.05	  ±19.33;	  INF-­‐ϒ	  1ng/ml	  MFI	  27.61	  ±14.74;	  INF-­‐ϒ	  100ng/ml	  MFI	  26.66;	  figure	  4.9B).	  
	   	  




















Figure	  4.9:	   Isolated	  monocytes	  cultured	  with	  INF-­‐ϒ	  display	  increased	  TACE	  activity	  in	  
an	  expression	  independent	  manner	  
Monocytes	  placed	  in	  PTFE	  culture	  for	  16-­‐hours	  and	  stimulated	  with	  INF-­‐ϒ	  at	  the	  doses	  shown	  
developed:	  
A	   Increased	  TACE	  activity	  
B	   No	  change	  in	  enzyme	  expression	  
N=2	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Evaluation	  of	  constitutively	  expressed	  TACE	  substrate	  behaviour	  in	  PTFE	  culture	  
In	  order	   to	   further	  determine	  the	  TACE	  behaviour	  of	   freshly	   isolated	  monocytes	  as	  well	  as	  
cells	   exposed	   to	   the	   two-­‐hit	   LPS	   model,	   we	   examined	   expression	   levels	   and	   shedding	  
patterns	   of	   constitutively	   expressed	   TACE	   substrates	   relevant	   to	   inflammation:	   TNFR-­‐1,	  
TNFR-­‐2	  and	  L-­‐selectin.	  
	  
Freshly	  isolated	  cells	  
Freshly	   isolated	  monocytes	  had	  baseline	  substrate	  expression	  and	  shedding	  characteristics	  
determined.	   Results	   showed	   that	   freshly	   isolated	   cells	   express	   detectable	   amounts	   of	   all	  
three	   substrates	   (TNFR-­‐1	   MFI	   20.93	   ±0.3;	   TNFR-­‐2	   MFI	   72.31	   ±3.42;	   L-­‐selectin	   MFI	   72.27	  
±27.25;	  fig	  4.11	  A-­‐C).	  
In	  response	  to	  an	  LPS	  stimulus	  of	  1μg/ml	  for	  one	  hour	  shedding	  of	  the	  three	  TACE	  substrates	  
was	  seen	  (representative	  histograms	  shown	  in	  fig	  4.10).	  In	  order	  to	  quantify	  this	  percentage	  
shedding	  of	  each	  available	  substrate	  was	  calculated	  for	  freshly	   isolated	  cells	  stimulated	  for	  
an	  hour	  with	  LPS	  1μg/ml.	  
This	  was	  done	  using	  the	  equation	  below:	  
(Baseline	  expression	  –	  expression	  after	  LPS	  1μg/ml	  one	  hour)	  X	  100	  /	  Baseline	  expression	  
	  
Percentage	   shedding	   of	   each	   substrate	   was	   calculated	   for	   freshly	   isolated	   cells	   (baseline	  
shedding	  values	  in	  freshly	  isolated	  cells:	  TNFR-­‐1	  87.8	  ±0.41%;	  TNFR-­‐2	  87.7±0.23%;	  L-­‐selectin	  
94.4	  ±0.53%;	  fig	  4.12).	  
Percentage	  shedding	  of	  these	  substrates	   in	  response	  to	  LPS	  1μg/ml	  for	  one	  hour	  was	  then	  
determined	  after	  untreated	  and	  LPS	  treated	  16-­‐hour	  PTFE	  culture.	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Figure	  4.10:	  Representative	  histograms	  demonstrating	  shedding	  of	  TACE	  substrates	  in	  
response	  to	  LPS	  stimulation	  in	  freshly	  isolated	  monocytes.	  
A	   L-­‐selectin	  
B	   TNFR-­‐1	  
C	   TNFR-­‐2	  
For	  each	  histogram	  black	  curve	  represents	  non-­‐stimulated	  controls	  whereas	  grey	  represents	  
cells	  stimulated	  with	  LPS	  1μg/ml	  for	  1	  hour	  at	  37°C	  in	  Eppendorf	  culture.	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Effect	  of	  untreated	  and	  LPS	  treated	  PTFE	  culture	  on	  TACE	  substrate	  expression	  and	  
shedding	  
Untreated	   –	   refers	   to	   cells	   placed	   in	   untreated	   PTFE	   culture	   for	   16	   hours.	   Cells	   then	   had	  
expression	  and	  percentage	  shedding	  in	  response	  to	  an	  LPS	  stimulus	  of	  1μg/ml	  for	  one	  hour	  
determined	  for	  each	  TACE	  substrate.	  
LPS	  treated	  –	  refers	  to	  cells	  placed	  in	  PTFE	  culture	  for	  16	  hours	  with	  the	  high	  concentration	  of	  
LPS	   (1μg/ml)	   that	  produced	  maximal	   changes	   in	  TACE	  behaviour	  previously.	  Cells	   then	  had	  
expression	  and	  percentage	  shedding	  in	  response	  to	  an	  LPS	  stimulus	  of	  1μg/ml	  for	  one	  hour	  
determined	  for	  each	  TACE	  substrate.	  
	  
TNFR-­‐1	  
Untreated	   16-­‐hour	   PTFE	   culture	   resulted	   in	   a	   reduction	   in	   TNFR-­‐1	   expression	   (freshly	  
isolated	  MFI	  20.93	  ±0.3	  vs.	  untreated	  culture	  MFI	  6.47	  ±2.46;	   fig	  4.11A).	  Shedding	  rates	   in	  
response	  to	  LPS	  1μg/ml	  for	  an	  hour	  were	  preserved	  at	  75.9%	  from	  the	  87.8%	  seen	  in	  freshly	  
isolated	  cells	  (fig.	  4.12A).	  
The	  additional	  of	  LPS	  to	  the	  16-­‐hour	  culture	  conditions	  resulted	  in	  no	  net	  change	  in	  TNFR-­‐1	  
expression	   (MFI	   6.63	   ±1.8;	   fig	   4.11A).	   Shedding	   rates	   on	   secondary	   LPS	   stimulation	   were	  
reduced	  to	  21%	  (fig	  4.12A).	  
	  
TNFR-­‐2	  
Untreated	  16-­‐hour	  PTFE	  culture	  did	  not	  alter	  TNFR-­‐2	  expression	  (freshly	  isolated	  MFI	  72.31	  
±3.42	   vs.	   untreated	   culture	  MFI	   92.3	   ±0.58;	   fig	   4.11B).	   Shedding	   rates	   in	   response	   to	   LPS	  
1μg/ml	  for	  an	  hour	  were	  reduced	  to	  67.2%	  from	  the	  87.7%	  seen	  in	  freshly	  isolated	  cells	  (fig	  
4.12B).	  
The	   addition	   of	   LPS	   to	   the	   16-­‐hour	   culture	   conditions	   resulted	   in	   increased	   TNFR-­‐2	  
expression	  (MFI	  254.2	  ±26.28;	  fig	  4.11B).	  Shedding	  rates	  on	  secondary	  LPS	  stimulation	  were	  
further	  reduced	  to	  9.7%	  (fig	  4.12B).	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L-­‐selectin	  
Untreated	  16-­‐hour	  PTFE	  culture	  significantly	  reduced	  L-­‐selectin	  expression	  (freshly	   isolated	  
MFI	   72.27	   ±27.25	   vs.	   untreated	   culture	   MFI	   24.57	   ±4.96;	   fig	   4.11C).	   Shedding	   rates	   in	  
response	   to	   LPS	   1μg/ml	   for	   an	   hour	  markedly	   reduced	   to	   16.6%	   from	   the	   94.4%	   seen	   in	  
freshly	  isolated	  cells	  (fig	  4.12C).	  
The	   additional	   of	   LPS	   to	   the	   16-­‐hour	   culture	   conditions	   resulted	   in	   a	   slight	   increase	   in	   L-­‐
selectin	  expression	  (MFI	  36.9	  ±1.1;	  fig	  4.11C).	  Shedding	  rates	  on	  secondary	  LPS	  stimulation	  
were	  further	  reduced	  to	  11.2%	  (fig	  4.12C).	  
	  
	  
As	  can	  be	  seen	  in	  the	  summary	  below	  TACE	  substrate	  behaviour	  was	  diverse:	  
	  
TNFR-­‐1:	   Expression	  reduced	  by	  untreated	  PTFE	  culture	  
Shedding	  reduced	  by	  LPS	  treated	  PTFE	  culture	  	  
TNFR-­‐2:	   Expression	  increased	  by	  LPS	  treated	  PTFE	  culture	  
Shedding	   reduced	   by	   untreated	   and	   further	   reduced	   by	   LPS	   treated	   PTFE	  
culture	  
L-­‐selectin:	   Expression	  decreased	  by	  untreated	  PTFE	  culture	  
	   	   Shedding	  reduced	  by	  untreated	  PTFE	  culture	  
	  
These	   differential	   patterns	   suggest	   that	   there	   are	   distinct	   regulatory	   processes	   seen	   in	  
addition	  to	  the	  TACE	  catalytic	  activity	  per	  se.	  
	   	  














Figure	  4.11:	  Expression	  of	  TACE	  substrates	  after	  16-­‐hour	  PTFE	  culture	  	  
	  
A:	   TNFR-­‐1	  
B:	   TNFR-­‐2	  
C:	   L-­‐selectin	  (see	  over)	  
N=3,	  *p<0.01	  (vs.	  baseline	  unless	  otherwise	  indicated	  by	  bars)	  
	  
‘Freshly	  isolated’	  refers	  to	  cells	  evaluated	  prior	  to	  PTFE	  culture	  Untreated	  culture	  to	  those	  
cultured	  in	  PTFE	  alone	  for	  16-­‐hours	  and	  LPS	  culture	  to	  those	  when	  LPS	  1μg/ml	  was	  added	  to	  
PTFE	  inserts.	  
	  













Figure	  4.11:	  Expression	  of	  TACE	  substrates	  after	  16-­‐hour	  PTFE	  culture	  	  
	  
C:	   L-­‐selectin	  
N=3,	  *p<0.01	  (vs.	  baseline	  unless	  otherwise	  indicated	  by	  bars)	  
	  
‘Freshly	  isolated’	  refers	  to	  cells	  evaluated	  prior	  to	  PTFE	  culture	  Untreated	  culture	  to	  those	  
cultured	  in	  PTFE	  alone	  for	  16-­‐hours	  and	  LPS	  culture	  to	  those	  when	  LPS	  1μg/ml	  was	  added	  to	  
PTFE	  inserts.	  
	   	  












B	   	   	   	   	   	   C	  
	  
	  
Figure	  4.12:	  The	  2-­‐hit	  LPS	  model	  alters	  TACE	  substrate	  shedding:	  
	  
A:	   TNFR-­‐1	  shedding	  
B:	   TNFR-­‐2	  shedding	  
C:	   L-­‐selectin	  shedding	  
N=3,	  *	  p<0.01	  vs.	  baseline	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4.5 Discussion	  
I	   used	   a	   two-­‐hit	   LPS	   model	   in	   an	   attempt	   to	   induce	   differential	   states	   of	   tolerance	   and	  
priming	  in	  monocytes	  isolated	  utilising	  the	  methods	  developed	  in	  Chapter	  Three.	  Being	  able	  
to	  model	   these	   response	   states	  would	  provide	   further	   insights	   into	   the	   immune	   response,	  
potentially	  identifying	  mechanisms	  that	  could	  be	  manipulated	  or	  targeted	  for	  clinical	  benefit	  
in	  sepsis	  patients.	  Therapies	  aimed	  at	  augmenting	  the	  immune	  response	  may	  be	  appropriate	  
in	   patients	   displaying	   a	   tolerant	   phenotype	   whereas	   those	   patients	   displaying	   a	   primed	  
phenotype	   may	   benefit	   from	   immune	   suppression.	   Whilst	   signalling	   alterations	   seen	   in	  
endotoxin	  tolerance	  have	  been	  investigated	  both	  in	  vitro	  and	  in	  vivo,	  the	  role	  of	  TACE	  is	  yet	  
to	  be	  evaluated.	  
As	  outlined	  in	  the	  background	  to	  this	  chapter,	  the	  construction	  of	  the	  two-­‐hit	  LPS	  model	  was	  
limited	  by	  the	  need	  to	  use	   isolated	  monocytes	   in	  sufficient	  numbers	  to	  run	  the	  FRET	  assay	  
[381].	  Additionally,	  we	  were	  concerned	  that	  monocytes	  may	  differentiate	  over	  the	  16-­‐hour	  
culture	  period	  potentially	  altering	  their	  phenotype.	  To	  try	  and	  prevent	  this	  we	  used	  PTFE	  cell	  
culture	   inserts	   during	   this	   period.	   Cells	   cultured	   in	   these	   inserts	   formed	   a	   thin	  monolayer	  
over	  the	  PTFE	  membrane	  when	  visualised	  by	  microscopy	  and	  were	  relatively	  easily	  retrieved	  
from	  culture	  conditions	  in	  a	  viable	  and	  functional	  state.	  
	  
Increased	   baseline	   TACE	   activity	   after	   untreated	   culture	   may	   represent	   activation	   or	  
maturation	  
We	   demonstrated	   that	   the	   monocytes	   placed	   in	   untreated	   16-­‐hour	   PTFE	   culture	   had	  
significantly	  elevated	  baseline	  TACE	  activity	  but	  no	  change	  in	  membrane	  expression.	  Hence	  
we	   surmise	   that	   this	   represents	   a	   true	   increase	   in	   activity	  per	   se.	   There	   is	  more	   than	  one	  
explanation	   as	   to	   what	   this	   may	   represent.	   Firstly,	   it	   is	   known	   that	   cells	   of	   the	  
monocyte/macrophage	  cell	  line	  are	  able	  to	  become	  activated	  in	  vitro	  and	  in	  vivo	  [411,	  412],	  
and	   the	   increased	   levels	   of	   activity	   seen	  may	   represent	   such	   a	   state.	   Although	  we	  used	   a	  
minimally	   adherent	   medium	   and	   a	   16-­‐hour	   culture	   period	   to	   try	   and	   induce	   a	   degree	   of	  
quiescence	   in	   the	   cells,	   there	  may	   be	   some	   activation.	   If	   this	   is	   true	   it	   is	   likely	   that	   some	  
degree	  of	  “basal”	  TACE	  activity	  is	  likely	  to	  be	  unavoidable	  using	  in	  vitro	  systems.	  
The	   second	   explanation	   for	   the	   increase	   in	   activity	   is	   maturation.	   Monocytes	   can	  
differentiate	   into	   dendritic	   cells	   or	   macrophages	   [413]	   and	   it	   is	   known	   that	   both	   MAPK	  
signalling	   and	   the	   cellular	   response	   to	   LPS	   are	   altered	   in	  macrophages	   [414,	   415].	   In	   our	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experiments,	   monocytes	   were	   stained	   for	   both	   CD14	   and	   CD16	   at	   baseline	   and	   after	  
untreated	   and	   treated	   16-­‐hour	   culture.	   Human	   monocytes	   mature	   from	   a	   CD14++CD16-­‐	  
phenotype	   to	   one	   that	   is	   CD14-­‐CD16+	   [296],	   and	   this	   latter	   group	   is	   thought	   to	   be	  
phenotypically	  more	  similar	  to	  the	  macrophage	  than	  the	  former.	   I	   found	  small	   increases	   in	  
CD16	  expression	  levels	  that	  may	  represent	  the	  early	  stages	  of	  maturation,	  and	  it	  should	  be	  
noted	  that	  the	  16-­‐hour	  time	  point	  that	  we	  examined	  represents	  an	  early	  time	  point	   in	  the	  
maturation	  pathway	  when	  compared	  to	  other	  studies	  that	  have	  examined	  this	  area	  [404].	  In	  
addition,	  I	  found	  that	  CD14	  levels	  were	  not	  reduced	  in	  the	  model,	  although	  it	  is	  important	  to	  
note	   that	   different	   CD14	   expression	   profiles	   have	   been	   noted	   in	   different	   tissue	  
macrophages	  [404].	  It	  has	  been	  reported	  that,	  compared	  to	  circulating	  monocytes,	  alveolar	  
macrophages	   express	   low	   levels	   of	   CD14	   whereas	   expression	   is	   preserved	   on	   peritoneal	  
macrophages.	  Given	  these	  caveats,	  it	  is	  quite	  possible	  that	  monocytes	  placed	  in	  PTFE	  culture	  
underwent	   a	   degree	   of	  maturation	   and	   this	  may	   explain	   the	   increased	   TACE	   activity	   seen	  
after	  untreated	  PTFE	  culture.	  
Such	  a	  process	  of	  in	  situ	  maturation	  would	  also	  explain	  the	  HLA-­‐DR	  expression	  profiles	  seen.	  
Since	  reduced	  HLA-­‐DR	  expression	  has	  been	  used	  as	  a	  marker	  of	  “monocyte	  deactivation”,	  a	  
clinical	  correlate	  of	  endotoxin	  tolerance	  seen	   in	  both	  sterile	   inflammation	   [416]	  and	  sepsis	  
[224],	  we	  measured	  HLA-­‐DR	  expression	  levels	  in	  our	  model.	  An	  increase	  in	  both	  the	  numbers	  
of	  cells	  expressing	  the	  molecule	  and	  total	  expression	  levels	  have	  been	  reported	  after	  short-­‐
term	  in	  vitro	  adherent	  culture	  [406,	  407]	  and	  may	  represent	  a	  maturation	  process	  under	  in	  
vitro	   culture	   conditions.	   This	   would	   explain	   the	   increase	   in	   HLA-­‐DR	   expression	   seen	   in	  
untreated	  PTFE	  culture.	  The	  subsequent	  reduction	  in	  MFI	  that	  we	  saw	  when	  LPS	  was	  added	  
to	  the	  culture	  might	  represent	  a	  response	  to	  stress	  during	  inflammatory	  conditions.	  
	  
Changes	  in	  TACE	  behaviour	  after	  LPS	  culture	  may	  reflect	  a	  state	  of	  net	  tolerance	  
We	  expected,	  based	  on	  the	  results	  of	  previous	  studies	  that	  have	  modelled	  tolerance	  in	  vitro	  
and	  in	  vivo	  [326,	  397,	  417],	  that	  the	  intermediate	  (1ng/ml)	  and	  high	  (1µg/ml)	  concentrations	  
of	   LPS	   used	   in	   16-­‐hour	   PTFE	   culture	   would	   induce	   tolerance.	   We	   found	   that	   these	  
concentrations	  produced	  higher	  baseline	  activity	  levels	  and	  attenuated	  the	  increase	  in	  TACE	  
activity	   induced	  by	  the	  second	  LPS	  treatment.	  These	  effects	  were	  most	  marked	  at	  the	  high	  
concentration.	  This	  change	  in	  the	  TACE	  activity	  profile	  to	  one	  of	  high	  activity	  levels	  that	  are	  
refractory	   to	   further	   stimulation	   is	   consistent	  with	   a	   “memory”	   of	   previous	   LPS	   exposure,	  
which	  may	  be	  similar	   to	  the	  “tolerance	  memory”	  seen	  by	  del	  Fresno	  and	  co-­‐workers	   [326]	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and	   used	   to	   describe	   refractoriness	   to	   an	   ex	   vivo	   LPS	   stimulus	   within	   their	   model	   of	  
tolerance.	   Thus	   these	   changes	   are	   in	   keeping	   with	   a	   net	   state	   of	   tolerance.	   The	  
refractoriness	   of	   the	   TACE	   response	   to	   secondary	   LPS	   stimulation	   does	   not	   seem	   to	  
represent	  the	  maximal	  inflammatory	  output	  of	  the	  cell,	  as	  16-­‐hour	  INF-­‐ϒ	  culture	  resulted	  in	  
TACE	  activity	  levels	  that	  exceeded	  those	  seen	  with	  LPS	  culture.	  
The	   definitive	   evidence	   that	   we	   modelled	   a	   net	   state	   of	   tolerance	   comes	   from	   the	  
attenuated	  levels	  of	  sol-­‐TNF	  levels	  generated	  after	  the	  second	  LPS	  “hit”.	  It	  is	  interesting	  that,	  
although	  this	  attenuation	  was	  significant	  for	  LPS	  pre-­‐treatments	  of	  1ng/m	  and	  1μg/ml,	  there	  
was	   a	   trend	   toward	   a	   similar	   pattern	   at	   a	   dose	   of	   1pg/ml,	   a	   dose	   that	   we	   expected	   to	  
generate	   priming.	   These	   patterns	   were	   consistent	   with	   the	   attenuated	   increase	   in	   TACE	  
activity	  seen	  on	  secondary	  LPS	  stimulation	  at	  all	  doses.	  This	  may	  be	  explained	  by	  considering	  
what	  is	  happening	  on	  a	  sub-­‐cellular	  level.	  During	  the	  culture	  period	  the	  cells	  are	  exposed	  to	  
a	   stimulus	   (LPS)	   that,	   in	   the	   case	   of	   tolerance,	   has	   been	   demonstrated	   to	   up-­‐regulate	  
numerous	  negative	  regulators	  including	  IRAK-­‐M,	  ST2	  and	  the	  short	  version	  of	  MyD88	  [324].	  
Interestingly	  there	  appears	  to	  be	  some	  discordance	  between	  murine	  and	  human	  models	  of	  
tolerance	  with	   only	   IRAK-­‐M	  having	   been	   confirmed	   as	   being	   elevated	   across	   both	   species	  
[208,	  326,	  327].	  In	  humans	  this	  elevation	  is	  seen	  in	  monocytes	  taken	  from	  patients	  with	  both	  
septic	  [418]	  and	  non-­‐septic	  aetiologies	  [326].	  
The	   signalling	   pathways	   involved	   in	   priming	   are	   not	   as	  well	   elucidated	  but	   are	   thought	   to	  
include	  an	  up-­‐regulation	  of	  inflammatory	  effectors	  acting	  through	  IRAK-­‐1	  [419].	  Any	  change	  
elicited	   in	  cell	   signalling	  within	  our	  model	   is	   likely	   to	  be	   induced	  at	  a	  maximal	   level	  by	   the	  
constant	  presence	  of	  LPS	  throughout	  the	  16-­‐hour	  culture	  period.	  Hence	  a	  reduced	  response	  
to	  a	  subsequent	  LPS	  stimulus	  is	  perhaps	  to	  be	  expected	  and	  may	  explain	  why	  the	  increase	  in	  
activity	   induced	  by	   this	   secondary	   stimulus	   is	   reduced	  as	   the	  concentration	  of	   LPS	  used	   in	  
PTFE	  culture	  is	  increased.	  This	  represents	  a	  general	  limitation	  of	  the	  model.	  
	  
Changes	  in	  MAPK	  signalling	  were	  induced	  by	  PTFE	  culture	  
We	   found	   that	   untreated	   16-­‐hour	   culture	   in	   PTFE	   produced	   an	   attenuation	   of	   the	  MAPK	  
response	  to	  LPS.	  As	  we	  thought	  that	  cells	  might	  be	  maturing	  during	  this	  period	  it	  is	  possible	  
that	   this	   process	   was	   altering	   the	   signalling	   characteristics	   of	   the	   monocytes.	   However,	  
MAPK	  signalling	   is	  similar	  across	  monocyte	  subsets	  and	  still	  present	   in	  macrophages	   [415],	  
hence	   these	   changes	   are	   unlikely	   to	   be	   explained	   by	   in	   situ	   maturation	   alone.	   We	   have	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previously	   shown	   that	   primary	   human	   monocytes	   mediate	   their	   TACE	   response	   to	   LPS	  
through	  p38MAPK	  [133].	  Therefore	  an	  attenuation	  of	  this	  MAPK	  signalling	  is	  in	  keeping	  with	  
the	   reduced	   TACE	   response	   to	   secondary	   LPS	   stimulation	   that	   we	   report	   after	   both	  
untreated	  and	  treated	  PTFE	  culture	  compared	  to	  freshly	  isolated	  cells.	  Attenuation	  of	  MAPK	  
activation	  has	  been	  reported	   in	  models	  of	  tolerance	  [329,	  330],	  but	  to	  our	  knowledge,	  has	  
not	  previously	  been	  measured	  in	  PTFE	  culture.	  
Given	   this	   attenuation	   of	   MAPK	   and	   TACE	   signalling,	   we	   had	   concerns	   that	   placing	  
monocytes	   in	   minimally	   adherent	   conditions	   would	   induce	   a	   state	   of	   anergy	   where	   cells	  
would	  become	  globally	  unresponsive.	  However,	   several	   factors	   indicated	   that	   this	  was	  not	  
the	   case.	   Elevated	   TACE	   activity	   levels,	   coupled	   with	   changes	   in	   CD14,	   CD16	   and	   HLA-­‐DR	  
levels	  in	  response	  to	  LPS	  gave	  us	  evidence	  that	  cells	  were	  capable	  of	  responding	  after	  PTFE	  
culture.	  The	  increase	  in	  CD14	  in	  response	  to	  16-­‐hour	  LPS	  culture	  is	  in	  keeping	  with	  previous	  
findings	  [420].	  CD16	  has	  been	  suggested	  as	  a	  possible	  metalloprotease	  substrate	  [421]	  and	  
the	  rapid	  reduction	  in	  levels	  of	  this	  cell	  surface	  marker	  after	  cells	  were	  exposed	  to	  LPS	  would	  
be	   in	   keeping	   with	   shedding,	   suggesting	   that	   some	   cellular	   enzymatic	   functions	   are	  
preserved.	   Further	   evidence	   that	   cells	   were	   capable	   of	   responding	   in	   PTFE	   culture	   is	  
provided	   by	   their	   retained	   ability	   to	   produce	   sol-­‐TNF	   during	   the	   16-­‐hour	   LPS	   treatment	  
period.	   It	   is	   known	   that	   adherence	   of	   the	  monocytic	   cell	   line	   THP-­‐1	   to	   collagen	   results	   in	  
p38MAPK	  activation	  [422].	  Thus,	  the	  absent	  p38MAPK	  response	  to	  LPS	  after	  untreated	  PTFE	  
culture,	  may	  represent	  signalling	  alterations	  as	  a	  result	  of	  the	  minimally	  adhesive	  conditions	  
used,	  another	  potential	  limitation	  of	  our	  model.	  
	  
Alternate	  TACE	  substrate	  behaviour	  
It	   is	   possible	   that	   TACE	   substrate	   specificity	   is	   altered	   by	   chronic	   LPS	   exposure;	   hence	  
increased	  enzyme	  activity	  may	  not	  always	  result	  in	  increased	  sol-­‐TNF	  production.	  This	  would	  
mean	  that	  the	  altered	  TACE	  activity	  profiles	  (increased	  baseline	  &	  reduced	  response	  to	  LPS)	  
seen	  in	  cells	  after	  two	  LPS	  hits	  may	  represent	  cleavage	  of	  substrates	  other	  than	  mem-­‐TNF.	  It	  
is	  difficult	  to	  imagine	  that	  TACE	  sheds	  its	  range	  of	  substrates	  [342]	  without	  some	  degree	  of	  
selectivity	  as	  some	  (e.g.	  TNF	  and	  TNFR-­‐1&2)	  may	  have	  opposing	  effects.	  
With	   specific	   regard	   to	   L-­‐selectin,	   shedding	   can	   be	   induced	   through	   several	   different	  
pathways	   [377].	   It	   is	   possible	   that	   differential	   signalling	   may	   produce	   conformational	  
changes	   in	   either	   TACE	   [365],	   or	   in	   upstream	   signalling	   that	   result	   in	   altered	   substrate	  
	   134	  
specificity.	   This	   latter	   point	   is	   consistent	  with	  work	   suggesting	   that	   signalling	   pathways	   in	  
tolerant	  cells	  are	  altered	  in	  a	  manner	  that	  renders	  the	  cell	  unresponsive	  to	  some	  stimuli	  (e.g.	  
LPS)	  but	   responsive	   to	  others	   (e.g.	   IL-­‐10)	   [324].	   In	  order	   to	   investigate	  possible	  changes	   in	  
substrate	  selectivity	   further	  we	  determined	  the	  shedding	  kinetics	  of	  other	  TACE	  substrates	  
relevant	  to	  inflammation.	  
We	  found	  that	  PTFE	  untreated	  and	  LPS	  treated	  culture	  produced	  differential	  effects	  on	  TNFR	  
and	  L-­‐selectin	  expression.	  However,	  all	   three	   substrates	   (TNFR-­‐1,	  TNFR-­‐2	  &	  L-­‐selectin)	  had	  
shedding	   impaired	  by	  both	   treated	  and	  untreated	  PTFE	   culture	  when	  compared	   to	   freshly	  
isolated	   cells.	   Hence	   we	   found	   no	   convincing	   evidence	   of	   altered	   substrate	  
affinity/specificity.	  
The	  increase	  in	  TNFR-­‐2	  expression	  seen	  after	  16-­‐hour	  LPS	  culture	  is	  in	  keeping	  with	  previous	  
reports	   suggesting	   that	   it	   is	   inducible	   both	   in	   vitro	   [423]	   and	   in	   vivo	   whereas,	   again	  
consistent	  with	  our	  findings,	  TNFR-­‐1	  is	  not	  [424].	  Pedron	  et	  al	  found	  that	  TNFR-­‐2	  shedding	  in	  
response	  to	  LPS	  is	  p38MAPK	  dependent	  but	  did	  not	  find	  the	  same	  for	  TNFR-­‐1	  [425].	  Hence	  
the	  increased	  TNFR-­‐2	  expression	  may	  represent	  p38MAPK	  impairment	  after	  LPS	  culture.	  The	  
fact	  that	  this	  is	  not	  seen	  for	  TNFR-­‐1	  may	  reflect	  differential	  upstream	  signalling	  between	  the	  
receptors.	   Both	   TNF	   receptors	   are	   normally	   rapidly	   shed	   in	   response	   to	   LPS	   [426]	   and	   L-­‐
selectin	   is	  shed	   in	  response	  to	  a	  number	  of	  stimuli	  such	  as	  LPS,	   IL-­‐8,	  antibody	  cross-­‐linking	  
and	   changes	   in	   tonicity	   [427-­‐429].	   The	   impaired	   TNF	   receptor	   shedding	   seen	   after	   LPS	  
culture	   could	   be	   considered	   to	   be	   in	   keeping	   with	   a	   state	   of	   tolerance.	   The	   impaired	   L-­‐
selectin	   shedding	   seen	   after	   untreated	   16-­‐hour	   culture	   is	   anomalous	   in	   this	   context	   but	  
perhaps	  explainable,	  as	  both	  PKC	  and	  p38MAPK	  have	  been	  implicated	  in	  upstream	  signalling	  
to	  L-­‐selectin.	  Hence	  shedding	  could	  occur	  despite	  impaired	  p38MAPK	  signalling,	  such	  as	  that	  
seen	  in	  our	  model.	  
	  
No	  evidence	  for	  priming	  was	  seen	  in	  the	  model	  
Based	  on	  previous	  studies	  we	  hypothesised	  that	  a	  low	  concentration	  of	  LPS	  (e.g.	  1pg/ml)	  in	  
the	   16-­‐hour	   PTFE	   culture	   should	   prime	   the	   cells	   to	   a	   subsequent	   LPS	   challenge	   in	   a	  
Shwartzman-­‐like	   reaction	   [395]	   [315].	  We	   saw	  no	  evidence	   for	  priming	   in	   either	   the	  TACE	  
activity,	   expression	   or	   sol-­‐TNF	   values.	   Priming	   of	   monocytes	   by	   LPS	   has	   previously	   been	  
described	   in	  Teflon®	  conditions	  but	  for	  enhanced	  superoxide	  release	  rather	  than	  TNF	   [430]	  
and	  encouraged	  by	  this	  we	  persisted,	  changing	  the	  stimulus	  used	   in	  PTFE	  culture	  to	   INF-­‐ϒ.	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However,	   this	  produced	  a	   similar	  pattern	   to	   that	   seen	  when	  we	  used	  THP-­‐1	  cells	   (Chapter	  
Three)	  and	  with	  LPS	  in	  PTFE	  culture:	  high	  baseline	  activity	  but	  no	  inducibility.	  
It	   is	   striking	  when	  reviewing	  the	   literature	  that	  other	  studies	  using	  LPS	  to	  prime	  cells	  have	  
either	   found	   adherence	   to	  be	   key	   [318]	   or	   have	  used	   adherent	   systems	   [319,	   320].	  Other	  
studies	  have	  used	   in	  vivo	  systems	  [315,	  316]	  hence	   it	   is	  plausible	  that,	   in	  keeping	  with	  our	  
hypothesis	   that	  monocytes	   are	   acutely	   responsive	   to	   their	  microenvironment,	   our	   system	  
fails	   to	   recapitulate	   all	   the	   necessary	   environmental	   cues	   required	   for	   priming.	   These	   are	  
likely	   to	   include	   adherence	   and	   cell-­‐cell	   signalling/contact	   and	   the	   absence	   of	   these	  
represents	  another	   limitation	  of	  our	  model.	  These	  omissions	  may	  have	  been	  compounded	  
by	  our	  decision	  to	  use	  a	  purified	  TLR-­‐4	  stimulus	  rather	  than	  whole	  bacteria.	  Furthermore,	  it	  
has	  been	  demonstrated	   that	   leukocytes	  produce	  different	  amounts	  of	   cytokines	   (including	  
TNF	  and	   IFN-­‐Υ)	  when	   stimulated	   in	  whole	  blood	  as	   compared	   to	  PBMC	  culture	   [431].	  Any	  
further	   work	   attempting	   to	   induce	   the	   primed	   state	   in	   monocytes	   should	   specifically	  
examine	  the	  role	  of	  these	  factors.	  
	  
Conclusions	  
We	  set	  out	  to	  create	  a	  model	  in	  which	  we	  could	  explore	  TACE	  activity	  profiles	  for	  evidence	  
of	  both	  priming	  and	  tolerance.	  Despite	  using	  a	  range	  of	  doses,	  the	  primary	  LPS	  treatment	  did	  
not	  prime	  in	  any	  way	  to	  secondary	  LPS,	  while	  only	  a	  very	  high	  concentration	  suppressed	  the	  
secondary	  response	  effectively.	  This	  absence	  of	  priming	  may	  result	   from	  the	  non-­‐adherent	  
culture	  or	   the	   fact	   that	  cells	   spent	  a	  prolonged	  period	  of	   time	   in	  culture	  with	  LPS.	  Further	  
work	  in	  this	  area	  should	  incorporate	  different	  lengths	  of	  LPS	  conditioning	  and	  incorporate	  a	  
washing	  step,	  whereby	  LPS	   is	  removed	  from	  the	  culture	  conditions,	  prior	  to	  any	  secondary	  
LPS	  exposure.	  The	  effect	  of	  using	  whole	  bacteria	  rather	  than	  a	  purified	  TLR	  stimulus	  should	  
also	  be	  evaluated.	  
The	  environment	  monocytes	  were	  exposed	  to	  during	  the	  16-­‐hour	  culture	  seemed	  to	  induce	  
a	  state	  of	  “pure”	  tolerance	  in	  which	  almost	  all	  aspects	  of	  inflammatory	  signalling	  examined	  
were	  attenuated.	  The	  system	  therefore	  seems	  ‘non-­‐interactive’	  i.e.	  the	  only	  way	  to	  change	  
the	  dynamic	   is	   to	   treat	  with	  a	  dose	  of	  LPS	   (1ug)	   that	   triggers	   the	  TACE	  activating	  pathway	  
and	   exhausts	   it.	   It	   is	   possible	   that	   lower	   doses	   may	   well	   trigger	   elements	   of	   the	   TACE	  
signalling	   mechanism	   (such	   as	   p38MAPK)	   but	   these	   underlying	   perturbations	   (not	   actual	  
TACE	   activation)	   have	   no	   effect,	   neither	   enhancing	   nor	   suppressing.	   We	   were	   unable	   to	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examine	   these	   in	   detail	   because	   the	   PTFE	   culture	   conditions	   themselves	   blunted	   this	  
response	  to	  LPS.	  
In	   conclusion,	   although	   the	   model	   produced	   changes	   in	   TACE	   behaviour	   that	   could	   be	  
considered	  in	  keeping	  with	  a	  net	  state	  of	  tolerance,	  our	  data	  exposed	  its	  limitations.	  These	  
related	  to	  the	  presence	  of	  LPS	  and	  the	  use	  of	  a	  minimally	  adherent	  medium	  throughout	  the	  
16-­‐hour	  culture	  period.	  These	  are	  compounded	  by	  the	  use	  of	  a	  single	  cell	  type	  (monocytes),	  
and	   a	   purified	   TLR-­‐4	   stimulus	   (LPS)	   meaning	   that	   it	   is	   unlikely	   my	   model	   correctly	  
recapitulates	  the	  complex	  interplay	  that	  occurs	  in	  vivo.	  However,	  this	  is	  a	  criticism	  that	  can	  
be	  levelled	  at	  in	  vitro	  models	  in	  general	  and	  it	  may	  be	  better	  to	  limit	  the	  use	  of	  such	  models	  
to	  testing	  specific	  hypothesises	  generated	  using	  in	  vivo	  systems.	  
Thus	   it	  may	   be	   the	   case	   that	   the	  model	   has	   limited	   application	   to	   clinical	   reality,	   yet	   the	  
techniques	  optimised	  whilst	  constructing	  it	  allowed	  us	  to	  refine	  our	  protocols	  for	  the	  clinical	  
study	  that	  we	  performed	  next.	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Summary	  
There	   are	   parallels	   between	   in	   vitro	   endotoxin	   tolerance	   and	   the	   in	   vivo	   phenomenon	   of	  
monocyte	  deactivation.	  Monocyte	  deactivation	  occurs	  in	  response	  to	  a	  number	  of	  different	  
pathologies	   and	   is	   characterised	   by	   reduced	   inflammatory	   cytokine	   production	   together	  
with	   reduced	   HLA-­‐DR	   expression	   and	   impaired	   antigen	   presentation.	   However,	   it	   is	  
incompletely	   understood	   and,	   at	   present	   is	   poorly	   categorised.	   I	   sought	   to	   determine	  
whether	   TACE	   activity	   and	   substrate	   shedding	   in	   critically	   ill	   patients	   with	   monocyte	  
deactivation	  would	  be	  altered	  when	  compared	  to	  healthy	  controls,	  and	  whether	  similarities	  
with	  the	  tolerance	  model	  detailed	  in	  Chapter	  Four	  could	  be	  identified.	  In	  addition,	  we	  hoped	  
to	  enhance	  understanding	  of	  deactivated	  monocyte	  functionality.	  
Blood	  samples	  (day	  0,	  2,	  4	  and	  6)	  were	  taken	  from	  mechanically	  ventilated	  patients	  who	  had	  
the	   systemic	   inflammatory	   response	   syndrome	   (SIRS).	   PBMCs	   were	   obtained	   via	   density	  
gradient	   centrifugation.	   An	   optimised	   flow	   cytometry	   protocol	   was	   designed	   in	   order	   to	  
identify	   all	   monocytes	   subpopulations	   in	   these	   preparations.	   However,	   samples	   obtained	  
from	  patients	  displayed	  a	  large	  variation	  in	  subset	  surface	  markers.	  It	  appears	  that	  accurate	  
determination	  of	  monocyte	  subsets	  may	  not	  be	  possible	  in	  the	  context	  of	  critical	  illness	  with	  
the	  surface	  markers	  we	  used,	  a	  limitation	  that	  may	  not	  have	  been	  fully	  appreciated.	  Instead	  
all	  monocytes	  were	  analysed	  together	  as	  one	  population,	  and	   identified	  as	  deactivated	  on	  
the	  basis	  of	  reduced	  HLA-­‐DR	  expression	  and	  sol-­‐TNF	  production	  on	  ex	  vivo	  LPS	  stimulation.	  
Monocytes	   were	   successfully	   isolated	   from	   patient	   samples	   using	   the	   CD14+	   selection	  
protocol	  generated	   in	  Chapter	  Three	  and	  their	  TACE	  activity	  profiles	  were	  quantified	  using	  
the	   FRET	   assay.	   Monocyte	   TACE	   basal	   and	   LPS-­‐induced	   activity	   profiles	   were	   altered	  
between	  healthy	  volunteers	  and	  patients,	  and	  between	  patients	  with	  septic	  and	  non-­‐septic	  
SIRS.	   By	   contrast,	   cell	   surface	   TACE	   expression	   levels	  were	   not	   different	   between	   groups.	  
Sepsis	  produced	  attenuated	  phosphorylated	  p38MAPK	  and	  TACE	  responses	  to	  LPS	  as	  well	  as	  
producing	  increased	  expression	  and	  impaired	  shedding	  of	  TNFR-­‐1.	  Expression	  and	  shedding	  
of	  TNFR-­‐2	  and	  L-­‐selectin	  were	  similar	  across	  the	  groups.	  
These	   results	   suggest	   that	   the	   systemic	   inflammatory	   response	   may	   produce	   a	  
heterogeneous	  response	  (as	  opposed	  to	  a	  homogeneous	  anergy)	  in	  monocytes	  exposed	  to	  a	  
single	   inflammatory	   stimulus.	   Thus	   cells	   appear	   to	   be	   ‘reprogrammed’	   with	   altered	  
regulation	  in	  specific	  pathways.	  Interestingly	  the	  preserved	  L-­‐selectin	  shedding	  with	  reduced	  
TACE	  activity	  and	  TNF	  responses	  provide	  evidence	  that	  cell	  migration	  may	  be	  preserved.	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5.1	   Background	  
Monocyte	   deactivation	  was	   first	   identified	   in	   the	   1990s	   in	   septic	   patients	   [154,	   224].	   This	  
phenomenon	   of	   reduced	   HLA-­‐DR	   expression,	   impaired	   antigen	   presentation	   and	   reduced	  
sol-­‐TNF	  release	  [224]	  has	  since	  been	  described	  in	  conditions	  producing	  sterile	  inflammation	  
such	  as	  trauma	  [432],	  burn	  injury	  [433],	  cardiopulmonary	  bypass	  [416]	  and	  surgery	  [51,	  53].	  
Hypo-­‐reactivity	  of	   immature,	  developing	  monocytes	   released	  as	  a	   result	  of	   systemic	   stress	  
has	  been	  suggested	  as	  a	  mechanism	  of	  deactivation	  [433],	  however	  more	  recent	  work	  has	  
demonstrated	  that	  HLA-­‐DR	   is	  down	  regulated	  across	  cells	  of	  differing	  maturity	  making	  this	  
explanation	   unlikely	   [53].	   It	   has	   also	   been	   suggested	   that	   phagocytic	   uptake	   of	   apoptotic	  
cells,	  found	  in	  increased	  numbers	  in	  sepsis	  [255],	  down	  regulates	  HLA-­‐DR	  expression	  and	  sol-­‐
TNF	  release	  by	  monocytes,	  however	  at	  present	  the	  mechanism	  through	  which	  deactivation	  
occurs	   is	  not	  known.	  Soluble	  mediators	   suggested	  as	   inducing	  deactivation	   include	  LPS,	   IL-­‐
10,	  catecholamines	  [154,	  434-­‐436]	  and	  steroids	  [437].	  
As	   well	   as	   being	   incompletely	   understood	   monocyte	   deactivation	   is	   poorly	   categorised.	  
Work	  in	  this	  area	  has	  often	  focused	  on	  sepsis	  and	  attempted	  to	  correlate	  the	  degree	  of	  HLA-­‐
DR	  down	  regulation	  to	  clinical	  outcomes.	  Some	   investigators	  have	  used	  the	  term	   ‘immune	  
paralysis’	  when	  referring	  to	  patients	  who	  have	  <30%	  of	  monocytes	  expressing	  HLA-­‐DR	  [224,	  
438],	  and	  suggested	  that	  these	  patients	  have	  worse	  clinical	  outcomes	  than	  others	  who	  have	  
greater	  numbers	  of	  cells	  expressing	  the	  molecule	  [286].	  However,	  a	  recent	  review	  failed	  to	  
find	  a	  threshold	  in	  HLA-­‐DR	  expression	  that	  successfully	  predicted	  unfavourable	  outcomes	  in	  
sepsis	  [225]	  and	  there	  is	  no	  accepted	  consensus	  around	  threshold	  levels	  or	  in	  measurement	  
techniques.	  Measurement	  of	  monocyte	  HLA-­‐DR	  expression	  in	  these	  studies	  is	  usually	  based	  
on	   limited,	   rather	   simplistic	   flow	   cytometry	   gating	   strategies	   such	   as	   forward	   and	   side	  
scatter	  properties	  and	  expression	  of	  single	  markers	  (e.g.	  CD14)	  [51,	  286,	  295],	  both	  of	  which	  
are	   known	   to	   vary	   considerably	   between	   monocyte	   subsets	   [297],	   and	   may	   be	   further	  
altered	   during	   disease.	   Given	   the	   broad	   range	   of	   aetiologies	   that	   produce	   deactivation,	  
some	   have	   argued	   it	   represents	   a	   more	   complex	   reprogramming	   of	   the	   cell.	   This	  
reprogramming	   is	   generated	  by	   the	   systemic	  CARS	   response	  and	  may	  produce	  differential	  
effects	  on	  specific	  cellular	  pathways	  and	  functions	  [416,	  439].	  
Several	  studies	  have	  shown	  that	  reduced	  HLA-­‐DR	  expression	  can	  be	  reversed	  by	  granulocyte	  
macrophage	   colony	   stimulating	   factor	   (GMCSF)	   both	   in	   vitro	   and	   in	   vivo	   [440,	   441].	   In	   a	  
study	  of	  patients	  with	  multi-­‐factorial	  sepsis,	  who	  were	  stratified	  to	  receive	  GMCSF	  therapy	  
on	   the	   basis	   of	   reduced	   HLA-­‐DR	   expression	   levels,	   it	   was	   found	   therapy	   shortened	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ventilation	  and	  length	  of	  ICU	  stay	  [226].	  However,	  a	  recent	  meta-­‐analysis	  concluded	  that,	  at	  
present,	  GMCSF	  did	  not	  have	  sufficient	  evidence	  to	  support	  its	  use	  in	  sepsis	  [282],	  although	  
only	  the	  study	  mentioned	  above	  used	  HLA-­‐DR	  expression	  levels	  to	  guide	  treatment.	  
There	   is	   evidence	   that	   TACE	   behaviour	   is	   of	   importance	   as	   a	   determinant	   of	   the	   in	   vivo	  
inflammatory	  response.	  Neutrophil	  TACE	  expression	  has	  previously	  been	  shown	  to	  increase	  
in	  septic	  SIRS	  and	  to	  correlate	  with	  both	  disease	  severity	  and	  mortality	  [355].	  TACE	  has	  been	  
shown	   to	   regulate	   the	   pulmonary	   endothelial	   inflammatory	   response	   to	   LPS	   [442],	   and	  
inflammatory	  mediators	  released	  by	  this	  process	  have	  been	  implicated	  in	  the	  generation	  of	  
remote	  organ	  injury	  [443].	  TACE	  knockout	  results	  in	  reduced	  inflammatory	  cytokine	  release	  
and	  a	  mortality	  benefit	  in	  a	  murine	  peritonitis	  model	  [444].	  Given	  these	  findings	  and	  the	  fact	  
that	   previous	   clinical	   work	   has	   found	   correlations	   between	   morbidity	   scores	   and	   soluble	  
TNF:	   TNFR	   receptor	   ratios	   [339]	   a	   detailed	   investigation	   of	   the	  monocyte	   functional	   TACE	  
response	  is	  well	  justified	  and	  yet	  to	  be	  performed,	  making	  our	  work	  novel.	  
We	   therefore	   decided	   to	   conduct	   a	   clinical	   study	   investigating	   monocytes	   obtained	   from	  
sepsis/SIRS	  patients	  and	  focusing	  on	  TACE	  behaviour	  and	  substrate	  shedding	  in	  deactivated	  
cells.	  By	   focusing	  on	  a	  single	  pathway	  that	   is	   involved	   in	  both	  acute	   inflammation	   [133]	  as	  
well	  as	   leukocyte	   rolling	  and	   tethering	   (through	   the	  effect	  of	  TACE	  on	  L-­‐selectin	   [158])	  we	  
aimed	  to	  determine	  whether	   these	   linked	  elements	  were	  differentially	  affected	  or	  globally	  
hypo-­‐responsive	   in	   response	   to	   a	   single,	   defined	   microbial	   stimulus,	   and	   if	   the	   patterns	  
observed	   differed	   under	   sterile	   versus	   infectious	   SIRS	   conditions.	   Hence	   monocytes	   may	  
display	   evidence	  of	   reprogramming	  as	  well	   as	   biomarker	   changes	   that	  may	  be	   specific	   for	  
sepsis-­‐induced	   deactivation.	   In	   addition	  we	   hoped	   to	   generate	   a	  more	   sophisticated	   flow	  
cytometry	  gating	  strategy	  than	  has	  previously	  been	  used	   in	  studies	  examining	  deactivation	  
in	  order	  to	  accurately	  identify	  monocytes	  and	  their	  subsets.	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5.2	  	   Aims	  
The	  specific	  aims	  for	  this	  chapter	  were:	  
1. To	   determine	   the	   effects	   of	   sepsis/SIRS	   on	   TACE	   behaviour	   and	   substrate	  
shedding.	  
2. To	   explore	   these	   data	   for	   evidence	   of	   differential	   effects	   on	   inflammatory	  
signalling	  and	  leukocyte	  rolling/tethering.	  
3. To	   develop	   an	   optimised	   flow	   cytometry	   protocol	   to	   accurately	   identify	  
monocytes	  and	  their	  subsets.	  
	  
5.3	   Protocols	  
Patient	  selection	  
An	   independent	   research	   ethics	   committee	   approved	   the	   study	   (North	   London	   REC	   3	  
reference:	  10/H0709/77)	  and	  we	  successfully	  achieved	  our	  aim	  of	  recruiting	  24	  patients.	  This	  
sample	  size	  was	  based	  on	  the	  calculation	  that	  to	  have	  90%	  power	  to	  detect	  a	  50%	  difference	  
in	  TACE	  activity	  between	  the	  two	  groups	  (p<0.05)	  24	  patients	  would	  be	  required.	  Intubated	  
and	   ventilated	   patients	   admitted	   to	   Charing	   Cross	   Hospital	  with	   SIRS,	   between	  May	   2010	  
and	  April	  2012,	  were	  screened	  by	  myself	  to	  see	  if	  they	  were	  eligible.	  We	  recruited	  patients	  
within	   48	   hours	   of	   admission	   to	   the	   ICU,	   and	   limited	   recruitment	   to	   those	   who	   were	  
expected	   to	   remain	   intubated	   for	   a	   further	   48	   hours	   or	   more.	   We	   excluded	   those	   with	  
immunosuppression	  and	  those	  who	  were	  receiving	  granulocyte	  colony	  stimulating	  factor.	  As	  
patients	   were	   incapacitated	   at	   the	   time	   of	   inclusion,	   consent	   was	   obtained	   from	   the	  
patient’s	   personal	   (relative/friend)	   or	   professional	   consultee.	   Retrospective	   consent	   was	  
then	  obtained	  from	  the	  patient	  once	  they	  had	  regained	  capacity.	  Appendix	  2	  contains	  copies	  
of	  the	  information	  sheets,	  consent	  forms	  and	  the	  study	  protocol.	  
Enrolled	  patients	  were	  subdivided	  them	  into	  non-­‐infectious	  SIRS	  (from	  here	  on	  referred	  to	  
as	  SIRS	  patients)	  and	  sepsis	  on	  the	  basis	  of	  their	  clinical	  picture	  at	  the	  point	  of	  recruitment.	  
Standard	   definitions	   for	   SIRS	   and	   sepsis	   as	   outlined	   in	   detail	   in	   section	   1.2	   of	   the	  
introduction	   were	   used	   (see	   protocol	   in	   appendix	   2	   on	   page	   270	   for	   further	   details).	   I	  
recruited	  patients	  within	  48	  hours	  of	  admission	  to	  the	  ICU,	  and	  limited	  recruitment	  to	  those	  
who	  were	  expected	   to	   remain	   intubated	   for	   a	   further	  48	  hours	  or	  more.	   I	   excluded	   those	  
with	   immunosuppression	   and	   those	   who	   were	   receiving	   granulocyte	   colony	   stimulating	  
	   142	  
factor.	  As	  patients	  were	   incapacitated	  at	  the	  time	  of	   inclusion,	  consent	  was	  obtained	  from	  
the	  patient’s	  personal	  (relative/friend)	  or	  professional	  consultee.	  Retrospective	  consent	  was	  
then	  obtained	  from	  the	  patient	  once	  they	  had	  regained	  capacity.	  
In	   addition	   to	   recruiting	   patients	   from	   the	   ICU,	   we	   recruited	   healthy	   volunteers	   from	  
laboratory	  staff	  at	   Imperial	  College	  London.	  Fifteen	  samples	  were	  obtained	  and	  volunteers	  
were	   excluded	   if	   they	   refused	   to	   consent,	   were	   immunosuppressed,	   had	   chronic	  
pathology/inter-­‐current	  illness	  and	  had	  recently	  undergone	  venesection.	  
	  
Sample	  collection	  
Blood	  (30ml)	  was	  obtained	  from	  patients	  at	  48-­‐hour	  time	  points	  from	  baseline	  (D0)	  to	  D6	  or	  
unit	   discharge.	   Samples	   were	   obtained	   from	   arterial	   cannulas	   wherever	   possible.	   Where	  
these	   were	   not	   present	   samples	   were	   taken	   from	   central	   venous	   catheters.	   EDTA	  
vacutainers	  were	  used	   for	  sample	  collection	  and	  cells	   transported	  on	   ice	   to	   the	   laboratory	  
facilities	  where	  they	  underwent	  immediate	  processing.	  
A	  single	  blood	  sample	  (30ml)	  was	  taken	  from	  each	  healthy	  volunteer.	  This	  was	  obtained	  by	  
peripheral	  venesection	  into	  EDTA	  vacutainers	  (on	  ice)	  and	  processed	  immediately.	  
	  
Monocyte	  isolation	  
Monocytes	  were	   isolated	   from	  whole	  blood	  using	  density	  gradient	  centrifugation	   followed	  
by	   magnetic	   activated	   cell	   selection	   utilising	   a	   CD14	   positive	   bead	   selection	   strategy	   as	  
outlined	   in	   detail	   in	   Chapter	   Two.	   Cells	  were	   stimulated	  with	   LPS	   and	   their	   TACE	   catalytic	  
activity	  determined	  by	  the	  FRET	  assay.	  
	  
PBMC	  treatment/stimulation	  
PBMCs	  were	   isolated	  from	  whole	  blood	  by	  differential	  centrifugation.	  HLA-­‐DR	  staining	  was	  
performed	  immediately	  after	  isolation	  to	  minimise	  any	  change	  in	  signal.	  Cells	  were	  then	  re-­‐
suspended	   at	   5x106	   CD14-­‐positive	   cells/ml	   and	   incubated	   for	   one	   hour	   at	   37°C	   in	   the	  
presence	   or	   absence	   of	   LPS	   (1μg/ml).	   Surface	   expression	   of	   TNFR-­‐1,	   TNFR-­‐2,	   TACE	   and	   L-­‐
selectin	  was	  determined	  by	  flow	  cytometry.	  In	  some	  cases	  CCR-­‐2	  was	  also	  measured.	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To	  determine	  ex	  vivo	  sol-­‐TNF	  production,	  cells	  were	  plated	  and	   left	   for	   four	  hours	  at	  37°C	  
with	   or	   without	   LPS	   (1μg/ml).	   Supernatants	   were	   then	   collected	   and	   sol-­‐TNF	   levels	   were	  
measured	  using	  ELISA.	  
	  
Quantification	  of	  MAPK	  response	  
This	   was	   performed	   as	   outlined	   in	   detail	   in	   Chapter	   Two.	   Briefly,	   PBMCs	   were	   fixed	   and	  
made	  permeable	  before	  being	  stained	  with	  antibodies	  specific	  for	  the	  activated	  form	  of	  the	  
MAPK	   enzyme.	   An	   LPS	   concentration	   of	   1µg/ml	   was	   used	  with	  monocytes	   stimulated	   for	  
either	  15	  or	  30	  minutes.	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5.4	  	   Results	  
Patient	  recruitment	  and	  demographic	  information:	  
Patient	  details	  are	  given	   in	   table	  5.1	  and	  consisted	  of	  eight	  SIRS	  patients	  and	   sixteen	  with	  
sepsis.	   As	   can	   be	   seen	   in	   the	   table	   the	   groups	   were	   well	   matched	   apart	   from	   a	   younger	  
mean	  age	   in	   the	  SIRS	  group.	  Patients	  were	   recruited	  using	   the	  documentation	  provided	   in	  
Appendix	  One,	  and	  outcome	  data	  (ICU	  and	  hospital	  discharge)	  was	  available	  for	  all.	  Further	  
details	   about	   the	   source	  of	   infection	  within	   the	   sepsis	   group	  are	  provided	   in	   table	  5.2.	  Of	  
these	  patients	  only	  eight	  (50%)	  generated	  positive	  microbiological	  data.	  Four	  (25%)	  cultured	  
gram-­‐positive	  organisms,	  three	  (18.75%)	  cultured	  gram-­‐negative	  organisms	  and	  one	  patient	  
(6.25%)	  both.	  
Although	  we	  recruited	  patients	  that	  we	  expected	  to	  remain	  on	  ICU	  for	  at	  least	  48	  hours	  (and	  
within	   48	   hours	   of	   intubation)	   some	   were	   discharged	   before	   a	   second	   sample	   could	   be	  
taken.	   This,	   in	   combination	   with	   the	   fact	   that	   some	   patients	   improved	   rapidly	   and	   were	  
discharged	  from	  ICU	  ahead	  of	  expectations,	  meant	  that	  serial	  samples	  were	  obtained	  from	  
14	  patients	  (58%).	  Seven	  patients	  (29%)	  provided	  three	  and	  four	  samples.	  
A	   single	   sample	   was	   also	   obtained	   from	   15	   healthy	   volunteers	   recruited	   from	   Imperial	  
College	  staff.	  This	  group	  had	  a	  mean	  age	  of	  33.3	  (±3.6)	  and	  was	  60%	  (n=9)	  male.	  
	   	  



























Table	  5.1:	  Demographic	  and	  outcome	  data	  
Demographic	  data	  obtained	  from	  SIRS	  and	  sepsis	  groups	  as	  well	  as	  further	  detail	  from	  SIRS	  
group	  detailing	  admitting	  team	  specialty	  and	  from	  sepsis	  group	  outlining	  site	  of	  sepsis.	  































































team	  for	  SIRS	  
patients	  
N	  (%)	  
Medicine	   2	  (25)	  
Neurosciences	   6	  (75)	  
Sepsis	  site	   N	  (%)	  
Pulmonary	   9	  (56)	  
Peritoneal	   3	  (18.8)	  
Soft	  tissue	   2	  (12.6)	  
Biliary	   1	  (6.3)	  
CNS	   1	  (6.3)	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Monocytes	  could	  be	  isolated	  from	  patient	  samples	  using	  the	  CD14	  bead	  positive-­‐selection	  
strategy.	  
Previously,	   in	   pilot	   experiments	   in	   our	   laboratory,	   isolation	   of	   monocytes	   from	   septic	  
patients	   using	   the	  mononuclear	   cell	   separation	   and	  negative	   selection	  method	   resulted	   in	  
low	  purity	  levels	  due	  to	  significant	  neutrophil	  contamination.	   In	  this	  study,	  PBMC	  prepared	  
from	   septic	   patient	   blood	   by	   density	   gradient	   centrifugation	   contained	   variable	   levels	   of	  
contamination	  with	  neutrophils	  (fig	  5.1A).	  These	  levels	  ranged	  from	  0%	  to	  60%	  of	  events	  on	  
the	  forward	  scatter	  (FSC;	  size)	  and	  side	  scatter	  (SSC;	  granularity)	  gates.	  However,	  using	  the	  
positive	   selection	   method,	   these	   neutrophils	   could	   be	   completely	   removed	   during	   the	  
magnetic	   bead	   isolation	   process	   (figure	   5.1B).	   Yields	   and	   purity	   were	   in	   line	   with	   those	  
described	  during	  validation	  work	  with	  healthy	  volunteer	  blood	  in	  Chapter	  Three.	  
	   	  


















Figure	   5.1:	   Isolation	   of	   monocytes	   from	   patient	   samples	   by	   positive,	   CD14	   immune-­‐
magnetic	  bead	  selection	  
A:	  Patient	  sample	  showing	  neutrophil	  infiltration	  of	  PBMC	  preparation	  	  
B:	  Enrichment	  of	  monocytes	  after	  CD14	  bead	  selection,	  with	  counting	  beads	  used	  to	  quantify	  
cell	  numbers.	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Development	   of	   an	   optimised,	   flow	   cytometry	   gating	   strategy	   to	   identify	   monocytes	   in	  
SIRS	  and	  sepsis	  patients	  
To	  accurately	  describe	  the	  monocyte	  response	  by	   flow	  cytometry,	  we	  aimed	  to	  analyse	  all	  
monocytes	   rather	   just	   those	   cells	   conforming	   to	   the	   classical	   CD14++CD16-­‐	   phenotype.	  
However,	  most	  well-­‐defined	  flow	  cytometric	  gating	  and	  analysis	  methods	  for	  monocytes	  are	  
standardised	   for	   normal	   blood	   leukocytes	   and	   may	   be	   incapable	   of	   dealing	   with	  
unpredictable	   phenotypic	   marker	   changes	   occurring	   during	   acute	   or	   prolonged	   SIRS.	   Our	  
previous	  protocol	   for	  examining	  monocytes	   in	  humans	  under	  normal	  or	  mild	   inflammatory	  
conditions	   employed	   FSC	   and	   SSC	   characteristics	   combined	   with	   expression	   of	   HLA-­‐DR,	  
which	   is	   not	   present	   on	   NK	   cells	   and	   neutrophils	   [53].	   In	   order	   to	   measure	   HLA-­‐DR	   in	  
severely	   ill	   patients	  where	   there	   is	   potential	   for	   considerable	   reductions	  of	   its	   expression,	  
we	  devised	  a	  gating	  strategy	  that	  was	  independent	  of	  this	  marker.	  An	  alternative	  and	  more	  
definitive	   marker	   for	   monocytes	   (M-­‐CSF	   receptor,	   CD115),	   was	   unsuitable	   because	   of	   its	  
rapid	   TACE-­‐dependent	   cleavage	   in	   response	   to	   LPS	   and	   other	   stimuli	   [316,	   445].	   We	  
therefore	  considered	  additional	  and	  more	  stable	  markers	  to	  ensure	  detection	  of	  monocytes.	  
Density	   gradient	   PBMC	   preparations	   from	   healthy	   individuals	   normally	   contain	   only	  
lymphocytes	   and	  monocytes.	   However,	   patient	   samples	   contained	   significant	   numbers	   of	  
neutrophils	   (fig	   5.1A),	   presumably	   due	   either	   neutrophilia	   or	   changes	   in	   their	   physical	  
properties.	  Our	  first	  step	  was	  to	  exclude	  granulocytes	  on	  the	  basis	  of	  their	  combined	  higher	  
SSC	   and	   lower	   FSC	   profile	   relative	   to	   monocytes	   (gate	   R1	   on	   fig	   5.1A).	   The	   majority	   of	  
lymphocytes	  were	  then	  excluded	  by	  gating	  on	  a	  CD11b	  high	  population	  (gate	  R2	  on	  fig	  5.1B).	  	  
The	   major	   remaining	   non-­‐monocyte	   population	   were	   NK	   cells,	   which	   express	   moderate	  
levels	  of	  both	  CD11b	  and	  CD16.	  If	  not	  excluded	  these	  cells	  could	  potentially	  contaminate	  the	  
monocyte	   CD14-­‐CD16+	   subset	   gate.	   Neural	   cell	   adhesion	   marker	   (NCAM)	   or	   CD56	   is	   an	  
antigen	  expressed	  by	  natural	  killer	   (NK)	  cells	   [446]	  but	  not	  monocytes	   [297].	  Thus	  staining	  
for	  CD56	  provided	  us	  with	  a	  means	  of	  differentiating	  between	  NK	  cells	  and	  monocytes.	  Cells	  
from	  the	  R1	  gate	  shown	  in	  figure	  5.1A	  were	  gated	  on	  both	  CD11b	  and	  CD56;	  this	  identified	  
two	  groups,	  a	  monocyte	  population	  that	  was	  CD11b+CD56-­‐	  (R2	  on	  fig	  5.1B)	  and	  an	  NK	  cell	  
population	   that	  was	  CD11b+CD56+	   (R3	  on	  Fig	  5.1B).	  Evaluation	  of	   cells	  within	   the	  R2	  gate	  
using	  CD14	  and	  CD16	  expression	  profiles	   (fig	  5.2C)	   indicated	  the	  majority	  of	  CD11b+CD56-­‐	  
events	  were	  comparable	  to	  the	  monocyte	  CD14/CD16	  continuum	  described	  in	  the	  literature.	  
In	   addition,	   CD14/CD16	   gating	   of	   cells	   thought	   to	   be	   NK	   cells	   and	   found	   in	   R3	  
(CD11b+CD56+)	  confirmed	  that	  they	  were	  CD14-­‐CD16+	  (fig	  5.1D)	  as	  expected.	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A	   	   	   	  











A:	   Granulocytes	   were	   excluded	   on	   the	   basis	   of	   their	   combined	   higher	   SSC	   and	   lower	   FSC	  
profile	  relative	  to	  monocytes	  by	  drawing	  gate	  around	  cells	  consistent	  with	  monocytes	  (gate	  
R1)	  
B:	   Cells	   within	   the	   R1	   gate	   were	   then	   gated	   on	   CD11b	   and	   CD56;	   this	   identified	   two	  
populations	  
CD11b+CD56-­‐	  (R2):	  monocytes	  
CD11b+CD56-­‐	  (R3):	  NK	  cells	  (R2	  &	  R3)	  
B	  and	  T	  lymphocytes	  are	  excluded	  by	  these	  gates	  and	  are	  found	  within	  the	  un-­‐gated	  CD11b-­‐
CD56-­‐	  population.	  
C:	   Population	   R2:	   monocytes	   displaying	   an	   appropriate	   CD14	   and	   CD16	   expression	  
continuum	  (see	  next	  page).	  
D:	   Population	   R3:	   NK	   cells	   (CD11b+	   CD56+)	   were	   confirmed	   to	   be	   CD14-­‐CD16+	   (see	   next	  
page).	  
	   	  












Figure	   5.2:	   A	   multi-­‐step	   flow	   cytometry	   protocol	   to	   identify	   monocytes	   in	   SIRS	   patient	  
PBMC	  preparations.	  
C:	   Population	   R2:	   monocytes	   displaying	   an	   appropriate	   CD14	   and	   CD16	   expression	  
continuum.	  
D:	  Population	  R3:	  NK	  cells	  (CD11b+	  CD56+)	  were	  confirmed	  to	  be	  CD14-­‐CD16+.	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Identification	  of	  three	  monocytes	  subsets	  in	  healthy	  volunteer	  blood	  using	  CD14,	  CD16	  
and	  CD64	  markers:	  
Having	  developed	  the	  strategy	  outlined	  above	  to	  identify	  monocytes	  we	  then	  further	  refined	  
it	   to	   identify	   the	   appropriate	   monocyte	   subsets.	   Human	   monocytes	   mature	   from	   an	  
immature	  CD14++CD16-­‐	  phenotype	   through	  an	   intermediate	  CD14+CD16+	  phenotype	   to	  a	  
mature	   CD14-­‐CD16+	   phenotype	   [297-­‐299].	   These	   is	   no	   consensus	   as	   to	   how	   these	  
populations	  should	  be	  grouped,	  with	  the	  intermediate	  group	  considered	  in	  different	  studies	  
as	   belonging	   to	   either	   the	   immature	   or	   the	  mature	   subset	   [447-­‐449].	   Other	   investigators	  
have	   argued	   that	   this	   intermediate	   group	   should	   be	   considered	   as	   a	   distinct	   subset	   [298,	  
447].	   Previously	   both	   our	   group	   and	   others	   have	   used	   CD64	   (Fc	   gamma	   receptor-­‐1)	   as	   a	  
method	  of	  characterising	  the	  intermediate	  population	  [53,	  405,	  447].	  Using	  this	  method	  the	  
immature	   and	   intermediate	   groups	   are	   found	   to	   express	   high	   levels	   of	   CD64	  whereas	   the	  
mature	  group	  express	  lower	  levels	  of	  the	  marker.	  In	  healthy	  volunteer	  cells,	  we	  were	  able	  to	  
consistently	  identify	  the	  three	  subsets	  on	  the	  basis	  of	  CD14	  and	  CD16	  expression.	  Figure	  5.3	  
illustrates	  the	  gating	  strategy	  used	  to	  identify	  these.	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Figure	   5.3:	   In	   healthy	   volunteer	   cells	   CD64	   allowed	   accurate	   identification	   of	   the	  
intermediate	  subset	  
A:	   Monocytes	   gated	   as	   previously	   described	   in	   figure	   5.1	   were	   subdivided	   into	   immature	  
CD14++CD16-­‐	   subset	   (R1)	  and	  CD16+	  (R2)	   cells	   (R2	  contains	  both	   intermediate	  and	  mature	  
subsets).	  
B:	  CD14++	  cells	  were	  gated	  on	  CD64	   in	  order	   to	  provide	  a	   reference	  point	  as	   to	  where	   the	  
intermediate	  monocyte	  gate	  should	  be	  drawn.	  
C:	  CD16+	  monocytes	   could	   then	  be	   subdivided	  on	   the	  basis	  of	  CD64	  expression	   into	  CD64+	  
cells	  (R4),	  and	  CD64-­‐	  cells	  (R5).	  
D:	  The	  CD64+	  cells	  (R4)	  consisted	  of	  the	  intermediate	  monocyte	  subset	  that	  is	  CD14+CD16+	  
(see	  next	  page).	  
E:	  The	  CD64-­‐	  cells	  (R5)	  contained	  mature	  CD14-­‐CD16+	  monocytes	  (see	  next	  page).	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D:	  The	  CD64+	  cells	  (R4)	  consisted	  of	  the	  intermediate	  monocyte	  subset	  that	  is	  CD14+CD16+.	  
E:	  The	  CD64-­‐	  cells	  (R5)	  contained	  mature	  CD14-­‐CD16+	  monocytes.	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Evaluation	  of	  monocyte	  subset	  gating	  in	  SIRS	  patients:	  
We	   attempted	   to	   apply	   the	   subset	   gates	   to	   patient	   samples.	   Although	  we	   had	   previously	  
successfully	  used	  this	  strategy	  in	  delineating	  subsets	  in	  patients	  undergoing	  elective	  surgery,	  
we	  had	  not	  previously	  used	  it	   in	  critically	  unwell	  patients.	  Applying	  the	  subset	  gates	  in	  this	  
context	   proved	   problematic,	   as	   alterations	   in	   expression	   of	   individual	   markers	   led	   to	  
distortion	  of	  the	  subset	  classification	  patterns	  common	  in	  healthy	  individuals.	  
As	   shown	   in	   figure	  5.4	   the	  utility	  of	  CD64	   in	  differentiating	  between	   the	   intermediate	  and	  
mature	   subsets	  was	   reduced	   and	  often	   completely	   lost	   (fig	   5.5).	   In	   the	   example	   shown	   in	  
figure	  5.4,	  lower	  CD64	  expression	  was	  no	  longer	  confined	  to	  CD14-­‐CD16+	  monocytes,	  which	  
could	   be	   interpreted	   as	   decreased	   CD64	   expression	   on	   the	   intermediate	   CD14+CD16+	  
subset.	   An	   additional	   uncertainty	   was	   apparent	   in	   the	   definition	   of	   the	   classical	  
CD14++CD16-­‐	   and	   intermediate	   CD14+CD16+	   subsets	   where	   a	   continuum	   of	   CD16	  
expression	   (fig	  5.5B)	  prevented	   identification	  of	  discreet	  populations.	  An	  extreme	   instance	  
was	  observed	  in	  one	  patient	  where	  the	  CD14-­‐CD16+	  expressing	  monocytes	  were	  effectively	  
absent	  during	  the	  course	  of	  sampling	  (fig	  5.5C).	  It	  is	  likely	  that	  some	  of	  these	  patterns	  can	  be	  
attributed	   to	  alterations	   in	  expression	  of	   the	  Fcγ	   receptors	  CD16	  and	  CD64,	  both	  of	  which	  
are	   modified	   during	   monocyte	   activation	   [309,	   450-­‐453],	   independently	   of	   the	   subset	  
differentiation	  process.	  
We	  considered	  that	  using	  monocyte	  subset	  gating	  regions	  based	  on	  the	  standard	  pattern	  in	  
healthy	  individuals	  could	  lead	  to	  segregation	  of	  populations	  according	  to	  altered	  functional	  
marker	  (e.g.	  CD16)	  expression	  rather	  than	  true	  subset	  identity.	  Hence,	  rather	  than	  attempt	  
such	  arbitrary	  gating	  and	  division	  of	  phenotype,	  we	  decided	  to	  perform	  our	  analysis	  on	  the	  
monocyte	  population	  as	  whole	  and	  exclude	  this	  as	  an	  analysis	  variable.	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Figure	  5.4:	  CD64	  is	  not	  a	  suitable	  monocyte	  subset	  differentiation	  marker	  in	  patient	  
samples	  
This	  gating	  process	  is	  identical	  to	  that	  shown	  for	  healthy	  volunteers	  in	  figure	  5.3	  
A:	  Patient	  monocytes	  were	  subdivided	  into	  CD14++CD16-­‐	  (R1)	  and	  CD16+	  (R2)	  gates	  
B:	  An	  attempt	  was	  made	  to	  differentiate	  the	  CD16+	  cells	  (R2)	  on	  the	  basis	  of	  CD64	  expression	  
(this	  was	  not	  always	  possible)	  
C:	  Where	  it	  was	  possible	  to	  differentiate	  cells	  based	  on	  CD64	  expression	  we	  found	  that	  the	  
CD64-­‐	  cells	  (R4)	  contained	  both	  mature	  CD14-­‐	  CD16+	  and	  intermediate	  CD14+	  CD16+	  
monocyte	  phenotypes.	  This	  meant	  that	  CD64	  was	  ineffective	  at	  distinguishing	  between	  these	  
two	  subsets.	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Figure	  5.5:	  Different	  surface	  marker	  profiles	  were	  seen	  within	  the	  monocyte	  gate:	  
A:	  Typical	  pattern	  of	  surface	  marker	  expression	  seen	  within	  the	  monocyte	  gate	  in	  healthy	  
volunteers	  
B:	  Surface	  marker	  expression	  seen	  within	  the	  monocyte	  gate	  in	  a	  patient	  with	  pneumonia	  
C:	  Surface	  marker	  expression	  seen	  within	  the	  monocyte	  gate	  in	  a	  patient	  with	  aspiration	  
pneumonia	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Total	  monocyte	  and	  neutrophil	  count	  differed	  between	  the	  groups:	  	  
Monocyte	   and	   neutrophil	   counts	  were	   obtained	   from	   the	  white	   cell	   differential	   that	   each	  
patient	   had	   measured	   daily	   whilst	   on	   the	   ICU.	   Both	   SIRS	   and	   sepsis	   patients	   displayed	   a	  
monocytosis	   that	   trended	   toward	  higher	   levels	   in	   the	  SIRS	  group	   than	   sepsis.	  As	  expected	  
the	  neutrophil	  count	  increased	  across	  both	  groups,	  this	  was	  more	  marked	  in	  sepsis	  patients	  
than	  in	  SIRS	  patients.	  Total	  cell	  counts	  for	  each	  group	  are	  shown	  in	  figure	  5.6.	  
	   	  















Figure	  5.6:	  Monocyte	  counts	  tended	  to	  be	  higher	  in	  the	  SIRS	  group	  whilst	  neutrophils	  
tended	  to	  be	  higher	  in	  sepsis.	  
Median	  neutrophil	  and	  monocyte	  counts	  for	  each	  group.	  	  
A:	   SIRS	  and	  sepsis	  patient’s	  (all	  patients	  within	  each	  group)	  monocyte	  count	  (x109/L)	  
B:	   SIRS	  and	  sepsis	  patient’s	  (all	  patients	  within	  each	  group)	  neutrophil	  count	  (x109/L)	  
Patient	  data	  shown	  as	  median	  and	  IQR.	  Normal	  range	  shown	  on	  x	  axis	  	  (median,	  5th	  to	  95th	  
centile).	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Monocyte	  HLA-­‐DR	  expression	  was	  reduced	  in	  SIRS	  and	  sepsis:	  
To	   confirm	   that	   the	   patient	   monocytes	   were	   deactivated,	   we	   measured	   membrane	  
expression	  of	  HLA-­‐DR.	   In	   keeping	  with	  our	  expectations,	   levels	  of	  HLA-­‐DR	  at	  baseline	   (D0)	  
were	  attenuated	  across	  both	  groups	  when	  compared	  to	  healthy	  volunteer	  subjects	  (fig	  5.7A	  
&	   B).	   The	   degree	   of	   attenuation	   at	   baseline	   between	   the	   two	   patient	   groups	  was	   similar	  
(MFI	  627.28	  ±306.33	  healthy	  controls	  vs.	  162.12	  ±154.08	  SIRS	  and	  192.81	  ±184.27	  sepsis).	  
Within	  the	  SIRS	  group	  the	  degree	  to	  which	  HLA-­‐DR	  levels	  were	  reduced	  remained	  relatively	  
constant	   between	   D0	   and	   both	   D2	   (166.86	   ±154)	   and	   D4	   (137.95	   ±91.18).	   At	   D6	   HLA-­‐DR	  
levels	  had	  increased	  to	  exceed	  those	  obtained	  at	  baseline	  (316.09	  ±	  214.68,	  fig	  5.3A)	  but	  did	  
not	   approach	   the	   levels	   seen	   in	   healthy	   controls.	   In	   contrast,	   for	   sepsis	   patients	   levels	  
continued	  to	  fall	  at	  both	  D2	  (111.25	  ±118.71)	  and	  D4	  (76.89	  ±100.62).	  
There	   was	   no	   convincing	   evidence	   of	   a	   recovery	   in	   HLA-­‐DR	   expression	   levels	   across	   the	  
groups	  by	  the	  end	  of	  the	  sampling	  timetable.	  
	   	  
















Figure	  5.7:	  Monocyte	  HLA-­‐DR	  expression	  was	  reduced	  across	  both	  groups	  when	  compared	  
to	  healthy	  volunteers	  (HV)	  
A:	  	  SIRS	  group,	  *	  p<0.05	  vs.	  HV	  	  
B:	  Sepsis	  group,	  *	  p<0.05	  vs.	  HV	  
Analysis	  of	  transformed	  data	  with	  graphical	  illustration	  of	  backlog	  data	  (mean	  &	  95%	  CI)	  
For	  both	  patient	  groups	  D0	  is	  sampling	  baseline,	  D2	  is	  day	  two,	  D4	  is	  day	  four	  and	  D6	  is	  day	  6	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Sol-­‐TNF	  production	  with	  ex	  vivo	  LPS	  stimulation	  was	  reduced	  in	  SIRS	  and	  sepsis:	  
Deactivated	   monocytes,	   in	   addition	   to	   expressing	   reduced	   levels	   of	   HLA-­‐DR,	   have	   been	  
shown	   to	   produce	   reduced	   levels	   of	   sol-­‐TNF	   upon	   ex	   vivo	   stimulation	   with	   LPS	   [224].	   In	  
order	   to	   further	   confirm	   that	   cells	   obtained	   from	   these	   patients	   were	   deactivated,	   we	  
measured	  sol-­‐TNF	  production	  after	  four-­‐hour	  LPS	  stimulation.	  
As	   expected,	   healthy	   volunteer	   PBMCs	   produced	   high	   levels	   of	   sol-­‐TNF	   during	   the	  
stimulation	  period	   (4102.81	  ±3397ρg/ml).	   In	   contrast,	   cells	   from	  patients	  of	   both	   the	   SIRS	  
and	   sepsis	   groups	   produced	   markedly	   lower	   levels	   of	   the	   cytokine	   when	   exposed	   to	   the	  
same	  culture	  conditions	  (501.38	  ±594.9ρg/ml	  SIRS	  D0	  vs.	  548.22	  ±1011.6ρg/ml	  sepsis	  D0,	  fig	  
5.8).	   A	   similar	   pattern	   of	   reduced	   sol-­‐TNF	   production	   was	   seen	   across	   the	   groups	   at	   D2	  
(936.65	   ±730.9ρg/ml	   SIRS	   vs.	   826.97	   ±944.9ρg/ml	   sepsis),	   D4	   (444.07	   ±159ρg/ml	   SIRS	   vs.	  
837.53	   ±811.4ρg/ml	   sepsis)	   and	   D6	   (618.14	   ±245.58ρg/ml	   SIRS	   vs.	   474.2	   ±450.1ρg/ml	  
sepsis).	  
	   	  


















Figure	  5.8:	  Sol-­‐TNF	  production	  on	  ex-­‐vivo	  LPS	  stimulation	  was	  reduced	  across	  the	  groups	  
A:	  SIRS	  
B:	  Sepsis	  
Data	  shown	  as	  median	  &	  IQR	  for	  PBMCS	  stimulated	  with	  LPS	  1μg/ml	  for	  four	  hours	  at	  37°C.	  
*	  P<0.05	  vs.	  healthy	  volunteer	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Higher	  baseline	  TACE	  activity	  was	  seen	  at	  D6	  in	  the	  SIRS	  group:	  
Having	  confirmed	  that	  cells	  were	  deactivated,	  we	  then	  went	  on	  to	  determine	  TACE	  activity	  
on	  isolated	  monocytes.	  In	  SIRS	  patients,	  monocytes	  had	  similar	  un-­‐stimulated	  TACE	  activity	  
(Fig	  5.9A)	  at	  baseline	  (D0)	  to	  those	  taken	  from	  healthy	  volunteers	  (32.74	  ±14.13	  HV	  vs.	  45.74	  
±27.35	  FU/min).	  Activity	  was	  not	  significantly	  different	  at	  either	  D2	  (24	  ±7.86)	  or	  D4	  (47.02	  
±11.9).	   By	   D6,	   in	   keeping	   with	   the	   results	   obtained	   for	   HLA-­‐DR	   expression	   in	   this	   group,	  
baseline	   TACE	   activity	   levels	   were	   significantly	   increased	   (86.26	   ±31.9)	   as	   compared	   to	  
healthy	   volunteers	   (fig	   5.9A,	   p<0.01).	   There	   were	   no	   significant	   differences	   in	   TACE	  
expression	  (table	  5.2).	  
Similar	   to	  previous	   results,	  healthy	   volunteers	   increased	   their	   TACE	  activity	   in	   response	   to	  
LPS	  stimulation	  (fig	  5.9B)	  by	  between	  x1.73	  to	  x4.4	  fold	  (un-­‐stimulated	  32.74	  ±14.13FU/min	  
vs.	  stimulated	  89.85	  ±42.31FU/min;	  p<0.001).	  This	  increase,	  whilst	  attenuated	  (Fig	  5.9)	  was	  
not	  significantly	  different	  in	  SIRS	  compared	  to	  healthy	  volunteers.	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89.8	  (28.82)	   129.88	  
(27.66)	  
Monocyte	  TACE	  







55.3	  (37.22)	   40.35	  
	  
	  
Table	  5.2:	  TACE	  activity	  profiles	  for	  SIRS	  patients’	  monocytes.	  
Values	  are	  given	  for	  both	  un-­‐stimulated	  cells	  and	  those	  stimulated	  with	  LPS.	  Un-­‐stimulated	  
monocyte	  TACE	  expression	  for	  each	  day	  is	  also	  shown.	  
	   	  


















Figure	   5.9:	   Monocytes	   from	   patients	   with	   SIRS	   displayed	   increased	   un-­‐stimulated	   TACE	  
activity	  but	  LPS	  induced	  activity	  was	  not	  significantly	  affected.	  
A:	   Un-­‐stimulated	  monocyte	   TACE	  activity	   (mean	   +	   95%CI),	   data	   shown	   is	   reverse	   log	   from	  
transformed	  raw	  data	  
B:	  Fold	  increase	  in	  activity	  on	  stimulation	  with	  LPS	  1μg/ml	  for	  one	  hour	  (mean	  +SD)	  
*P<0.01	  compared	  to	  healthy	  volunteer	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Higher	  baseline	  TACE	  activity	  and	  reduced	  LPS-­‐induced	  up-­‐regulation	  in	  sepsis	  patients:	  
In	  sepsis	  patients,	  monocytes	  displayed	  significantly	  elevated	  baseline	  TACE	  activity	  on	  D0,	  
D2	  and	  D4	   (Fig	   5.10A).	   This	  was	   accompanied	  by	   a	   reduced	  TACE	  activity	   response	   to	   LPS	  
when	  compared	  to	  healthy	  volunteer	  cells.	  This	  attenuation	  in	  LPS-­‐induced	  activity	  persisted	  
until	  the	  sampling	  timetable	  was	  complete	  (Fig	  5.10B).	  
There	  were	  no	  significant	  differences	  in	  TACE	  expression	  (Table	  5.3).	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Table	  5.3:	  TACE	  activity	  profiles	  for	  sepsis	  patients’	  monocytes.	  
Values	  are	  given	  for	  both	  un-­‐stimulated	  cells	  and	  those	  stimulated	  with	  LPS.	  Un-­‐stimulated	  
monocyte	  TACE	  expression	  for	  each	  day	  is	  also	  shown.	  
	   	  
















Figure	  5.10:	  Monocytes	  from	  patients	  with	  sepsis	  displayed	  increased	  un-­‐stimulated	  TACE	  
activity	  at	  D0,	  D2	  &	  D4,	  but	  LPS	  induced	  activity	  was	  attenuated	  throughout.	  
A:	   Un-­‐stimulated	  monocyte	   TACE	  activity	   (mean	   +	   95%CI),	   data	   shown	   is	   reverse	   log	   from	  
transformed	  raw	  data	  
B:	  Fold	  increase	  in	  activity	  on	  stimulation	  with	  LPS	  1μg/ml	  for	  one	  hour	  
*P<0.01	  compared	  to	  healthy	  volunteer	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Higher	  baseline	  and	  reduced	  LPS-­‐induced	  phospho-­‐p38MAPK	  levels	  in	  sepsis	  patients:	  
After	  observing	  the	  attenuated	  TACE	  response	  to	  LPS	   in	  monocytes	  from	  sepsis	  patients	  at	  
interim	  analysis,	  we	  adapted	  our	  protocol	  to	  determine	  p38MAPK	  activation,	  a	  crucial	  step	  
in	  the	  TACE	  response	  to	  LPS	  [133].	  Data	  was	  obtained	  from	  the	  last	  nine	  patients	  recruited	  
with	   sepsis	   at	   both	   D0	   and	   D2.	   Only	   two	   samples	   were	   obtained	   for	   D4	   and	   one	   for	   D6	  
therefore	  these	  were	  not	   included	   in	  the	  analysis.	  Samples	  were	  also	  obtained	  for	   the	   last	  
two	  patients	  with	  SIRS,	  but	  only	  at	  baseline.	  
In	  sepsis	  patients’	  monocytes	  un-­‐stimulated	  p38MAPK	  levels	  were	  significantly	  higher	  at	  day	  
two	  when	  compared	  to	  those	  from	  D0	  and	  healthy	  volunteers	  (fig	  5.11).	  In	  healthy	  volunteer	  
monocytes	   (n=8)	   LPS	   induced	   a	   significant	   increase	   in	   phospho-­‐p38MAPK	   levels	   fifteen	  
minutes	  after	  stimulation	  (MFI	  134	  ±74.72	  un-­‐stimulated	  vs.	  371.47	  ±171.16	  LPS	  stimulated,	  
p<0.01;	   fig.	   5.12A).	   Consistent	   with	   the	   reduced	   TACE	   response	   to	   LPS	   (fig	   5.10B)	   this	  
increase	   was	   attenuated	   in	   sepsis	   patients	   at	   D0	   (MFI	   159.99	   ±86.25	   un-­‐stimulated	   vs.	  
223.34	  ±120.23	  LPS	  stimulated;	  non-­‐significant;	  fig.	  5.12C)	  and	  D2	  (MFI	  354.37	  ±158.22	  un-­‐
stimulated	  vs.	  417	  ±206.77	  LPS	  stimulated;	  non-­‐significant).	  
In	  contrast	  to	  the	  findings	  in	  sepsis,	  monocytes	  from	  SIRS	  patients	  appeared	  to	  start	  from	  a	  
similar	  level	  to	  healthy	  volunteers	  and	  have	  a	  preserved	  response	  to	  LPS	  (MFI	  159.99	  ±86.25	  
un-­‐stimulated	  vs.	  344.7	  ±92.07	  LPS	  stimulated,	  fig.	  5.12B).	  
	   	  










Figure	  5.11:	  Baseline	  phospho-­‐p38	  MAPK	  levels	  were	  elevated	  in	  sepsis	  patient	  monocytes	  
at	  day	  two	  
Un-­‐stimulated	  phospho-­‐p38	  MAPK	  levels	  for	  healthy	  volunteers	  (n=8)	  and	  sepsis	  patients	  
(n=9).	  
*	  P<0.05	  vs.	  healthy	  volunteer	  and	  sepsis	  D0	  
	   	  
















Figure	  5.12:	  The	  p38MAPK	  response	  to	  LPS	  was	  present	  in	  healthy	  volunteers	  and	  SIRS	  
patients,	  but	  attenuated	  in	  sepsis.	  
P38	  MAPK	  phosphorylation	  in	  response	  to	  LPS	  1μg/ml	  for	  0,	  15	  and	  30-­‐minutes.	  
Figures	  are	  for	  PBMCs	  gated	  on	  monocytes.	  	  
A:	  Healthy	  volunteers,	  n=8	  
B:	  SIRS	  patients,	  n=2	  
C:	  Sepsis	  patients,	  n=9	  
*P<0.05	  vs.	  un-­‐stimulated	  (HV	  t=0)	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Higher	  baseline	  TNFR-­‐1	  expression	  and	  reduced	  LPS-­‐induced	  shedding	  in	  sepsis	  patients:	  
Within	  the	  SIRS	  group	  monocyte	  TNFR-­‐1	  expression	  on	  D0	  was	  not	  significantly	  different	  to	  
that	  seen	  on	  healthy	  volunteer	  cells	   (MFI:	  19.46	  ±8.18	  HV	  vs.	  28	  ±19.88	  SIRS	  D0,	   fig	  5.13).	  
There	  were	  no	  significant	  differences	  in	  these	  values	  at	  D2	  (MFI:	  17.8	  ±6.37),	  D4	  (MFI:	  8.05	  
±5.1)	  or	  D6	  (MFI:	  14.92	  ±12.49).	  Although	  higher	  on	  all	  sampling	  days,	  TNFR-­‐1	  expression	  in	  
the	   sepsis	   group	   was	   not	   significantly	   different	   from	   healthy	   volunteers	   at	   D0	   (MFI	   27.1	  
±10.92),	   D2	   (MFI	   35.54	   ±27.9)	   or	   D4	   (37.21	   ±21.69).	   However,	   expression	   levels	   were	  
elevated	  at	  D6	  (MFI	  70.79	  ±29.2,	  p<0.01	  vs.	  HV	  and	  sepsis	  D0,	  fig	  5.13).	  
In	  response	  to	  LPS	  the	  percentage	  shedding	  of	  TNFR-­‐1	  was	  calculated	  in	  the	  same	  manner	  as	  
outlined	   in	   Chapter	   Four.	   Healthy	   volunteer	   monocytes	   shed	   TNFR-­‐1	   as	   expected	   in	  
response	  to	  LPS	  (76.1%)	  as	  did	  SIRS	  patients	  (69.5%	  D0,	  73.5%	  D2,	  87.6%	  D4	  and	  59.1%	  D6).	  
There	  were	  no	  significant	  differences	  in	  this	  percentage	  shedding	  between	  these	  groups	  (fig	  
5.14).	  In	  addition	  to	  the	  elevated	  monocyte	  TNFR-­‐1	  expression	  seen	  in	  sepsis	  patients	  there	  
was	   significantly	   reduced	   shedding	   in	   response	   to	   LPS	   at	   D0	   (43.2%,	   fig	   5.14B).	   Whilst	  
shedding	  was	  not	   significantly	   different	   at	   the	  other	   sampling	   time	  points	   (MFI	   59.2%	  D2,	  
33.7%	  D4	  and	  40.1%	  D6,	   fig	  5.14),	   this	  may	  show	  a	   trend	   toward	   reduced	  shedding	   in	   the	  
sepsis	  group.	  
	   	  















Figure	  5.13:	  TNFR-­‐1	  expression	  in	  SIRS	  was	  not	  affected	  but	  in	  sepsis	  it	  was	  elevated	  
MFI	  of	  TNFR-­‐1	  on	  monocytes	  taken	  from:	  
A:	  SIRS	  patients	  (mean	  +	  SD)	  
B:	  Sepsis	  patients	  (mean	  +	  95%	  CI),	  data	  shown	  is	  reverse	  log	  from	  transformed	  raw	  data	  
*P<0.01	  vs.	  HV	  and	  sepsis	  D0	  	   	  
















Figure	  5.14:	  TNFR-­‐1	  shedding	  in	  response	  to	  LPS	  was	  reduced	  in	  sepsis	  but	  not	  in	  SIRS	  
Percentage	  shedding	  of	  TNFR-­‐1	  expressed	  on	  monocytes	   in	  response	  to	  LPS	  1μg/ml	  for	  one	  
hour	  	  
A:	  SIRS	  patients	  
B:	  Sepsis	  patients	  
*P<0.01	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TNFR-­‐2	  expression	  and	  LPS-­‐induced	  shedding	  were	  unchanged	  in	  SIRS	  and	  sepsis	  patients:	  
As	  shown	  in	  figure	  5.15,	  expression	  of	  TNFR-­‐2	  at	  D0	  was	  not	  significantly	  different	  between	  
healthy	   volunteers	   (MFI	   17.26	   ±8.07),	   SIRS	   patients	   (MFI	   23.48	   ±9.32)	   or	   sepsis	   patients	  
(26.94	  ±19.07).	  Expression	  levels	  were	  not	  significantly	  different	  at	  D2	  (MFI	  27.9	  ±14.04	  SIRS	  
&	  13.29	  ±5.05	  sepsis),	  D4	  (MFI	  14.28	  ±9.51	  SIRS	  &	  12.78	  ±4.96	  sepsis)	  or	  D6	  (MFI	  17.0	  ±8.88	  
SIRS	  &	  11.58	  ±5.6	  sepsis).	  
In	   response	   to	   LPS,	   healthy	   volunteer	   monocytes	   shed	   the	  majority	   of	   surface	   expressed	  
TNFR-­‐2	   (86.0%)	   and	   this	   response	   was	  maintained	   in	   SIRS	   patients	   (78.1%	   D0,	   79.5%	   D2,	  
71.1%	  D4	  &	  79.0%	  D6,	  fig	  5.16A).	  In	  the	  sepsis	  group	  TNFR2	  shedding	  was	  apparent	  (65.6%	  
D0,	   65.8%	  D2,	   55%	  D4	  &	   54.3%	  D6,	   fig	   5.16B),	   but	   the	   levels	  were	   reduced	   as	   compared	  
healthy	  volunteers	  and	  SIRS	  patients.	  Whilst	  non-­‐significant	   this	  may	  show	  a	   trend	   toward	  
reduced	  shedding	  in	  the	  sepsis	  group	  and	  therefore	  similar	  to	  the	  difference	  found	  between	  
the	  patients	  groups	  with	  TNFR1	  shedding.	  
	   	  
















Figure	  5.15:	  There	  were	  no	  significant	  differences	   in	  TNFR-­‐2	  expression	  between	  patients	  
and	  healthy	  volunteers	  
MFI	  of	  TNFR-­‐2	  expressed	  on	  monocytes	  taken	  from	  
A:	  SIRS	  patients	  
B:	  Sepsis	  patients	  
	   	  

















Figure	  5.16:	  TNFR-­‐2	  shedding	  did	  not	  differ	  significantly	  between	  the	  groups	  but	  there	  was	  
a	  trend	  toward	  reduced	  shedding	  in	  the	  sepsis	  group	  
Percentage	  shedding	  of	  TNFR-­‐2	  expressed	  on	  monocytes	   in	  response	  to	  LPS	  1μg/ml	  for	  one	  
hour	  (median,	  IQR)	  
A:	  SIRS	  patients	  
B:	  Sepsis	  patients	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L-­‐selectin	  expression	  and	  LPS-­‐induced	  shedding	  were	  unchanged	  in	  both	  SIRS	  and	  sepsis:	  
As	  shown	  in	  figure	  5.17,	  monocyte	  L-­‐selectin	  expression	   levels	  at	  D0	  were	  similar	  between	  
healthy	  volunteers	  (MFI	  92.27	  ±60.75),	  SIRS	  patients	  (MFI	  84.88	  ±63.96)	  and	  sepsis	  patients	  
(MFI	  111.57	  ±71.19).	  Similarly	  there	  were	  no	  significant	  differences	  in	  expression	  at	  D2	  (MFI	  
139.35	  ±81.94	  SIRS,	  52.23	  ±22.53	   sepsis),	  D4	   (MFI	  38.76	  ±33.78	  SIRS,	  62.18	  ±21.64	   sepsis)	  
and	  D6	  (MFI	  78.08	  ±8.81	  SIRS,	  63.63	  ±27.56	  sepsis).	  
In	   response	   to	   LPS,	   monocytes	   from	   healthy	   volunteers	   shed	   the	   majority	   of	   L-­‐selectin	  
(85.2%,	   fig.	   5.18).	   Near	   complete	   shedding	   also	   occurred	   on	  monocytes	   taken	   from	   both	  
SIRS	  patients	  (89.4%)	  and	  sepsis	  patients	  (71%)	  at	  D0.	  This	  pattern	  was	  also	  seen	  at	  D2,	  D4	  
and	  D6	  although	  there	  was	  some	  variation	  (fig.	  5.18).	  These	  results	  of	  unchanged	  L-­‐selectin	  
shedding	  in	  the	  septic	  group	  were	  in	  marked	  contrast	  to	  the	  reductions	  of	  LPS-­‐induced	  TACE	  
activation	  and	  TNFR1	   shedding,	   suggesting	  differential	   pathway	  modulation	  with	  potential	  
functional	  significance.	  
	   	  



















Figure	  5.17:	  L-­‐selectin	  expression	  levels	  were	  not	  affected	  by	  SIRS	  or	  sepsis	  
L-­‐selectin	  expressed	  on	  monocytes	  (median,	  IQR)	  taken	  from	  
A:	   SIRS	  patients	  
B:	   Sepsis	  patients	   	  



















Figure	  5.18:	  L-­‐selectin	  shedding	  in	  response	  to	  LPS	  was	  preserved	  in	  both	  SIRS	  and	  sepsis	  
Percentage	  shedding	  of	  L-­‐selectin	  (median,	  IQR)	  expressed	  on	  monocytes	  in	  response	  to	  LPS	  
1μg/ml	  for	  one	  hour	  
A:	   SIRS	  patients	  
B:	   Sepsis	  patients	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   SIRS	   Sepsis	  
HLA-­‐DR	  expression	   Down-­‐regulated	   Down-­‐regulated	  
Sol-­‐TNF	  production	   Reduced	   Reduced	  
TACE:	  
Basal	  activity	  
















































Table	  5.4:	  Complete	  data	  for	  SIRS	  and	  sepsis	  patients	  summarising	  relevant	  TACE	  and	  
associated	  substrate	  behaviour	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Expression	  of	  chemokine	  receptor	  two	  (CCR2)	  on	  monocytes	  from	  SIRS	  and	  sepsis	  patients:	  
To	   identify	   an	   inflammatory	   process	   that	   might	   be	   linked	   to	   the	   preserved	   L–selectin	  
shedding	  phenotype	  in	  SIRS	  and	  sepsis	  patients’	  monocytes,	  we	  investigated	  their	  migration	  
capability.	   As	   a	   critical	   mediator	   of	   monocyte	   chemotaxis	   and	   migration	   we	   determined	  
whether	   patient	   monocytes	   expressed	   CCR-­‐2,	   the	   receptor	   for	   monocyte	   chemotactic	  
protein-­‐1	  (MCP-­‐1)	  [454]	  [455].	  
For	  the	  final	  six	  patients	  (two	  with	  SIRS	  and	  four	  with	  sepsis)	  recruited	  we	  stained	  for	  CCR-­‐2	  
at	  D0	  and	  compared	  this	  to	  levels	  obtained	  from	  the	  final	  four	  healthy	  volunteers.	  Although	  
patient	   monocytes	   expressed	   the	   receptor	   there	   was	   a	   non-­‐significant	   trend	   toward	   this	  
being	  at	  lower	  levels	  than	  in	  healthy	  volunteer	  cells	  (MFI	  358.83	  ±210.25	  healthy	  volunteer	  
vs.	  155.93	  ±81.23	  patients;	  p=0.06;	  fig	  5.19).	  
	  	   	  











Figure	  5.19:	  Monocytes	  taken	  from	  patients	  expressed	  CCR2	  but	  displayed	  a	  trend	  toward	  
reduced	  levels	  when	  compared	  to	  healthy	  volunteers	  
Monocyte	  CCR2	  expression,	  mean	  +SD	  
N=4	  healthy	  volunteers	  
N=6	  patients	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5.5	  Discussion	  
	  
In	   this	   study	   I	   successfully	  developed	  and	   refined	  a	   flow	  cytometry	  protocol	   to	   identify	  all	  
human	   monocyte	   subpopulations.	   I	   found	   that	   monocytes	   expressed	   characteristics	  
previously	  described	  as	  the	  ‘deactivation’	  phenotype.	  However,	  with	  respect	  to	  TACE	  activity	  
and	  substrate	  shedding,	  there	  appeared	  to	  be	  a	  more	  complex	  pattern	  that	   is	   indicative	  of	  
‘reprogramming’	   of	   the	   normal	   response.	   These	   patterns	   appeared	   different	   according	   to	  
different	  SIRS	  aetiologies,	  i.e.	  sepsis,	  but	  not	  non-­‐septic	  SIRS,	  produced	  a	  down	  regulation	  of	  
HLA-­‐DR	  and	  sol-­‐TNF	  release	  combined	  with	  increased	  baselines	  (yet	  reduced	  inducibility)	  of	  
p38MAPK	  and	  TACE	  activity	  (table	  5.4).	  It	  was	  also	  apparent	  that	  the	  TACE	  activity	  profiles	  in	  
isolated	  monocyte	  were	  altered	   in	  a	  manner	   that	  was	  broadly	   similar	   to	   those	   induced	  by	  
the	  model	  of	  in	  vitro	  tolerance	  developed	  in	  Chapter	  Four.	  
	  
Demographics	  
The	   patient	   groups	   were	   well	   matched	   apart	   from	   a	   younger	   age	   group	   within	   the	   SIRS	  
group.	   This	   is	   likely	   to	   reflect	   the	   fact	   that	   sepsis	   occurs	  with	   increasing	   incidence	   as	   age	  
increases	   [456].	   A	   high	   number	   of	   these	   SIRS	   patients	   are	   from	   neurosciences	   as	   Charing	  
Cross	   Hospital	   is	   a	   tertiary	   referral	   centre	   for	   this	   specialty.	   The	   fact	   that	   the	   healthy	  
volunteer	   group	   has	   a	   younger	   age	   than	   either	   of	   the	   patient	   groups	  was	   unavoidable	   as	  
these	  were	   recruited	   from	  staff	  at	   Imperial	  College	  London.	   Indeed	  with	  specific	   regard	   to	  
PBMC	   HLA-­‐DR,	   increasing	   age	   has	   been	   found	   to	   increase	   expression	   [457],	   potentially	  
enhancing	  the	  significance	  of	  the	  fall	  we	  saw	  with	  this	  marker	  in	  sepsis.	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Monocyte	  subset	  markers	  	  
Our	  first	  aim	  was	  to	  successfully	  construct	  a	  flow	  cytometry	  protocol	  that	  would	  allow	  us	  to	  
identify	  monocytes	   in	  PBMC	  preparations	   that	  were	  often	   contaminated	  with	  neutrophils.	  
We	   found	   that	   using	   FSC,	   SSC,	   CD11b	   and	   CD56	   allowed	   us	   to	   do	   this	   in	   an	   HLA-­‐DR	  
independent	   manner,	   meaning	   that	   we	   could	   then	   accurately	   quantify	   expression	   of	   the	  
MHC	  class	  II	  molecule.	  This	  represented	  an	  advance	  on	  our	  previous	  protocol	  that	  included	  
HLA-­‐DR	  in	  the	  gating	  strategy	  [53],	  and	  on	  numerous	  HLA-­‐DR	  SIRS	  related	  studies,	  which	  had	  
used	  more	  simplistic	  methods	  of	  identifying	  monocytes,	  and	  had	  not	  attempted	  to	  examine	  
subsets	  [458-­‐461].	  
As	  mentioned	   in	   the	   introduction	   to	   this	   chapter,	  whilst	   it	   has	   been	   recognised	   for	   some	  
time	   that	   human	   monocytes	   are	   heterogeneous,	   there	   is	   no	   consensus	   on	   how	   these	  
subsets	   should	  be	  classified.	  We	  had	  aimed	   to	  use	  expression	  of	  CD14,	  CD16	  and	  CD64	   to	  
categorise	   subsets	   and	   determine	   how	   these	   behaved	   individually	   in	   SIRS.	  We	   found	   that	  
significant	   distortion	   of	   these	   markers	   occurred	   in	   patient	   samples.	   This	   should	   not	   be	  
considered	  a	  surprising	  finding	  given	  that	   levels	  of	  CD64	  [462],	  CD16	  [307]	  and	  CD14	  [463]	  
change	  in	  the	  context	  of	  critical	  illness	  and	  that	  the	  CD14-­‐CD16+	  subset	  expands	  [305,	  310].	  
What	   was	   striking	   was	   the	   degree	   to	   which	   these	   alterations	   dramatically	   altered	   the	  
appearance	  of	  the	  cells	  contained	  within	  the	  monocyte	  gate	  and	  obscured	  the	  cut-­‐off	  points	  
between	   the	   subsets.	   This	   made	   distinguishing	   the	   classical	   CD14++CD16-­‐	   from	   the	  
intermediate	   CD14+CD16+	   group	   difficult	   and,	   in	   conjunction	   with	   the	   reduced	   ability	   of	  
CD64	  expression	  to	  differentiate	  between	  the	  overlapping	  intermediate	  (CD14+CD16+)	  and	  
mature	   (CD14-­‐CD16+)	   groups,	  made	   it	   difficult	   to	   draw	   the	   gates	   required	   to	   identify	   the	  
monocyte	   subsets.	   Any	   subset	   gates	   that	   were	   drawn	   would	   be	   arbitrary	   in	   nature	   with	  
potential	   implications	   on	   any	   results	   obtained,	   calling	   into	   question	   the	   legitimacy	   of	  
categorising	  monocytes	   as	   discrete	   subpopulations	   in	   critical	   illness	   based	  on	   the	  markers	  
we	   used.	   While	   recognising	   the	   potential	   exclusion	   of	   CD14-­‐CD16+	   and	   perhaps	   some	  
CD14+CD16+	  monocytes	  from	  our	  TACE	  activity	  studies	  by	  our	  use	  of	  a	  CD14+	  positive	  bead	  
selection	   protocol,	   for	   flow	   cytometric	   analysis	  we	   decided	   it	  was	   necessary	   to	   avoid	   any	  
arbitrary	   or	   imprecise	   sub-­‐division	   of	   monocytes	   and	   to	   evaluate	   the	   population	   in	   its	  
entirety.	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Cells	   from	   both	   groups	  were	   deactivated	   and	   could	   not	   be	   differentiated	   using	   HLA-­‐DR	  
expression	  levels	  alone	  
Having	   developed	   our	   flow	   cytometry	   protocol,	   I	   then	   established	   that	   cells	   from	   both	  
patient	   groups	   showed	   changes	   consistent	   with	   a	   state	   of	   deactivation,	   namely	   reduced	  
HLA-­‐DR	  expression	  and	  sol-­‐TNF	  production	  on	  ex	  vivo	  LPS	  stimulation.	   In	  Chapter	  Four	  we	  
demonstrated	   that	  even	  normal	  monocytes,	  once	   cultured	   for	   a	  prolonged	  period	  of	   time	  
(16	  hours)	   showed	  changes	   in	  p38MAPK	  activation	   status	  and	  activity	  profiles.	   In	  order	   to	  
minimise	   any	   phenotypic	   change	   in	   the	   cells,	   the	   duration	   of	   the	   ex	   vivo	   stimulation	  was	  
deliberately	  short	  (four	  hours).	  The	  fact	  that	  sol-­‐TNF	  levels	  were	  significantly	  reduced	  across	  
all	  four	  samples	  in	  sepsis	  whereas	  in	  SIRS	  this	  was	  only	  significant	  at	  D0	  is	  likely	  due	  to	  the	  
lower	   numbers	   of	   patients	  within	   this	   latter	   group.	   Consistent	  with	   a	   previous	   study	   [54],	  
levels	  of	  HLA-­‐DR	  did	  not	  differ	  between	  SIRS	  and	  septic	  patients	  and	   therefore	  would	   lack	  
any	  diagnostic	  value	  for	  the	  presence	  of	  infection.	  
	  
TACE	  activity	  profiles	  
Isolation	  of	  monocytes	  allowed	  the	  kinetics	  of	  the	  acute	  TACE	  response	  to	  be	  elicited.	  This	  is	  
the	   first	   time	   its	   catalytic	   activity	  has	  been	  directly	  measured	   in	   critical	   illness.	  Within	   the	  
sepsis	  group,	  baseline	  TACE	  activity	  was	  enhanced	  and	  LPS-­‐induced	  activity	  decreased,	  in	  a	  
manner	   similar	   to	   that	   generated	   by	   LPS	   exposure	   in	   the	   tolerance	   model	   I	   developed.	  
Exposure	  to	  LPS	  has	  been	  suggested	  as	  an	  initiator	  of	  monocyte	  deactivation	  [436],	  this	  may	  
occur	   directly	   or	   indirectly	   through	   the	   induction	   of	   other	   mediators	   such	   as	   IL-­‐10	   to	  
produce	  the	  changes	  in	  TACE	  behaviour	  seen.	  It	  has	  been	  shown	  that	  IL-­‐10	  inhibits	  TACE	  in	  a	  
TIMP-­‐3	   dependent	   and	   independent	   manner	   [366].	   Alternatively,	   TACE	   activity	   may	   have	  
reached	  a	  ceiling	  in	  these	  patients	  and	  further	  induction	  ex	  vivo	  was	  not	  possible.	  Although	  
LPS-­‐induced	   enzyme	   activity	   values	   were	   attenuated	   from	   D0,	   the	   peak	   increase	   in	   basal	  
TACE	  activity	  was	  seen	  at	  D2	   in	   the	  sepsis	  group.	  This	  corresponded	  to	   the	  point	  at	  which	  
un-­‐stimulated	   phosphorylated	   levels	   of	   p38MAPK	   were	   elevated	   in	   monocytes	   and	   a	  
reduction	  in	  response	  to	  LPS	  was	  seen.	  Given	  that	  p38MAPK	  activates	  TACE	  [133],	  this	  may	  
offer	  some	  explanation	  as	  to	  how	  the	  changes	  in	  TACE	  behaviour	  are	  occurring.	  Our	  findings	  
may	  be	   in	   line	  with	  those	  of	  Rosengart	  and	  colleagues	  who	  performed	  western	  blotting	  of	  
mixed	   cells	   obtained	   from	   BAL	   fluid	   and	   found	   that	   a	   sub-­‐group	   of	   trauma	   patients	   had	  
elevated	  levels	  of	  phospho-­‐p38MAPK	  that	  were	  refractory	  to	  ex	  vivo	  stimulation	  [464].	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Within	  the	  SIRS	  group	  no	  significant	  increases	  in	  basal	  TACE	  activity	  were	  seen	  except	  on	  D6.	  
As	  patients	  improved	  or	  died	  they	  were	  removed	  from	  the	  study,	  meaning	  those	  remaining	  
in	  the	  study	  at	  D6	  were	  likely	  to	  be	  making	  unsatisfactory/slow	  clinical	  progress.	  Therefore	  
these	   changes	   in	   TACE	   behaviour	   seen	   at	   D6	   in	   the	   SIRS	   group	   may	   represent	  
nosocomial/secondary	  infection.	  We	  did	  not	  see	  any	  increase	  in	  monocyte	  TACE	  cell	  surface	  
expression	  as	  has	  previously	  been	  reported	  on	  neutrophils	  in	  sepsis	  [355],	  meaning	  that	  the	  
activity	  changes	  we	  report	  reflect	  a	  true	  change	  in	  activity	  as	  opposed	  to	  more	  enzyme.	  
	  
TACE	  substrates	  -­‐	  TNFRs	  
By	   examining	   both	   expression	   levels	   and	   shedding	   profiles	   of	   the	   TNF	   receptors	   and	   L-­‐
selectin,	  we	  aimed	  to	  develop	  a	  more	  complete	  understanding	  of	  how	  cells	  were	  behaving	  
with	   respect	   to	  TACE-­‐mediated	   functions.	  We	   found	  no	  differences	   in	  either	  expression	  or	  
shedding	  for	  either	  of	  the	  TNF	  receptors	  in	  SIRS	  patients’	  monocytes.	  In	  contrast	  within	  the	  
sepsis	   group	   there	   was	   attenuated	   shedding	   of	   TNFR-­‐1	   at	   D0	   and	   significantly	   increased	  
expression	   by	   D6.	   This	   increased	   expression	   of	   monocyte	   TNFR-­‐1	   has	   previously	   been	  
reported	   [50].	  TNFR-­‐1	   signalling	   forms	  part	  of	   the	  “extrinsic”	  death	   receptor	  pathway	   that	  
induces	  apoptosis	  in	  leukocytes	  [465]	  and	  has	  been	  implicated	  in	  neutrophil	  apoptosis	  [466].	  
It	   has	   also	   been	   shown	   that	   recruited,	   exudative	  macrophages	   accumulate	   in	   early	   acute	  
lung	   injury	   but	   then	   decline	   as	   a	   result	   of	   apoptosis	   [467].	   It	   can	   be	   speculated	   that	   this	  
increase	   in	  monocyte	   TNFR-­‐1	   expression	   in	   sepsis	   represents	   a	   limit	   (brake)	   on	   classically	  
activated	  inflammatory	  monocytes,	  such	  that	  they	  are	  removed	  as	  appropriate	  to	  orientate	  
monocyte	   function	   towards	   an	   alternatively	   activated	   tissue	   repair	   phenotype.	   Indeed	  
monocyte	   apoptosis	   has	   been	   demonstrated	   in	   sepsis	   and	   has	   been	   suggested	   to	   be	  
protective	  [468],	  which	  may	  be	  in	  keeping	  with	  this	  hypothesis.	  Other	  potential	  reasons	  for	  
this	  increase	  in	  TNFR-­‐1	  may	  include	  the	  mitochondrial	  dysfunction	  seen	  in	  sepsis	  [469],	  given	  
that	  recent	  work	  has	  suggested	  mitochondria	  may	  mediate	  TNFR-­‐1	  ectodomain	  shedding	  via	  
a	  calcium	  dependent	  process	  [470].	  
Although	  we	   saw	  no	   significant	   differences	   in	   TNFR-­‐2	   expression	   and	   shedding	  within	   the	  
sepsis	  group,	  there	  was	  a	  trend	  toward	  impaired	  shedding	  over	  time	  that	  was	  not	  present	  in	  
the	  SIRS	  group.	  Further	  work,	  with	  greater	  patient	  numbers	  and	  thus	  increased	  power	  may	  
be	   needed	   to	   demonstrate	   this	   conclusively.	   These	   patterns	   of	   TNF	   receptor	   expression	  
were	  not	  comparable	  with	  those	  seen	   in	  the	  tolerance	  model	  we	  constructed	   in	  vitro,	  and	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may	  suggest,	  as	  might	  be	  expected,	  that	  the	  in	  vivo	  situation	  is	  more	  complicated	  than	  it	  is	  
feasible	  to	  model	  using	  a	  single	  cell	  type	  (monocytes)	  and	  stimulus	  (LPS).	  
	  
TACE	  substrates	  –	  L-­‐selectin	  
In	  contrast	  to	  TNFR-­‐1,	  in	  both	  SIRS	  and	  sepsis	  the	  expression	  and	  shedding	  of	  the	  adhesion	  
molecule	   L-­‐selectin	   were	   no	   different	   to	   that	   seen	   in	   healthy	   volunteers.	   Our	   data	  
demonstrates	  perturbation	  of	  MAPK	  signalling	   in	   the	  sepsis	  group,	  which	  would	  appear	   to	  
contradict	   the	   findings	   of	   Killock	   et	   al	   who	   found	   L-­‐selectin	   shedding	   to	   be	   p38MAPK	  
dependent	   [377]	   through	   the	   use	   of	   a	  MAPK	   inhibitor.	   However,	   some	   investigators	   have	  
questioned	   the	   selectivity	   of	   these	   inhibitors	   [471]	   and	  moreover,	   unpublished	   data	   from	  
our	   group	   found	   that	   p38MAPK	   inhibition	   did	   not	   inhibit	   L-­‐selectin	   shedding	   [472].	  
Kermarrec	   and	   colleagues	   found	   increased	   soluble	   L-­‐selectin	   in	   patients	   with	   peritoneal	  
sepsis	  and	   surmised	   that	   this	  was	  due	   to	   increased	  neutrophil	   TACE	  expression	   [355].	  Our	  
results	   of	   unaltered,	   or	   partially	   reduced,	   L-­‐selectin	   shedding	   and	   no	   changes	   in	   TACE	  
expression	   in	   sepsis	  patients’	  monocytes	   suggest	   that	  marked	  differences	  may	  exist	   in	   the	  
regulation	   of	   neutrophil	   and	   monocyte	   TACE	   related	   shedding.	   The	   unchanged	   baseline	  
expression,	   higher	   TACE	   activity	   but	   maintained	   substrate	   expression	   in	   sepsis	   patients	  
highlights	   the	   lack	  of	  a	  simple	   relationship	  between	  TACE	  expression,	  catalytic	  activity	  and	  
substrate	  shedding.	  In	  general,	  when	  comparing	  the	  relationship	  between	  TACE	  activity	  and	  
substrate	  shedding,	  it	  may	  be	  helpful	  to	  think	  of	  TNF	  separately	  given	  the	  high	  affinity	  that	  
TACE	  displays	  for	  this	  substrate	  when	  compared	  to	  non-­‐TNF	  substrates	  [375].	  For	  TNF	  there	  
appears	  to	  be	  a	  direct	  relationship	  between	  TACE	  activity	  and	  cleavage	  rates.	  In	  contrast,	  the	  
lower	  affinity	  to	  non-­‐TNF	  substrates	  [375]	  means	  additional	  steps	  are	  required	  for	  cleavage	  
that	  limit	  their	  shedding	  even	  in	  the	  presence	  of	  catalytically	  active	  TACE	  (as	  observed	  in	  the	  
sepsis	  group).	  
The	   impact	  of	  L-­‐selectin	  shedding	  on	  monocyte	  function	   is	  still	  unclear.	  Some	  investigators	  
have	  demonstrated	  that	  neutrophil	  rolling	  was	  impaired	  if	  L-­‐selectin	  shedding	  was	  inhibited	  
and	  produced	  leukocyte	  accumulation	  [473].	  Others	  have	  reported	  that	  inhibiting	  L-­‐selectin	  
shedding	  had	  no	  effect	  on	  neutrophil	   rolling	  or	  migration	   [474].	   The	   idea	  of	   some	  cellular	  
functions	   (such	   as	   L-­‐selectin	   shedding)	   being	   preserved	  whilst	   others	   are	   suppressed	   is	   in	  
keeping	   with	   recent	   findings	   suggesting	   that	   bacterial	   reprogramming	   of	   PBMCs	   impairs	  
their	  phagocytic	  capacity,	  but	  preserves	  their	  ability	  to	  stimulate	  naïve	  T-­‐lymphocytes	  [439].	  
It	  is	  also	  in	  keeping	  with	  compartmentalisation	  hypothesis	  of	  SIRS/CARS	  regulation,	  i.e.	  cells	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are	  suppressed	  systemically	  but	  are	  capable	  of	  entering	  the	  tissues,	  once	  there	  they	  may	  be	  
capable	   of	   mounting	   an	   inflammatory	   response.	   This	   is	   similar	   to	   Munford	   and	   Pugin’s	  
argument	  that	  the	  systemic	  response	  to	  injury/inflammation	  is	  anti-­‐inflammatory	  [58].	  
	  
Limitations	  
There	  are	  some	  limitations	  of	  this	  study	  that	  should	  be	  considered.	  The	  definition	  for	  sepsis	  
used	   is	  of	  suspected	   infection	   in	  combination	  with	  two	  out	  of	  the	  four	  SIRS	  criteria.	  Whilst	  
this	  is	  generally	  the	  accepted	  clinical	  definition	  it	  is	  broad.	  Hence,	  it	  is	  entirely	  possible	  that	  
some	  patients	  in	  the	  sepsis	  group	  have	  sterile	  SIRS	  and	  vice	  versa.	  There	  is	  also	  considerable	  
heterogeneity	  within	   the	   sepsis	   group	  with	   patients	   presenting	  with	   infection	   in	   different	  
tissues	  and	  with	  different	  organisms.	  In	  future	  it	  may	  be	  more	  appropriate	  to	  try	  and	  study	  a	  
more	  homogenous	  population	  by	  concentrating	  on	  specific	  pathologies	  (e.g.	  pneumonia)	  or	  
organisms.	  
Although	   the	   FRET	   assay	   used	   isolated	   monocyte	   preparations	   when	   measuring	   TCAE	  
activity	   profiles	   there	   remains	   a	   possibility	   that	   these	   contained	   some	   low	   level	  
contamination	   with	   other	   circulating	   leukocytes/apoptotic	   cells.	   These	   may	   have	  
contributed,	   in	   part,	   to	   the	   elevated	   unstimulated	   levels	   of	   TACE	   activity	   seen	  within	   the	  
sepsis	  group.	  However,	  the	  elevated	  basal	  p38MAPK	  levels	  in	  monocytes	  taken	  from	  sepsis	  
patients	   would	   seem	   to	   indicate	   that	   there	   are	   mechanistic	   data,	   taken	   from	   intact	  
monocytes,	   which	   support	   these	   changes.	   It	   is	   possible	   that	   the	   changes	   in	   TACE	   activity	  
profiles	  within	  the	  sepsis	  group	  (increased	  baseline	  and	  loss	  of	  induced	  LPS	  response),	  rather	  
than	   reflecting	   immune	   suppression,	   are	   just	   reflective	   of	   maximal	   immune	   stimulation.	  
Further	  work	  is	  clearly	  required	  to	  accurately	  discriminate	  between	  these	  two	  scenarios.	  
In	   the	   introduction	   to	   this	   thesis	   I	   discussed	   the	   possibility	   that	   the	   immune	   response	   is	  
compartmentalised.	   Some	   investigators	   have	   argued	   that	   the	   systemic	   circulation	   is,	   by	  
default,	   anti-­‐inflammatory	   [58].	   Thus,	   the	   systemic	   changes	   we	   describe	   may	   not	   be	  
representative	  of	   the	  processes	  occurring	  within	   infected	   tissue	  beds.	   In	   the	   future,	  when	  
possible,	  it	  would	  be	  of	  benefit	  to	  compare	  and	  contrast	  the	  immune	  response	  in	  cells	  taken	  
from	   the	   systemic	   circulation	   to	   that	   seen	   in	   cells	   taken	   from	   infected	   tissues.	   I	   have	  
expanded	  on	  this	  theme	  in	  the	  final	  discussion	  contained	  in	  Chapter	  Seven.	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Conclusions	  
I	  have	  contributed	  to	  the	  knowledge	  base	   in	  this	   field	   in	  several	  areas.	  Firstly,	   through	  the	  
construction	  of	  a	  flow	  cytometry	  protocol	  which	  allows	  us	  to	  identify	  monocytes.	  Secondly,	  I	  
have	   identified	   that	  monocyte	   surface	  markers	   change	   in	   critical	   illness,	   in	   a	  manner	   that	  
may	   preclude	   accurate	   identification	   of	   subsets.	   Although	   it	   may	   be	   possible	   to	   identify	  
subsets	  using	  recently	  identified	  differential	  markers	  [475],	  my	  findings	  mean	  that	  previous	  
patient	  subset	  data	  may	  be	  misleading.	  Thirdly,	  I	  have	  shown	  that	  the	  acute	  TACE	  response	  
is	  differentially	  affected	  in	  SIRS	  arising	  from	  non-­‐infectious	  and	  septic	  aetiologies.	  In	  sepsis	  a	  
rapid	   decrease	   in	   LPS	   induced	   activity	   and	   increases	   in	   baseline	   activity,	   MAPK	   signalling	  
changes	  and	  alterations	  in	  TNFR-­‐1	  expression	  and	  shedding	  profiles	  are	  seen	  (table	  5.4)	  and	  
could	  plausibly	  be	  used	  as	  diagnostic	  biomarkers.	  
Finally,	  I	  have	  shown	  that	  monocyte-­‐signalling	  pathways	  appear	  to	  be	  differentially	  affected	  
in	   sepsis.	   These	   cells	   appear	   reprogrammed	   rather	   than	  deactivated.	   In	   sepsis	   the	   cellular	  
response	  phenotype	  may	   change	  depending	  on	   the	   stimulus,	   the	   cell	   and	   its	   environment	  
[476],	  but	   to	  our	  knowledge,	   this	   is	   the	   first	   time	   that	  differential	   responses	   (preserved	  L-­‐
selectin	  shedding,	   impaired	  p38	  activation	  and	  TNF	  release)	  to	  a	  single	  stimulus	  (LPS)	  have	  
been	  demonstrated	  and	  serves	  to	  illustrate	  the	  complexity	  of	  the	  situation.	  What	  allowed	  us	  
to	   demonstrate	   these	   novel	   findings	   was	   our	   capacity	   to	   focus	   on	   several	   aspects	   of	   a	  
pathway:	  p38MAPK	  (the	  signal),	  TACE	  (a	  regulatory	  protein)	  and	  TNFR/L-­‐selectin	  (the	  target	  
effector	  molecules).	  Further	  investigation	  of	  these	  pathways	  will	  enhance	  our	  understanding	  
of	  the	  changes	  seen	  in	  monocyte	  signalling	  pathways	  during	  sepsis.	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Chapter	  6	  
Investigation	  of	  the	  influence	  of	  cellular	  environment	  on	  TACE	  activation	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Summary	  
In	   Chapter	   Four	   I	   obtained	   evidence	   for	   LPS-­‐mediated	   inactivation	   of	   the	  monocyte	   TACE	  
response,	   but	   not	   for	   priming.	   These	   experiments	   were	   performed	   in	   blood-­‐derived	  
monocytes	  cultured	  under	  minimally	  adherent	  conditions	  to	  reduce	  any	  spontaneous	  ex	  vivo	  
activation.	  However,	  during	   inflammation	   in	  vivo,	  monocytes	  come	   into	  prolonged	  contact	  
with	   the	   microvascular	   endothelium	   through	   margination	   and	   then	   with	   extravascular	  
parenchymal	   cells	   following	   migration.	   In	   the	   case	   of	   systemic	   inflammation,	   widespread	  
margination	  of	   leukocytes	   is	  seen	  and	  therefore	  cell	  contact	  or	  proximity	  may	  be	  a	  central	  
process	  related	  to	  the	  priming	  of	  blood	  monocyte	  responses.	  On	  this	  basis,	  we	  hypothesised	  
that	   cell	   contact-­‐related	   processes	   are	   essential	   for	   optimal	   TACE	   activation	   in	  monocytes	  
under	  inflammatory	  conditions.	  
In	  order	  to	  test	  this	  hypothesis,	   I	  compared	  the	  responses	  of	  cells	  stimulated	  both	  in	  static	  
culture	  conditions	   (to	  produce	  a	  cell-­‐cell	   contact	  environment)	  and	   in	  a	   rotating	  wheel	   (to	  
minimise	   cell-­‐cell	   interactions,	   simulating	   the	   circulating	   cell	   condition).	   These	   models	  
demonstrated	   that	   the	  TACE	   response	   to	   LPS	  was	  ablated	   in	   low	  cell-­‐cell	  proximity	   states,	  
indicating	   that	   a	   contact	   or	   proximity-­‐dependent	   signal	   was	   required	   for	   optimal	   TACE	  
activation.	   We	   next	   sought	   to	   determine	   where	   the	   proximity-­‐dependent	   signal	   acted	  
upstream	  or	  downstream	  of	  p38MAPK	  signalling.	  LPS-­‐induced	  monocyte	  phospho-­‐p38MAPK	  
levels	  were	   similarly	   elevated	   in	   static	   and	   rotation	   culture	   conditions,	   indicating	   that	   the	  
contact	  signal	  does	  not	  directly	  influence	  p38-­‐MAPK	  activation,	  but	  rather	  acts	  downstream	  
to	  p38MAPK	  in	  promoting	  TACE	  activation.	  
I	  then	  attempted	  to	  determine	  the	  nature	  of	  the	  contact-­‐related	  signal.	  We	  focused	  on	  the	  
two	   principle	   processes,	   which	   we	   considered	   would	   operate	   under	   close	   cell	   proximity	  
conditions:	  secreted	  soluble	  mediators	  and	  cell	  adhesion	  molecule-­‐related	  signalling.	  	  Based	  
on	  the	  previous	   literature	  on	  TACE	  activation	  and	  substrate	  cleavage,	  we	   investigated	  ROS	  
and	   adenosine	   triphosphate	   (ATP)	   for	   soluble	  mediators,	   and	   β1	   and	   β2	   integrins	   for	   cell	  
adhesion	   molecules.	   Although	   hydrogen	   peroxide	   (H2O2)	   as	   a	   source	   of	   ROS	   effectively	  
induced	  TACE	  responses	   in	  rotation	  culture,	  blocking	  extracellular	  ROS	  (whilst	  reducing	  the	  
response	   to	   H2O2)	   did	   not	   block	   the	   response	   to	   LPS,	   leading	   us	   to	   conclude	   that	  
extracellular	  ROS	  did	  not	  mediate	  the	  contact-­‐related	  signal.	  In	  contrast	  to	  previous	  reports,	  
ATP	   alone	   had	   no	   effect	   on	   TACE	   activity.	   Using	   a	   combination	   of	   antibodies	   to	   block	   or	  
stimulate	   monocyte	   integrins,	   we	   found	   some	   evidence	   of	   integrin-­‐mediated	   signalling	  
impacting	  on	  the	  TACE	  pathway.	  We	  conclude	  on	  the	  basis	  of	  this	  data	  that	  cell	  proximity-­‐
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dependent	   intra-­‐cellular	  ROS	  signalling	  promotes	  TACE	  activation	  by	  acting	  downstream	  of	  
p38MAPK.	  
	  
6.1	   Background	  
The	   inability	   to	   discern	   a	   primed	   phenotype	   from	   in	   vitro	   experimentation	   and	   in	   vivo	  
observations	  thus	  far	  is	  striking.	  In	  the	  patient	  samples,	  this	  was	  not	  particularly	  surprising,	  
as	   priming	   by	   its	   very	   nature	   is	   an	   early	   event	   during	   the	   course	   of	   sepsis/SIRS	   and	  may	  
precede	  the	  development	  of	  the	  clinical	  condition.	  The	   in	  vitro	  findings	  however,	   led	  us	  to	  
reappraise	   our	   thinking	   and	   hypothesise	   that	   the	   TACE	   response	   to	   LPS	   seen	   when	  
monocytes	  were	  stimulated	   in	  Eppendorfs	   represented	  maximal	   inflammatory	   signalling	   in	  
response	  to	  this	  stimulus.	  In	  this	  situation	  cells	  will	  be	  in	  close	  proximity	  at	  the	  bottom	  of	  the	  
Eppendorf.	  We	   therefore	  hypothesised	   that	  a	   signal	   indicating	   cell	  proximity,	  or	  even	  cell-­‐
cell	  contact,	  may	  be	  required	  for	  maximal	  inflammatory	  signalling.	  It	  could	  be	  this	  proximity	  
signal	   which	   represents	   “priming”	   of	   the	   monocyte	   to	   the	   LPS	   stimulus.	   Indeed,	   in	   the	  
concluding	  remarks	  to	  Chapter	  Four	  I	  wrote,	  “It	  is	  striking	  when	  reviewing	  the	  literature	  that	  
other	   studies	   using	   LPS	   to	   prime	   cells	   have	   either	   found	   adherence	   to	   be	   key	   or	   used	  
adherent	  systems.”	  
In	  order	  for	  us	  to	  further	  develop	  this	  concept,	  we	  first	  stimulated	  monocytes	  with	  LPS	  in	  the	  
minimally	  adhesive	  PTFE	  medium	  that	  we	  used	  to	  create	  the	  two	  hit	  model	  in	  Chapter	  Four.	  
We	   then	   directly	   compared	   responses	   under	   conditions	   that	   promoted	   cell-­‐cell	   proximity,	  
using	  the	  standard	  static	  culture	  set-­‐up,	  to	  those	  in	  rotation	  culture	  to	  simulate	  normal,	  non-­‐
adherent	   resting	   conditions.	   The	   rotating	   culture	   consisted	   of	   monocytes	   placed	   in	  
Eppendorfs	  at	  normal	  densities	  and	  mixed	  continuously	  by	  rotation	  on	  a	  wheel.	  During	  this	  
period	   the	   Eppendorfs	   are	   held	   in	   the	   horizontal	   plane,	   whilst	   the	   wheel	   rotates	   in	   the	  
vertical	  plane.	  This	  method	  allowed	  a	  reduction	  of	  cell-­‐cell	  or	  cell-­‐plastic	   interactions	  while	  
maintaining	   all	   other	   conditions	   present	   during	   static	   Eppendorf	   stimulation	   constant.	  We	  
deliberately	  created	  a	  single	  cell	  model	  system	  for	  several	  reasons;	  firstly,	  because	  the	  FRET	  
assay	  requires	  a	  single	  cell	  type	  and	  secondly,	  to	  limit	  cell-­‐cell	  interactions	  to	  those	  occurring	  
between	  monocytes.	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From	   the	   literature	   and	   our	   previous	   investigation	   [133],	   we	   identified	   several	   candidate	  
mediators	   and	  mechanisms	   likely	   to	  be	   involved	   in	   transducing	  any	   contact-­‐related	   signal.	  
We	  identified	  three	  key	  groups:	  ROS,	  ATP	  and	  integrins.	  
	  
Reactive	  oxygen	  species	  
Molecules	   mediating	   any	   proximity	   signal	   would	   need	   to	   be	   rapidly	   released,	   labile,	   and	  
tightly	   regulated.	   ROS	   fit	   this	   profile	   and	   are	   produced	   by	   leukocytes	   in	   response	   to	  
stimulation	   resulting	   in	   both	   intra-­‐cellular	   [202]	   and	   extra-­‐cellular	   release	   [477].	   Extra-­‐
cellular	   release	  would	   result	   in	  a	  proximity-­‐dependent	  concentration	  and	  activity	  gradient.	  
Indeed	   extracellular	   neutrophil	   ROS	   production	   has	   been	   shown	   to	   induce	   changes	   in	  
adjacent	   endothelial	   cell	   adhesion	  molecule	   expression	   and	   inflammatory	   signalling	   [477],	  
demonstrating	  that	  ROS	  act	  as	  inter-­‐cellular	  messengers.	  
Our	   previous	   investigation	   found	   TLR-­‐4	   stimulation	   by	   LPS	   resulted	   in	   ROS	  mediated	   p38	  
MAPK	   induction	   to	   produce	   TACE	   activation	   [133].	   However,	   the	   anti-­‐oxidant	   N-­‐acetyl	  
cysteine,	   whilst	   producing	   complete	   inhibition	   of	   TACE	   activation,	   produced	   only	   partial	  
inhibition	  of	  p38MAPK	  phosphorylation	   [133].	  This	  partial	  discrepancy	  could	  be	   in	  keeping	  
with	  a	  separate	  ROS	  signalling	  event	  downstream	  of	  p38MAPK	  to	  activate	  TACE,	  potentially	  




ATP	   is	   released	   extra-­‐cellularly	   from	   monocytes	   in	   response	   to	   microbial	   components.	   It	  
signals	  through	  the	  purinergic	  P2X7	  receptor	  that	  is	  expressed	  on	  monocytes	  and	  signalling	  
induces	   an	   autocrine	   release	   of	   IL-­‐1β	   and	   IL-­‐18	   [478].	   Similar	   to	   ROS,	   this	   extra-­‐cellular	  
release	  would	  result	  in	  a	  concentration/activity	  gradient	  of	  ATP	  that	  could	  mediate	  any	  cell	  
proximity	  signal.	  ATP	  has	  already	  been	  implicated	  in	  signalling	  pathways	  that	  may	  intersect	  
on	   monocyte	   inflammatory	   signalling	   including	   reactive	   oxygen	   species	   [479],	   p38-­‐MAPK	  
[480]	  and	  TACE	  mediated	   shedding	  of	  heparin	  binding	  epithelial	   growth	   factor-­‐like	  growth	  
factor	  [481].	  Furthermore,	  ATP-­‐mediated	  activation	  of	  the	  P2X7	  receptor	  on	  monocytes	  has	  
been	  shown	  to	  result	  in	  shedding	  of	  L-­‐selectin	  [482].	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Integrins	  
Previous	   in	   vivo	   work	   from	   our	   group	   demonstrated	   that	   low-­‐dose	   intravenous	   LPS	  
produced	   priming	   in	   lung-­‐marginated	   monocytes	   evidenced	   by	   their	   enhanced	   TNF	  
expression	   in	   response	   to	  a	   subsequent	   LPS	   stimulus	   [316].	   It	   is	   possible	   that,	   rather	   than	  
LPS	  as	  a	  direct	  agent	  of	  priming,	  its	  effect	  is	  through	  LPS-­‐induced	  prolonged	  margination	  of	  
monocytes	   in	  contact	  with	  the	  pulmonary	  endothelium.	  Such	  monocytes	  are	   in	  the	  vicinity	  
of	   other	   marginated	   leukocytes	   as	   it	   is	   thought	   that	   marginated	   monocytes	   facilitate	  
neutrophil	   extravasation	   [193].	   Monocytes	   in	   co-­‐culture	   with	   endothelial	   cells	   have	   been	  
shown	   to	   synthesise	   more	   prostanoids,	   cytokines	   and	   chemokines	   than	   those	   in	  
monoculture	  conditions	   [317,	  483-­‐485]	  and	   it	   is	  known	  that	  cell-­‐cell	  adhesion	   interactions,	  
such	   as	   the	   β-­‐2	   integrin-­‐ICAM-­‐1	   interaction,	   enhance	   the	   inflammatory	   response	   in	  
monocytes	   [378].	   Monocytes	   lacking	   the	   membrane	   protein	   CD11b	   (a	   sub-­‐unit	   of	   the	  
integrin	   receptor)	   display	   a	   reduced	   inflammatory	   response	   to	   LPS	   and	   the	   integrin	  
activation	   process	   has	   been	   shown	   to	   involve	   p38MAPK	   [373].	   Furthermore,	   it	   has	   been	  
demonstrated	   that	   adherent	  monocytes	   are	  primed	   to	  produce	  more	  TNF	   than	   their	   non-­‐
adherent	  counterparts	  in	  response	  to	  an	  LPS	  challenge	  [379,	  486].	  As	  previously	  mentioned	  
it	   is	  now	  known	   that	   increased	  LPS	   induced	  TACE	  activity	   is	  mediated	  via	  p38MAPK	   [133].	  
Together	   these	   factors	   are	   supportive	   of	   a	   common	  pathway	   linking	   both	   TACE	   activation	  
and	  the	  integrin	  receptors	  that	  mediate	  cell-­‐cell	  interaction	  [372].	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6.2	   Aims	  
	  
The	  specific	  aims	  for	  this	  chapter	  were	  to:	  
1. Evaluate	  LPS-­‐induced	  TACE	  and	  p38MAPK	  activation	  under	  cell	  contact	  and	  non-­‐
contact	  promoting	  conditions	  in	  vitro.	  
2. Investigate	  the	  proximity-­‐	  or	  contact-­‐related	  mechanisms	  responsible	  for	  any	  





30	  ml	  of	  donor	  blood	  was	  obtained	  by	  venesection	  from	  healthy	  volunteers	  who	  had	  given	  
informed	   consent.	   Exclusion	   criteria	   were	   inter-­‐current	   illness	   or	   immune-­‐suppression.	  
Blood	  was	  extracted	  directly	  into	  vacutainers	  containing	  EDTA.	  
	  
Monocyte	  stimulation	  and	  model	  conditions	  
Monocytes	   were	   isolated	   from	   whole	   blood	   using	   differential	   centrifugation	   followed	   by	  
magnetic	  activated	  cell	  sorting	  utilising	  a	  CD14	  positive	  bead	  selection	  strategy	  as	  outlined	  in	  
detail	   in	   Chapter	   Two.	   Cells	  were	   then	  placed	   in	   Eppendorfs	   at	   a	   density	   of	   5x106/ml	   and	  
stimulated	  with	   LPS	   1μg/ml	   for	   one	   hour	   at	   37°C.	  Wherever	  H2O2	  and	  ATP	  were	   used	   the	  
concentration	   they	  were	   used	   at	   is	   specified	   in	   the	   text.	  Where	   antibodies	   and	   inhibitors	  
were	   used,	   cells	   were	   treated	   with	   these	   and	   left	   on	   ice	   for	   15	   minutes	   before	   being	  
stimulated.	  Antibodies	  used	  were	  low	  endotoxin	  and	  azide	  preparation	  wherever	  possible.	  
For	  the	  stimulation	  period	  some	  cells	  were	  left	  in	  static	  conditions	  but	  others	  were	  placed	  in	  
a	  wheel	  that	  continuously	  rotated	  (x20	  per	  min)	  throughout.	  Cells	  were	  then	  retrieved	  and	  
placed	  in	  the	  FRET	  assay	  as	  previously	  described.	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Quantification	  of	  the	  MAPK	  response	  
This	  was	  performed	  as	  outlined	  in	  detail	  in	  Chapter	  Two.	  Briefly,	  cells	  were	  fixed	  and	  made	  
permeable	  before	  being	  stained	  with	  antibodies	  specific	  for	  the	  activated	  form	  of	  the	  MAPK	  
enzyme.	  Cell	  stimulation	  was	  performed	  at	  the	  same	  density	  and	  conditions	  as	  outlined	  for	  
the	  TACE	  response.	  An	  LPS	  concentration	  of	  1µg/ml	  was	  used	  with	  monocytes	  stimulated	  for	  
15	  minutes.	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6.4	   Results	  
	  
The	  kinetics	  of	  the	  acute	  TACE	  response	  to	  LPS	  are	  altered	  when	  monocytes	  are	  stimulated	  
directly	  in	  PTFE:	  
In	  order	  to	  determine	  whether	  the	  acute	  TACE	  response	  was	  affected	  by	  minimally	  adhesive	  
conditions,	  isolated	  monocytes	  were	  stimulated	  with	  1µg/ml	  of	  LPS	  directly	  in	  PTFE	  wells	  (fig	  
6.1).	  Activity	  was	  then	  determined	  using	  the	  FRET	  assay.	  
LPS	  stimulation	  in	  PTFE	  produced	  no	  increase	  in	  TACE	  activity	  at	  either	  the	  one	  hour	  or	  two	  
hours	  time	  point	  (12.7	  ±0.53	  FU/min	  and	  18.6	  ±1.69	  FU/min	  respectively)	  when	  compared	  to	  
un-­‐stimulated	   controls	   (14	   ±3.74	   FU/min).	   This	   was	   in	   marked	   contrast	   to	   stimulation	   in	  
polypropylene	   Eppendorfs	   (fig	   3.9,	   below),	   and	  provided	   evidence	   for	   our	   hypothesis	   that	  








Figure	   3.9:	   Isolated	  monocytes	  display	  an	   expression	   independent	  up-­‐regulation	  of	   TACE	  
activity	  in	  response	  to	  LPS.	  
Positively	   selected,	   isolated	   monocytes	   incubated	   with	   LPS	   1μg/ml	   for	   one	   hour	   display	  
increased	  TACE	  catalytic	  activity	  (n=5,	  *p<0.01)	  
	   	  












Figure	  6.1	   The	  kinetics	  of	  the	  acute	  TACE	  response	  to	  LPS	  are	  altered	  when	  monocytes	  
are	  stimulated	  directly	  in	  PTFE:	  
	  
N=2	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TACE	  activity	  up-­‐regulation	  response	  to	  LPS	  is	  reduced	  when	  monocytes	  are	  stimulated	  in	  
rotation	  culture	  
Purified	  monocytes	   were	   stimulated	  with	   LPS	   (1µg/ml)	   in	   Eppendorf	   tubes	   at	   37°C	   under	  
static	   or	   rotation	   conditions	   for	   one	   hour	   and	   then	   processed	   for	   measurement	   of	   TACE	  
activity	   under	   standard	   conditions.	   Monocytes	   in	   static	   culture	   up-­‐regulated	   their	   TACE	  
activity	   by	   x2.3	   fold	   (23.1	   ±4.81FU/min	   to	   46.37	   ±0.71FU/min)	   (fig	   6.2).	   Rotation	   culture	  
reduced	   un-­‐stimulated	   monocyte	   TACE	   activity	   (fig	   6.2)	   and	   markedly	   reduced	   the	   up-­‐
regulation	   seen	   in	   response	   to	   LPS	   (Static	   LPS	   46.37	   ±0.71FU/min	   vs.	   rotation	   LPS	   15.21	  
±2.2FU/min,	   p<0.05;	   fig	   6.2).	   The	   increase	   in	   TACE	   activity	  with	   LPS	   treatment	   in	   rotation	  
culture	   was	   small	   (rotation	   3.25FU/min	   vs.	   static	   23.27FU/min)	   and	   was	   not	   statistically	  
significantly	   different	   from	   baseline.	   TACE	   expression	   levels	   were	   unchanged	   across	   the	  
groups	  at	  baseline	  (MFI	  23.81	  ±13.75	  static	  vs.	  22.0	  ±9.14	  rotation;	  non-­‐significant)	  and	  after	  
LPS	  stimulation	  (MFI	  19.18	  ±10.77	  static	  vs.	  18.98	  ±5.86	  rotation;	  non-­‐significant).	  
	   	  













Figure	  6.2:	  The	  acute	  TACE	  response	  was	  attenuated	  in	  rotation	  culture	  
TACE	   activity	   for	   isolated	   monocytes	   placed	   in	   suspension	   and	   rotation	   culture	   then	  
stimulated	  with	  LPS	  1μg/ml	  for	  one	  hour	  
Dark	  bars	  represent	  un-­‐stimulated	  cells,	  light	  bars	  LPS	  stimulated	  
N=4	  
*P<0.05	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Increasing	  cell	  density	  could	  inhibit	  the	  acute	  TACE	  response	  seen	  in	  static	  culture:	  
In	  order	   to	   confirm	   that	   cell-­‐cell	   proximity	  had	  an	  effect	  on	   the	  acute	  TACE	   response,	   the	  
effect	  of	  varying	  cell	  density	  in	  static	  culture	  was	  determined.	  Cells	  were	  stimulated	  for	  one	  
hour	  with	  LPS	  and	  TACE	  activity	  determined.	  As	  shown	   in	   figure	  6.3,	   the	  magnitude	  of	   the	  
TACE	  response	  to	  LPS	  was	  reduced	  by	  a	  factor	  of	  two	  when	  cell	  density	  was	  reduced	  from	  
the	   standard	   5x106	   cells/ml	   to	   5x105	  cells/ml.	   A	   reduction	   in	   activity	  was	   observed	   at	   the	  
highest	   cell	   density;	   a	   likely	   reflection	   of	   ‘overcrowding’	   phenomenon	   such	   as	   reduced	  
availability	   of	   LPS.	   Some	   decrease	   in	   the	   baseline	   activity	   was	   apparent	   at	   the	   lowest	  
density.	  Repeat	  experiments	  will	  be	  needed	  to	  confirm	  these	  findings.	  
	   	  









Figure	  6.3:	  The	  TACE	  response	  to	  LPS	  may	  be	  density	  dependent	  
Monocytes	   were	   stimulated	   with/without	   LPS	   1μg/ml	   for	   one	   hour	   at	   37°C	   at	   specified	  
densities	  
TACE	  activity	  vales	  are	  in	  FU/min	  and	  given	  as	  mean	  +SD	  for	  monocytes	  
Dark	  bars	  are	  for	  untreated	  cells,	  grey	  bars	  for	  LPS	  treated	  
N=2	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LPS-­‐induced	  p38MAPK	  activation	  is	  independent	  of	  cell	  proximity	  
Monocytes	  were	  then	  stimulated	  in	  static	  and	  rotation	  culture	  to	  determine	  whether,	  similar	  
to	   the	   reduced	  TACE	   response,	   the	  p38MAPK	   response	   to	   LPS	  was	  diminished	  by	   rotation	  
culture.	   As	   can	   be	   seen	   in	   fig	   6.4,	   phospho-­‐p38MAPK	   levels	  were	   similar	   both	   at	   baseline	  
(MFI	   59.43	   ±8.12	   static	   vs.	   58.82	   ±11.83	   rotation)	   and	   after	   LPS	   stimulation	   (MFI	   226.31	  
±36.36	  static	  vs.	  211.84	  ±34.36	  rotation).	  
This	   finding	   was	   unexpected	   and	   led	   us	   to	   reappraise	   our	   concept	   of	   the	   LPS-­‐induced	  
p38MAPK-­‐TACE	   signalling	   pathway.	   As	   illustrated	   by	   the	   schematic	   in	   figure	   6.5,	   we	   now	  
hypothesized	   that,	   because	   the	   phospho-­‐p38MAPK	   response	   was	   maintained	   and	   is	  
essential	   for	   TACE	   activation	   [133],	   any	   contact-­‐related	   signal	   would	   need	   to	   be	   acting	  
downstream.	   This	   may	   either	   intersect	   directly	   on	   the	   p38MAPK-­‐TACE	   pathway	   or	   act	   in	  
parallel	   to	   it.	   Alternatively,	   although	   the	   p38MAPK	   pathway	   is	   required	   for	   the	   TACE	  
activation,	  an	  alternative	  contact-­‐dependent	  pathway	  or	  process	  is	  also	  essential.	  
	   	  











Figure	  6.4:	  The	  p38MAPK	  response	  was	  maintained	  across	  culture	  conditions	  
Phospho-­‐p38MAPK	  response	  after	  LPS	  stimulation	  1μg/ml	  for	  15	  minutes	  
Dark	  bars	  represent	  un-­‐stimulated	  cells,	  light	  bars	  LPS	  stimulated	  
N=4	  
*	  P<0.01	  
	   	  





Figure	  6.5:	  Schematic	  illustrating	  contact/proximity	  signal	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H2O2	   treatment	   produced	   an	   increase	   in	  monocyte	   TACE	   activity	   independent	   of	   culture	  
conditions:	  
To	   investigate	   the	   likely	   cell	   proximity	   and/or	   contact-­‐dependent	   mechanisms	   of	   TACE	  
activation,	   we	   first	   considered	   the	   role	   of	   extracellular	   ROS	   signalling.	   Because	   of	   their	  
extremely	   short	   half-­‐life,	   extra-­‐cellular	   ROS	   act	   over	   only	   very	   short	   distances	   between	  
adjacent	  cells	  under	  physiological	  conditions.	  Addition	  of	  H2O2	  to	  monocytes	  had	  previously	  
been	   shown	   to	   activate	   TACE	   in	   a	   p38MAPK-­‐dependent	   fashion,	   but	   only	   at	   a	   high,	   non-­‐
physiological	  range,	  of	  concentrations	  (e.g.	  0.5-­‐5mM)	  [133].	  To	  first	  assess	  whether	  H2O2	  at	  
these	  high	  concentrations	  could	  bypass	  the	  need	  for	  cell	  proximity	  in	  TACE	  activation,	  it	  was	  
added	   to	   cells	   in	  both	   static	   and	   rotating	   culture	   conditions	   at	   a	   concentration	  of	   0.5mM,	  
alone	   or	   in	   combination	  with	   LPS	   (1µg/ml).	   As	   can	   be	   seen	   (fig	   6.6),	   the	   addition	   of	   H2O2	  
produced	  an	  increase	  in	  TACE	  activity	  that	  was	  independent	  of	  culture	  conditions.	  
To	   explore	   in	  more	   depth	  whether	   H2O2-­‐induced	   TACE	   activation	   (proximity-­‐independent)	  
could	  substitute	  for	  the	  lack	  of	  LPS-­‐induced	  TACE	  activation	  in	  rotation	  conditions,	  additional	  
dose	   response	   experiments	   were	   performed.	   More	   specifically,	   whether	   H2O2	   added	   at	  
limiting	   concentrations	   could	   substitute	   for	   the	  missing	   p38MAPK	   downstream	   signal	   and	  
thereby	   enhance	   LPS-­‐induced	   TACE	   up-­‐regulation	   in	   suspension	   culture.	   This	   produced	   a	  
dose	   dependent	   increase	   in	   TACE	   activity	   (0.2mM	   21.82	   ±2.68FU/min,	   0.5mM	   36.63	  
±2.95FU/min,	  2mM	  76.05	  ±7.07FU/min	  and	  5mM	  55.7	  ±1.83FU/min,	  fig	  6.7).	  There	  was	  no	  
added	  effect	  if	  these	  doses	  of	  H2O2	  were	  used	  in	  combination	  with	  LPS	  1μg/ml	  (0.2mM+LPS	  
26.3	   ±3.33FU/min,	   0.5mM+LPS	   49.39	   ±2.39FU/min,	   2mM+LPS	   77.35	   ±21.58FU/min	   and	  
5mM+LPS	  43.2	   ±3.38	  5FU/min).	   These	   results	   indicated	   that	   added	  H2O2	  did	   not	   synergise	  
with	   LPS	   to	   enhance	   TACE	   activation	   in	   rotation	   culture,	   but	   did	   not	   rule	   out	   a	   role	   for	  
release	   and	   signalling	   of	   endogenous	   (intracellular)	   ROS	   in	   LPS-­‐induced	   TACE	   activation	   in	  
static	  culture.	  
	   	  












Figure	  6.6:	  The	  addition	  of	  H2O2	  to	  rotation	  culture	  produced	  an	  increase	  in	  TACE	  activity	  
Graphical	  illustration	  of	  data	  contained	  in	  table	  6.2	  
TACE	   activity	   values	   (mean	   +SD)	   for	   isolated	  monocytes	   stimulated	   for	   one	   hour	  with	   LPS	  
1μg/ml,	  H2O2	  0.5mM	  or	  both.	  
N=2	  
	   	  













Figure	   6.7:	   H2O2	   in	   rotation	   culture	   conditions	   produced	   a	   dose	   dependent	   increase	   in	  
activity	  with	  no	  additional	  effect	  when	  added	  with	  LPS	  
TACE	  activity	  values	  (mean	  +SD)	  for	  isolated	  monocytes	  stimulated	  for	  one	  hour	  with	  H2O2	  at	  
a	  range	  of	  doses	  either	  in	  isolation	  or	  in	  conjunction	  with	  LPS	  1μg/ml.	  
Dark	  bars	   represent	  monocytes	   stimulated	  with	  H2O2	   only,	   light	   bars	   stimulated	  with	  H2O2	  
and	  LPS.	  
N=2	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Inhibition	  of	  extracellular	  ROS	  activity	  did	  not	  attenuate	  the	  TACE	  response	  to	  LPS	  in	  static	  
culture:	  
Having	  shown	  the	  potential	  for	  extracellular	  ROS	  to	  potentially	  bypass	  or	  substitute	  for	  any	  
contact-­‐related	   signal,	  we	  used	   a	   combination	   of	   non-­‐cell	   permeable	   agents	   to	   accelerate	  
depletion	   of	   the	   extracellular	   environment	   of	   any	   ROS	   generated	   during	   LPS	   stimulation.	  
Previously	  the	  broad	  spectrum	  cell	  permeable	  ROS	  inhibitor	  was	  used	  to	  demonstrate	  their	  
role	  in	  TACE	  activation,	  but	  in	  order	  to	  assess	  the	  role	  of	  extracellular	  ROS,	  cell	  impermeable	  
inhibitors	  were	  required	  [133].	  Cell-­‐impermeable	  superoxide	  dismutase	  (SOD)	  and	  catalase	  
have	   previously	   been	   used	   to	   demonstrate	   extracellular	   ROS	   activity	   in	   vitro	   [487],	   as	  
illustrated	  schematically	  in	  fig	  6.8,	  with	  catalase	  effectively	  degrading	  H2O2	  derived	  from	  SOD	  
conversion	  of	  the	  O2-­‐	  free	  radical.	  As	  shown	  in	  figure	  6.8A	  the	  addition	  of	  either	  catalase	  or	  
SOD	  attenuated	   the	   TACE	   response	   to	  H2O2	   (48.21%	   inhibition	  with	   catalase,	   56.53%	  with	  
SOD	   and	   51.15%	   both)	   in	   static	   culture	   conditions,	   confirming	   their	   efficacy	   in	   this	   assay.	  
However,	   these	   results	   were	   not	   reproduced	   when	   used	   in	   combination	   with	   LPS	   (<1%	  
inhibition	   with	   catalase,	   SOD	   or	   in	   combination,	   fig	   6.8B).	   It	   is	   not	   possible	   from	   these	  
limited	  data	  to	  ascertain	  whether	  extra-­‐cellular	  ROS	  were	  completely	  inhibited	  by	  SOD	  and	  
catalase,	  either	  given	  individually	  or	  in	  combination.	  
On	  the	  basis	  of	  the	  limited	  experiments	  outlined	  above	  we	  concluded	  that,	  whilst	  H2O2	  was	  
able	  to	  induce	  a	  TACE	  response	  in	  suspension	  culture,	  extracellular	  ROS	  could	  be	  excluded	  as	  
the	   p38MAPK-­‐downstream,	   contact-­‐related	   signal	   elicited	   by	   LPS	   in	   static	   culture.	   Rather	  
than	  continuing	  these	  experiments,	  we	  moved	  to	  consider	  other	  potential	  mediators	  of	  the	  
contact	  signal.	  
	   	  













Figure	  6.8:	  Schematic	  illustrating	  ROS	  metabolic	  pathways	  	  
Reactive	  oxygen	  species	  may	  be	  produced	  through	  the	  action	  of	  flavoprotein	  oxoreductase,	  
resulting	   in	   the	   production	   of	   superoxide	   (O2-­‐).	   This	   reactive	   molecule	   is	   dismutated	   by	  
superoxide	  dismutase	  (SOD)	  to	  H2O2.	  This	  is	  subsequently	  reduced	  by	  the	  Fenton	  reaction	  to	  a	  
reactive	  hydroxyl	   radical	   (OH-­‐).	  Catalase	   then	  catalyses	   the	  breakdown	  of	  H2O2	   to	  H2O	  and	  
O2,	  preventing	  OH-­‐	  accumulation.	  
	   	  
















Figure	  6.9:	  The	  TACE	  response	  to	  H2O2	  could	  be	  attenuated	  by	  the	  use	  of	  catalase	  and	  SOD	  
but	  that	  to	  LPS	  could	  not	  
A:	  Monocytes	  in	  static	  culture	  stimulated	  with	  H2O2	  2mM	  in	  the	  presence/absence	  of	  
catalase	  (1000u/ml),	  SOD	  (1000u/ml)	  or	  both	  
B:	  Monocytes	  in	  static	  culture	  stimulated	  with	  LPS	  1μg/ml	  in	  the	  presence/absence	  of	  
catalase	  (1000u/ml),	  SOD	  (1000u/ml)	  or	  both	  
N=2	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ATP	  does	  not	  induce	  TACE	  activity	  up-­‐regulation	  
ATP	   was	   added	   to	   monocytes	   in	   static	   culture	   at	   a	   range	   of	   concentrations	   designed	   to	  
stimulate	  either	  low	  or	  high	  affinity	  purinergic	  receptors.	  ATP	  at	  a	  concentration	  of	  3mM	  is	  
sufficient	   to	   stimulate	   the	   P2x7	   receptor	   expressed	   on	  monocytes	   [488,	   489].	   Contrary	   to	  
our	   expectation,	   cells	   stimulated	   with	   ATP	   at	   this	   concentration	   in	   the	   presence	   of	   LPS	  
displayed	   an	   inhibited	   response	   to	   LPS	   (LPS	   46.85	   ±1.91	   FU/min	   vs.	   LPS	   &	   ATP	   11.83	  
±6.69FU/min;	  fig	  6.10A).	  The	  addition	  of	  ATP	  to	  rotation	  culture	  conditions	  at	  a	  dose	  of	  3mM	  
appeared	   to	   have	   no	   effect	   on	   either	   baseline	   (unstimulated	   16.4	   FU/min	   vs.	   ATP	   10.78	  
FU/min)	  or	  LPS	  induced	  activity	  levels	  (LPS	  17.8	  FU/min	  vs.	  LPS	  &	  ATP	  11.88	  FU/min).	  
Lower	   concentrations	   of	   ATP	   stimulate	   different	   purinergic	   receptors	   such	   as	   the	   P2Z	  
receptor	  [490].	  Hence	  we	  examined	  the	  effect	  that	  these	  lower	  concentrations	  had	  on	  basal	  
TACE	  activity.	  There	  were	  no	  differences	  in	  activity	  seen	  across	  the	  range	  of	  concentrations	  
used	  (fig	  6.10B).	  In	  view	  of	  previous	  studies	  that	  had	  demonstrated	  ATP	  induced	  shedding	  of	  
TACE	   substrates,	   this	   was	   surprising	   but	   may	   reflect	   the	   fact	   that	   these	   studies	   did	   not	  
examine	  TNF	  cleavage	  [481,	  482].	  
	   	  















Figure	  6.10:	  The	  effect	  of	  ATP	  on	  baseline	  and	  LPS	   induced	  TACE	  activity	   in	  static	  culture	  
conditions	  
A:	  Isolated	  monocytes	  stimulated	  in	  static	  culture	  with	  LPS	  1μg/ml,	  ATP	  3mM	  or	  both	  for	  one	  
hour	  (n=2)	  
B:	  ATP	  dose	  response	  (one	  hour	  stimulation)	  in	  static	  culture	  using	  isolated	  monocytes	  (n=2)	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Pharmacological	  ATP	  inhibition	  did	  not	  affect	  the	  TACE	  response	  to	  LPS:	  
To	   further	   exclude	   a	   stimulatory	   effect	   of	   ATP	   we	   used	   suramin	   (a	   general,	   non-­‐specific	  
inhibitor	   of	   ATP)	   as	   well	   as	   A740003	   (an	   inhibitor	   of	   the	   P2X7	   receptor)	   in	   static	   culture	  
conditions.	   Inhibition	   of	   ATP	   with	   either	   suramin	   or	   A740003	   had	   no	   effect	   on	   the	   TACE	  
response	  to	  LPS	  (fig	  6.11).	  This	  was	  consistent	  with	  our	  previous	  results	  and	  would	  seem	  to	  
exclude	  a	  stimulatory	  effect	  of	  ATP.	  Suramin	  alone	  appeared	  to	  produce	  a	  reduction	  in	  un-­‐
stimulated	   TACE	   activity	   (un-­‐stimulated	   14.46	   ±6.2FU/min	   vs.	   suramin	   7.15	   ±1FU/min;	   fig	  
6.11).	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Figure	  6.11:	  Inhibition	  of	  ATP	  appeared	  to	  restore	  the	  LPS	  response	  in	  cells	  stimulated	  ATP	  
&	  LPS	  In	  static	  culture	  conditions	  
Isolated	  monocytes	  cultured	  with	  LPS	  1μg/ml,	  suramin	  (sur)	  230μM,	  A740003	  (A74)	  10μM	  
separately	  or	  in	  combination	  for	  one	  hour	  in	  static	  conditions	  (n=3)	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CD18	  blockade	  may	  reduce	  basal	  and	  LPS-­‐inducible	  TACE	  activity	  in	  static	  culture:	  
To	  try	  and	  ascertain	  whether	  the	  contact-­‐related	  signal	  was	  mediated	  by	  integrins	  a	  panel	  of	  
antibodies	  were	  used.	  These	  were	  as	  follows:	  
1. Anti-­‐CD18	  blocking	  antibody	  in	  order	  to	  block	  macrophage-­‐1	  antigen	  (Mac-­‐1,	  CD11b	  
CD18),	  lymphocyte	  function-­‐associated	  antigen-­‐1	  (LFA-­‐1,	  CD11aCD18)	  in	  addition	  to	  
alphaXbeta2	  (CD11cCD18)	  and	  alphaDbeta2	  (CD11dCD18)	  
2. Anti-­‐CD11b	  blocking	  antibody	  to	  block	  Mac-­‐1	  
3. Anti-­‐CD29	  stimulating	  antibody	  to	  determine	  the	  role	  of	  very	   late	  antigen-­‐4	  (VLA-­‐4	  
(CD49dCD29)	  
Blocking	  antibodies	  were	  used	  in	  static	  culture	  to	  try	  and	  block	  the	  contact-­‐related	  signal	  (fig	  
6.12).	  The	  anti-­‐CD29	  stimulating	  antibody	  was	  used	  in	  rotation	  culture	  conditions	  to	  try	  and	  
replicate	  the	  contact-­‐related	  signal	  and	  generate	  a	  TACE	  response	  to	  LPS.	  LPS	  induced	  TACE	  
activity	  appeared	  to	  be	  diminished	  by	  CD18	  blockade	  (26.57	  ±8.68	  vs.	  18.3	  ±4.1,	  LPS-­‐only	  vs.	  
LPS	  +	  CD18	  mAb),	  with	  a	  similar	  relative	  reduction	   in	  baseline	  TACE	  activity	  (15.24	  ±5.1	  vs.	  
7.68	  ±5.9	  Fu/min,	  no	  antibody	  vs.	  CD18	  mAb).	  Effects	  were	  less	  clear	  with	  CD11b	  blockade,	  
possibly	  implicating	  the	  LFA-­‐1	  integrin,	  which	  consists	  of	  the	  CD11a	  and	  CD18	  heterodimers.	  
The	  addition	  of	  the	  stimulating	  antibody	  to	  rotation	  culture	  conditions	  did	  not	  generate	  an	  
increase	  in	  TACE	  activity	  either	  alone	  or	  in	  combination	  with	  LPS	  (8.81	  ±0.44	  antibody	  alone	  
vs.	  10.28	  ±2.47	  with	  LPS),	  making	  VLA-­‐4	  an	  unlikely	  mediator	  for	  the	  contact-­‐related	  signal.	  
	   	  










Figure	  6.12:	  The	  CD18	  blocking	  antibody	  may	  reduce	  basal	  TACE	  activity	  and	  the	  response	  
to	  LPS	  
Isolated	   monocytes	   were	   pre-­‐treated	   with	   anti-­‐CD18	   and	   CD11b	   antibodies	   before	   being	  
exposed	  to	  LPS	  1μg/ml	  for	  one	  hour	  in	  static	  culture	  conditions.	  
N=2	  
Similarly	  cells	  were	  pre-­‐treated	  with	  an	  anti-­‐CD29	  antibody	  then	  exposed	  to	  LPS	  in	  rotation	  
culture	  conditions.	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6.5	   Discussion	  
The	   primary	   aim	   in	   this	   chapter	   was	   to	   elicit	   any	   differences	   in	   monocyte	   inflammatory	  
signalling	   that	   may	   be	   present	   in	   culture	   conditions	   where	   cells	   were	   in	   proximity	   when	  
compared	  to	  conditions	  where	  contact	  was	  minimised.	  
	  
Static	  vs.	  rotation	  culture	  –	  TACE	  activity	  
	  In	  order	  to	  do	  this	  we	  manipulated	  the	  conditions	  in	  which	  monocytes	  were	  stimulated	  with	  
LPS.	  We	  first	  stimulated	  them	  in	  a	  minimally	  adherent	  medium	  (PTFE)	   in	  which	  cells	  are	   in	  
proximity	   but	   only	   in	   a	   single	   plane,	   as	  monocytes	   form	   a	   thin	  monolayer	   over	   the	   PTFE	  
insert.	   These	   conditions	   produced	   an	   attenuation	   of	   the	   TACE	   response	   to	   LPS.	   We	   next	  
placed	  monocytes	   in	  rotation	  culture	  to	  completely	  minimise	  cell	  proximity,	  and	  compared	  
this	   to	   the	  static	   conditions	  we	  used	   to	  elicit	   the	  TACE	   response	   in	  previous	  chapters.	  Our	  
results	  show	  that	  full	  TACE	  activation	  required	  cells	  to	  be	  in	  proximity	  with	  one	  another,	  and	  
that	   the	   TACE	   response	   to	   LPS	  was	   almost	   completely	   lost	  when	   cells	  were	   stimulated	   in	  
rotation	  culture.	  In	  addition	  the	  TACE	  response	  in	  the	  static	  culture	  was	  density	  dependent	  
lending	   further	   weight	   to	   the	   argument	   that	   cell	   proximity	   impacts	   on	   inflammatory	  
signalling.	  Adherent	  monocytes	  have	  been	  shown	  to	  produce	  more	  sol-­‐TNF	   in	   response	   to	  
an	   LPS	   stimulus	   than	   their	   non-­‐adherent	   counterparts	   [379],	   indicating	   a	   potential	   TACE	  
effect	  in	  this	  context.	  
The	   fact	   that	   TACE	   activity	   may	   be	   modified	   by	   adhesion	   or	   proximity	   should	   not	   be	  
considered	  surprising.	  Several	  members	  of	  the	  metalloprotease	  family	  have	  been	  shown	  to	  
interact	   with	   integrins	   via	   their	   disintegrin	   domain	   and	   TACE	   itself	   has	   been	   shown	   to	  
interact	  with	  both	  the	  actin	  cytoskeleton	  [371]	  and	  the	  α5β1	  integrin	  VLA-­‐5	  [372].	  Although	  
ultimately	   it	  may	  not	  be	   integrins	   that	  deliver	   the	  signal,	   it	   is	  plausible	   that	   the	  process	  of	  
leukocyte	   recruitment	  and	   leukocyte-­‐endothelial	   interaction	   facilitates	  TNF	   release,	   as	   this	  
would	   help	   focus	   the	   inflammatory	   response,	   prevent	   wider	   systemic	   release	   or	   help	  
exclude	  some	  of	   the	  systemic	  “noise”	  that	  may	  be	  present	   in	  sepsis.	  As	  well	  as	  preventing	  
monocytes	  from	  substrate	  shedding	  (e.g.	  of	  TNF	  &	  TNFR)	  before	  they	  reach	  the	  target	  site	  
this	   process	   may	   allow	   cells	   to	   “switch	   off”	   after	   responding	   in	   one	   environment	   (e.g.	  
adherent)	  by	  shedding	  their	  receptors	  (TNFR1/2)	  in	  order	  to	  prevent	  further,	  inappropriate,	  
activation.	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This	   situation	   may	   be	   considered	   analogous	   to	   that	   of	   marginated	   or	   rolling	   monocytes,	  
which	   are	   adherent	   within	   the	   microcirculation	   and	   produce	   an	   inflammatory	   signal.	  
Adherent	   monocytes	   have	   been	   shown	   to	   produce	   more	   sol-­‐TNF	   in	   response	   to	   an	   LPS	  
stimulus	  than	  their	  non-­‐adherent	  counterparts	  [379],	  but	  the	  potential	  role	  of	  TACE	  cleavage	  
as	   a	   limiting	   step	   was	   not	   examined.	   Leukocytes	   are	   often	   present	   in	   close	   proximity	   in	  
sepsis	  where	  they	  cluster	  in	  the	  peripheral	  vasculature,	  meaning	  that	  there	  is	  a	  real	  in	  vivo	  
correlate	  for	  our	  in	  vitro	  model.	  
	  
Static	  vs.	  rotation	  culture	  –	  p38MAPK	  
Having	   elicited	   these	   differences	   in	   TACE	   signalling	   within	   the	   model,	   we	   next	   moved	   to	  
determine	   any	   effect	   on	   p38MAPK	   phosphorylation.	   We	   found	   that	   p38MAPK	   was	  
phosphorylated	   in	   response	   to	   LPS	   across	   all	   culture	   conditions,	  which	   led	   us	   to	   conclude	  
that	  any	  proximity	  signal	  must	  be	  acting	  downstream	  of	  p38MAPK	  (fig	  6.3).	  This	  is	  in	  keeping	  
with	   the	   results	   of	   Aplin	   and	   co-­‐workers	   [491]	  who	   found	   p38MAPK	   phosphorylation	   and	  
nuclear	   accumulation	   to	   be	   adhesion	   independent,	   but	   in	   opposition	   to	   the	   findings	   of	  
Detmers	   et	   al	   who	   demonstrated	   that,	   in	   neutrophils,	   p38MAPK	   functions	   to	   signal	  
leukocyte	   dependent	   integrin	   adhesion	   [492].	   Our	   results	   indicate	   that	   the	   p38MAPK	  
response,	   although	   essential,	   is	   not	   sufficient	   to	   produce	   TACE	   activation	   and	   that	   an	  
additional	  cell	  proximity	  signal,	  downstream	  of	  p38MAPK,	  is	  required.	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ROS	  
We	  then	  sought	  to	  determine	  the	  nature	  of	  this	  signal	  and	  focused	  our	  attention	  on	  three	  
areas:	   ROS,	   ATP	   and	   integrins.	   The	   addition	   of	   H2O2	   (to	   provide	   a	   source	   of	   ROS)	   to	   both	  
static	  and	  rotating	  culture	  produced	  a	  TACE	  response.	  In	  rotation	  culture	  conditions	  this	  was	  
dose	  dependent	  with	  no	  synergistic	  effect	  when	  added	  with	  LPS.	  It	  was	  unclear	  from	  these	  
data	  whether	  the	  response	  generated	  by	  H2O2	  was	  reproducing	  the	  same	  response	  as	  LPS	  in	  
static	  culture	  conditions.	  We	  further	  tested	  this	  by	  using	  SOD	  and	  catalase	  to	  deplete	  extra-­‐
cellular	  ROS	  in	  static	  culture	  conditions.	  Despite	  being	  able	  to	  attenuate	  the	  TACE	  response	  
to	  ROS	  the	  addition	  of	  SOD,	  catalase	  or	  both	  had	  no	  effect	  on	  the	  response	  to	  LPS.	  
The	  effect	  of	   SOD	  may	  at	   first	   appear	  paradoxical	   given	   that	   it	   produces	  H2O2	   rather	   than	  
catalyses	  its	  breakdown.	  However,	  it	  is	  possible	  that	  the	  alteration	  in	  the	  extra-­‐cellular	  redox	  
environment	  directly	  modulates	  TACE,	  this	  has	  previously	  been	  described	  as	  the	  mechanism	  
through	  which	  p38MAPK	  modulates	  TACE	  [133].	  There	  is	  also	  a	  possibility	  that	  intra-­‐cellular	  
OH-­‐	  is	  produced	  [493]	  and	  then	  released	  in	  to	  the	  extra	  cellular	  environment	  and	  potentially	  
would	  not	  be	  removed	  through	  the	  action	  of	  SOD	  or	  catalase.	  However,	  monocytes	  do	  not	  
produce	  OH-­‐	   in	  vitro	   in	   the	  absence	  of	  exogenous	   iron	   [494],	  making	   this	   risk	   small	   in	  our	  
system.	  Given	  that	  the	  SOD	  and	  catalase	  we	  used	  are	  cell	   impermeable,	  our	  data	   led	  us	  to	  
conclude	  that	  extra-­‐cellular	  ROS	  do	  not	  mediate	  the	  contact	  signal.	  However,	   it	   is	  possible	  
that	   intra-­‐cellular	   ROS	   are	   released	   as	   a	   result	   of	   contact	   signalling.	   Hence	   these	   are	  
bypassed	  by	  using	  an	  external	   source	  of	  ROS	   (H2O2),	  but	  when	  LPS	   is	  used	  as	   the	  stimulus	  
ROS	  would	  be	  intracellular	  and	  contact	  dependent.	  This	  contention,	  which	  is	  not	  excluded	  by	  
our	  data,	  was	  reinforced	  by	  the	  findings	  of	  other	  investigators	  who	  have	  demonstrated	  that	  
integrin	  activation	  induces	  intracellular	  ROS	  release	  [495-­‐497].	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Although	  extracellular	  ROS	  may	  not	  directly	  mediate	  any	  proximity	  signal,	  the	  significance	  of	  
the	  TACE	  response	  generated	  by	  their	  addition	  must	  be	  considered.	  It	  is	  important	  for	  us	  to	  
highlight	   that	  H2O2	  penetrates	   the	  monocyte	   cell	  membrane	   [498]	  hence	  will	   result	   in	   the	  
production	  of	  both	  extracellular	  and	  intracellular	  ROS	  with	  actions	  in	  both	  of	  these	  areas.	  It	  
is	   possible	   that	   these	   highly	   reactive	  molecules,	   rather	   than	   acting	   in	   a	   selective	  manner,	  
flood	   the	   cell	   and	  bypass	   the	  normal	  mechanisms	   that	   exist	   to	   regulate	   them.	   This	  would	  
result	  in	  the	  activation	  of	  numerous	  signalling	  cascades	  in	  addition	  to	  upstream	  signalling	  to	  
TACE	   though	   p38MAPK	   as	   previously	   demonstrated	   [133],	   producing	   an	   increase	   in	   TACE	  
activity.	  It	  is	  plausible	  that	  the	  synergism	  seen	  when	  LPS	  and	  H2O2	  were	  both	  added	  to	  static	  
culture	  conditions	  has	  a	  degree	  of	  biological	  relevance	  given	  extracellular	  ROS	  are	  released	  
from	  neutrophils	  and	  can	  modulate	  adjacent	  cells	  [477].	  As	  neutrophils	  and	  monocytes	  are	  
in	   close	   proximity	   at	   inflammatory	   sites,	   it	   may	   be	   that	   extracellular	   ROS,	   released	   from	  
neutrophils,	  augment	  monocyte	  inflammatory	  signalling.	  
	  
ATP	  
We	  next	  examined	  the	  role	  of	  ATP	  as	  a	  potential	  signal	  mediator.	  We	  hypothesised	  that	  ATP	  
would	  reproduce	  the	  proximity	  signal	  and	  hence	  produce	  a	  TACE	  response	  to	  LPS	  in	  rotation	  
culture.	  In	  fact	  this	  was	  not	  the	  case,	  ATP	  and	  LPS	  added	  to	  rotation	  culture	  conditions	  had	  
no	  effect	  on	  TACE	  activity.	  Furthermore,	  to	  our	  surprise,	  ATP	  inhibited	  the	  TACE	  response	  to	  
LPS	   in	  static	  culture.	  This	   finding	  was	   reinforced	  by	  data	  generated	  using	  both	   the	  general	  
inhibitor	   of	   ATP	   suramin	   and	   A740003	   an	   inhibitor	   of	   the	   P2X7	   receptor.	   These	   two	  
inhibitors	  had	  no	  effect	  on	  the	  TACE	  response	  to	  LPS.	  These	  findings	  led	  us	  to	  reappraise	  our	  
original	   hypothesis.	   ATP	   is	   broken	   down	   by	   the	   cell	   surface	   enzyme	   CD39	   (nucleoside	  
triphosphate	  diphosphohydrolase-­‐1)	   an	   ectoenzyme	   that	   degrades	  ATP	   to	  AMP	   [499].	   Cell	  
proximity	  states	  result	  in	  breakdown	  of	  ATP	  through	  this	  mechanism	  and	  may	  result	  in	  a	  loss	  
of	  the	  negative	  regulation	  that	  ATP	  would	  normally	  provide.	  Hence	  it	  is	  possible	  that	  ATP	  has	  
a	  role	  in	  the	  TACE	  pathway,	  however,	  its	  lack	  of	  effect	  in	  rotation	  culture	  means	  it	  does	  not	  
recapitulate	  the	  proximity	  signal	  that	  is	  missing	  therein.	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Integrins	  
Our	  final	  candidate	  group	  was	  integrins.	  Monocytes	  express	  (amongst	  others)	  Mac-­‐1,	  VLA-­‐4,	  
LFA-­‐1,	   alphaXbeta2	   and	   alphaDbeta2.	   Hence	   we	   used	   a	   series	   of	   blocking/stimulating	  
antibodies	   to	   try	   and	   delineate	   which,	   if	   any,	   of	   these	   integrins	   mediated	   the	   proximity	  
signal	   required	   for	   full	  activation	  of	   the	  TACE	  pathway.	  The	  CD11b	  blocking	  antibodies	  did	  
not	  prevent	   the	  TACE	  response	   to	  LPS	   in	  static	  culture	  meaning	   it	  was	  unlikely	   that	  Mac-­‐1	  
was	   responsible	   for	   mediating	   the	   proximity	   signal	   in	   our	   system.	   It	   should	   not	   be	  
completely	  ruled	  out	  on	  the	  basis	  of	  our	  data	  however,	  as	   ligation	  of	  the	  monocyte	  Mac-­‐1	  
integrin	   has	   been	   shown	   to	   enhance	   TNF	  mRNA	   expression	   in	   response	   to	   LPS	   [378]	   and	  
similarly	   is	   required	   for	   full	   LPS	   induced	   gene	   expression	   in	   macrophages	   [373].	   The	  
stimulating	  CD29	  antibody	  did	  not	  reconstitute	  the	  response	  in	  rotation	  culture	  leading	  us	  to	  
conclude	  that	  VLA-­‐4	  is	  unlikely	  to	  mediate	  proximity	  in	  our	  system.	  
The	  CD18	  blocking	  antibody	  appeared	  to	  reduce	  both	  basal	  TACE	  activity	  and	  the	  response	  
to	  LPS.	  This	  may	  mean	  that	  CD18	  activation	  is	  required	  for	  full	  TACE	  signalling	  in	  response	  to	  
LPS.	   This	  would	   be	   in	   keeping	  with	   other	  work	   that	   has	   shown	   that	   CD18	   cross-­‐linking	   in	  
human	   neutrophils	   induced	   degranulation,	   L-­‐selectin	   shedding	   and	   actin	   polymerisation	  
[500].	  Any	  interaction	  between	  integrins	  and	  TACE	  is	  likely	  to	  occur	  through	  the	  disintegrin	  
domain	  of	  the	  enzyme	  that	  is	  thought	  to	  function	  as	  an	  integrin	  binding	  molecule	  [343].	  This	  
process	   may	   result	   in	   “backwards”	   signalling	   in	   which	   the	   integrin	   mediated	   contact	  
influences	   TACE	   activity	   as	   the	   disintegrin	   domain	   has	   a	   regulatory	   role	   on	   the	   catalytic	  
domain	  of	  the	  enzyme	  [501,	  502].	  
Further	  investigation	  in	  this	  area	  is	  clearly	  warranted,	  as	  we	  did	  not	  block	  every	  component	  
of	  each	  integrin	  (only	  those	  we	  deemed	  most	  likely)	  and	  there	  are	  other	  integrins	  expressed	  
on	  monocytes,	  which	  we	  did	  not	   investigate.	  The	  role	  of	  CD18	  should	  be	  assessed	  in	  more	  
detail	  and	  other	  candidate	   integrins	  should	  be	  considered.	   In	  particular	  the	   integrin	  VLA-­‐5,	  
that	  has	  been	   shown	   to	   co-­‐localise	  with	  TACE	  on	   the	   cell	  membrane	  of	  a	  human	  cell	   line,	  
[372]	  should	  be	  examined.	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Conclusions	  
We	  set	  out	  to	  determine	  whether	  adherence	  was	  a	  key	  component	  of	  the	  TACE	  pathway	  as	  
we	  hypothesised	   that	   the	  TACE	   response	   to	   LPS	   seen	   in	   static	   culture	   represents	  maximal	  
inflammatory	   output,	   which	  would	   explain	   the	   absence	   of	   the	   primed	   phenotype	   for	   our	  
experimental	  data.	  The	  data	  we	  generated	   is	  consistent	  with	   this	  hypothesis	  of	  adherence	  
priming	  and,	  whilst	  we	  were	  unable	  to	  elicit	  the	  exact	  nature	  of	  the	  signal	  required	  for	  this	  
response,	   we	   have	   advanced	   our	   understanding	   of	   the	   TACE	   pathway	   considerably.	   A	  
schematic	  outlining	  the	  potential	  interactions	  with	  this	  modified	  pathway	  is	  shown	  in	  figure	  
6.13.	   	  






Figure	  6.13:	  Modified	  outline	  of	  potential	  pathway	  incorporating	  potential	  mediators	  of	  
proximity/contact	  signal	  
Contact	  signal	  may	  be	  directly	  mediated	  by	  integrins	  generating	  intra-­‐cellular	  ROS.	  ROS	  may	  
then	  intersect	  on	  the	  TACE	  pathway	  downstream	  of	  p38MAPK	  or	  work	  in	  parallel	  acting	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In	   the	   introduction	   I	  discussed	  the	  urgent	  need	   for	   further	   treatments	   to	  help	  supplement	  
our	  armamentarium	  when	  battling	  sepsis.	  Whilst	  it	  is	  certainly	  the	  case	  that	  the	  widespread	  
and	  uncontrolled	  use	  of	   antibiotics	  has	  promoted	   the	  emergence	  of	   resistance,	   this	   is	   not	  
the	   complete	   story.	   In	   fact,	   only	   a	   year	   after	   the	   discovery	   of	   penicillin	   some	   strains	   of	  
Staphylococcus	   aureus	   were	   already	   resistant	   [503].	   In	   addition,	   analysis	   of	   permafrost	  
samples	   from	   30,000	   years	   ago	   has	   identified	   genes	   encoding	   resistance	   to	   beta-­‐lactam,	  
tetracycline	   and	   glycopeptide	   antibiotics	   [504],	   meaning	   that	   antibiotic	   resistance	   was	  
inevitable.	   Thus	   the	   need	   to	   fully	   understand	   the	   processes	   of	   immunity	   (good)	   and	  
inflammation	   (bad)	   have	   become	   ever	  more	   pressing	   in	   order	   to	   avoid	   a	   continued	   over-­‐
reliance	  on	  antibiotics.	   I	  would	   contend	   that	   the	  US	  Surgeon	  Generals	  1967	  proclamation,	  
“the	  war	  on	   infectious	  diseases	  has	  been	  won”	  [505],	  was	  at	  best	  premature	  and	  at	  worst	  
incorrect.	  Hence	  the	  need	  for	  basic	  scientific	  and	  clinical	  research	  into	  this	  area	  is	  warranted.	  
The	  principal	  aim	  of	  this	  project	  was	  to	  determine	  how	  monocyte	  TACE	  activity	  is	  affected	  by	  
sepsis	  and	  during	  an	   inflammatory	   response.	  Over	   the	   last	   four	   chapters	   I	  have	  presented	  
the	   data	   I	   obtained	   whilst	   attempting	   to	   elucidate	   the	   mechanisms	   involved.	   Having	  
demonstrated	  that	  TACE	  biology	  in	  cell	   lines	   is	  different	  to	  that	   in	  primary	  cells,	   I	  refined	  a	  
method	  of	  isolating	  primary	  cells	  from	  both	  volunteers	  and	  patients	  for	  the	  remainder	  of	  the	  
project.	  We	  then	  attempted	  to	  model	  states	  of	  tolerance	  and	  priming	  in	  vitro	  and	  found	  that	  
TACE	  activity	  profiles	  within	  cells	  placed	  in	  model	  conditions	  were	  different	  to	  those	  seen	  in	  
freshly	  isolated	  cells,	  they	  displayed	  both	  higher	  baseline	  activity	  and	  a	  reduced	  response	  to	  
LPS.	  We	  carried	  out	  a	  clinical	  project	  in	  which	  we	  successfully	  determined	  TACE	  activity	  and	  
substrate-­‐shedding	  profiles	   in	  monocytes	  obtained	  from	  patients	  with	  sepsis	  and	  SIRS,	  and	  
found	   evidence	   of	   differential	   reprogramming	   in	   sepsis	   compared	   to	   non-­‐infectious	   SIRS.	  
Lastly	  we	  examined	  how	  TACE	  signalling	  is	  affected	  by	  cell	  proximity	  and	  found	  that	  cell-­‐to-­‐
cell	  contact	  was	  critical	  for	  activation	  of	  TACE.	  Whilst	  the	  discussions	  in	  the	  results	  chapters	  
were	  limited	  to	  the	  scope	  of	  that	  chapter,	  here	  in	  this	  final	  discussion	  I	  will	  attempt	  to	  draw	  
the	   findings	   together	   and	  make	   some	   conclusions,	   highlighting	   our	   key	   achievements	   and	  
their	  novelty.	   These	  are	  mainly	  with	   regard	   to	   the	  plasticity	  of	  monocytes:	   specifically	   the	  
alterations	  they	  display	  in	  sepsis	  and	  in	  response	  to	  changes	  in	  their	  microenvironment.	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7.1	  An	  isolation	  method	  that	  enabled	  the	  study	  of	  monocyte	  associated	  enzyme	  activity	  
We	  began	  our	  work	  by	  investigating	  the	  utility	  of	  the	  immortalised	  human	  cell	  line	  THP-­‐1	  in	  
investigating	  TACE	  behaviour.	  We	  previously	  used	   this	  cell	   line	   to	  establish	  a	  FRET-­‐peptide	  
based	  TACE	  enzyme	  activity	  assay,	  because	   it	   shared	   similar	   characteristics	   to	   the	  primary	  
cells	   in	   terms	   of	   surface	   expression	   of	   the	  mature	   TACE	   isoform	   and	   its	   response	   to	   LPS	  
[133].	   However,	   it	   became	   apparent	   that	   these	   cells	   did	   not	   produce	   a	   TACE	   response	  
comparable	   to	   that	   seen	   in	   primary	   cells	   in	   a	   reliable	   and	   reproducible	   fashion.	   This	  
difference	   may	   be	   explained	   as,	   in	   common	   with	   many	   lines,	   the	   THP-­‐1	   cell	   is	   an	  
immortalised	  (leukaemic)	  cell	   line	  [382].	  Previously	  when	  used	  by	  our	  group	  the	  THP-­‐1	  cell	  
line	  did	  produce	  a	  TACE	  response	  to	  LPS	   [381],	  although	  their	  passages	  and	   lots	  had	  to	  be	  
carefully	  matched.	  However,	  the	  cells	  that	  I	  purchased	  appeared	  not	  to	  have	  retained	  their	  
TACE	  responsiveness.	  Cells	  in	  culture	  are	  prone	  to	  phenotypic	  and	  genotypic	  drift	  [506],	  and	  
can	  vary	  considerably	  in	  their	  	  response	  to	  LPS	  [507],	  potentially	  explaining	  why	  I	  was	  unable	  
to	   reproduce	   our	   previous	   findings	   with	   the	   THP-­‐1	   cells.	   Previously	   such	   phenotype	  
instability	  was	  encountered	  with	  MonoMac6	  cell	  line	  that	  displayed	  temporal	  alterations	  in	  
their	  TACE	  response	  [133,	  381].	  Thus	  my	  findings	  led	  us	  to	  conclude	  that	  the	  mechanism	  of	  
TACE	  activity	  regulation	  in	  vivo	  can	  only	  realistically	  be	  evaluated	  through	  the	  use	  of	  primary	  
cells.	  
We	   then	   successfully	   validated	   a	   method	   of	   isolating	   monocytes	   using	   a	   CD14	   positive	  
immune-­‐magnetic	  bead	  selection	  protocol,	  which	  was	  faster	  and	  more	  economical	  than	  our	  
previous	   protocol	   of	   negative	   selection,	   and	   did	   not	   appear	   to	   impact	   on	   the	   LPS-­‐TLR4	  
signalling	   axis.	   Our	   previous	   attempts	   at	   isolating	  monocytes	   from	   sepsis	   patients	   using	   a	  
negative	  bead	  selection	  protocol	  had	  been	  unsuccessful,	  primarily	  due	  to	  contamination	  by	  
neutrophils,	  whose	  phenotype	  tends	  to	  exhibit	  significant	  changes	  with	  sepsis.	  However,	  we	  
were	   able	   to	   isolate	  monocytes	  with	   a	   reasonable	  purity	   by	  positive	   selection	   from	   septic	  
patients	   blood	   for	   use	   in	   the	   FRET	   assay,	   which	   represents	   a	   significant	   advance.	   This	  
facilitated	   for	   the	   first	   time	   the	   direct	  measurement	   of	   TACE	   catalytic	   activity	   in	   patients	  
with	   sepsis	   and	   could	   be	   widely	   adopted	   for	   other	   clinical	   conditions.	   The	   speed	   of	   the	  
monocyte	   positive	   selection	   method	   and	   its	   avoidance	   of	   issues	   related	   to	   leukocyte	  
phenotype	  change	  during	   inflammation	  are	  clearly	  advantages	  for	  clinical	  studies.	  A	  recent	  
review	   of	   leukocyte	   isolation	   methods	   concluded	   that	   “positive	   selection	   strategies…	   be	  
adopted	  as	  the	  procedure	  of	  choice”	  [508].	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7.2	  Resetting	  of	  the	  LPS-­‐TACE	  axis	  in	  sepsis	  
We	  next	   found	   evidence	   that	   the	   LPS-­‐TACE	   axis	   appears	   to	   be	   reset	   in	   sepsis.	  Monocytes	  
isolated	   from	   patients	   with	   sepsis	   displayed	   altered	   TACE	   characteristics.	   These	   were	  
increased	  baseline	  activity	  and	  refractoriness	  to	  further	  stimulation	  with	  LPS,	  with	  reduced	  
TNFR	  but	  retained	  L-­‐selectin	  shedding.	  Similar	  findings	  were	  seen	  in	  the	  PTFE	  culture	  model	  
used	   in	  Chapter	  Four,	  although	  L-­‐selectin	  shedding	  was	  also	   impaired	   in	  these	  cells.	  Whilst	  
these	   changes	   could	   be	   in	   keeping	   with	   a	   state	   of	   tolerance,	   we	   found	   no	   evidence	   of	  
priming	   in	  either	  PTFE	  or	  sepsis	  patients’	  monocytes.	  Our	  use	  of	  primary	  monocytes	  and	  a	  
minimally	   adherent	   medium	   in	   the	   PTFE	   model	   removed	   the	   variables	   of	   cell	   lines	   and	  
minimised	  the	  influence	  of	  cell	  contact,	  thus	  enabling	  dissection	  of	  TACE	  refractoriness	  as	  a	  
direct	   function	   of	   LPS	   exposure.	   The	   PTFE	   system	   always	   tended	   toward	   this	   state	   of	  
increased	  basal	  TACE	  activity	  and	  reduced	  response	  to	  secondary	  LPS	  stimulation,	  no	  matter	  
what	   concentration	   of	   LPS	   was	   used	   in	   the	   16-­‐hour	   culture	   period.	   Given	   the	   broad	  
substrate	   base	   of	   TACE	   [342],	   it	   is	   difficult	   to	   draw	   firm	   conclusions	   as	   to	   the	   functional	  
significance	   of	   these	   changes	   in	   TACE	   behaviour	   yet	   changes	   in	   activity	   may	   represent	  
altered	  substrate	  affinity/specificity.	  However,	  within	  the	  PTFE	  model	  we	  found	  no	  evidence	  
of	  altered	  TACE	  specificity	  for	  the	  substrates	  TNFR-­‐1,	  TNFR-­‐2	  and	  L-­‐selectin	  as	  the	  shedding	  
of	  all	  three	  was	  impaired.	  These	  findings	  raise	  questions	  as	  to	  how	  sepsis	  simulation	  should	  
be	  carried	  out	  in	  vitro.	  
Our	  work	  highlights	  the	  differences	  in	  monocyte	  TACE	  response	  in	  situations	  where	  cells	  are	  
in	   close	   proximity.	   This	   means	   that	   techniques	   using	   adherence	   as	   a	   means	   of	   isolating	  
monocytes	   should	   be	   avoided	   as	   they	   could	   induce	   a	   change	   in	   the	   cellular	   response	  
phenotype	  and	  hence	  impact	  on	  results	  [509].	  Care	  should	  be	  taken	  to	  control	  cell	  contact	  
status	   during	   the	   stimulation	   period	   with	   an	   emphasis	   placed	   on	   reproducing	   the	   in	   vivo	  
situation.	   This	  may	  mean	   that	   different	   systems	   are	   used	   to	   represent	   the	   circulating	   cell	  
and	  the	  marginated	  cell,	  perhaps	  using	  co-­‐culture	  systems	  where	  possible	  and	  appropriate.	  
It	   is	  possible	  that	  the	  absence	  of	  contact	  during	  the	  PTFE	  culture	  period	  may	  have	  affected	  
monocyte	  behaviour	   in	   our	  model	   although	   the	   consistencies	   between	  our	   in	   vitro	   and	   in	  
vivo	  TACE	  activity	  data	  are	  striking.	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7.3	  The	  TACE	  response	  is	  dependent	  on	  cell	  proximity	  
We	  were	  surprised	  by	   the	   lack	  of	  a	  primed	  response	   in	   the	  PTFE	  model	  but	   surmised	   that	  
this	  may	  be	  due	   to	  a	   lack	  of	   cell	   contact	   and	   created	  a	  model	   to	  explore	   this	   further.	  We	  
found	   that	   the	  monocyte	   TACE	   response	   is	   dependent	   on	   cell	   contact.	   In	   neutrophils	   it	   is	  
thought	  that	  the	  two-­‐hit	  priming	  process	  acts	  as	  a	  brake	  to	  ensure	  that	  damaging	  mediators	  
such	  as	  ROS	  are	  not	  released	  inappropriately	  [311].	  Thus	  it	  may	  be	  that	  this	  reliance	  on	  cell	  
proximity	   to	   allow	   full	   inflammatory	   signalling	   represents	   a	   brake	   to	   ensure	   monocyte	  
inflammatory	  products	  are	  spatially	  regulated,	  and	  released	  by	  cells	  only	  in	  close	  proximity	  
with	  the	  endothelium	  and/or	  other	  cells.	  Monocytes	  are	  inherently	  adherent	  cells;	  more	  so	  
than	   neutrophils,	   thus	   contact	   may	   represent	   the	   predominant	   regulatory	   process	   in	  
monocytes	  whereas	  neutrophils	   respond	  to	  chemical	  mediators.	   It	   can	  be	  argued	   that	   this	  
state	   represents	   the	  primed	  phenotype	  and	   it	  would	  appear	   that	   the	  monocytes	  placed	   in	  
LPS	   PTFE	   culture,	   as	   well	   as	   those	   obtained	   from	   sepsis	   patients,	   have	   this	   regulatory	  
mechanism	  disturbed.	  This	  would	  explain	  the	  absence	  of	  priming	  in	  the	  PTFE	  culture	  model.	  
Our	  results	  would	  be	  in	  keeping	  with	  the	  primed	  response	  representing	  monocytes	  in	  close	  
proximity	  that	  are	  capable	  of	  full	  inflammatory	  signalling.	  Thus	  it	  would	  appear	  that	  this	  may	  
provide	  a	  means	  of	  spatially	  regulating	  the	  SIRS/CARS	  response	  using	  compartmentalisation:	  
circulating	   cells	   are	   different	   from	   those	   marginated	   in	   the	   microcirculation	   which	   may	  
themselves	   be	   different	   to	   those	   in	   the	   tissues.	   Such	   a	   situation	   would	   help	   to	   prevent	  
circulating	   cells	   from	   releasing	   their	   inflammatory	   products	   and	   generating	   disseminated	  
systemic	  inflammation.	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7.4	  Monocyte	  subsets	  in	  sepsis	  and	  SIRS	  	  
One	  of	   the	   achievements	   of	   our	   clinical	   study	  was	   to	   create	   a	   flow	   cytometry	   protocol	   in	  
which	   we	   could	   accurately	   identify	   monocytes	   without	   gating	   on	   HLA-­‐DR.	   This	   allowed	  
accurate	   measurement	   of	   the	   expression	   of	   this	   antigen-­‐presenting	   molecule	   without	  
excluding	  cells	  expressing	  only	  low	  levels,	  such	  as	  are	  seen	  in	  sepsis	  [292]	  and	  that	  would	  be	  
excluded	   using	   an	   HLA-­‐DR+	   gate.	   As	   part	   of	   this	   flow	   cytometry	   protocol	   we	   intended	   to	  
identify	   the	   previously	   characterised	   monocyte	   subsets:	   immature	   (CD14++CD16-­‐),	  
intermediate	   (CD14+CD16+)	   and	   mature	   (CD14-­‐CD16+)	   [297-­‐299].	   However,	   it	   became	  
apparent	   that	   both	   sepsis	   and	   SIRS	   distorted	   the	   expression	   of	   the	   monocyte	   surface	  
markers	  that	  we	  were	  using	  to	  identify	  the	  subsets.	  This	  occurred	  to	  such	  a	  degree	  in	  some	  
patients	  that	  we	  decided	  against	  drawing	  arbitrary	  gates,	  which	  may	  have	  impacted	  on	  our	  
results,	  and	  evaluated	  the	  monocytes	  as	  an	  entirety.	  
Whilst	   it	   is	   recognised	   that	   there	   is	   an	   expansion	   of	   the	   CD16+	   monocyte	   population	   in	  
sepsis	   [305-­‐307],	   to	   our	   knowledge,	   no	   other	   investigators	   have	   reported	   this	   inability	   to	  
accurately	   distinguish	   between	   the	   subsets.	  Whilst	   it	   may	   be	   possible	   to	   identify	   subsets	  
based	  on	  the	  expression	  of	  recently	  identified	  alternative	  surface	  markers	  [475]	  our	  results	  
would	  caution	  against	  drawing	  conclusions	  on	  subset	  functionality	  [510]	  based	  on	  standard	  
monocyte	  surface	  markers.	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7.5	  Markers	  of	  sepsis	  
Having	   identified	   this	   monocyte	   population	   we	   found	   that	   cells	   from	   both	   patients	   with	  
sepsis	  and	  SIRS	  expressed	  features	  consistent	  with	  monocyte	  deactivation	  –	  reduced	  HLA-­‐DR	  
expression	   and	   reduced	   sol-­‐TNF	   release	   on	   ex	   vivo	   LPS	   stimulation	   [224].	   We	   could	   not	  
identify	  any	  differences	  between	  the	  groups	  based	  on	  these	  two	  markers	  meaning	  that	  they	  
lack	   the	   capacity	   to	   distinguish	   between	   septic	   and	   non-­‐septic	   aetiologies.	   However,	   on	  
examination	  of	  p38MAPK	  signalling,	  TACE	  activity	  profiles	  and	  TACE	  substrate	  shedding	  we	  
identified	   several	   potential	   differences.	   In	   comparison	   to	   SIRS	   patients,	   monocytes	   from	  
sepsis	  patients	  had	  elevated	  baseline	  levels	  of	  phosphorylated	  p38MAPK	  and	  TACE,	  as	  well	  
as	   a	   reduced	   response	   to	   LPS.	   They	   also	   displayed	   increased	   expression	   and	   impaired	  
shedding	  of	  TNFR-­‐1.	  
The	  changes	   in	  p38MAPK	  and	  TACE	  activity	  were	  both	  present	   from	  baseline	   in	   the	  sepsis	  
group	   and	   this	   raises	   the	   possibility	   that	   these	   could	   be	   used	   as	  markers	   to	   differentiate	  
sepsis	   from	   SIRS.	   Although	   further	   work	   is	   clearly	   required,	   these	   data	   highlight	   possible	  
differences	  in	  the	  aetiology	  of,	  and	  signalling	  changes	  induced	  by,	  monocyte	  deactivation.	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7.6	  The	  nature	  of	  the	  deactivated	  monocyte	  phenotype	  in	  sepsis	  
All	   monocytes	   obtained	   from	   patients	   with	   SIRS	   and	   sepsis	   displayed	   characteristics	  
consistent	  with	  a	  state	  of	  deactivation	  [224]	  –	  reduced	  HLA-­‐DR	  expression	  and	  reduced	  sol-­‐
TNF	  release	  on	  ex	  vivo	  LPS	  stimulation.	  This	  has	  been	  considered	  representative	  of	  a	  state	  of	  
immune	   suppression	   and	   similar	   to	   the	   tolerant	   monocyte	   phenotype	   [50,	   323,	   511].	  
However,	  by	  focusing	  on	  the	  TACE	  pathway,	  we	  were	  able	  to	   identify	  differences	  between	  
the	  groups.	  Sepsis	  patients’	  monocytes	  displayed	  increased	  un-­‐stimulated	  TACE	  activity	  and	  
a	  reduced	  response	  to	  LPS	  from	  D0,	  whereas	  these	  changes	  were	  not	  seen	  in	  SIRS	  until	  the	  
end	  of	  the	  study	  period.	  In	  addition,	  there	  was	  evidence	  of	  a	  differential	  responsiveness	  of	  
the	  cellular	  signalling	  pathways.	  
In	  sepsis	  patients	  we	  found	  preliminary	  evidence	  to	  suggest	  that	  the	  p38MAPK	  pathway	  was	  
“turned	  off”	  whereas	  the	  (unknown)	  L-­‐selectin	  pathway	  was,	  for	  the	  most	  part,	  “turned	  on”	  
explaining	   the	   retained	   ability	   of	   their	  monocytes	   to	   shed	   L-­‐selectin.	   It	   can	   be	   speculated	  
that	   sepsis	  produces	  a	   situation	   in	  which	  a	  number	  of	  pathways	  are	   “turned	  off”	  whereas	  
others	  are	  left	  “turned	  on”,	  a	  situation	  that	  could	  be	  considered	  a	  state	  of	  reprogramming;	  a	  
term	   that	   others	   have	   also	   suggested	   [50,	   323,	   439].	   This	   appears	   to	   be	   different	   to	   non-­‐
infectious	  SIRS	  patients	  where	  both	  of	  these	  pathways	  appeared	  to	  be	  “turned	  on”.	  
Such	  reprogramming	  of	  the	  monocyte	  in	  sepsis	  may	  involve	  differential	  effects	  on	  circulating	  
cells	   as	   opposed	   to	   tissue	   macrophages.	   Hence	   there	   may	   be	   a	   circulating	   monocyte	  
phenotype	   that	   displays	   reduced	   inflammatory	   signalling	   (as	   a	   result	   of	   the	   p38MAPK	  
pathway	   being	   turned	   off)	   and	   a	   tissue	   macrophage	   phenotype.	   The	   function	   of	   this	  
reprogrammed	   monocyte	   may	   be	   to	   prevent	   an	   inappropriate	   and	   continued	   release	   of	  
inflammatory	   products.	   As	  we	   speculated	   in	   the	   discussion	   to	   Chapter	   Five	   the	   increased	  
expression	  of	  TNFR-­‐1	  on	   these	   cells	   is	  of	   interest	   in	   this	   regard	  as	  TNFR-­‐1	   signalling	   forms	  
part	  of	  the	  “extrinsic”	  death	  receptor	  pathway	  that	  induces	  apoptosis	  in	  leukocytes.	  Thus	  it	  
may	  be	  that	  this	  represents	  a	  method	  of	  removing	  classically	  activated	  monocytes	  in	  order	  
that	  monocyte	  function	  is	  reoriented	  toward	  a	  tissue	  repair	  phenotype.	  
There	  is	  an	  alternative	  explanation;	  as	  we	  said	  in	  the	  introduction,	  “circulating	  inflammatory	  
cells	  would	  be	  required	  to	  switch	  from	  a	  relatively	  passive	  to	  more	  pro-­‐inflammatory	  state	  
while	  migrating	   into	   the	   inflamed	  tissue	  via	   the	  vascular	  endothelium”.	  Our	  work	  suggests	  
that	   cells	   in	   close	   proximity	   to	   one	   another,	   such	   as	   may	   be	   seen	   on	   the	   vascular	  
endothelium	  have	  enhanced	  inflammatory	  signalling	  capacity	  when	  compared	  to	  those	  not	  
in	   proximity.	   Thus	   circulating	   septic,	   reprogrammed,	   cells	   with	   reduced	   inflammatory	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signalling	  (through	  “turned	  off”	  p38MAPK)	  may	  have	  this	  partially	  restored	  (“turned	  on”)	  by	  
proximity,	  and	  produce	  an	  inflammatory	  focus.	  The	  fact	  that	  monocytes	  from	  septic	  patients	  
did	  not	  demonstrate	  this	  when	  stimulated	  in	  the	  cell	  dense	  conditions,	  such	  as	  were	  present	  
in	   Eppendorfs	   used	   for	   the	   LPS	   stimulation,	   may	  mean	   that	   other	   cues	   are	   required.	   Co-­‐
culture	  experiments	  using	  monocytes	  and	  endothelial	  cells	  may	  provide	  further	  information	  
in	  this	  regard.	  
The	  retained	  (“turned	  on”)	  L-­‐selectin	  shedding	  capacity	  may	  mean	  that	  these	  reprogrammed	  
cells	  are	  capable	  of	  migrating	  across	   the	  endothelium	   into	   the	   inflamed	  tissue	   in	  a	  normal	  
manner.	  Our	  preliminary	  results	  using	  a	  chemotaxis	  assay	  suggested	  that	  this	  might	  be	  the	  
case.	   Once	   in	   the	   tissue	   further	   phenotypic	   changes	   may	   occur	   as	   a	   result	   of	   the	   local	  
cytokine	   environment	   and	   continued	   contact	  with	   the	   extra-­‐cellular	  matrix.	   Further	  work,	  
comparing	  tissue	  macrophages	  to	  circulating	  monocytes,	  will	  reveal	  further	  details	  and	  may	  
provide	  further	  evidence	  of	  a	  spatial	  regulation	  of	  the	  SIRS/CARS	  response.	  
In	   non-­‐infectious	   SIRS	   the	   situation	   was	   different,	   as	   the	   p38MAPK	   pathway	   remained	  
“turned	  on”.	  Hence,	  despite	  outwardly	  appearing	  deactivated,	  these	  cells	  are	  still	  capable	  of	  
mounting	   a	   normal	   TACE	   response	   on	   ex	   vivo	   stimulation	   and	   it	   may	   be	   that	   these	  
circulating	  cells	  are	  “primed”	  for	  a	  secondary	  inflammatory	  stimulus.	  Certainly	  the	  situation	  
seems	   more	   complicated	   than	   a	   simple	   homogenous	   deactivation	   response	   to	  
heterogeneous	  stimuli	  (SIRS	  and	  sepsis).	  Although	  in	  SIRS	  patients	  these	  cells	  retain	  a	  TACE	  
response	   to	   LPS	   they	   produce	   lower	   levels	   of	   sol-­‐TNF	   on	   ex	   vivo	   stimulation	   than	   freshly	  
isolated	  cells.	  Once	  again,	   the	  effect	  of	  cell	  proximity	   is	   likely	   to	  be	  of	  key	   importance	  and	  
should	  be	  examined	  closely	  in	  any	  future	  work	  in	  this	  area.	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7.7	  Concluding	  remarks	  
The	   current	  paradigm	  of	   sepsis	   is	   based	  on	   the	  body’s	   attempt	   to	   restore	  homeostasis,	   in	  
doing	  so	  it	  becomes	  immune-­‐compromised	  leading	  to	  a	  vicious	  cycle	  of	  recurrent	   infection	  
and	  organ	   injury.	  Part	  of	   this	   theory	  has	   its	  origin	   in	  changes	   to	   the	  monocyte	  phenotype,	  
which	  can	  be	  classified	  at	  two	  levels:	  
	  1.	  Refractoriness	  to	  further	  stimulation	  in	  ex	  vivo	  assays	  (e.g.	  LPS-­‐induced	  TNF	  expression)	  
and	  
2.	  The	  presence	  of	  an	  in	  vivo	  phenotype	  implying	  reduced	  (immune)	  function	  (e.g.	  HLA-­‐DR).	  
This	  study	  revealed	  that	  ex	  vivo	  analysis	  of	  TACE,	  and	  related	  substrate	  shedding,	  may	  be	  a	  
valid	  approach	  to	  discriminating	  between	  different	  aetiologies	  of	  SIRS,	  contrasting	  the	   lack	  
of	  clear	  differences	  found	  using	  the	  standard	  measures	  described	  above.	  By	  varying	  the	  ex	  
vivo	  conditions,	  we	  were	  also	  able	  to	  obtain	  some	  insight	   into	  factors	  affecting	  changes	  to	  
TACE	   behaviour	   during	   sepsis,	   indicating	   the	  multifactorial	   nature	   of	   this	   response	   and	   in	  
particular	   the	   previously	   unappreciated	   role	   of	   cell	   proximity	   as	   a	   limiting	   step	   in	   TACE	  
catalytic	   activation.	   The	   physiological	   consequences	   of	   these	   changes	   in	   TACE	   related	  
biology	   are	   not	   clear	   as	   yet,	   but	   they	  do	  highlight	   the	  need	   to	   perform	  monocyte	   ex	   vivo	  
assays	   of	   more	   functional	   relevance	   to	   innate	   immune	   system	   response	   to	   infection	   and	  
injury.	  
With	   specific	   regard	   to	  our	   initial	  aims,	   the	   limiting	   role	  of	   cell	  proximity	  and	  our	  use	  of	  a	  
non-­‐adherent	  medium	   in	   our	   in	   vitro	  model	  meant	   that,	   whilst	   we	  may	   have	  modelled	   a	  
tolerant	  phenotype,	  we	  were	  not	  able	   to	  model	  priming.	  However,	   later	   results	   suggested	  
that	   the	   primed	   phenotype	   is	   proximity	   dependent	   and	   that	   this	   state	   may	   be	   signalled	  
through	   integrins	   and	   intra-­‐cellular	   ROS.	   TACE	   signalling	   did	   appear	   to	   be	   differentially	  
affected	   across	   these	   phenotypes	   with	   our	   tolerance	   model	   producing	   increased	   un-­‐
stimulated	   TACE	  activity	   and	   a	   reduced	   response	   to	   LPS.	   These	   findings	  were	   also	   seen	   in	  
monocytes	   taken	   from	   patients	   with	   sepsis,	   where	   evidence	   of	   reprogramming	   was	   seen	  
within	  the	  p38MAPK/TACE	  pathway,	  which	  appeared	  to	  be	  “turned	  off”.	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Our	  results	  fit	  more	  with	  a	  compartmentalised	  immune	  response	  with	  an	  anti-­‐inflammatory	  
response	   dominating	   systemically.	   This	   highlights	   the	   limitations	   of	   using	   plasma	   as	   the	  
window	   through	   which	   to	   view	   the	   immune	   response.	   Future	   work	   should	   focus	   on	   the	  
processes	   occurring	  within	   both	   the	  microcirculation	   and	   the	   tissues.	   Comparing	   these	   to	  
the	   systemic	   circulation	  may	  provide	  a	  more	  accurate	   representation	  of	   the	  nature	  of	   the	  
innate	   immune	  response.	  This	  more	   rigorous	  and	   technically	  demanding	  approach	  may	  be	  
essential	  to	  unravel	  the	  complexities	  of	  infectious	  and	  non-­‐infectious	  SIRS	  and	  in	  the	  design	  
of	  effective	  immunotherapeutic	  strategies.	  
	   	  
	   237	  
	  	  	  	  	  
References	  
	   	  
	   238	  
1.	   Fleming,	  A.,	  On	  the	  antibacterial	  action	  of	  cultures	  of	  a	  penicillium,	  with	  
special	  reference	  to	  their	  use	  in	  the	  isolation	  of	  B.	  influenzae.	  1929.	  Bull	  World	  Health	  Organ,	  2001.	  79(8):	  p.	  780-­‐90.	  2.	   Walsh,	  C.,	  Molecular	  mechanisms	  that	  confer	  antibacterial	  drug	  resistance.	  Nature,	  2000.	  406(6797):	  p.	  775-­‐81.	  3.	   Barbosa,	  T.M.	  and	  S.B.	  Levy,	  The	  impact	  of	  antibiotic	  use	  on	  resistance	  
development	  and	  persistence.	  Drug	  Resist	  Updat,	  2000.	  3(5):	  p.	  303-­‐311.	  4.	   Jevons,	  M.P.,	  A.W.	  Coe,	  and	  M.T.	  Parker,	  Methicillin	  resistance	  in	  
staphylococci.	  Lancet,	  1963.	  1(7287):	  p.	  904-­‐7.	  5.	   Shlaes,	  D.M.,	  et	  al.,	  Society	  for	  Healthcare	  Epidemiology	  of	  America	  and	  
Infectious	  Diseases	  Society	  of	  America	  Joint	  Committee	  on	  the	  Prevention	  of	  
Antimicrobial	  Resistance:	  guidelines	  for	  the	  prevention	  of	  antimicrobial	  
resistance	  in	  hospitals.	  Clin	  Infect	  Dis,	  1997.	  25(3):	  p.	  584-­‐99.	  6.	   O'Callaghan,	  D.J.	  and	  A.C.	  Gordon,	  Sepsis:	  an	  update	  for	  physicians.	  Clin	  Med,	  2011.	  11(6):	  p.	  619-­‐22.	  7.	   Harrison,	  D.A.,	  C.A.	  Welch,	  and	  J.M.	  Eddleston,	  The	  epidemiology	  of	  severe	  
sepsis	  in	  England,	  Wales	  and	  Northern	  Ireland,	  1996	  to	  2004:	  secondary	  
analysis	  of	  a	  high	  quality	  clinical	  database,	  the	  ICNARC	  Case	  Mix	  
Programme	  Database.	  Crit	  Care,	  2006.	  10(2):	  p.	  R42.	  8.	   Martin,	  G.S.,	  et	  al.,	  The	  epidemiology	  of	  sepsis	  in	  the	  United	  States	  from	  1979	  
through	  2000.	  N	  Engl	  J	  Med,	  2003.	  348(16):	  p.	  1546-­‐54.	  9.	   Angus,	  D.C.,	  et	  al.,	  Epidemiology	  of	  severe	  sepsis	  in	  the	  United	  States:	  
analysis	  of	  incidence,	  outcome,	  and	  associated	  costs	  of	  care.	  Crit	  Care	  Med,	  2001.	  29(7):	  p.	  1303-­‐10.	  10.	   Dellinger,	  R.P.,	  et	  al.,	  Surviving	  Sepsis	  Campaign	  guidelines	  for	  management	  
of	  severe	  sepsis	  and	  septic	  shock.	  Intensive	  Care	  Med,	  2004.	  30(4):	  p.	  536-­‐55.	  11.	   Levy,	  M.M.,	  et	  al.,	  The	  Surviving	  Sepsis	  Campaign:	  results	  of	  an	  international	  
guideline-­‐based	  performance	  improvement	  program	  targeting	  severe	  
sepsis.	  Intensive	  Care	  Med,	  2010.	  36(2):	  p.	  222-­‐31.	  12.	   Charles,	  P.G.	  and	  M.L.	  Grayson,	  The	  dearth	  of	  new	  antibiotic	  development:	  
why	  we	  should	  be	  worried	  and	  what	  we	  can	  do	  about	  it.	  Med	  J	  Aust,	  2004.	  
181(10):	  p.	  549-­‐53.	  13.	   Ranieri,	  V.M.,	  et	  al.,	  Drotrecogin	  alfa	  (activated)	  in	  adults	  with	  septic	  shock.	  N	  Engl	  J	  Med,	  2012.	  366(22):	  p.	  2055-­‐64.	  14.	   American	  College	  of	  Chest	  Physicians/Society	  of	  Critical	  Care	  Medicine	  
Consensus	  Conference:	  definitions	  for	  sepsis	  and	  organ	  failure	  and	  
guidelines	  for	  the	  use	  of	  innovative	  therapies	  in	  sepsis.	  Crit	  Care	  Med,	  1992.	  
20(6):	  p.	  864-­‐74.	  15.	   Rivers,	  E.,	  et	  al.,	  Early	  goal-­‐directed	  therapy	  in	  the	  treatment	  of	  severe	  
sepsis	  and	  septic	  shock.	  N	  Engl	  J	  Med,	  2001.	  345(19):	  p.	  1368-­‐77.	  16.	   Rangel-­‐Frausto,	  M.S.,	  et	  al.,	  The	  natural	  history	  of	  the	  systemic	  
inflammatory	  response	  syndrome	  (SIRS).	  A	  prospective	  study.	  JAMA,	  1995.	  
273(2):	  p.	  117-­‐23.	  17.	   Dinarello,	  C.A.,	  Historical	  insights	  into	  cytokines.	  Eur	  J	  Immunol,	  2007.	  37	  
Suppl	  1:	  p.	  S34-­‐45.	  18.	   Thomas,	  L.,	  Germs.	  N	  Engl	  J	  Med,	  1972.	  287(11):	  p.	  553-­‐5.	  19.	   Goris,	  R.J.,	  et	  al.,	  Multiple-­‐organ	  failure.	  Generalized	  autodestructive	  
inflammation?	  Archives	  of	  surgery,	  1985.	  120(10):	  p.	  1109-­‐15.	  
	   239	  
20.	   Goris,	  R.J.,	  Multiple	  organ	  failure:	  whole	  body	  inflammation?	  Schweiz	  Med	  Wochenschr,	  1989.	  119(11):	  p.	  347-­‐53.	  21.	   Hotchkiss,	  R.S.	  and	  I.E.	  Karl,	  The	  pathophysiology	  and	  treatment	  of	  sepsis.	  N	  Engl	  J	  Med,	  2003.	  348(2):	  p.	  138-­‐50.	  22.	   Miyauchi,	  T.,	  et	  al.,	  Involvement	  of	  endothelin	  in	  the	  regulation	  of	  human	  
vascular	  tonus.	  Potent	  vasoconstrictor	  effect	  and	  existence	  in	  endothelial	  
cells.	  Circulation,	  1990.	  81(6):	  p.	  1874-­‐80.	  23.	   Gomez-­‐Jimenez,	  J.,	  et	  al.,	  L-­‐arginine:	  nitric	  oxide	  pathway	  in	  endotoxemia	  
and	  human	  septic	  shock.	  Crit	  Care	  Med,	  1995.	  23(2):	  p.	  253-­‐8.	  24.	   Levi,	  M.,	  et	  al.,	  Pathogenesis	  of	  disseminated	  intravascular	  coagulation	  in	  
sepsis.	  JAMA,	  1993.	  270(8):	  p.	  975-­‐9.	  25.	   Riche,	  F.C.,	  et	  al.,	  Inflammatory	  cytokine	  response	  in	  patients	  with	  septic	  
shock	  secondary	  to	  generalized	  peritonitis.	  Crit	  Care	  Med,	  2000.	  28(2):	  p.	  433-­‐7.	  26.	   Casey,	  L.C.,	  R.A.	  Balk,	  and	  R.C.	  Bone,	  Plasma	  cytokine	  and	  endotoxin	  levels	  
correlate	  with	  survival	  in	  patients	  with	  the	  sepsis	  syndrome.	  Ann	  Intern	  Med,	  1993.	  119(8):	  p.	  771-­‐8.	  27.	   Cannon,	  J.G.,	  et	  al.,	  Circulating	  interleukin-­‐1	  and	  tumor	  necrosis	  factor	  in	  
septic	  shock	  and	  experimental	  endotoxin	  fever.	  J	  Infect	  Dis,	  1990.	  161(1):	  p.	  79-­‐84.	  28.	   Martin,	  C.,	  et	  al.,	  Prognostic	  values	  of	  serum	  cytokines	  in	  septic	  shock.	  Intensive	  Care	  Med,	  1994.	  20(4):	  p.	  272-­‐7.	  29.	   Tracey,	  K.J.,	  et	  al.,	  Shock	  and	  tissue	  injury	  induced	  by	  recombinant	  human	  
cachectin.	  Science,	  1986.	  234(4775):	  p.	  470-­‐4.	  30.	   Tracey,	  K.J.,	  et	  al.,	  Anti-­‐cachectin/TNF	  monoclonal	  antibodies	  prevent	  septic	  
shock	  during	  lethal	  bacteraemia.	  Nature,	  1987.	  330(6149):	  p.	  662-­‐4.	  31.	   Beutler,	  B.,	  I.W.	  Milsark,	  and	  A.C.	  Cerami,	  Passive	  immunization	  against	  
cachectin/tumor	  necrosis	  factor	  protects	  mice	  from	  lethal	  effect	  of	  
endotoxin.	  Science,	  1985.	  229(4716):	  p.	  869-­‐71.	  32.	   Silva,	  A.T.,	  K.F.	  Bayston,	  and	  J.	  Cohen,	  Prophylactic	  and	  therapeutic	  effects	  
of	  a	  monoclonal	  antibody	  to	  tumor	  necrosis	  factor-­‐alpha	  in	  experimental	  
gram-­‐negative	  shock.	  J	  Infect	  Dis,	  1990.	  162(2):	  p.	  421-­‐7.	  33.	   Lorente,	  J.A.	  and	  J.C.	  Marshall,	  Neutralization	  of	  tumor	  necrosis	  factor	  in	  
preclinical	  models	  of	  sepsis.	  Shock,	  2005.	  24	  Suppl	  1:	  p.	  107-­‐19.	  34.	   Reinhart,	  K.	  and	  W.	  Karzai,	  Anti-­‐tumor	  necrosis	  factor	  therapy	  in	  sepsis:	  
update	  on	  clinical	  trials	  and	  lessons	  learned.	  Crit	  Care	  Med,	  2001.	  29(7	  Suppl):	  p.	  S121-­‐5.	  35.	   Zeni,	  F.,	  B.	  Freeman,	  and	  C.	  Natanson,	  Anti-­‐inflammatory	  therapies	  to	  treat	  
sepsis	  and	  septic	  shock:	  a	  reassessment.	  Crit	  Care	  Med,	  1997.	  25(7):	  p.	  1095-­‐100.	  36.	   Fisher,	  C.J.,	  Jr.,	  et	  al.,	  Treatment	  of	  septic	  shock	  with	  the	  tumor	  necrosis	  
factor	  receptor:Fc	  fusion	  protein.	  The	  Soluble	  TNF	  Receptor	  Sepsis	  Study	  
Group.	  N	  Engl	  J	  Med,	  1996.	  334(26):	  p.	  1697-­‐702.	  37.	   Bone,	  R.C.,	  Sir	  Isaac	  Newton,	  sepsis,	  SIRS,	  and	  CARS.	  Crit	  Care	  Med,	  1996.	  
24(7):	  p.	  1125-­‐8.	  38.	   Newton,	  I.,	  Philosophiæ	  naturalis	  principia	  mathematica1687,	  Londini,:	  Jussu	  Societatis	  Regiæ	  ac	  Typis	  Josephi	  Streater.	  Prostat	  apud	  plures	  Bibliopolas.	  4	  p.l.,	  383,	  400-­‐510	  p.,	  1	  l.	  
	   240	  
39.	   Meakins,	  J.L.,	  et	  al.,	  Delayed	  hypersensitivity:	  indicator	  of	  acquired	  failure	  of	  
host	  defenses	  in	  sepsis	  and	  trauma.	  Ann	  Surg,	  1977.	  186(3):	  p.	  241-­‐50.	  40.	   Christou,	  N.V.,	  Host-­‐defence	  mechanisms	  in	  surgical	  patients:	  a	  correlative	  
study	  of	  the	  delayed	  hypersensitivity	  skin-­‐test	  response,	  granulocyte	  
function	  and	  sepsis.	  Can	  J	  Surg,	  1985.	  28(1):	  p.	  39-­‐46,	  49.	  41.	   Lederer,	  J.A.,	  M.L.	  Rodrick,	  and	  J.A.	  Mannick,	  The	  effects	  of	  injury	  on	  the	  
adaptive	  immune	  response.	  Shock,	  1999.	  11(3):	  p.	  153-­‐9.	  42.	   Oberholzer,	  A.,	  C.	  Oberholzer,	  and	  L.L.	  Moldawer,	  Sepsis	  syndromes:	  
understanding	  the	  role	  of	  innate	  and	  acquired	  immunity.	  Shock,	  2001.	  
16(2):	  p.	  83-­‐96.	  43.	   Cavaillon,	  J.M.,	  "Septic	  Plasma":	  an	  immunosuppressive	  milieu.	  Am	  J	  Respir	  Crit	  Care	  Med,	  2002.	  166(11):	  p.	  1417-­‐8.	  44.	   Prins,	  J.M.,	  et	  al.,	  Release	  of	  tumor	  necrosis	  factor	  alpha	  and	  interleukin	  6	  
during	  antibiotic	  killing	  of	  Escherichia	  coli	  in	  whole	  blood:	  influence	  of	  
antibiotic	  class,	  antibiotic	  concentration,	  and	  presence	  of	  septic	  serum.	  Infect	  Immun,	  1995.	  63(6):	  p.	  2236-­‐42.	  45.	   Majetschak,	  M.,	  et	  al.,	  Regulation	  of	  whole	  blood	  tumor	  necrosis	  factor	  
production	  upon	  endotoxin	  stimulation	  after	  severe	  blunt	  trauma.	  J	  Trauma,	  1997.	  43(6):	  p.	  880-­‐7.	  46.	   Brandtzaeg,	  P.,	  et	  al.,	  Net	  inflammatory	  capacity	  of	  human	  septic	  shock	  
plasma	  evaluated	  by	  a	  monocyte-­‐based	  target	  cell	  assay:	  identification	  of	  
interleukin-­‐10	  as	  a	  major	  functional	  deactivator	  of	  human	  monocytes.	  J	  Exp	  Med,	  1996.	  184(1):	  p.	  51-­‐60.	  47.	   Ertel,	  W.,	  et	  al.,	  Downregulation	  of	  proinflammatory	  cytokine	  release	  in	  
whole	  blood	  from	  septic	  patients.	  Blood,	  1995.	  85(5):	  p.	  1341-­‐7.	  48.	   Kawamura,	  T.,	  R.	  Wakusawa,	  and	  K.	  Inada,	  Interleukin-­‐10	  and	  interleukin-­‐
1	  receptor	  antagonists	  increase	  during	  cardiac	  surgery.	  Can	  J	  Anaesth,	  1997.	  44(1):	  p.	  38-­‐42.	  49.	   Adrie,	  C.,	  et	  al.,	  Successful	  cardiopulmonary	  resuscitation	  after	  cardiac	  
arrest	  as	  a	  "sepsis-­‐like"	  syndrome.	  Circulation,	  2002.	  106(5):	  p.	  562-­‐8.	  50.	   Adib-­‐Conquy,	  M.	  and	  J.M.	  Cavaillon,	  Compensatory	  anti-­‐inflammatory	  
response	  syndrome.	  Thromb	  Haemost,	  2009.	  101(1):	  p.	  36-­‐47.	  51.	   Allen,	  M.L.,	  et	  al.,	  Early	  postoperative	  monocyte	  deactivation	  predicts	  
systemic	  inflammation	  and	  prolonged	  stay	  in	  pediatric	  cardiac	  intensive	  
care.	  Crit	  Care	  Med,	  2002.	  30(5):	  p.	  1140-­‐5.	  52.	   Flohe,	  S.,	  et	  al.,	  Influence	  of	  surgical	  intervention	  in	  the	  immune	  response	  of	  
severely	  injured	  patients.	  Intensive	  Care	  Med,	  2004.	  30(1):	  p.	  96-­‐102.	  53.	   Handy,	  J.M.,	  et	  al.,	  HLA-­‐DR	  expression	  and	  differential	  trafficking	  of	  
monocyte	  subsets	  following	  low	  to	  intermediate	  risk	  surgery.	  Anaesthesia,	  2010.	  65(1):	  p.	  27-­‐35.	  54.	   Lukaszewicz,	  A.C.,	  et	  al.,	  Monocytic	  HLA-­‐DR	  expression	  in	  intensive	  care	  
patients:	  interest	  for	  prognosis	  and	  secondary	  infection	  prediction.	  Crit	  Care	  Med,	  2009.	  37(10):	  p.	  2746-­‐52.	  55.	   Monneret,	  G.,	  et	  al.,	  The	  anti-­‐inflammatory	  response	  dominates	  after	  septic	  
shock:	  association	  of	  low	  monocyte	  HLA-­‐DR	  expression	  and	  high	  
interleukin-­‐10	  concentration.	  Immunol	  Lett,	  2004.	  95(2):	  p.	  193-­‐8.	  56.	   O'Sullivan,	  S.T.,	  et	  al.,	  Major	  injury	  leads	  to	  predominance	  of	  the	  T	  helper-­‐2	  
lymphocyte	  phenotype	  and	  diminished	  interleukin-­‐12	  production	  associated	  
	   241	  
with	  decreased	  resistance	  to	  infection.	  Ann	  Surg,	  1995.	  222(4):	  p.	  482-­‐90;	  discussion	  490-­‐2.	  57.	   Bone,	  R.C.,	  Immunologic	  dissonance:	  a	  continuing	  evolution	  in	  our	  
understanding	  of	  the	  systemic	  inflammatory	  response	  syndrome	  (SIRS)	  and	  
the	  multiple	  organ	  dysfunction	  syndrome	  (MODS).	  Ann	  Intern	  Med,	  1996.	  
125(8):	  p.	  680-­‐7.	  58.	   Munford,	  R.S.	  and	  J.	  Pugin,	  Normal	  responses	  to	  injury	  prevent	  systemic	  
inflammation	  and	  can	  be	  immunosuppressive.	  Am	  J	  Respir	  Crit	  Care	  Med,	  2001.	  163(2):	  p.	  316-­‐21.	  59.	   Keel,	  M.,	  et	  al.,	  Different	  pattern	  of	  local	  and	  systemic	  release	  of	  
proinflammatory	  and	  anti-­‐inflammatory	  mediators	  in	  severely	  injured	  
patients	  with	  chest	  trauma.	  J	  Trauma,	  1996.	  40(6):	  p.	  907-­‐12;	  discussion	  912-­‐4.	  60.	   Bastian,	  D.,	  et	  al.,	  Systemic	  and	  local	  cytokine	  kinetics	  after	  total	  hip	  
replacement	  surgery.	  Eur	  Surg	  Res,	  2008.	  41(4):	  p.	  334-­‐40.	  61.	   Marie,	  C.,	  et	  al.,	  Cytokines	  and	  soluble	  cytokine	  receptors	  in	  pleural	  effusions	  
from	  septic	  and	  nonseptic	  patients.	  Am	  J	  Respir	  Crit	  Care	  Med,	  1997.	  
156(5):	  p.	  1515-­‐22.	  62.	   Chinnaiyan,	  A.M.,	  et	  al.,	  Molecular	  signatures	  of	  sepsis:	  multiorgan	  gene	  
expression	  profiles	  of	  systemic	  inflammation.	  Am	  J	  Pathol,	  2001.	  159(4):	  p.	  1199-­‐209.	  63.	   Philippart,	  F.,	  C.	  Fitting,	  and	  J.M.	  Cavaillon,	  Lung	  microenvironment	  
contributes	  to	  the	  resistance	  of	  alveolar	  macrophages	  to	  develop	  tolerance	  
to	  endotoxin.	  Crit	  Care	  Med,	  2012.	  64.	   Callery,	  M.P.,	  M.J.	  Mangino,	  and	  M.W.	  Flye,	  A	  biologic	  basis	  for	  limited	  
Kupffer	  cell	  reactivity	  to	  portal-­‐derived	  endotoxin.	  Surgery,	  1991.	  110(2):	  p.	  221-­‐30.	  65.	   Millo,	  J.L.,	  et	  al.,	  Compartmentalisation	  of	  cytokines	  and	  cytokine	  inhibitors	  
in	  ventilator-­‐associated	  pneumonia.	  Intensive	  Care	  Med,	  2004.	  30(1):	  p.	  68-­‐74.	  66.	   Millar,	  A.B.,	  et	  al.,	  Tumour	  necrosis	  factor	  in	  bronchopulmonary	  secretions	  
of	  patients	  with	  adult	  respiratory	  distress	  syndrome.	  Lancet,	  1989.	  
2(8665):	  p.	  712-­‐4.	  67.	   Hyers,	  T.M.,	  et	  al.,	  Tumor	  necrosis	  factor	  levels	  in	  serum	  and	  
bronchoalveolar	  lavage	  fluid	  of	  patients	  with	  the	  adult	  respiratory	  distress	  
syndrome.	  Am	  Rev	  Respir	  Dis,	  1991.	  144(2):	  p.	  268-­‐71.	  68.	   Jorens,	  P.G.,	  et	  al.,	  Interleukin	  8	  (IL-­‐8)	  in	  the	  bronchoalveolar	  lavage	  fluid	  
from	  patients	  with	  the	  adult	  respiratory	  distress	  syndrome	  (ARDS)	  and	  
patients	  at	  risk	  for	  ARDS.	  Cytokine,	  1992.	  4(6):	  p.	  592-­‐7.	  69.	   Tran	  Van	  Nhieu,	  J.,	  et	  al.,	  Expression	  of	  tumor	  necrosis	  factor-­‐alpha	  gene	  in	  
alveolar	  macrophages	  from	  patients	  with	  the	  adult	  respiratory	  distress	  
syndrome.	  Am	  Rev	  Respir	  Dis,	  1993.	  147(6	  Pt	  1):	  p.	  1585-­‐9.	  70.	   Pugin,	  J.,	  et	  al.,	  Proinflammatory	  activity	  in	  bronchoalveolar	  lavage	  fluids	  
from	  patients	  with	  ARDS,	  a	  prominent	  role	  for	  interleukin-­‐1.	  Am	  J	  Respir	  Crit	  Care	  Med,	  1996.	  153(6	  Pt	  1):	  p.	  1850-­‐6.	  71.	   Dehoux,	  M.S.,	  et	  al.,	  Compartmentalized	  cytokine	  production	  within	  the	  
human	  lung	  in	  unilateral	  pneumonia.	  Am	  J	  Respir	  Crit	  Care	  Med,	  1994.	  
150(3):	  p.	  710-­‐6.	  
	   242	  
72.	   Mateo,	  R.B.,	  J.S.	  Reichner,	  and	  J.E.	  Albina,	  Interleukin-­‐6	  activity	  in	  wounds.	  Am	  J	  Physiol,	  1994.	  266(6	  Pt	  2):	  p.	  R1840-­‐4.	  73.	   Waage,	  A.,	  et	  al.,	  Local	  production	  of	  tumor	  necrosis	  factor	  alpha,	  
interleukin	  1,	  and	  interleukin	  6	  in	  meningococcal	  meningitis.	  Relation	  to	  the	  
inflammatory	  response.	  J	  Exp	  Med,	  1989.	  170(6):	  p.	  1859-­‐67.	  74.	   Dugernier,	  T.L.,	  et	  al.,	  Compartmentalization	  of	  the	  inflammatory	  response	  
during	  acute	  pancreatitis:	  correlation	  with	  local	  and	  systemic	  
complications.	  Am	  J	  Respir	  Crit	  Care	  Med,	  2003.	  168(2):	  p.	  148-­‐57.	  75.	   Olszyna,	  D.P.,	  et	  al.,	  Chemotactic	  activity	  of	  CXC	  chemokines	  interleukin-­‐8,	  
growth-­‐related	  oncogene-­‐alpha,	  and	  epithelial	  cell-­‐derived	  neutrophil-­‐
activating	  protein-­‐78	  in	  urine	  of	  patients	  with	  urosepsis.	  J	  Infect	  Dis,	  2000.	  
182(6):	  p.	  1731-­‐7.	  76.	   Rivera-­‐Chavez,	  F.A.,	  et	  al.,	  Regional	  and	  systemic	  cytokine	  responses	  to	  
acute	  inflammation	  of	  the	  vermiform	  appendix.	  Ann	  Surg,	  2003.	  237(3):	  p.	  408-­‐16.	  77.	   Holzheimer,	  R.G.,	  M.	  Schein,	  and	  D.H.	  Wittmann,	  Inflammatory	  response	  in	  
peritoneal	  exudate	  and	  plasma	  of	  patients	  undergoing	  planned	  
relaparotomy	  for	  severe	  secondary	  peritonitis.	  Archives	  of	  surgery,	  1995.	  
130(12):	  p.	  1314-­‐9;	  discussion	  1319-­‐20.	  78.	   Adib-­‐Conquy,	  M.,	  et	  al.,	  Paradoxical	  priming	  effects	  of	  IL-­‐10	  on	  cytokine	  
production.	  Int	  Immunol,	  1999.	  11(5):	  p.	  689-­‐98.	  79.	   Takabayashi,	  T.,	  et	  al.,	  A	  new	  biologic	  role	  for	  C3a	  and	  C3a	  desArg:	  
regulation	  of	  TNF-­‐alpha	  and	  IL-­‐1	  beta	  synthesis.	  J	  Immunol,	  1996.	  156(9):	  p.	  3455-­‐60.	  80.	   Beutler,	  B.,	  Innate	  immunity:	  an	  overview.	  Mol	  Immunol,	  2004.	  40(12):	  p.	  845-­‐59.	  81.	   Carroll,	  M.C.	  and	  D.E.	  Isenman,	  Regulation	  of	  humoral	  immunity	  by	  
complement.	  Immunity,	  2012.	  37(2):	  p.	  199-­‐207.	  82.	   Kimbrell,	  D.A.	  and	  B.	  Beutler,	  The	  evolution	  and	  genetics	  of	  innate	  
immunity.	  Nat	  Rev	  Genet,	  2001.	  2(4):	  p.	  256-­‐67.	  83.	   Janeway,	  C.A.,	  Jr.,	  Approaching	  the	  asymptote?	  Evolution	  and	  revolution	  in	  
immunology.	  Cold	  Spring	  Harb	  Symp	  Quant	  Biol,	  1989.	  54	  Pt	  1:	  p.	  1-­‐13.	  84.	   Galanos,	  C.,	  et	  al.,	  Synthetic	  and	  natural	  Escherichia	  coli	  free	  lipid	  A	  express	  
identical	  endotoxic	  activities.	  Eur	  J	  Biochem,	  1985.	  148(1):	  p.	  1-­‐5.	  85.	   Poltorak,	  A.,	  et	  al.,	  Defective	  LPS	  signaling	  in	  C3H/HeJ	  and	  C57BL/10ScCr	  
mice:	  mutations	  in	  Tlr4	  gene.	  Science,	  1998.	  282(5396):	  p.	  2085-­‐8.	  86.	   Poltorak,	  O.M.,	  E.S.	  Chukhray,	  and	  I.Y.	  Torshin,	  Dissociative	  thermal	  
inactivation,	  stability,	  and	  activity	  of	  oligomeric	  enzymes.	  Biochemistry	  (Mosc),	  1998.	  63(3):	  p.	  303-­‐11.	  87.	   Wright,	  S.D.,	  et	  al.,	  CD14,	  a	  receptor	  for	  complexes	  of	  lipopolysaccharide	  
(LPS)	  and	  LPS	  binding	  protein.	  Science,	  1990.	  249(4975):	  p.	  1431-­‐3.	  88.	   Muta,	  T.	  and	  K.	  Takeshige,	  Essential	  roles	  of	  CD14	  and	  lipopolysaccharide-­‐
binding	  protein	  for	  activation	  of	  toll-­‐like	  receptor	  (TLR)2	  as	  well	  as	  TLR4	  
Reconstitution	  of	  TLR2-­‐	  and	  TLR4-­‐activation	  by	  distinguishable	  ligands	  in	  
LPS	  preparations.	  Eur	  J	  Biochem,	  2001.	  268(16):	  p.	  4580-­‐9.	  89.	   Nagai,	  Y.,	  et	  al.,	  Essential	  role	  of	  MD-­‐2	  in	  LPS	  responsiveness	  and	  TLR4	  
distribution.	  Nat	  Immunol,	  2002.	  3(7):	  p.	  667-­‐72.	  90.	   Aderem,	  A.	  and	  R.J.	  Ulevitch,	  Toll-­‐like	  receptors	  in	  the	  induction	  of	  the	  
innate	  immune	  response.	  Nature,	  2000.	  406(6797):	  p.	  782-­‐7.	  
	   243	  
91.	   Alexopoulou,	  L.,	  et	  al.,	  Recognition	  of	  double-­‐stranded	  RNA	  and	  activation	  
of	  NF-­‐kappaB	  by	  Toll-­‐like	  receptor	  3.	  Nature,	  2001.	  413(6857):	  p.	  732-­‐8.	  92.	   Creagh,	  E.M.	  and	  L.A.	  O'Neill,	  TLRs,	  NLRs	  and	  RLRs:	  a	  trinity	  of	  pathogen	  
sensors	  that	  co-­‐operate	  in	  innate	  immunity.	  Trends	  Immunol,	  2006.	  27(8):	  p.	  352-­‐7.	  93.	   Cinel,	  I.	  and	  S.M.	  Opal,	  Molecular	  biology	  of	  inflammation	  and	  sepsis:	  a	  
primer.	  Crit	  Care	  Med,	  2009.	  37(1):	  p.	  291-­‐304.	  94.	   Johnson,	  G.B.,	  G.J.	  Brunn,	  and	  J.L.	  Platt,	  Activation	  of	  mammalian	  Toll-­‐like	  
receptors	  by	  endogenous	  agonists.	  Crit	  Rev	  Immunol,	  2003.	  23(1-­‐2):	  p.	  15-­‐44.	  95.	   Ulloa,	  L.	  and	  K.J.	  Tracey,	  The	  "cytokine	  profile":	  a	  code	  for	  sepsis.	  Trends	  Mol	  Med,	  2005.	  11(2):	  p.	  56-­‐63.	  96.	   Johnson,	  G.B.,	  G.J.	  Brunn,	  and	  J.L.	  Platt,	  Cutting	  edge:	  an	  endogenous	  
pathway	  to	  systemic	  inflammatory	  response	  syndrome	  (SIRS)-­‐like	  reactions	  
through	  Toll-­‐like	  receptor	  4.	  J	  Immunol,	  2004.	  172(1):	  p.	  20-­‐4.	  97.	   Pahl,	  H.L.,	  Activators	  and	  target	  genes	  of	  Rel/NF-­‐kappaB	  transcription	  
factors.	  Oncogene,	  1999.	  18(49):	  p.	  6853-­‐66.	  98.	   Finkel,	  T.,	  Signal	  transduction	  by	  reactive	  oxygen	  species.	  J	  Cell	  Biol,	  2011.	  
194(1):	  p.	  7-­‐15.	  99.	   Brown,	  D.I.	  and	  K.K.	  Griendling,	  Nox	  proteins	  in	  signal	  transduction.	  Free	  Radic	  Biol	  Med,	  2009.	  47(9):	  p.	  1239-­‐53.	  100.	   Aguirre,	  J.	  and	  J.D.	  Lambeth,	  Nox	  enzymes	  from	  fungus	  to	  fly	  to	  fish	  and	  
what	  they	  tell	  us	  about	  Nox	  function	  in	  mammals.	  Free	  Radic	  Biol	  Med,	  2010.	  49(9):	  p.	  1342-­‐53.	  101.	   Giorgio,	  M.,	  et	  al.,	  Electron	  transfer	  between	  cytochrome	  c	  and	  p66Shc	  
generates	  reactive	  oxygen	  species	  that	  trigger	  mitochondrial	  apoptosis.	  Cell,	  2005.	  122(2):	  p.	  221-­‐33.	  102.	   Hsu,	  H.Y.	  and	  M.H.	  Wen,	  Lipopolysaccharide-­‐mediated	  reactive	  oxygen	  
species	  and	  signal	  transduction	  in	  the	  regulation	  of	  interleukin-­‐1	  gene	  
expression.	  J	  Biol	  Chem,	  2002.	  277(25):	  p.	  22131-­‐9.	  103.	   Bae,	  Y.S.,	  et	  al.,	  Epidermal	  growth	  factor	  (EGF)-­‐induced	  generation	  of	  
hydrogen	  peroxide.	  Role	  in	  EGF	  receptor-­‐mediated	  tyrosine	  
phosphorylation.	  J	  Biol	  Chem,	  1997.	  272(1):	  p.	  217-­‐21.	  104.	   Lee,	  S.R.,	  et	  al.,	  Reversible	  inactivation	  of	  protein-­‐tyrosine	  phosphatase	  1B	  
in	  A431	  cells	  stimulated	  with	  epidermal	  growth	  factor.	  J	  Biol	  Chem,	  1998.	  
273(25):	  p.	  15366-­‐72.	  105.	   Salmeen,	  A.,	  et	  al.,	  Redox	  regulation	  of	  protein	  tyrosine	  phosphatase	  1B	  
involves	  a	  sulphenyl-­‐amide	  intermediate.	  Nature,	  2003.	  423(6941):	  p.	  769-­‐73.	  106.	   Matsuzawa,	  A.,	  et	  al.,	  ROS-­‐dependent	  activation	  of	  the	  TRAF6-­‐ASK1-­‐p38	  
pathway	  is	  selectively	  required	  for	  TLR4-­‐mediated	  innate	  immunity.	  Nat	  Immunol,	  2005.	  6(6):	  p.	  587-­‐92.	  107.	   McCubrey,	  J.A.,	  M.M.	  Lahair,	  and	  R.A.	  Franklin,	  Reactive	  oxygen	  species-­‐
induced	  activation	  of	  the	  MAP	  kinase	  signaling	  pathways.	  Antioxid	  Redox	  Signal,	  2006.	  8(9-­‐10):	  p.	  1775-­‐89.	  108.	   Tobiume,	  K.,	  M.	  Saitoh,	  and	  H.	  Ichijo,	  Activation	  of	  apoptosis	  signal-­‐
regulating	  kinase	  1	  by	  the	  stress-­‐induced	  activating	  phosphorylation	  of	  pre-­‐
formed	  oligomer.	  J	  Cell	  Physiol,	  2002.	  191(1):	  p.	  95-­‐104.	  
	   244	  
109.	   Saitoh,	  M.,	  et	  al.,	  Mammalian	  thioredoxin	  is	  a	  direct	  inhibitor	  of	  apoptosis	  
signal-­‐regulating	  kinase	  (ASK)	  1.	  EMBO	  J,	  1998.	  17(9):	  p.	  2596-­‐606.	  110.	   Schreck,	  R.,	  P.	  Rieber,	  and	  P.A.	  Baeuerle,	  Reactive	  oxygen	  intermediates	  as	  
apparently	  widely	  used	  messengers	  in	  the	  activation	  of	  the	  NF-­‐kappa	  B	  
transcription	  factor	  and	  HIV-­‐1.	  EMBO	  J,	  1991.	  10(8):	  p.	  2247-­‐58.	  111.	   Ushio-­‐Fukai,	  M.	  and	  R.W.	  Alexander,	  Reactive	  oxygen	  species	  as	  mediators	  
of	  angiogenesis	  signaling:	  role	  of	  NAD(P)H	  oxidase.	  Mol	  Cell	  Biochem,	  2004.	  264(1-­‐2):	  p.	  85-­‐97.	  112.	   Forstermann,	  U.,	  et	  al.,	  Isoforms	  of	  nitric	  oxide	  synthase.	  Properties,	  cellular	  
distribution	  and	  expressional	  control.	  Biochemical	  pharmacology,	  1995.	  
50(9):	  p.	  1321-­‐32.	  113.	   Woo,	  H.A.,	  et	  al.,	  Inactivation	  of	  peroxiredoxin	  I	  by	  phosphorylation	  allows	  
localized	  H(2)O(2)	  accumulation	  for	  cell	  signaling.	  Cell,	  2010.	  140(4):	  p.	  517-­‐28.	  114.	   Niethammer,	  P.,	  et	  al.,	  A	  tissue-­‐scale	  gradient	  of	  hydrogen	  peroxide	  
mediates	  rapid	  wound	  detection	  in	  zebrafish.	  Nature,	  2009.	  459(7249):	  p.	  996-­‐9.	  115.	   Bienert,	  G.P.,	  et	  al.,	  Specific	  aquaporins	  facilitate	  the	  diffusion	  of	  hydrogen	  
peroxide	  across	  membranes.	  J	  Biol	  Chem,	  2007.	  282(2):	  p.	  1183-­‐92.	  116.	   Miller,	  E.W.,	  B.C.	  Dickinson,	  and	  C.J.	  Chang,	  Aquaporin-­‐3	  mediates	  
hydrogen	  peroxide	  uptake	  to	  regulate	  downstream	  intracellular	  signaling.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2010.	  107(36):	  p.	  15681-­‐6.	  117.	   Cargnello,	  M.	  and	  P.P.	  Roux,	  Activation	  and	  function	  of	  the	  MAPKs	  and	  their	  
substrates,	  the	  MAPK-­‐activated	  protein	  kinases.	  Microbiol	  Mol	  Biol	  Rev,	  2011.	  75(1):	  p.	  50-­‐83.	  118.	   Robbins,	  D.J.,	  et	  al.,	  Regulation	  and	  properties	  of	  extracellular	  signal-­‐
regulated	  protein	  kinases	  1	  and	  2	  in	  vitro.	  J	  Biol	  Chem,	  1993.	  268(7):	  p.	  5097-­‐106.	  119.	   Gaestel,	  M.,	  Specificity	  of	  signaling	  from	  MAPKs	  to	  MAPKAPKs:	  kinases'	  
tango	  nuevo.	  Front	  Biosci,	  2008.	  13:	  p.	  6050-­‐9.	  120.	   Roux,	  P.P.	  and	  J.	  Blenis,	  ERK	  and	  p38	  MAPK-­‐activated	  protein	  kinases:	  a	  
family	  of	  protein	  kinases	  with	  diverse	  biological	  functions.	  Microbiol	  Mol	  Biol	  Rev,	  2004.	  68(2):	  p.	  320-­‐44.	  121.	   Carriere,	  A.,	  et	  al.,	  The	  RSK	  factors	  of	  activating	  the	  Ras/MAPK	  signaling	  
cascade.	  Front	  Biosci,	  2008.	  13:	  p.	  4258-­‐75.	  122.	   Asp,	  E.	  and	  P.	  Sunnerhagen,	  Mkp1	  and	  Mkp2,	  two	  MAPKAP-­‐kinase	  
homologues	  in	  Schizosaccharomyces	  pombe,	  interact	  with	  the	  MAP	  kinase	  
Sty1.	  Mol	  Genet	  Genomics,	  2003.	  268(5):	  p.	  585-­‐97.	  123.	   Buxade,	  M.,	  J.L.	  Parra-­‐Palau,	  and	  C.G.	  Proud,	  The	  Mnks:	  MAP	  kinase-­‐
interacting	  kinases	  (MAP	  kinase	  signal-­‐integrating	  kinases).	  Front	  Biosci,	  2008.	  13:	  p.	  5359-­‐73.	  124.	   Ronkina,	  N.,	  A.	  Kotlyarov,	  and	  M.	  Gaestel,	  MK2	  and	  MK3-­‐-­‐a	  pair	  of	  
isoenzymes?	  Front	  Biosci,	  2008.	  13:	  p.	  5511-­‐21.	  125.	   Cuenda,	  A.,	  et	  al.,	  Activation	  of	  stress-­‐activated	  protein	  kinase-­‐3	  (SAPK3)	  by	  
cytokines	  and	  cellular	  stresses	  is	  mediated	  via	  SAPKK3	  (MKK6);	  comparison	  
of	  the	  specificities	  of	  SAPK3	  and	  SAPK2	  (RK/p38).	  EMBO	  J,	  1997.	  16(2):	  p.	  295-­‐305.	  
	   245	  
126.	   Klotz,	  L.O.,	  et	  al.,	  Mitogen-­‐activated	  protein	  kinase	  (p38-­‐,	  JNK-­‐,	  ERK-­‐)	  
activation	  pattern	  induced	  by	  extracellular	  and	  intracellular	  singlet	  oxygen	  
and	  UVA.	  Eur	  J	  Biochem,	  1999.	  260(3):	  p.	  917-­‐22.	  127.	   Guyton,	  K.Z.,	  et	  al.,	  Activation	  of	  mitogen-­‐activated	  protein	  kinase	  by	  H2O2.	  
Role	  in	  cell	  survival	  following	  oxidant	  injury.	  J	  Biol	  Chem,	  1996.	  271(8):	  p.	  4138-­‐42.	  128.	   Lander,	  H.M.,	  et	  al.,	  Redox	  regulation	  of	  cell	  signalling.	  Nature,	  1996.	  
381(6581):	  p.	  380-­‐1.	  129.	   Schieke,	  S.M.,	  et	  al.,	  Activation	  pattern	  of	  mitogen-­‐activated	  protein	  kinases	  
elicited	  by	  peroxynitrite:	  attenuation	  by	  selenite	  supplementation.	  FEBS	  Lett,	  1999.	  448(2-­‐3):	  p.	  301-­‐3.	  130.	   Han,	  J.,	  et	  al.,	  A	  MAP	  kinase	  targeted	  by	  endotoxin	  and	  hyperosmolarity	  in	  
mammalian	  cells.	  Science,	  1994.	  265(5173):	  p.	  808-­‐11.	  131.	   Rouse,	  J.,	  et	  al.,	  A	  novel	  kinase	  cascade	  triggered	  by	  stress	  and	  heat	  shock	  
that	  stimulates	  MAPKAP	  kinase-­‐2	  and	  phosphorylation	  of	  the	  small	  heat	  
shock	  proteins.	  Cell,	  1994.	  78(6):	  p.	  1027-­‐37.	  132.	   Freshney,	  N.W.,	  et	  al.,	  Interleukin-­‐1	  activates	  a	  novel	  protein	  kinase	  cascade	  
that	  results	  in	  the	  phosphorylation	  of	  Hsp27.	  Cell,	  1994.	  78(6):	  p.	  1039-­‐49.	  133.	   Scott,	  A.J.,	  et	  al.,	  Reactive	  oxygen	  species	  and	  p38	  MAPK	  mediate	  TNF-­‐alpha	  
converting	  enzyme	  (TACE/ADAM17)	  activation	  in	  primary	  human	  
monocytes.	  The	  Journal	  of	  biological	  chemistry,	  2011.	  134.	   Keyse,	  S.M.,	  Protein	  phosphatases	  and	  the	  regulation	  of	  mitogen-­‐activated	  
protein	  kinase	  signalling.	  Curr	  Opin	  Cell	  Biol,	  2000.	  12(2):	  p.	  186-­‐92.	  135.	   Lee,	  J.C.,	  et	  al.,	  A	  protein	  kinase	  involved	  in	  the	  regulation	  of	  inflammatory	  
cytokine	  biosynthesis.	  Nature,	  1994.	  372(6508):	  p.	  739-­‐46.	  136.	   Shapiro,	  L.	  and	  C.A.	  Dinarello,	  Osmotic	  regulation	  of	  cytokine	  synthesis	  in	  
vitro.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  1995.	  92(26):	  p.	  12230-­‐4.	  137.	   Beyaert,	  R.,	  et	  al.,	  The	  p38/RK	  mitogen-­‐activated	  protein	  kinase	  pathway	  
regulates	  interleukin-­‐6	  synthesis	  response	  to	  tumor	  necrosis	  factor.	  EMBO	  J,	  1996.	  15(8):	  p.	  1914-­‐23.	  138.	   Berenson,	  L.S.,	  et	  al.,	  Selective	  requirement	  of	  p38alpha	  MAPK	  in	  cytokine-­‐
dependent,	  but	  not	  antigen	  receptor-­‐dependent,	  Th1	  responses.	  J	  Immunol,	  2006.	  176(8):	  p.	  4616-­‐21.	  139.	   Gaestel,	  M.,	  MAPKAP	  kinases	  -­‐	  MKs	  -­‐	  two's	  company,	  three's	  a	  crowd.	  Nature	  reviews.	  Molecular	  cell	  biology,	  2006.	  7(2):	  p.	  120-­‐30.	  140.	   Gordon,	  S.	  and	  P.R.	  Taylor,	  Monocyte	  and	  macrophage	  heterogeneity.	  Nat	  Rev	  Immunol,	  2005.	  5(12):	  p.	  953-­‐64.	  141.	   Gordon,	  S.,	  Biology	  of	  the	  macrophage.	  J	  Cell	  Sci	  Suppl,	  1986.	  4:	  p.	  267-­‐86.	  142.	   Gordon,	  S.,	  The	  role	  of	  the	  macrophage	  in	  immune	  regulation.	  Res	  Immunol,	  1998.	  149(7-­‐8):	  p.	  685-­‐8.	  143.	   Riedemann,	  N.C.,	  R.F.	  Guo,	  and	  P.A.	  Ward,	  Novel	  strategies	  for	  the	  
treatment	  of	  sepsis.	  Nat	  Med,	  2003.	  9(5):	  p.	  517-­‐24.	  144.	   Soehnlein,	  O.	  and	  L.	  Lindbom,	  Phagocyte	  partnership	  during	  the	  onset	  and	  
resolution	  of	  inflammation.	  Nat	  Rev	  Immunol,	  2010.	  10(6):	  p.	  427-­‐39.	  145.	   Zhao,	  Q.,	  et	  al.,	  MAP	  kinase	  phosphatase	  1	  controls	  innate	  immune	  
responses	  and	  suppresses	  endotoxic	  shock.	  J	  Exp	  Med,	  2006.	  203(1):	  p.	  131-­‐40.	  146.	   Zanotti,	  S.,	  A.	  Kumar,	  and	  A.	  Kumar,	  Cytokine	  modulation	  in	  sepsis	  and	  
septic	  shock.	  Expert	  Opin	  Investig	  Drugs,	  2002.	  11(8):	  p.	  1061-­‐75.	  
	   246	  
147.	   Michie,	  H.R.,	  et	  al.,	  Detection	  of	  circulating	  tumor	  necrosis	  factor	  after	  
endotoxin	  administration.	  N	  Engl	  J	  Med,	  1988.	  318(23):	  p.	  1481-­‐6.	  148.	   Hesse,	  D.G.,	  et	  al.,	  Cytokine	  appearance	  in	  human	  endotoxemia	  and	  primate	  
bacteremia.	  Surg	  Gynecol	  Obstet,	  1988.	  166(2):	  p.	  147-­‐53.	  149.	   Michie,	  H.R.,	  et	  al.,	  Tumor	  necrosis	  factor	  and	  endotoxin	  induce	  similar	  
metabolic	  responses	  in	  human	  beings.	  Surgery,	  1988.	  104(2):	  p.	  280-­‐6.	  150.	   Navarro-­‐Sarabia,	  F.,	  et	  al.,	  Adalimumab	  for	  treating	  rheumatoid	  arthritis.	  J	  Rheumatol,	  2006.	  33(6):	  p.	  1075-­‐81.	  151.	   Lawson,	  M.M.,	  A.G.	  Thomas,	  and	  A.K.	  Akobeng,	  Tumour	  necrosis	  factor	  
alpha	  blocking	  agents	  for	  induction	  of	  remission	  in	  ulcerative	  colitis.	  Cochrane	  Database	  Syst	  Rev,	  2006.	  3:	  p.	  CD005112.	  152.	   Dinarello,	  C.A.,	  Biology	  of	  interleukin	  1.	  FASEB	  J,	  1988.	  2(2):	  p.	  108-­‐15.	  153.	   Last-­‐Barney,	  K.,	  et	  al.,	  Synergistic	  and	  overlapping	  activities	  of	  tumor	  
necrosis	  factor-­‐alpha	  and	  IL-­‐1.	  J	  Immunol,	  1988.	  141(2):	  p.	  527-­‐30.	  154.	   Docke,	  W.D.,	  et	  al.,	  Monocyte	  deactivation	  in	  septic	  patients:	  restoration	  by	  
IFN-­‐gamma	  treatment.	  Nat	  Med,	  1997.	  3(6):	  p.	  678-­‐81.	  155.	   Moore,	  K.W.,	  et	  al.,	  Interleukin-­‐10.	  Annu	  Rev	  Immunol,	  1993.	  11:	  p.	  165-­‐90.	  156.	   Bogdan,	  C.	  and	  C.	  Nathan,	  Modulation	  of	  macrophage	  function	  by	  
transforming	  growth	  factor	  beta,	  interleukin-­‐4,	  and	  interleukin-­‐10.	  Ann	  N	  Y	  Acad	  Sci,	  1993.	  685:	  p.	  713-­‐39.	  157.	   Turner,	  M.,	  et	  al.,	  Induction	  of	  the	  interleukin	  1	  receptor	  antagonist	  protein	  
by	  transforming	  growth	  factor-­‐beta.	  Eur	  J	  Immunol,	  1991.	  21(7):	  p.	  1635-­‐9.	  158.	   Peschon,	  J.J.,	  et	  al.,	  An	  essential	  role	  for	  ectodomain	  shedding	  in	  mammalian	  
development.	  Science,	  1998.	  282(5392):	  p.	  1281-­‐4.	  159.	   Hooper,	  N.M.,	  E.H.	  Karran,	  and	  A.J.	  Turner,	  Membrane	  protein	  secretases.	  Biochem	  J,	  1997.	  321	  (	  Pt	  2):	  p.	  265-­‐79.	  160.	   Kiessling,	  L.L.	  and	  E.J.	  Gordon,	  Transforming	  the	  cell	  surface	  through	  
proteolysis.	  Chem	  Biol,	  1998.	  5(3):	  p.	  R49-­‐62.	  161.	   Hehlgans,	  T.	  and	  D.N.	  Mannel,	  The	  TNF-­‐TNF	  receptor	  system.	  Biol	  Chem,	  2002.	  383(10):	  p.	  1581-­‐5.	  162.	   Aderka,	  D.,	  The	  potential	  biological	  and	  clinical	  significance	  of	  the	  soluble	  
tumor	  necrosis	  factor	  receptors.	  Cytokine	  Growth	  Factor	  Rev,	  1996.	  7(3):	  p.	  231-­‐40.	  163.	   Aderka,	  D.,	  et	  al.,	  Shedding	  kinetics	  of	  soluble	  tumor	  necrosis	  factor	  (TNF)	  
receptors	  after	  systemic	  TNF	  leaking	  during	  isolated	  limb	  perfusion.	  
Relevance	  to	  the	  pathophysiology	  of	  septic	  shock.	  J	  Clin	  Invest,	  1998.	  
101(3):	  p.	  650-­‐9.	  164.	   Feterowski,	  C.,	  et	  al.,	  CC	  chemokine	  receptor	  2	  regulates	  leukocyte	  
recruitment	  and	  IL-­‐10	  production	  during	  acute	  polymicrobial	  sepsis.	  Eur	  J	  Immunol,	  2004.	  34(12):	  p.	  3664-­‐73.	  165.	   Chishti,	  A.D.,	  et	  al.,	  Neutrophil	  chemotaxis	  and	  receptor	  expression	  in	  
clinical	  septic	  shock.	  Intensive	  Care	  Med,	  2004.	  30(4):	  p.	  605-­‐11.	  166.	   Ness,	  T.L.,	  et	  al.,	  Immunomodulatory	  role	  of	  CXCR2	  during	  experimental	  
septic	  peritonitis.	  J	  Immunol,	  2003.	  171(7):	  p.	  3775-­‐84.	  167.	   Ricciotti,	  E.	  and	  G.A.	  FitzGerald,	  Prostaglandins	  and	  inflammation.	  Arterioscler	  Thromb	  Vasc	  Biol,	  2011.	  31(5):	  p.	  986-­‐1000.	  
	   247	  
168.	   Kabashima,	  K.	  and	  S.	  Narumiya,	  The	  DP	  receptor,	  allergic	  inflammation	  
and	  asthma.	  Prostaglandins	  Leukot	  Essent	  Fatty	  Acids,	  2003.	  69(2-­‐3):	  p.	  187-­‐94.	  169.	   Funk,	  C.D.,	  Prostaglandins	  and	  leukotrienes:	  advances	  in	  eicosanoid	  biology.	  Science,	  2001.	  294(5548):	  p.	  1871-­‐5.	  170.	   Oga,	  T.,	  et	  al.,	  Prostaglandin	  F(2alpha)	  receptor	  signaling	  facilitates	  
bleomycin-­‐induced	  pulmonary	  fibrosis	  independently	  of	  transforming	  
growth	  factor-­‐beta.	  Nat	  Med,	  2009.	  15(12):	  p.	  1426-­‐30.	  171.	   Noda,	  M.,	  et	  al.,	  Neuroprotective	  role	  of	  bradykinin	  because	  of	  the	  
attenuation	  of	  pro-­‐inflammatory	  cytokine	  release	  from	  activated	  microglia.	  J	  Neurochem,	  2007.	  101(2):	  p.	  397-­‐410.	  172.	   Nakahata,	  N.,	  Thromboxane	  A2:	  physiology/pathophysiology,	  cellular	  signal	  
transduction	  and	  pharmacology.	  Pharmacol	  Ther,	  2008.	  118(1):	  p.	  18-­‐35.	  173.	   Hinshaw,	  L.B.,	  et	  al.,	  Effects	  of	  acetylsalicylic	  acid	  on	  the	  canine	  response	  to	  
endotoxin.	  J	  Pharmacol	  Exp	  Ther,	  1967.	  157(3):	  p.	  665-­‐71.	  174.	   Northover,	  B.J.	  and	  G.	  Subramanian,	  Analgesic-­‐antipyretic	  drugs	  as	  
antagonists	  of	  endotoxin	  shock	  in	  dogs.	  J	  Pathol	  Bacteriol,	  1962.	  83:	  p.	  463-­‐8.	  175.	   Hauser,	  B.,	  et	  al.,	  Nitric	  oxide	  synthase	  inhibition	  in	  sepsis?	  Lessons	  learned	  
from	  large-­‐animal	  studies.	  Anesth	  Analg,	  2005.	  101(2):	  p.	  488-­‐98.	  176.	   Hauser,	  W.,	  et	  al.,	  Expression	  of	  nitric	  oxide	  synthase	  isoforms	  in	  
hypothalamo-­‐pituitary-­‐adrenal	  axis	  during	  the	  development	  of	  spontaneous	  
hypertension	  in	  rats.	  Brain	  Res	  Mol	  Brain	  Res,	  2005.	  138(2):	  p.	  198-­‐204.	  177.	   Kilbourn,	  R.G.,	  C.	  Szabo,	  and	  D.L.	  Traber,	  Beneficial	  versus	  detrimental	  
effects	  of	  nitric	  oxide	  synthase	  inhibitors	  in	  circulatory	  shock:	  lessons	  
learned	  from	  experimental	  and	  clinical	  studies.	  Shock,	  1997.	  7(4):	  p.	  235-­‐46.	  178.	   Belcher,	  E.,	  J.	  Mitchell,	  and	  T.	  Evans,	  Myocardial	  dysfunction	  in	  sepsis:	  no	  
role	  for	  NO?	  Heart,	  2002.	  87(6):	  p.	  507-­‐9.	  179.	   Lopez,	  A.,	  et	  al.,	  Multiple-­‐center,	  randomized,	  placebo-­‐controlled,	  double-­‐
blind	  study	  of	  the	  nitric	  oxide	  synthase	  inhibitor	  546C88:	  effect	  on	  survival	  
in	  patients	  with	  septic	  shock.	  Crit	  Care	  Med,	  2004.	  32(1):	  p.	  21-­‐30.	  180.	   Ley,	  K.,	  et	  al.,	  Getting	  to	  the	  site	  of	  inflammation:	  the	  leukocyte	  adhesion	  
cascade	  updated.	  Nat	  Rev	  Immunol,	  2007.	  7(9):	  p.	  678-­‐89.	  181.	   Kansas,	  G.S.,	  Selectins	  and	  their	  ligands:	  current	  concepts	  and	  controversies.	  Blood,	  1996.	  88(9):	  p.	  3259-­‐87.	  182.	   McEver,	  R.P.	  and	  R.D.	  Cummings,	  Role	  of	  PSGL-­‐1	  binding	  to	  selectins	  in	  
leukocyte	  recruitment.	  J	  Clin	  Invest,	  1997.	  100(11	  Suppl):	  p.	  S97-­‐103.	  183.	   Yoshida,	  M.,	  et	  al.,	  Leukocyte	  adhesion	  to	  vascular	  endothelium	  induces	  E-­‐
selectin	  linkage	  to	  the	  actin	  cytoskeleton.	  J	  Cell	  Biol,	  1996.	  133(2):	  p.	  445-­‐55.	  184.	   Abbal,	  C.,	  et	  al.,	  Lipid	  raft	  adhesion	  receptors	  and	  Syk	  regulate	  selectin-­‐
dependent	  rolling	  under	  flow	  conditions.	  Blood,	  2006.	  108(10):	  p.	  3352-­‐9.	  185.	   Simon,	  S.I.,	  et	  al.,	  Neutrophil	  tethering	  on	  E-­‐selectin	  activates	  beta	  2	  
integrin	  binding	  to	  ICAM-­‐1	  through	  a	  mitogen-­‐activated	  protein	  kinase	  
signal	  transduction	  pathway.	  J	  Immunol,	  2000.	  164(8):	  p.	  4348-­‐58.	  186.	   Campbell,	  J.J.,	  et	  al.,	  Biology	  of	  chemokine	  and	  classical	  chemoattractant	  
receptors:	  differential	  requirements	  for	  adhesion-­‐triggering	  versus	  
	   248	  
chemotactic	  responses	  in	  lymphoid	  cells.	  J	  Cell	  Biol,	  1996.	  134(1):	  p.	  255-­‐66.	  187.	   Campbell,	  J.J.,	  et	  al.,	  Chemokines	  and	  the	  arrest	  of	  lymphocytes	  rolling	  under	  
flow	  conditions.	  Science,	  1998.	  279(5349):	  p.	  381-­‐4.	  188.	   Middleton,	  J.,	  et	  al.,	  Transcytosis	  and	  surface	  presentation	  of	  IL-­‐8	  by	  venular	  
endothelial	  cells.	  Cell,	  1997.	  91(3):	  p.	  385-­‐95.	  189.	   von	  Hundelshausen,	  P.,	  et	  al.,	  RANTES	  deposition	  by	  platelets	  triggers	  
monocyte	  arrest	  on	  inflamed	  and	  atherosclerotic	  endothelium.	  Circulation,	  2001.	  103(13):	  p.	  1772-­‐7.	  190.	   Huo,	  Y.,	  et	  al.,	  Circulating	  activated	  platelets	  exacerbate	  atherosclerosis	  in	  
mice	  deficient	  in	  apolipoprotein	  E.	  Nat	  Med,	  2003.	  9(1):	  p.	  61-­‐7.	  191.	   Shamri,	  R.,	  et	  al.,	  Lymphocyte	  arrest	  requires	  instantaneous	  induction	  of	  an	  
extended	  LFA-­‐1	  conformation	  mediated	  by	  endothelium-­‐bound	  chemokines.	  Nat	  Immunol,	  2005.	  6(5):	  p.	  497-­‐506.	  192.	   Arnaout,	  M.A.,	  B.	  Mahalingam,	  and	  J.P.	  Xiong,	  Integrin	  structure,	  allostery,	  
and	  bidirectional	  signaling.	  Annu	  Rev	  Cell	  Dev	  Biol,	  2005.	  21:	  p.	  381-­‐410.	  193.	   Kreisel,	  D.,	  et	  al.,	  In	  vivo	  two-­‐photon	  imaging	  reveals	  monocyte-­‐dependent	  
neutrophil	  extravasation	  during	  pulmonary	  inflammation.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2010.	  107(42):	  p.	  18073-­‐8.	  194.	   Holman,	  J.M.,	  Jr.	  and	  T.M.	  Saba,	  Hepatocyte	  injury	  during	  post-­‐operative	  
sepsis:	  activated	  neutrophils	  as	  potential	  mediators.	  J	  Leukoc	  Biol,	  1988.	  
43(3):	  p.	  193-­‐203.	  195.	   Astiz,	  M.E.,	  et	  al.,	  Microvascular	  function	  and	  rheologic	  changes	  in	  
hyperdynamic	  sepsis.	  Crit	  Care	  Med,	  1995.	  23(2):	  p.	  265-­‐71.	  196.	   Bainton,	  D.F.,	  J.L.	  Ullyot,	  and	  M.G.	  Farquhar,	  The	  development	  of	  
neutrophilic	  polymorphonuclear	  leukocytes	  in	  human	  bone	  marrow.	  J	  Exp	  Med,	  1971.	  134(4):	  p.	  907-­‐34.	  197.	   Weingarten,	  R.,	  et	  al.,	  Interactions	  of	  lipopolysaccharide	  with	  neutrophils	  in	  
blood	  via	  CD14.	  J	  Leukoc	  Biol,	  1993.	  53(5):	  p.	  518-­‐24.	  198.	   Wright,	  S.D.,	  et	  al.,	  Activation	  of	  the	  adhesive	  capacity	  of	  CR3	  on	  neutrophils	  
by	  endotoxin:	  dependence	  on	  lipopolysaccharide	  binding	  protein	  and	  CD14.	  J	  Exp	  Med,	  1991.	  173(5):	  p.	  1281-­‐6.	  199.	   Akira,	  S.	  and	  K.	  Takeda,	  Toll-­‐like	  receptor	  signalling.	  Nat	  Rev	  Immunol,	  2004.	  4(7):	  p.	  499-­‐511.	  200.	   Sarma,	  J.V.	  and	  P.A.	  Ward,	  The	  complement	  system.	  Cell	  Tissue	  Res,	  2011.	  
343(1):	  p.	  227-­‐35.	  201.	   Babior,	  B.M.,	  NADPH	  oxidase.	  Curr	  Opin	  Immunol,	  2004.	  16(1):	  p.	  42-­‐7.	  202.	   Babior,	  B.M.,	  The	  leukocyte	  NADPH	  oxidase.	  Isr	  Med	  Assoc	  J,	  2002.	  4(11):	  p.	  1023-­‐4.	  203.	   Babior,	  B.M.,	  J.D.	  Lambeth,	  and	  W.	  Nauseef,	  The	  neutrophil	  NADPH	  oxidase.	  Arch	  Biochem	  Biophys,	  2002.	  397(2):	  p.	  342-­‐4.	  204.	   Coxon,	  A.,	  et	  al.,	  A	  novel	  role	  for	  the	  beta	  2	  integrin	  CD11b/CD18	  in	  
neutrophil	  apoptosis:	  a	  homeostatic	  mechanism	  in	  inflammation.	  Immunity,	  1996.	  5(6):	  p.	  653-­‐66.	  205.	   Gamberale,	  R.,	  et	  al.,	  Modulation	  of	  human	  neutrophil	  apoptosis	  by	  immune	  
complexes.	  J	  Immunol,	  1998.	  161(7):	  p.	  3666-­‐74.	  206.	   Colotta,	  F.,	  et	  al.,	  Modulation	  of	  granulocyte	  survival	  and	  programmed	  cell	  
death	  by	  cytokines	  and	  bacterial	  products.	  Blood,	  1992.	  80(8):	  p.	  2012-­‐20.	  
	   249	  
207.	   DeLeo,	  F.R.,	  Modulation	  of	  phagocyte	  apoptosis	  by	  bacterial	  pathogens.	  Apoptosis,	  2004.	  9(4):	  p.	  399-­‐413.	  208.	   Kobayashi,	  S.D.,	  et	  al.,	  Neutrophils	  in	  the	  innate	  immune	  response.	  Archivum	  immunologiae	  et	  therapiae	  experimentalis,	  2005.	  53(6):	  p.	  505-­‐17.	  209.	   Soehnlein,	  O.,	  A.	  Zernecke,	  and	  C.	  Weber,	  Neutrophils	  launch	  monocyte	  
extravasation	  by	  release	  of	  granule	  proteins.	  Thromb	  Haemost,	  2009.	  
102(2):	  p.	  198-­‐205.	  210.	   Soehnlein,	  O.,	  L.	  Lindbom,	  and	  C.	  Weber,	  Mechanisms	  underlying	  
neutrophil-­‐mediated	  monocyte	  recruitment.	  Blood,	  2009.	  114(21):	  p.	  4613-­‐23.	  211.	   Berahovich,	  R.D.,	  et	  al.,	  Proteolytic	  activation	  of	  alternative	  CCR1	  ligands	  in	  
inflammation.	  J	  Immunol,	  2005.	  174(11):	  p.	  7341-­‐51.	  212.	   Borregaard,	  N.,	  O.E.	  Sorensen,	  and	  K.	  Theilgaard-­‐Monch,	  Neutrophil	  
granules:	  a	  library	  of	  innate	  immunity	  proteins.	  Trends	  Immunol,	  2007.	  
28(8):	  p.	  340-­‐5.	  213.	   Marshall,	  J.C.,	  The	  pathogenesis	  and	  molecular	  biology	  of	  sepsis.	  Crit	  Care	  Resusc,	  2006.	  8(3):	  p.	  227-­‐9.	  214.	   Chua,	  F.	  and	  G.J.	  Laurent,	  Neutrophil	  elastase:	  mediator	  of	  extracellular	  
matrix	  destruction	  and	  accumulation.	  Proc	  Am	  Thorac	  Soc,	  2006.	  3(5):	  p.	  424-­‐7.	  215.	   Janoff,	  A.,	  et	  al.,	  Experimental	  emphysema	  induced	  with	  purified	  human	  
neutrophil	  elastase:	  tissue	  localization	  of	  the	  instilled	  protease.	  Am	  Rev	  Respir	  Dis,	  1977.	  115(3):	  p.	  461-­‐78.	  216.	   Taooka,	  Y.,	  et	  al.,	  Effects	  of	  neutrophil	  elastase	  inhibitor	  on	  bleomycin-­‐
induced	  pulmonary	  fibrosis	  in	  mice.	  Am	  J	  Respir	  Crit	  Care	  Med,	  1997.	  
156(1):	  p.	  260-­‐5.	  217.	   Tamakuma,	  S.,	  et	  al.,	  Relationship	  between	  neutrophil	  elastase	  and	  acute	  
lung	  injury	  in	  humans.	  Pulm	  Pharmacol	  Ther,	  2004.	  17(5):	  p.	  271-­‐9.	  218.	   Johansson,	  J.,	  et	  al.,	  Neutrophil-­‐derived	  heparin	  binding	  protein-­‐-­‐a	  mediator	  
of	  increased	  vascular	  permeability	  after	  burns?	  Burns,	  2009.	  35(8):	  p.	  1185-­‐7.	  219.	   Auffray,	  C.,	  et	  al.,	  Monitoring	  of	  blood	  vessels	  and	  tissues	  by	  a	  population	  of	  
monocytes	  with	  patrolling	  behavior.	  Science,	  2007.	  317(5838):	  p.	  666-­‐70.	  220.	   Hume,	  D.A.,	  et	  al.,	  The	  mononuclear	  phagocyte	  system	  revisited.	  J	  Leukoc	  Biol,	  2002.	  72(4):	  p.	  621-­‐7.	  221.	   Gordon,	  S.,	  Alternative	  activation	  of	  macrophages.	  Nat	  Rev	  Immunol,	  2003.	  
3(1):	  p.	  23-­‐35.	  222.	   Stefater,	  J.A.,	  3rd,	  et	  al.,	  Metchnikoff's	  policemen:	  macrophages	  in	  
development,	  homeostasis	  and	  regeneration.	  Trends	  Mol	  Med,	  2011.	  
17(12):	  p.	  743-­‐52.	  223.	   Geng,	  Y.,	  et	  al.,	  Monocyte	  deactivation	  by	  interleukin	  10	  via	  inhibition	  of	  
tyrosine	  kinase	  activity	  and	  the	  Ras	  signaling	  pathway.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  1994.	  91(18):	  p.	  8602-­‐6.	  224.	   Volk,	  H.D.,	  et	  al.,	  Monocyte	  deactivation-­‐-­‐rationale	  for	  a	  new	  therapeutic	  
strategy	  in	  sepsis.	  Intensive	  care	  medicine,	  1996.	  22	  Suppl	  4:	  p.	  S474-­‐81.	  225.	   Cheron,	  A.,	  et	  al.,	  [Low	  monocytic	  HLA-­‐DR	  expression	  and	  risk	  of	  secondary	  
infection].	  Ann	  Fr	  Anesth	  Reanim,	  2010.	  29(5):	  p.	  368-­‐76.	  
	   250	  
226.	   Meisel,	  C.,	  et	  al.,	  Granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  to	  
reverse	  sepsis-­‐associated	  immunosuppression:	  a	  double-­‐blind,	  randomized,	  
placebo-­‐controlled	  multicenter	  trial.	  Am	  J	  Respir	  Crit	  Care	  Med,	  2009.	  
180(7):	  p.	  640-­‐8.	  227.	   Versteeg,	  H.H.,	  M.P.	  Peppelenbosch,	  and	  C.A.	  Spek,	  The	  pleiotropic	  effects	  
of	  tissue	  factor:	  a	  possible	  role	  for	  factor	  VIIa-­‐induced	  intracellular	  
signalling?	  Thromb	  Haemost,	  2001.	  86(6):	  p.	  1353-­‐9.	  228.	   Gando,	  S.,	  et	  al.,	  Significant	  correlations	  between	  tissue	  factor	  and	  thrombin	  
markers	  in	  trauma	  and	  septic	  patients	  with	  disseminated	  intravascular	  
coagulation.	  Thromb	  Haemost,	  1998.	  79(6):	  p.	  1111-­‐5.	  229.	   Vickers,	  J.,	  et	  al.,	  Monocyte	  tissue	  factor	  (CD142)	  and	  Mac-­‐1	  (CD11b)	  are	  
increased	  in	  septic	  patients.	  Thromb	  Haemost,	  1998.	  79(6):	  p.	  1219-­‐20.	  230.	   Russell,	  J.A.,	  Management	  of	  sepsis.	  N	  Engl	  J	  Med,	  2006.	  355(16):	  p.	  1699-­‐713.	  231.	   Raaphorst,	  J.,	  et	  al.,	  Early	  inhibition	  of	  activated	  fibrinolysis	  predicts	  
microbial	  infection,	  shock	  and	  mortality	  in	  febrile	  medical	  patients.	  Thromb	  Haemost,	  2001.	  86(2):	  p.	  543-­‐9.	  232.	   Esmon,	  C.T.,	  Structure	  and	  functions	  of	  the	  endothelial	  cell	  protein	  C	  
receptor.	  Crit	  Care	  Med,	  2004.	  32(5	  Suppl):	  p.	  S298-­‐301.	  233.	   Walker,	  F.J.,	  P.W.	  Sexton,	  and	  C.T.	  Esmon,	  The	  inhibition	  of	  blood	  
coagulation	  by	  activated	  Protein	  C	  through	  the	  selective	  inactivation	  of	  
activated	  Factor	  V.	  Biochim	  Biophys	  Acta,	  1979.	  571(2):	  p.	  333-­‐42.	  234.	   Fulcher,	  C.A.,	  et	  al.,	  Proteolytic	  inactivation	  of	  human	  factor	  VIII	  
procoagulant	  protein	  by	  activated	  human	  protein	  C	  and	  its	  analogy	  with	  
factor	  V.	  Blood,	  1984.	  63(2):	  p.	  486-­‐9.	  235.	   van	  Hinsbergh,	  V.W.,	  et	  al.,	  Activated	  protein	  C	  decreases	  plasminogen	  
activator-­‐inhibitor	  activity	  in	  endothelial	  cell-­‐conditioned	  medium.	  Blood,	  1985.	  65(2):	  p.	  444-­‐51.	  236.	   Joyce,	  D.E.,	  et	  al.,	  Gene	  expression	  profile	  of	  antithrombotic	  protein	  c	  defines	  
new	  mechanisms	  modulating	  inflammation	  and	  apoptosis.	  J	  Biol	  Chem,	  2001.	  276(14):	  p.	  11199-­‐203.	  237.	   Murakami,	  K.,	  et	  al.,	  Activated	  protein	  C	  prevents	  LPS-­‐induced	  pulmonary	  
vascular	  injury	  by	  inhibiting	  cytokine	  production.	  Am	  J	  Physiol,	  1997.	  
272(2	  Pt	  1):	  p.	  L197-­‐202.	  238.	   Riedemann,	  N.C.,	  R.F.	  Guo,	  and	  P.A.	  Ward,	  The	  enigma	  of	  sepsis.	  J	  Clin	  Invest,	  2003.	  112(4):	  p.	  460-­‐7.	  239.	   Shin,	  H.S.,	  et	  al.,	  Chemotactic	  and	  anaphylatoxic	  fragment	  cleaved	  from	  the	  
fifth	  component	  of	  guinea	  pig	  complement.	  Science,	  1968.	  162(3851):	  p.	  361-­‐3.	  240.	   Sacks,	  T.,	  et	  al.,	  Oxygen	  radicals	  mediate	  endothelial	  cell	  damage	  by	  
complement-­‐stimulated	  granulocytes.	  An	  in	  vitro	  model	  of	  immune	  vascular	  
damage.	  J	  Clin	  Invest,	  1978.	  61(5):	  p.	  1161-­‐7.	  241.	   Goldstein,	  I.M.	  and	  G.	  Weissmann,	  Generation	  of	  C5-­‐derived	  lysosomal	  
enzyme-­‐releasing	  activity	  (C5a)	  by	  lysates	  of	  leukocyte	  lysosomes.	  J	  Immunol,	  1974.	  113(5):	  p.	  1583-­‐8.	  242.	   Creasey,	  A.A.	  and	  K.	  Reinhart,	  Tissue	  factor	  pathway	  inhibitor	  activity	  in	  
severe	  sepsis.	  Crit	  Care	  Med,	  2001.	  29(7	  Suppl):	  p.	  S126-­‐9.	  243.	   Liaw,	  P.C.,	  et	  al.,	  Patients	  with	  severe	  sepsis	  vary	  markedly	  in	  their	  ability	  to	  
generate	  activated	  protein	  C.	  Blood,	  2004.	  104(13):	  p.	  3958-­‐64.	  
	   251	  
244.	   Lawson,	  C.A.,	  et	  al.,	  Monocytes	  and	  tissue	  factor	  promote	  thrombosis	  in	  a	  
murine	  model	  of	  oxygen	  deprivation.	  J	  Clin	  Invest,	  1997.	  99(7):	  p.	  1729-­‐38.	  245.	   Markiewski,	  M.M.,	  R.A.	  DeAngelis,	  and	  J.D.	  Lambris,	  Complexity	  of	  
complement	  activation	  in	  sepsis.	  J	  Cell	  Mol	  Med,	  2008.	  12(6A):	  p.	  2245-­‐54.	  246.	   Quezado,	  Z.M.,	  et	  al.,	  The	  third	  component	  of	  complement	  protects	  against	  
Escherichia	  coli	  endotoxin-­‐induced	  shock	  and	  multiple	  organ	  failure.	  J	  Exp	  Med,	  1994.	  179(2):	  p.	  569-­‐78.	  247.	   Wessels,	  M.R.,	  et	  al.,	  Studies	  of	  group	  B	  streptococcal	  infection	  in	  mice	  
deficient	  in	  complement	  component	  C3	  or	  C4	  demonstrate	  an	  essential	  role	  
for	  complement	  in	  both	  innate	  and	  acquired	  immunity.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  1995.	  92(25):	  p.	  11490-­‐4.	  248.	   Fischer,	  M.B.,	  et	  al.,	  Increased	  susceptibility	  to	  endotoxin	  shock	  in	  
complement	  C3-­‐	  and	  C4-­‐deficient	  mice	  is	  corrected	  by	  C1	  inhibitor	  
replacement.	  J	  Immunol,	  1997.	  159(2):	  p.	  976-­‐82.	  249.	   Ward,	  P.A.,	  Role	  of	  the	  complement	  in	  experimental	  sepsis.	  J	  Leukoc	  Biol,	  2008.	  83(3):	  p.	  467-­‐70.	  250.	   Walport,	  M.J.,	  Complement.	  First	  of	  two	  parts.	  N	  Engl	  J	  Med,	  2001.	  344(14):	  p.	  1058-­‐66.	  251.	   Hoffmann,	  M.	  and	  R.W.	  Dutton,	  Immune	  response	  restoration	  with	  
macrophage	  culture	  supernatants.	  Science,	  1971.	  172(3987):	  p.	  1047-­‐8.	  252.	   Dutton,	  R.W.,	  et	  al.,	  Cell	  components	  in	  the	  immune	  response.	  IV.	  
Relationships	  and	  possible	  interactions.	  Cell	  Immunol,	  1970.	  1(2):	  p.	  196-­‐206.	  253.	   Mahanonda,	  R.,	  et	  al.,	  Monocyte	  activation	  by	  Porphyromonas	  gingivalis	  
LPS	  in	  aggressive	  periodontitis	  with	  the	  use	  of	  whole-­‐blood	  cultures.	  J	  Dent	  Res,	  2004.	  83(7):	  p.	  540-­‐5.	  254.	   Wolk,	  K.,	  et	  al.,	  Impaired	  antigen	  presentation	  by	  human	  monocytes	  during	  
endotoxin	  tolerance.	  Blood,	  2000.	  96(1):	  p.	  218-­‐23.	  255.	   Hotchkiss,	  R.S.	  and	  D.W.	  Nicholson,	  Apoptosis	  and	  caspases	  regulate	  death	  
and	  inflammation	  in	  sepsis.	  Nat	  Rev	  Immunol,	  2006.	  6(11):	  p.	  813-­‐22.	  256.	   Zhu,	  J.	  and	  W.E.	  Paul,	  CD4	  T	  cells:	  fates,	  functions,	  and	  faults.	  Blood,	  2008.	  
112(5):	  p.	  1557-­‐69.	  257.	   Murphy,	  K.M.	  and	  S.L.	  Reiner,	  The	  lineage	  decisions	  of	  helper	  T	  cells.	  Nat	  Rev	  Immunol,	  2002.	  2(12):	  p.	  933-­‐44.	  258.	   Afzali,	  B.,	  et	  al.,	  The	  role	  of	  T	  helper	  17	  (Th17)	  and	  regulatory	  T	  cells	  (Treg)	  
in	  human	  organ	  transplantation	  and	  autoimmune	  disease.	  Clin	  Exp	  Immunol,	  2007.	  148(1):	  p.	  32-­‐46.	  259.	   Sakaguchi,	  S.,	  Naturally	  arising	  CD4+	  regulatory	  t	  cells	  for	  immunologic	  
self-­‐tolerance	  and	  negative	  control	  of	  immune	  responses.	  Annu	  Rev	  Immunol,	  2004.	  22:	  p.	  531-­‐62.	  260.	   Kurosaki,	  T.,	  B-­‐lymphocyte	  biology.	  Immunol	  Rev,	  2010.	  237(1):	  p.	  5-­‐9.	  261.	   Weber,	  S.U.,	  et	  al.,	  Induction	  of	  Bim	  and	  Bid	  gene	  expression	  during	  
accelerated	  apoptosis	  in	  severe	  sepsis.	  Crit	  Care,	  2008.	  12(5):	  p.	  R128.	  262.	   Boomer,	  J.S.,	  et	  al.,	  Immunosuppression	  in	  patients	  who	  die	  of	  sepsis	  and	  
multiple	  organ	  failure.	  JAMA,	  2011.	  306(23):	  p.	  2594-­‐605.	  263.	   Venet,	  F.,	  et	  al.,	  Increased	  circulating	  regulatory	  T	  cells	  (CD4(+)CD25	  
(+)CD127	  (-­‐))	  contribute	  to	  lymphocyte	  anergy	  in	  septic	  shock	  patients.	  Intensive	  Care	  Med,	  2009.	  35(4):	  p.	  678-­‐86.	  
	   252	  
264.	   Heininger,	  A.,	  et	  al.,	  Cytomegalovirus	  reactivation	  and	  associated	  outcome	  
of	  critically	  ill	  patients	  with	  severe	  sepsis.	  Crit	  Care,	  2011.	  15(2):	  p.	  R77.	  265.	   Kalil,	  A.C.	  and	  D.F.	  Florescu,	  Prevalence	  and	  mortality	  associated	  with	  
cytomegalovirus	  infection	  in	  nonimmunosuppressed	  patients	  in	  the	  
intensive	  care	  unit.	  Crit	  Care	  Med,	  2009.	  37(8):	  p.	  2350-­‐8.	  266.	   Adib-­‐Conquy,	  M.	  and	  J.M.	  Cavaillon,	  Stress	  molecules	  in	  sepsis	  and	  systemic	  
inflammatory	  response	  syndrome.	  FEBS	  Lett,	  2007.	  581(19):	  p.	  3723-­‐33.	  267.	   Oda,	  S.,	  et	  al.,	  Sequential	  measurement	  of	  IL-­‐6	  blood	  levels	  in	  patients	  with	  
systemic	  inflammatory	  response	  syndrome	  (SIRS)/sepsis.	  Cytokine,	  2005.	  
29(4):	  p.	  169-­‐75.	  268.	   Gregoric,	  P.,	  et	  al.,	  SIRS	  score	  on	  admission	  and	  initial	  concentration	  of	  IL-­‐6	  
as	  severe	  acute	  pancreatitis	  outcome	  predictors.	  Hepatogastroenterology,	  2010.	  57(98):	  p.	  349-­‐53.	  269.	   Mokart,	  D.,	  et	  al.,	  Procalcitonin,	  interleukin	  6	  and	  systemic	  inflammatory	  
response	  syndrome	  (SIRS):	  early	  markers	  of	  postoperative	  sepsis	  after	  
major	  surgery.	  Br	  J	  Anaesth,	  2005.	  94(6):	  p.	  767-­‐73.	  270.	   Gebhard,	  F.,	  et	  al.,	  Is	  interleukin	  6	  an	  early	  marker	  of	  injury	  severity	  
following	  major	  trauma	  in	  humans?	  Archives	  of	  surgery,	  2000.	  135(3):	  p.	  291-­‐5.	  271.	   Taniguchi,	  T.,	  et	  al.,	  Change	  in	  the	  ratio	  of	  interleukin-­‐6	  to	  interleukin-­‐10	  
predicts	  a	  poor	  outcome	  in	  patients	  with	  systemic	  inflammatory	  response	  
syndrome.	  Crit	  Care	  Med,	  1999.	  27(7):	  p.	  1262-­‐4.	  272.	   Taniguchi,	  T.,	  et	  al.,	  The	  ratio	  of	  interleukin-­‐6	  to	  interleukin-­‐10	  correlates	  
with	  severity	  in	  patients	  with	  chest	  and	  abdominal	  trauma.	  Am	  J	  Emerg	  Med,	  1999.	  17(6):	  p.	  548-­‐51.	  273.	   Levy,	  M.M.,	  et	  al.,	  2001	  SCCM/ESICM/ACCP/ATS/SIS	  International	  Sepsis	  
Definitions	  Conference.	  Crit	  Care	  Med,	  2003.	  31(4):	  p.	  1250-­‐6.	  274.	   Harbarth,	  S.,	  et	  al.,	  Diagnostic	  value	  of	  procalcitonin,	  interleukin-­‐6,	  and	  
interleukin-­‐8	  in	  critically	  ill	  patients	  admitted	  with	  suspected	  sepsis.	  Am	  J	  Respir	  Crit	  Care	  Med,	  2001.	  164(3):	  p.	  396-­‐402.	  275.	   Wu,	  H.P.,	  et	  al.,	  Plasma	  transforming	  growth	  factor-­‐beta1	  level	  in	  patients	  
with	  severe	  community-­‐acquired	  pneumonia	  and	  association	  with	  disease	  
severity.	  J	  Formos	  Med	  Assoc,	  2009.	  108(1):	  p.	  20-­‐7.	  276.	   Guignant,	  C.,	  et	  al.,	  Assessment	  of	  pro-­‐vasopressin	  and	  pro-­‐adrenomedullin	  
as	  predictors	  of	  28-­‐day	  mortality	  in	  septic	  shock	  patients.	  Intensive	  Care	  Med,	  2009.	  35(11):	  p.	  1859-­‐67.	  277.	   Seligman,	  R.,	  et	  al.,	  Prognostic	  value	  of	  midregional	  pro-­‐atrial	  natriuretic	  
peptide	  in	  ventilator-­‐associated	  pneumonia.	  Intensive	  Care	  Med,	  2008.	  
34(11):	  p.	  2084-­‐91.	  278.	   Koch,	  A.,	  et	  al.,	  Serum	  resistin	  levels	  in	  critically	  ill	  patients	  are	  associated	  
with	  inflammation,	  organ	  dysfunction	  and	  metabolism	  and	  may	  predict	  
survival	  of	  non-­‐septic	  patients.	  Crit	  Care,	  2009.	  13(3):	  p.	  R95.	  279.	   Kibe,	  S.,	  K.	  Adams,	  and	  G.	  Barlow,	  Diagnostic	  and	  prognostic	  biomarkers	  of	  
sepsis	  in	  critical	  care.	  J	  Antimicrob	  Chemother,	  2011.	  66	  Suppl	  2:	  p.	  ii33-­‐40.	  280.	   O'Grady,	  N.P.,	  et	  al.,	  Guidelines	  for	  evaluation	  of	  new	  fever	  in	  critically	  ill	  
adult	  patients:	  2008	  update	  from	  the	  American	  College	  of	  Critical	  Care	  
Medicine	  and	  the	  Infectious	  Diseases	  Society	  of	  America.	  Crit	  Care	  Med,	  2008.	  36(4):	  p.	  1330-­‐49.	  
	   253	  
281.	   Reinhart,	  K.,	  et	  al.,	  Randomized,	  placebo-­‐controlled	  trial	  of	  the	  anti-­‐tumor	  
necrosis	  factor	  antibody	  fragment	  afelimomab	  in	  hyperinflammatory	  
response	  during	  severe	  sepsis:	  The	  RAMSES	  Study.	  Crit	  Care	  Med,	  2001.	  
29(4):	  p.	  765-­‐9.	  282.	   Bo,	  L.,	  et	  al.,	  Granulocyte-­‐colony	  stimulating	  factor	  (G-­‐CSF)	  and	  
granulocyte-­‐macrophage	  colony	  stimulating	  factor	  (GM-­‐CSF)	  for	  sepsis:	  a	  
meta-­‐analysis.	  Crit	  Care,	  2011.	  15(1):	  p.	  R58.	  283.	   Hynninen,	  M.,	  et	  al.,	  Predictive	  value	  of	  monocyte	  histocompatibility	  
leukocyte	  antigen-­‐DR	  expression	  and	  plasma	  interleukin-­‐4	  and	  -­‐10	  levels	  in	  
critically	  ill	  patients	  with	  sepsis.	  Shock,	  2003.	  20(1):	  p.	  1-­‐4.	  284.	   Opal,	  S.M.	  and	  V.A.	  DePalo,	  Anti-­‐inflammatory	  cytokines.	  Chest,	  2000.	  
117(4):	  p.	  1162-­‐72.	  285.	   Gogos,	  C.A.,	  et	  al.,	  Pro-­‐	  versus	  anti-­‐inflammatory	  cytokine	  profile	  in	  patients	  
with	  severe	  sepsis:	  a	  marker	  for	  prognosis	  and	  future	  therapeutic	  options.	  J	  Infect	  Dis,	  2000.	  181(1):	  p.	  176-­‐80.	  286.	   Monneret,	  G.,	  et	  al.,	  Persisting	  low	  monocyte	  human	  leukocyte	  antigen-­‐DR	  
expression	  predicts	  mortality	  in	  septic	  shock.	  Intensive	  Care	  Med,	  2006.	  
32(8):	  p.	  1175-­‐83.	  287.	   Monneret,	  G.,	  et	  al.,	  Monitoring	  immune	  dysfunctions	  in	  the	  septic	  patient:	  a	  
new	  skin	  for	  the	  old	  ceremony.	  Mol	  Med,	  2008.	  14(1-­‐2):	  p.	  64-­‐78.	  288.	   Koppelman,	  B.,	  et	  al.,	  Interleukin-­‐10	  down-­‐regulates	  MHC	  class	  II	  alphabeta	  
peptide	  complexes	  at	  the	  plasma	  membrane	  of	  monocytes	  by	  affecting	  
arrival	  and	  recycling.	  Immunity,	  1997.	  7(6):	  p.	  861-­‐71.	  289.	   Krakauer,	  T.	  and	  J.J.	  Oppenheim,	  IL-­‐1	  and	  tumor	  necrosis	  factor-­‐alpha	  each	  
up-­‐regulate	  both	  the	  expression	  of	  IFN-­‐gamma	  receptors	  and	  enhance	  IFN-­‐
gamma-­‐induced	  HLA-­‐DR	  expression	  on	  human	  monocytes	  and	  a	  human	  
monocytic	  cell	  line	  (THP-­‐1).	  J	  Immunol,	  1993.	  150(4):	  p.	  1205-­‐11.	  290.	   Basta,	  P.V.,	  et	  al.,	  A	  beta-­‐adrenergic	  agonist	  modulates	  DR	  alpha	  gene	  
transcription	  via	  enhanced	  cAMP	  levels	  in	  a	  glioblastoma	  multiforme	  line.	  J	  Immunol,	  1989.	  142(8):	  p.	  2895-­‐901.	  291.	   Schwiebert,	  L.M.,	  et	  al.,	  Modulation	  of	  MHC	  class	  II	  expression	  in	  human	  
cells	  by	  dexamethasone.	  Cell	  Immunol,	  1995.	  165(1):	  p.	  12-­‐9.	  292.	   Tschoeke,	  S.K.	  and	  L.L.	  Moldawer,	  Human	  leukocyte	  antigen	  expression	  in	  
sepsis:	  what	  have	  we	  learned?	  Critical	  care	  medicine,	  2005.	  33(1):	  p.	  236-­‐7.	  293.	   Ayala,	  A.,	  W.	  Ertel,	  and	  I.H.	  Chaudry,	  Trauma-­‐induced	  suppression	  of	  
antigen	  presentation	  and	  expression	  of	  major	  histocompatibility	  class	  II	  
antigen	  complex	  in	  leukocytes.	  Shock,	  1996.	  5(2):	  p.	  79-­‐90.	  294.	   Tschaikowsky,	  K.,	  et	  al.,	  Coincidence	  of	  pro-­‐	  and	  anti-­‐inflammatory	  
responses	  in	  the	  early	  phase	  of	  severe	  sepsis:	  Longitudinal	  study	  of	  
mononuclear	  histocompatibility	  leukocyte	  antigen-­‐DR	  expression,	  
procalcitonin,	  C-­‐reactive	  protein,	  and	  changes	  in	  T-­‐cell	  subsets	  in	  septic	  and	  
postoperative	  patients.	  Crit	  Care	  Med,	  2002.	  30(5):	  p.	  1015-­‐23.	  295.	   Docke,	  W.D.,	  et	  al.,	  Monitoring	  temporary	  immunodepression	  by	  flow	  
cytometric	  measurement	  of	  monocytic	  HLA-­‐DR	  expression:	  a	  multicenter	  
standardized	  study.	  Clin	  Chem,	  2005.	  51(12):	  p.	  2341-­‐7.	  296.	   Ziegler-­‐Heitbrock,	  L.,	  The	  CD14+	  CD16+	  blood	  monocytes:	  their	  role	  in	  
infection	  and	  inflammation.	  J	  Leukoc	  Biol,	  2007.	  81(3):	  p.	  584-­‐92.	  
	   254	  
297.	   Cros,	  J.,	  et	  al.,	  Human	  CD14dim	  monocytes	  patrol	  and	  sense	  nucleic	  acids	  
and	  viruses	  via	  TLR7	  and	  TLR8	  receptors.	  Immunity,	  2010.	  33(3):	  p.	  375-­‐86.	  298.	   Skrzeczynska-­‐Moncznik,	  J.,	  et	  al.,	  Peripheral	  blood	  CD14high	  CD16+	  
monocytes	  are	  main	  producers	  of	  IL-­‐10.	  Scand	  J	  Immunol,	  2008.	  67(2):	  p.	  152-­‐9.	  299.	   Wong,	  K.L.,	  et	  al.,	  Gene	  expression	  profiling	  reveals	  the	  defining	  features	  of	  
the	  classical,	  intermediate,	  and	  nonclassical	  human	  monocyte	  subsets.	  Blood,	  2011.	  118(5):	  p.	  e16-­‐31.	  300.	   Belge,	  K.U.,	  et	  al.,	  The	  proinflammatory	  CD14+CD16+DR++	  monocytes	  are	  a	  
major	  source	  of	  TNF.	  J	  Immunol,	  2002.	  168(7):	  p.	  3536-­‐42.	  301.	   Szaflarska,	  A.,	  et	  al.,	  Antitumor	  response	  of	  CD14+/CD16+	  monocyte	  
subpopulation.	  Exp	  Hematol,	  2004.	  32(8):	  p.	  748-­‐55.	  302.	   Nockher,	  W.A.,	  L.	  Bergmann,	  and	  J.E.	  Scherberich,	  Increased	  soluble	  CD14	  
serum	  levels	  and	  altered	  CD14	  expression	  of	  peripheral	  blood	  monocytes	  in	  
HIV-­‐infected	  patients.	  Clin	  Exp	  Immunol,	  1994.	  98(3):	  p.	  369-­‐74.	  303.	   Rivier,	  A.,	  et	  al.,	  Blood	  monocytes	  of	  untreated	  asthmatics	  exhibit	  some	  
features	  of	  tissue	  macrophages.	  Clin	  Exp	  Immunol,	  1995.	  100(2):	  p.	  314-­‐8.	  304.	   Nockher,	  W.A.	  and	  J.E.	  Scherberich,	  Expanded	  CD14+	  CD16+	  monocyte	  
subpopulation	  in	  patients	  with	  acute	  and	  chronic	  infections	  undergoing	  
hemodialysis.	  Infect	  Immun,	  1998.	  66(6):	  p.	  2782-­‐90.	  305.	   Fingerle,	  G.,	  et	  al.,	  The	  novel	  subset	  of	  CD14+/CD16+	  blood	  monocytes	  is	  
expanded	  in	  sepsis	  patients.	  Blood,	  1993.	  82(10):	  p.	  3170-­‐6.	  306.	   Blumenstein,	  M.,	  et	  al.,	  Cytokine	  production	  precedes	  the	  expansion	  of	  
CD14+CD16+	  monocytes	  in	  human	  sepsis:	  a	  case	  report	  of	  a	  patient	  with	  
self-­‐induced	  septicemia.	  Shock,	  1997.	  8(1):	  p.	  73-­‐5.	  307.	   Shalova,	  I.N.,	  et	  al.,	  CD16	  regulates	  TRIF-­‐dependent	  TLR4	  response	  in	  
human	  monocytes	  and	  their	  subsets.	  J	  Immunol,	  2012.	  188(8):	  p.	  3584-­‐93.	  308.	   Skrzeczynska,	  J.,	  et	  al.,	  CD14+CD16+	  monocytes	  in	  the	  course	  of	  sepsis	  in	  
neonates	  and	  small	  children:	  monitoring	  and	  functional	  studies.	  Scand	  J	  Immunol,	  2002.	  55(6):	  p.	  629-­‐38.	  309.	   Herra,	  C.M.,	  C.T.	  Keane,	  and	  A.	  Whelan,	  Increased	  expression	  of	  Fc	  gamma	  
receptors	  on	  neutrophils	  and	  monocytes	  may	  reflect	  ongoing	  bacterial	  
infection.	  J	  Med	  Microbiol,	  1996.	  44(2):	  p.	  135-­‐40.	  310.	   Fingerle-­‐Rowson,	  G.,	  et	  al.,	  Expansion	  of	  CD14+CD16+	  monocytes	  in	  
critically	  ill	  cardiac	  surgery	  patients.	  Inflammation,	  1998.	  22(4):	  p.	  367-­‐79.	  311.	   Condliffe,	  A.M.,	  E.	  Kitchen,	  and	  E.R.	  Chilvers,	  Neutrophil	  priming:	  
pathophysiological	  consequences	  and	  underlying	  mechanisms.	  Clin	  Sci	  (Lond),	  1998.	  94(5):	  p.	  461-­‐71.	  312.	   Swain,	  S.D.,	  T.T.	  Rohn,	  and	  M.T.	  Quinn,	  Neutrophil	  priming	  in	  host	  defense:	  
role	  of	  oxidants	  as	  priming	  agents.	  Antioxid	  Redox	  Signal,	  2002.	  4(1):	  p.	  69-­‐83.	  313.	   Thomas,	  L.	  and	  R.A.	  Good,	  Studies	  on	  the	  generalized	  Shwartzman	  reaction:	  
I.	  General	  observations	  concerning	  the	  phenomenon.	  J	  Exp	  Med,	  1952.	  
96(6):	  p.	  605-­‐24.	  314.	   Billiau,	  A.,	  et	  al.,	  Anti-­‐interferon-­‐gamma	  antibody	  protects	  mice	  against	  the	  
generalized	  Shwartzman	  reaction.	  Eur	  J	  Immunol,	  1987.	  17(12):	  p.	  1851-­‐4.	  
	   255	  
315.	   Heremans,	  H.,	  et	  al.,	  Interferon	  gamma,	  a	  mediator	  of	  lethal	  
lipopolysaccharide-­‐induced	  Shwartzman-­‐like	  shock	  reactions	  in	  mice.	  J	  Exp	  Med,	  1990.	  171(6):	  p.	  1853-­‐69.	  316.	   O'Dea,	  K.P.,	  et	  al.,	  Mobilization	  and	  margination	  of	  bone	  marrow	  Gr-­‐1high	  
monocytes	  during	  subclinical	  endotoxemia	  predisposes	  the	  lungs	  toward	  
acute	  injury.	  J	  Immunol,	  2009.	  182(2):	  p.	  1155-­‐66.	  317.	   O'Dea,	  K.P.,	  et	  al.,	  Regulation	  of	  monocyte	  subset	  proinflammatory	  
responses	  within	  the	  lung	  microvasculature	  by	  the	  p38	  MAPK/MK2	  
pathway.	  Am	  J	  Physiol	  Lung	  Cell	  Mol	  Physiol,	  2011.	  301(5):	  p.	  L812-­‐21.	  318.	   Cuschieri,	  J.,	  et	  al.,	  Platelet-­‐activating	  factor	  priming	  of	  inflammatory	  cell	  
activity	  requires	  cellular	  adherence.	  Surgery,	  2002.	  132(2):	  p.	  157-­‐66.	  319.	   Schaeffer,	  V.,	  et	  al.,	  The	  priming	  effect	  of	  C5a	  on	  monocytes	  is	  
predominantly	  mediated	  by	  the	  p38	  MAPK	  pathway.	  Shock,	  2007.	  27(6):	  p.	  623-­‐30.	  320.	   Hoogerwerf,	  J.J.,	  et	  al.,	  Priming	  of	  alveolar	  macrophages	  upon	  instillation	  of	  
lipopolysaccharide	  in	  the	  human	  lung.	  Am	  J	  Respir	  Cell	  Mol	  Biol,	  2010.	  
42(3):	  p.	  349-­‐56.	  321.	   Snelgrove,	  R.J.,	  et	  al.,	  A	  critical	  function	  for	  CD200	  in	  lung	  immune	  
homeostasis	  and	  the	  severity	  of	  influenza	  infection.	  Nat	  Immunol,	  2008.	  
9(9):	  p.	  1074-­‐83.	  322.	   Beeson,	  P.B.,	  Development	  of	  tolerance	  to	  typhoid	  bacterial	  pyrogen	  and	  its	  
abolition	  by	  reticulo-­‐endothelial	  blockade.	  Proc	  Soc	  Exp	  Biol	  Med,	  1946.	  
61:	  p.	  248-­‐50.	  323.	   Cavaillon,	  J.M.	  and	  M.	  Adib-­‐Conquy,	  Bench-­‐to-­‐bedside	  review:	  endotoxin	  
tolerance	  as	  a	  model	  of	  leukocyte	  reprogramming	  in	  sepsis.	  Crit	  Care,	  2006.	  
10(5):	  p.	  233.	  324.	   Biswas,	  S.K.	  and	  E.	  Lopez-­‐Collazo,	  Endotoxin	  tolerance:	  new	  mechanisms,	  
molecules	  and	  clinical	  significance.	  Trends	  Immunol,	  2009.	  30(10):	  p.	  475-­‐87.	  325.	   Cavaillon,	  J.M.,	  et	  al.,	  Endotoxin	  tolerance:	  is	  there	  a	  clinical	  relevance?	  J	  Endotoxin	  Res,	  2003.	  9(2):	  p.	  101-­‐7.	  326.	   del	  Fresno,	  C.,	  et	  al.,	  Potent	  phagocytic	  activity	  with	  impaired	  antigen	  
presentation	  identifying	  lipopolysaccharide-­‐tolerant	  human	  monocytes:	  
demonstration	  in	  isolated	  monocytes	  from	  cystic	  fibrosis	  patients.	  J	  Immunol,	  2009.	  182(10):	  p.	  6494-­‐507.	  327.	   van	  't	  Veer,	  C.,	  et	  al.,	  Induction	  of	  IRAK-­‐M	  is	  associated	  with	  
lipopolysaccharide	  tolerance	  in	  a	  human	  endotoxemia	  model.	  J	  Immunol,	  2007.	  179(10):	  p.	  7110-­‐20.	  328.	   Kobayashi,	  K.,	  et	  al.,	  IRAK-­‐M	  is	  a	  negative	  regulator	  of	  Toll-­‐like	  receptor	  
signaling.	  Cell,	  2002.	  110(2):	  p.	  191-­‐202.	  329.	   Kraatz,	  J.,	  et	  al.,	  Macrophage	  TNF	  secretion	  in	  endotoxin	  tolerance:	  role	  of	  
SAPK,	  p38,	  and	  MAPK.	  J	  Surg	  Res,	  1999.	  83(2):	  p.	  158-­‐64.	  330.	   Durando,	  M.M.,	  K.E.	  Meier,	  and	  J.A.	  Cook,	  Endotoxin	  activation	  of	  mitogen-­‐
activated	  protein	  kinase	  in	  THP-­‐1	  cells;	  diminished	  activation	  following	  
endotoxin	  desensitization.	  J	  Leukoc	  Biol,	  1998.	  64(2):	  p.	  259-­‐64.	  331.	   Nimah,	  M.,	  et	  al.,	  Contribution	  of	  MKP-­‐1	  regulation	  of	  p38	  to	  endotoxin	  
tolerance.	  Shock,	  2005.	  23(1):	  p.	  80-­‐7.	  332.	   Carswell,	  E.A.,	  et	  al.,	  An	  endotoxin-­‐induced	  serum	  factor	  that	  causes	  
necrosis	  of	  tumors.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  1975.	  72(9):	  p.	  3666-­‐70.	  
	   256	  
333.	   Aggarwal,	  B.B.,	  et	  al.,	  Human	  tumor	  necrosis	  factor.	  Production,	  
purification,	  and	  characterization.	  J	  Biol	  Chem,	  1985.	  260(4):	  p.	  2345-­‐54.	  334.	   Pfeffer,	  K.,	  Biological	  functions	  of	  tumor	  necrosis	  factor	  cytokines	  and	  their	  
receptors.	  Cytokine	  Growth	  Factor	  Rev,	  2003.	  14(3-­‐4):	  p.	  185-­‐91.	  335.	   Locksley,	  R.M.,	  N.	  Killeen,	  and	  M.J.	  Lenardo,	  The	  TNF	  and	  TNF	  receptor	  
superfamilies:	  integrating	  mammalian	  biology.	  Cell,	  2001.	  104(4):	  p.	  487-­‐501.	  336.	   Tang,	  P.,	  M.C.	  Hung,	  and	  J.	  Klostergaard,	  Human	  pro-­‐tumor	  necrosis	  factor	  
is	  a	  homotrimer.	  Biochemistry,	  1996.	  35(25):	  p.	  8216-­‐25.	  337.	   Kusters,	  S.,	  et	  al.,	  In	  vivo	  evidence	  for	  a	  functional	  role	  of	  both	  tumor	  
necrosis	  factor	  (TNF)	  receptors	  and	  transmembrane	  TNF	  in	  experimental	  
hepatitis.	  Eur	  J	  Immunol,	  1997.	  27(11):	  p.	  2870-­‐5.	  338.	   Alexopoulou,	  L.,	  et	  al.,	  Transmembrane	  TNF	  protects	  mutant	  mice	  against	  
intracellular	  bacterial	  infections,	  chronic	  inflammation	  and	  autoimmunity.	  Eur	  J	  Immunol,	  2006.	  36(10):	  p.	  2768-­‐80.	  339.	   Pellegrini,	  J.D.,	  et	  al.,	  A	  membrane	  TNF-­‐alpha/TNFR	  ratio	  correlates	  to	  
MODS	  score	  and	  mortality.	  Shock,	  1996.	  6(6):	  p.	  389-­‐96.	  340.	   Black,	  R.A.,	  et	  al.,	  A	  metalloproteinase	  disintegrin	  that	  releases	  tumour-­‐
necrosis	  factor-­‐alpha	  from	  cells.	  Nature,	  1997.	  385(6618):	  p.	  729-­‐33.	  341.	   Black,	  R.A.,	  Tumor	  necrosis	  factor-­‐alpha	  converting	  enzyme.	  Int	  J	  Biochem	  Cell	  Biol,	  2002.	  34(1):	  p.	  1-­‐5.	  342.	   Edwards,	  D.R.,	  M.M.	  Handsley,	  and	  C.J.	  Pennington,	  The	  ADAM	  
metalloproteinases.	  Mol	  Aspects	  Med,	  2008.	  29(5):	  p.	  258-­‐89.	  343.	   Gooz,	  M.,	  ADAM-­‐17:	  the	  enzyme	  that	  does	  it	  all.	  Crit	  Rev	  Biochem	  Mol	  Biol,	  2010.	  45(2):	  p.	  146-­‐69.	  344.	   Scheller,	  J.,	  et	  al.,	  ADAM17:	  a	  molecular	  switch	  to	  control	  inflammation	  and	  
tissue	  regeneration.	  Trends	  Immunol,	  2011.	  32(8):	  p.	  380-­‐7.	  345.	   Solomon,	  K.A.,	  et	  al.,	  Cutting	  edge:	  a	  dominant	  negative	  form	  of	  TNF-­‐alpha	  
converting	  enzyme	  inhibits	  proTNF	  and	  TNFRII	  secretion.	  J	  Immunol,	  1999.	  
163(8):	  p.	  4105-­‐8.	  346.	   Shimizu,	  M.,	  et	  al.,	  Effects	  of	  TNF-­‐alpha-­‐converting	  enzyme	  inhibition	  on	  
acute	  lung	  injury	  induced	  by	  endotoxin	  in	  the	  rat.	  Shock,	  2009.	  32(5):	  p.	  535-­‐40.	  347.	   Arndt,	  P.G.,	  et	  al.,	  Leukocyte	  ADAM17	  regulates	  acute	  pulmonary	  
inflammation.	  PLoS	  One,	  2011.	  6(5):	  p.	  e19938.	  348.	   Allinson,	  T.M.,	  et	  al.,	  ADAMs	  family	  members	  as	  amyloid	  precursor	  protein	  
alpha-­‐secretases.	  J	  Neurosci	  Res,	  2003.	  74(3):	  p.	  342-­‐52.	  349.	   Borrell-­‐Pages,	  M.,	  et	  al.,	  TACE	  is	  required	  for	  the	  activation	  of	  the	  EGFR	  by	  
TGF-­‐alpha	  in	  tumors.	  EMBO	  J,	  2003.	  22(5):	  p.	  1114-­‐24.	  350.	   McGowan,	  P.M.,	  et	  al.,	  ADAM-­‐17	  predicts	  adverse	  outcome	  in	  patients	  with	  
breast	  cancer.	  Annals	  of	  oncology	  :	  official	  journal	  of	  the	  European	  Society	  for	  Medical	  Oncology	  /	  ESMO,	  2008.	  19(6):	  p.	  1075-­‐81.	  351.	   McGowan,	  P.M.,	  et	  al.,	  ADAM-­‐17	  expression	  in	  breast	  cancer	  correlates	  with	  
variables	  of	  tumor	  progression.	  Clin	  Cancer	  Res,	  2007.	  13(8):	  p.	  2335-­‐43.	  352.	   McGowan,	  P.M.,	  et	  al.,	  ADAM-­‐17:	  a	  novel	  therapeutic	  target	  for	  triple	  
negative	  breast	  cancer.	  Annals	  of	  oncology	  :	  official	  journal	  of	  the	  European	  Society	  for	  Medical	  Oncology	  /	  ESMO,	  2012.	  
	   257	  
353.	   Cesaro,	  A.,	  et	  al.,	  Differential	  expression	  and	  regulation	  of	  ADAM17	  and	  
TIMP3	  in	  acute	  inflamed	  intestinal	  epithelia.	  Am	  J	  Physiol	  Gastrointest	  Liver	  Physiol,	  2009.	  296(6):	  p.	  G1332-­‐43.	  354.	   Blaydon,	  D.C.,	  et	  al.,	  Inflammatory	  skin	  and	  bowel	  disease	  linked	  to	  
ADAM17	  deletion.	  N	  Engl	  J	  Med,	  2011.	  365(16):	  p.	  1502-­‐8.	  355.	   Kermarrec,	  N.,	  et	  al.,	  Regulation	  of	  peritoneal	  and	  systemic	  neutrophil-­‐
derived	  tumor	  necrosis	  factor-­‐alpha	  release	  in	  patients	  with	  severe	  
peritonitis:	  role	  of	  tumor	  necrosis	  factor-­‐alpha	  converting	  enzyme	  cleavage.	  Crit	  Care	  Med,	  2005.	  33(6):	  p.	  1359-­‐64.	  356.	   Gonzales,	  P.E.,	  et	  al.,	  Inhibition	  of	  the	  tumor	  necrosis	  factor-­‐alpha-­‐
converting	  enzyme	  by	  its	  pro	  domain.	  J	  Biol	  Chem,	  2004.	  279(30):	  p.	  31638-­‐45.	  357.	   Schlondorff,	  J.,	  J.D.	  Becherer,	  and	  C.P.	  Blobel,	  Intracellular	  maturation	  and	  
localization	  of	  the	  tumour	  necrosis	  factor	  alpha	  convertase	  (TACE).	  Biochem	  J,	  2000.	  347	  Pt	  1:	  p.	  131-­‐8.	  358.	   Tellier,	  E.,	  et	  al.,	  The	  shedding	  activity	  of	  ADAM17	  is	  sequestered	  in	  lipid	  
rafts.	  Exp	  Cell	  Res,	  2006.	  312(20):	  p.	  3969-­‐80.	  359.	   Zhang,	  Z.,	  et	  al.,	  Reactive	  oxygen	  species	  mediate	  tumor	  necrosis	  factor	  
alpha-­‐converting,	  enzyme-­‐dependent	  ectodomain	  shedding	  induced	  by	  
phorbol	  myristate	  acetate.	  FASEB	  J,	  2001.	  15(2):	  p.	  303-­‐5.	  360.	   Zhang,	  Z.,	  et	  al.,	  Activation	  of	  tumor	  necrosis	  factor-­‐alpha-­‐converting	  
enzyme-­‐mediated	  ectodomain	  shedding	  by	  nitric	  oxide.	  J	  Biol	  Chem,	  2000.	  
275(21):	  p.	  15839-­‐44.	  361.	   Myers,	  T.J.,	  et	  al.,	  Mitochondrial	  reactive	  oxygen	  species	  mediate	  GPCR-­‐
induced	  TACE/ADAM17-­‐dependent	  transforming	  growth	  factor-­‐alpha	  
shedding.	  Mol	  Biol	  Cell,	  2009.	  20(24):	  p.	  5236-­‐49.	  362.	   Peiretti,	  F.,	  et	  al.,	  Intracellular	  maturation	  and	  transport	  of	  tumor	  necrosis	  
factor	  alpha	  converting	  enzyme.	  Exp	  Cell	  Res,	  2003.	  285(2):	  p.	  278-­‐85.	  363.	   Srour,	  N.,	  et	  al.,	  TACE/ADAM-­‐17	  maturation	  and	  activation	  of	  sheddase	  
activity	  require	  proprotein	  convertase	  activity.	  FEBS	  Lett,	  2003.	  554(3):	  p.	  275-­‐83.	  364.	   Armstrong,	  L.,	  et	  al.,	  Contribution	  of	  TNF-­‐alpha	  converting	  enzyme	  and	  
proteinase-­‐3	  to	  TNF-­‐alpha	  processing	  in	  human	  alveolar	  macrophages.	  Am	  J	  Respir	  Cell	  Mol	  Biol,	  2006.	  34(2):	  p.	  219-­‐25.	  365.	   Xu,	  P.,	  et	  al.,	  TACE	  activation	  by	  MAPK-­‐mediated	  regulation	  of	  cell	  surface	  
dimerization	  and	  TIMP3	  association.	  Science	  signaling,	  2012.	  5(222):	  p.	  ra34.	  366.	   Brennan,	  F.M.,	  et	  al.,	  Interleukin-­‐10	  regulates	  TNF-­‐alpha-­‐converting	  
enzyme	  (TACE/ADAM-­‐17)	  involving	  a	  TIMP-­‐3	  dependent	  and	  independent	  
mechanism.	  Eur	  J	  Immunol,	  2008.	  38(4):	  p.	  1106-­‐17.	  367.	   Xu,	  P.	  and	  R.	  Derynck,	  Direct	  activation	  of	  TACE-­‐mediated	  ectodomain	  
shedding	  by	  p38	  MAP	  kinase	  regulates	  EGF	  receptor-­‐dependent	  cell	  
proliferation.	  Mol	  Cell,	  2010.	  37(4):	  p.	  551-­‐66.	  368.	   Bzowska,	  M.,	  et	  al.,	  Tumour	  necrosis	  factor-­‐alpha	  stimulates	  expression	  of	  
TNF-­‐alpha	  converting	  enzyme	  in	  endothelial	  cells.	  Eur	  J	  Biochem,	  2004.	  
271(13):	  p.	  2808-­‐20.	  369.	   Doedens,	  J.R.	  and	  R.A.	  Black,	  Stimulation-­‐induced	  down-­‐regulation	  of	  
tumor	  necrosis	  factor-­‐alpha	  converting	  enzyme.	  J	  Biol	  Chem,	  2000.	  
275(19):	  p.	  14598-­‐607.	  
	   258	  
370.	   Robertshaw,	  H.J.	  and	  F.M.	  Brennan,	  Release	  of	  tumour	  necrosis	  factor	  alpha	  
(TNFalpha)	  by	  TNFalpha	  cleaving	  enzyme	  (TACE)	  in	  response	  to	  septic	  
stimuli	  in	  vitro.	  Br	  J	  Anaesth,	  2005.	  94(2):	  p.	  222-­‐8.	  371.	   Canault,	  M.,	  et	  al.,	  FHL2	  interacts	  with	  both	  ADAM-­‐17	  and	  the	  cytoskeleton	  
and	  regulates	  ADAM-­‐17	  localization	  and	  activity.	  J	  Cell	  Physiol,	  2006.	  
208(2):	  p.	  363-­‐72.	  372.	   Bax,	  D.V.,	  et	  al.,	  Integrin	  alpha5beta1	  and	  ADAM-­‐17	  interact	  in	  vitro	  and	  co-­‐
localize	  in	  migrating	  HeLa	  cells.	  J	  Biol	  Chem,	  2004.	  279(21):	  p.	  22377-­‐86.	  373.	   Perera,	  P.Y.,	  et	  al.,	  CD11b/CD18	  acts	  in	  concert	  with	  CD14	  and	  Toll-­‐like	  
receptor	  (TLR)	  4	  to	  elicit	  full	  lipopolysaccharide	  and	  taxol-­‐inducible	  gene	  
expression.	  J	  Immunol,	  2001.	  166(1):	  p.	  574-­‐81.	  374.	   Gooz,	  P.,	  et	  al.,	  A	  disintegrin	  and	  metalloenzyme	  (ADAM)	  17	  activation	  is	  
regulated	  by	  alpha5beta1	  integrin	  in	  kidney	  mesangial	  cells.	  PLoS	  One,	  2012.	  7(3):	  p.	  e33350.	  375.	   Mohan,	  M.J.,	  et	  al.,	  The	  tumor	  necrosis	  factor-­‐alpha	  converting	  enzyme	  
(TACE):	  a	  unique	  metalloproteinase	  with	  highly	  defined	  substrate	  
selectivity.	  Biochemistry,	  2002.	  41(30):	  p.	  9462-­‐9.	  376.	   Althoff,	  K.,	  et	  al.,	  Recognition	  sequences	  and	  structural	  elements	  contribute	  
to	  shedding	  susceptibility	  of	  membrane	  proteins.	  Biochem	  J,	  2001.	  353(Pt	  3):	  p.	  663-­‐72.	  377.	   Killock,	  D.J.	  and	  A.	  Ivetic,	  The	  cytoplasmic	  domains	  of	  TNFalpha-­‐converting	  
enzyme	  (TACE/ADAM17)	  and	  L-­‐selectin	  are	  regulated	  differently	  by	  p38	  
MAPK	  and	  PKC	  to	  promote	  ectodomain	  shedding.	  Biochem	  J,	  2010.	  428(2):	  p.	  293-­‐304.	  378.	   Fan,	  S.T.	  and	  T.S.	  Edgington,	  Integrin	  regulation	  of	  leukocyte	  inflammatory	  
functions.	  CD11b/CD18	  enhancement	  of	  the	  tumor	  necrosis	  factor-­‐alpha	  
responses	  of	  monocytes.	  J	  Immunol,	  1993.	  150(7):	  p.	  2972-­‐80.	  379.	   Rosengart,	  M.R.,	  et	  al.,	  The	  actin	  cytoskeleton:	  an	  essential	  component	  for	  
enhanced	  TNFalpha	  production	  by	  adherent	  monocytes.	  Shock,	  2002.	  
17(2):	  p.	  109-­‐13.	  380.	   Zhang,	  Z.,	  et	  al.,	  Reactive	  oxygen	  species	  mediate	  tumor	  necrosis	  factor	  
alpha-­‐converting,	  enzyme-­‐dependent	  ectodomain	  shedding	  induced	  by	  
phorbol	  myristate	  acetate.	  FASEB	  journal	  :	  official	  publication	  of	  the	  Federation	  of	  American	  Societies	  for	  Experimental	  Biology,	  2001.	  15(2):	  p.	  303-­‐5.	  381.	   Alvarez-­‐Iglesias,	  M.,	  et	  al.,	  Continuous	  real-­‐time	  measurement	  of	  tumor	  
necrosis	  factor-­‐alpha	  converting	  enzyme	  activity	  on	  live	  cells.	  Lab	  Invest,	  2005.	  85(11):	  p.	  1440-­‐8.	  382.	   Tsuchiya,	  S.,	  et	  al.,	  Establishment	  and	  characterization	  of	  a	  human	  acute	  
monocytic	  leukemia	  cell	  line	  (THP-­‐1).	  Int	  J	  Cancer,	  1980.	  26(2):	  p.	  171-­‐6.	  383.	   Schwende,	  H.,	  et	  al.,	  Differences	  in	  the	  state	  of	  differentiation	  of	  THP-­‐1	  cells	  
induced	  by	  phorbol	  ester	  and	  1,25-­‐dihydroxyvitamin	  D3.	  J	  Leukoc	  Biol,	  1996.	  59(4):	  p.	  555-­‐61.	  384.	   Naitoh,	  T.,	  M.	  Kitahara,	  and	  N.	  Tsuruzoe,	  Tumor	  necrosis	  factor-­‐alpha	  is	  
induced	  through	  phorbol	  ester-­‐-­‐and	  glycated	  human	  albumin-­‐dependent	  
pathway	  in	  THP-­‐1	  cells.	  Cell	  Signal,	  2001.	  13(5):	  p.	  331-­‐4.	  385.	   O'Sullivan,	  A.W.,	  J.H.	  Wang,	  and	  H.P.	  Redmond,	  The	  role	  of	  P38	  MAPK	  and	  
PKC	  in	  BLP	  induced	  TNF-­‐alpha	  release,	  apoptosis,	  and	  NFkappaB	  activation	  
in	  THP-­‐1	  monocyte	  cells.	  J	  Surg	  Res,	  2009.	  151(1):	  p.	  138-­‐44.	  
	   259	  
386.	   Tamai,	  R.,	  et	  al.,	  Synergistic	  effects	  of	  lipopolysaccharide	  and	  interferon-­‐
gamma	  in	  inducing	  interleukin-­‐8	  production	  in	  human	  monocytic	  THP-­‐1	  
cells	  is	  accompanied	  by	  up-­‐regulation	  of	  CD14,	  Toll-­‐like	  receptor	  4,	  MD-­‐2	  
and	  MyD88	  expression.	  Journal	  of	  endotoxin	  research,	  2003.	  9(3):	  p.	  145-­‐53.	  387.	   Cauwels,	  A.,	  et	  al.,	  Coexistence	  of	  CD14-­‐dependent	  and	  independent	  
pathways	  for	  stimulation	  of	  human	  monocytes	  by	  gram-­‐positive	  bacteria.	  Infection	  and	  immunity,	  1997.	  65(8):	  p.	  3255-­‐60.	  388.	   Zhang,	  X.,	  et	  al.,	  Suppressive	  effects	  of	  hydroxytyrosol	  on	  oxidative	  stress	  
and	  nuclear	  Factor-­‐kappaB	  activation	  in	  THP-­‐1	  cells.	  Biological	  &	  pharmaceutical	  bulletin,	  2009.	  32(4):	  p.	  578-­‐82.	  389.	   Li,	  S.	  and	  J.	  Zhang,	  Lipopolysaccharide	  induces	  autotaxin	  expression	  in	  
human	  monocytic	  THP-­‐1	  cells.	  Biochemical	  and	  biophysical	  research	  communications,	  2009.	  378(2):	  p.	  264-­‐8.	  390.	   Tahara,	  E.,	  et	  al.,	  Activation	  of	  protein	  kinase	  C	  by	  phorbol	  12-­‐myristate	  13-­‐
acetate	  suppresses	  the	  growth	  of	  lung	  cancer	  cells	  through	  KLF6	  induction.	  Cancer	  Biol	  Ther,	  2009.	  8(9):	  p.	  801-­‐7.	  391.	   Hurtado,	  O.,	  et	  al.,	  Up-­‐regulation	  of	  TNF-­‐alpha	  convertase	  (TACE/ADAM17)	  
after	  oxygen-­‐glucose	  deprivation	  in	  rat	  forebrain	  slices.	  Neuropharmacology,	  2001.	  40(8):	  p.	  1094-­‐102.	  392.	   Pradines-­‐Figueres,	  A.	  and	  C.R.	  Raetz,	  Processing	  and	  secretion	  of	  tumor	  
necrosis	  factor	  alpha	  in	  endotoxin-­‐treated	  Mono	  Mac	  6	  cells	  are	  dependent	  
on	  phorbol	  myristate	  acetate.	  J	  Biol	  Chem,	  1992.	  267(32):	  p.	  23261-­‐8.	  393.	   Hughes,	  P.J.,	  et	  al.,	  The	  vitamin	  D	  receptor-­‐mediated	  activation	  of	  
phosphatidylinositol	  3-­‐kinase	  (PI3Kalpha)	  plays	  a	  role	  in	  the	  1alpha,25-­‐
dihydroxyvitamin	  D3-­‐stimulated	  increase	  in	  steroid	  sulphatase	  activity	  in	  
myeloid	  leukaemic	  cell	  lines.	  J	  Cell	  Biochem,	  2008.	  103(5):	  p.	  1551-­‐72.	  394.	   Zakharova,	  E.,	  et	  al.,	  Mycoplasma	  suppression	  of	  THP-­‐1	  Cell	  TLR	  responses	  
is	  corrected	  with	  antibiotics.	  PLoS	  One,	  2010.	  5(3):	  p.	  e9900.	  395.	   Morris,	  M.	  and	  L.	  Li,	  Molecular	  mechanisms	  and	  pathological	  consequences	  
of	  endotoxin	  tolerance	  and	  priming.	  Archivum	  immunologiae	  et	  therapiae	  experimentalis,	  2012.	  60(1):	  p.	  13-­‐8.	  396.	   van	  Leeuwen,	  H.J.,	  et	  al.,	  The	  role	  of	  tumour	  necrosis	  factor	  in	  the	  kinetics	  of	  
lipopolysaccharide-­‐mediated	  neutrophil	  priming	  in	  whole	  blood.	  Clin	  Exp	  Immunol,	  2005.	  140(1):	  p.	  65-­‐72.	  397.	   Porta,	  C.,	  et	  al.,	  Tolerance	  and	  M2	  (alternative)	  macrophage	  polarization	  
are	  related	  processes	  orchestrated	  by	  p50	  nuclear	  factor	  kappaB.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2009.	  106(35):	  p.	  14978-­‐83.	  398.	   Foster,	  S.L.,	  D.C.	  Hargreaves,	  and	  R.	  Medzhitov,	  Gene-­‐specific	  control	  of	  
inflammation	  by	  TLR-­‐induced	  chromatin	  modifications.	  Nature,	  2007.	  
447(7147):	  p.	  972-­‐8.	  399.	   Li,	  L.,	  et	  al.,	  Characterization	  of	  interleukin-­‐1	  receptor-­‐associated	  kinase	  in	  
normal	  and	  endotoxin-­‐tolerant	  cells.	  J	  Biol	  Chem,	  2000.	  275(30):	  p.	  23340-­‐5.	  400.	   Petit-­‐Bertron,	  A.F.,	  et	  al.,	  Adherence	  influences	  monocyte	  responsiveness	  to	  
interleukin-­‐10.	  J	  Leukoc	  Biol,	  2003.	  73(1):	  p.	  145-­‐54.	  401.	   Krause,	  S.W.,	  M.	  Kreutz,	  and	  R.	  Andreesen,	  Differential	  effects	  of	  cell	  
adherence	  on	  LPS-­‐stimulated	  cytokine	  production	  by	  human	  monocytes	  and	  
macrophages.	  Immunobiology,	  1996.	  196(5):	  p.	  522-­‐34.	  
	   260	  
402.	   van	  der	  Meer,	  J.W.,	  et	  al.,	  Suspension	  cultures	  of	  mononuclear	  phagocytes	  in	  
the	  teflon	  culture	  bag.	  Cell	  Immunol,	  1979.	  42(1):	  p.	  208-­‐12.	  403.	   Yun,	  J.K.,	  et	  al.,	  Human	  monocyte/macrophage	  adhesion	  and	  cytokine	  
production	  on	  surface-­‐modified	  
poly(tetrafluoroethylene/hexafluoropropylene)	  polymers	  with	  and	  without	  
protein	  preadsorption.	  J	  Biomed	  Mater	  Res,	  1995.	  29(2):	  p.	  257-­‐68.	  404.	   Andreesen,	  R.,	  et	  al.,	  Surface	  phenotype	  analysis	  of	  human	  monocyte	  to	  
macrophage	  maturation.	  J	  Leukoc	  Biol,	  1990.	  47(6):	  p.	  490-­‐7.	  405.	   Geissmann,	  F.,	  S.	  Jung,	  and	  D.R.	  Littman,	  Blood	  monocytes	  consist	  of	  two	  
principal	  subsets	  with	  distinct	  migratory	  properties.	  Immunity,	  2003.	  
19(1):	  p.	  71-­‐82.	  406.	   McPeek,	  M.,	  et	  al.,	  The	  expression	  of	  HLA-­‐DR	  by	  monocytes	  from	  black	  and	  
from	  white	  donors:	  different	  requirements	  for	  protein	  synthesis.	  Clin	  Exp	  Immunol,	  1992.	  87(1):	  p.	  163-­‐8.	  407.	   Smith,	  B.R.	  and	  K.A.	  Ault,	  Increase	  of	  surface	  Ia-­‐like	  antigen	  expression	  on	  
human	  monocytes	  independent	  of	  antigenic	  stimuli.	  J	  Immunol,	  1981.	  
127(5):	  p.	  2020-­‐7.	  408.	   Adib-­‐Conquy,	  M.	  and	  J.M.	  Cavaillon,	  Gamma	  interferon	  and	  
granulocyte/monocyte	  colony-­‐stimulating	  factor	  prevent	  endotoxin	  
tolerance	  in	  human	  monocytes	  by	  promoting	  interleukin-­‐1	  receptor-­‐
associated	  kinase	  expression	  and	  its	  association	  to	  MyD88	  and	  not	  by	  
modulating	  TLR4	  expression.	  J	  Biol	  Chem,	  2002.	  277(31):	  p.	  27927-­‐34.	  409.	   Haas,	  J.G.,	  et	  al.,	  Inhibition	  of	  lipopolysaccharide-­‐induced	  in	  vitro	  
desensitization	  by	  interferon-­‐gamma.	  Eur	  J	  Immunol,	  1990.	  20(5):	  p.	  1181-­‐4.	  410.	   Randow,	  F.,	  et	  al.,	  In	  vitro	  prevention	  and	  reversal	  of	  lipopolysaccharide	  
desensitization	  by	  IFN-­‐gamma,	  IL-­‐12,	  and	  granulocyte-­‐macrophage	  colony-­‐
stimulating	  factor.	  J	  Immunol,	  1997.	  158(6):	  p.	  2911-­‐8.	  411.	   Poupot,	  M.,	  et	  al.,	  Design	  of	  phosphorylated	  dendritic	  architectures	  to	  
promote	  human	  monocyte	  activation.	  FASEB	  J,	  2006.	  20(13):	  p.	  2339-­‐51.	  412.	   Kelley,	  J.L.,	  et	  al.,	  Activation	  of	  human	  blood	  monocytes	  by	  adherence	  to	  
tissue	  culture	  plastic	  surfaces.	  Exp	  Mol	  Pathol,	  1987.	  46(3):	  p.	  266-­‐78.	  413.	   Geissmann,	  F.,	  et	  al.,	  Development	  of	  monocytes,	  macrophages,	  and	  
dendritic	  cells.	  Science,	  2010.	  327(5966):	  p.	  656-­‐61.	  414.	   Rozenova,	  K.A.,	  et	  al.,	  Studies	  on	  the	  role	  of	  acid	  sphingomyelinase	  and	  
ceramide	  in	  the	  regulation	  of	  tumor	  necrosis	  factor	  alpha	  (TNFalpha)-­‐
converting	  enzyme	  activity	  and	  TNFalpha	  secretion	  in	  macrophages.	  J	  Biol	  Chem,	  2010.	  285(27):	  p.	  21103-­‐13.	  415.	   Tudhope,	  S.J.,	  et	  al.,	  Different	  mitogen-­‐activated	  protein	  kinase-­‐dependent	  
cytokine	  responses	  in	  cells	  of	  the	  monocyte	  lineage.	  J	  Pharmacol	  Exp	  Ther,	  2008.	  324(1):	  p.	  306-­‐12.	  416.	   Wilhelm,	  W.,	  et	  al.,	  Monocyte	  deactivation	  in	  severe	  human	  sepsis	  or	  
following	  cardiopulmonary	  bypass.	  Shock,	  2002.	  17(5):	  p.	  354-­‐60.	  417.	   Draisma,	  A.,	  et	  al.,	  Development	  of	  endotoxin	  tolerance	  in	  humans	  in	  vivo.	  Crit	  Care	  Med,	  2009.	  37(4):	  p.	  1261-­‐7.	  418.	   Escoll,	  P.,	  et	  al.,	  Rapid	  up-­‐regulation	  of	  IRAK-­‐M	  expression	  following	  a	  
second	  endotoxin	  challenge	  in	  human	  monocytes	  and	  in	  monocytes	  isolated	  
from	  septic	  patients.	  Biochem	  Biophys	  Res	  Commun,	  2003.	  311(2):	  p.	  465-­‐72.	  
	   261	  
419.	   Maitra,	  U.,	  et	  al.,	  Low-­‐dose	  endotoxin	  induces	  inflammation	  by	  selectively	  
removing	  nuclear	  receptors	  and	  activating	  CCAAT/enhancer-­‐binding	  
protein	  delta.	  J	  Immunol,	  2011.	  186(7):	  p.	  4467-­‐73.	  420.	   Hopkins,	  H.A.,	  M.M.	  Monick,	  and	  G.W.	  Hunninghake,	  Lipopolysaccharide	  
upregulates	  surface	  expression	  of	  CD14	  on	  human	  alveolar	  macrophages.	  Am	  J	  Physiol,	  1995.	  269(6	  Pt	  1):	  p.	  L849-­‐54.	  421.	   Dekkers,	  P.E.,	  et	  al.,	  The	  metalloproteinase	  inhibitor	  GI5402	  inhibits	  
endotoxin-­‐induced	  soluble	  CD27	  and	  CD16	  release	  in	  healthy	  humans.	  Infect	  Immun,	  2000.	  68(5):	  p.	  3036-­‐9.	  422.	   Sondag,	  C.M.	  and	  C.K.	  Combs,	  Adhesion	  of	  monocytes	  to	  type	  I	  collagen	  
stimulates	  an	  APP-­‐dependent	  proinflammatory	  signaling	  response	  and	  
release	  of	  Abeta1-­‐40.	  J	  Neuroinflammation,	  2010.	  7:	  p.	  22.	  423.	   Hart,	  P.H.,	  et	  al.,	  Regulation	  of	  surface	  and	  soluble	  TNF	  receptor	  expression	  
on	  human	  monocytes	  and	  synovial	  fluid	  macrophages	  by	  IL-­‐4	  and	  IL-­‐10.	  J	  Immunol,	  1996.	  157(8):	  p.	  3672-­‐80.	  424.	   Bertok,	  S.,	  et	  al.,	  Characterization	  of	  TNF	  receptor	  subtype	  expression	  and	  
signaling	  on	  pulmonary	  endothelial	  cells	  in	  mice.	  Am	  J	  Physiol	  Lung	  Cell	  Mol	  Physiol,	  2011.	  300(5):	  p.	  L781-­‐9.	  425.	   Pedron,	  T.,	  R.	  Girard,	  and	  R.	  Chaby,	  TLR4-­‐dependent	  lipopolysaccharide-­‐
induced	  shedding	  of	  tumor	  necrosis	  factor	  receptors	  in	  mouse	  bone	  marrow	  
granulocytes.	  The	  Journal	  of	  biological	  chemistry,	  2003.	  278(23):	  p.	  20555-­‐64.	  426.	   van	  der	  Poll,	  T.,	  et	  al.,	  Down-­‐regulation	  of	  surface	  receptors	  for	  TNF	  and	  IL-­‐
1	  on	  circulating	  monocytes	  and	  granulocytes	  during	  human	  endotoxemia:	  
effect	  of	  neutralization	  of	  endotoxin-­‐induced	  TNF	  activity	  by	  infusion	  of	  a	  
recombinant	  dimeric	  TNF	  receptor.	  J	  Immunol,	  1997.	  158(3):	  p.	  1490-­‐7.	  427.	   Rizoli,	  S.B.,	  O.D.	  Rotstein,	  and	  A.	  Kapus,	  Cell	  volume-­‐dependent	  regulation	  
of	  L-­‐selectin	  shedding	  in	  neutrophils.	  A	  role	  for	  p38	  mitogen-­‐activated	  
protein	  kinase.	  J	  Biol	  Chem,	  1999.	  274(31):	  p.	  22072-­‐80.	  428.	   Palecanda,	  A.,	  et	  al.,	  Rapid	  activation-­‐independent	  shedding	  of	  leukocyte	  L-­‐
selectin	  induced	  by	  cross-­‐linking	  of	  the	  surface	  antigen.	  Eur	  J	  Immunol,	  1992.	  22(5):	  p.	  1279-­‐86.	  429.	   Kishimoto,	  T.K.,	  et	  al.,	  Neutrophil	  Mac-­‐1	  and	  MEL-­‐14	  adhesion	  proteins	  
inversely	  regulated	  by	  chemotactic	  factors.	  Science,	  1989.	  245(4923):	  p.	  1238-­‐41.	  430.	   Megyeri,	  P.,	  K.M.	  Pabst,	  and	  M.J.	  Pabst,	  Serine	  protease	  inhibitors	  block	  
priming	  of	  monocytes	  for	  enhanced	  release	  of	  superoxide.	  Immunology,	  1995.	  86(4):	  p.	  629-­‐35.	  431.	   De	  Groote,	  D.,	  et	  al.,	  Direct	  stimulation	  of	  cytokines	  (IL-­‐1	  beta,	  TNF-­‐alpha,	  
IL-­‐6,	  IL-­‐2,	  IFN-­‐gamma	  and	  GM-­‐CSF)	  in	  whole	  blood.	  I.	  Comparison	  with	  
isolated	  PBMC	  stimulation.	  Cytokine,	  1992.	  4(3):	  p.	  239-­‐48.	  432.	   West,	  S.D.	  and	  C.	  Mold,	  Monocyte	  deactivation	  correlates	  with	  injury	  
severity	  score,	  but	  not	  with	  heme	  oxygenase-­‐1	  levels	  in	  trauma	  patients.	  J	  Surg	  Res,	  2012.	  172(1):	  p.	  5-­‐10.	  433.	   Muthu,	  K.,	  et	  al.,	  Perturbed	  bone	  marrow	  monocyte	  development	  following	  
burn	  injury	  and	  sepsis	  promote	  hyporesponsive	  monocytes.	  J	  Burn	  Care	  Res,	  2008.	  29(1):	  p.	  12-­‐21.	  
	   262	  
434.	   Wang,	  P.,	  et	  al.,	  Interleukin	  (IL)-­‐10	  inhibits	  nuclear	  factor	  kappa	  B	  (NF	  
kappa	  B)	  activation	  in	  human	  monocytes.	  IL-­‐10	  and	  IL-­‐4	  suppress	  cytokine	  
synthesis	  by	  different	  mechanisms.	  J	  Biol	  Chem,	  1995.	  270(16):	  p.	  9558-­‐63.	  435.	   Reddy,	  R.C.,	  et	  al.,	  Alveolar	  macrophage	  deactivation	  in	  murine	  septic	  
peritonitis:	  role	  of	  interleukin	  10.	  Infect	  Immun,	  2001.	  69(3):	  p.	  1394-­‐401.	  436.	   Wolk,	  K.,	  et	  al.,	  Multiple	  mechanisms	  of	  reduced	  major	  histocompatibility	  
complex	  class	  II	  expression	  in	  endotoxin	  tolerance{Wolk,	  2003	  #3365}.	  J	  Biol	  Chem,	  2003.	  278(20):	  p.	  18030-­‐6.	  437.	   Le	  Tulzo,	  Y.,	  et	  al.,	  Monocyte	  human	  leukocyte	  antigen-­‐DR	  transcriptional	  
downregulation	  by	  cortisol	  during	  septic	  shock.	  Am	  J	  Respir	  Crit	  Care	  Med,	  2004.	  169(10):	  p.	  1144-­‐51.	  438.	   Volk,	  H.D.,	  P.	  Reinke,	  and	  W.D.	  Docke,	  Clinical	  aspects:	  from	  systemic	  
inflammation	  to	  'immunoparalysis'.	  Chem	  Immunol,	  2000.	  74:	  p.	  162-­‐77.	  439.	   Andre,	  M.C.,	  et	  al.,	  Bacterial	  reprogramming	  of	  PBMCs	  impairs	  monocyte	  
phagocytosis	  and	  modulates	  adaptive	  T	  cell	  responses.	  J	  Leukoc	  Biol,	  2012.	  
91(6):	  p.	  977-­‐89.	  440.	   Williams,	  M.A.,	  et	  al.,	  Monocyte	  anergy	  in	  septic	  shock	  is	  associated	  with	  a	  
predilection	  to	  apoptosis	  and	  is	  reversed	  by	  granulocyte-­‐macrophage	  
colony-­‐stimulating	  factor	  ex	  vivo.	  J	  Infect	  Dis,	  1998.	  178(5):	  p.	  1421-­‐33.	  441.	   Nierhaus,	  A.,	  et	  al.,	  Reversal	  of	  immunoparalysis	  by	  recombinant	  human	  
granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  in	  patients	  with	  severe	  
sepsis.	  Intensive	  Care	  Med,	  2003.	  29(4):	  p.	  646-­‐51.	  442.	   Dreymueller,	  D.,	  et	  al.,	  Lung	  endothelial	  ADAM17	  regulates	  the	  acute	  
inflammatory	  response	  to	  lipopolysaccharide.	  EMBO	  Mol	  Med,	  2012.	  4(5):	  p.	  412-­‐23.	  443.	   Markovic,	  N.,	  et	  al.,	  Mediators	  released	  from	  LPS-­‐challenged	  lungs	  induce	  
inflammatory	  responses	  in	  liver	  vascular	  endothelial	  cells	  and	  neutrophilic	  
leukocytes.	  Am	  J	  Physiol	  Gastrointest	  Liver	  Physiol,	  2009.	  297(6):	  p.	  G1066-­‐76.	  444.	   Long,	  C.,	  et	  al.,	  In	  vivo	  role	  of	  leukocyte	  ADAM17	  in	  the	  inflammatory	  and	  
host	  responses	  during	  E.	  coli-­‐mediated	  peritonitis.	  J	  Leukoc	  Biol,	  2010.	  
87(6):	  p.	  1097-­‐101.	  445.	   Rovida,	  E.,	  et	  al.,	  TNF-­‐alpha-­‐converting	  enzyme	  cleaves	  the	  macrophage	  
colony-­‐stimulating	  factor	  receptor	  in	  macrophages	  undergoing	  activation.	  J	  Immunol,	  2001.	  166(3):	  p.	  1583-­‐9.	  446.	   Robertson,	  M.J.	  and	  J.	  Ritz,	  Biology	  and	  clinical	  relevance	  of	  human	  natural	  
killer	  cells.	  Blood,	  1990.	  76(12):	  p.	  2421-­‐38.	  447.	   Grage-­‐Griebenow,	  E.,	  et	  al.,	  Identification	  of	  a	  novel	  dendritic	  cell-­‐like	  
subset	  of	  CD64(+)	  /	  CD16(+)	  blood	  monocytes.	  Eur	  J	  Immunol,	  2001.	  31(1):	  p.	  48-­‐56.	  448.	   Grage-­‐Griebenow,	  E.,	  H.D.	  Flad,	  and	  M.	  Ernst,	  Heterogeneity	  of	  human	  
peripheral	  blood	  monocyte	  subsets.	  J	  Leukoc	  Biol,	  2001.	  69(1):	  p.	  11-­‐20.	  449.	   Grage-­‐Griebenow,	  E.,	  et	  al.,	  Human	  MO	  subsets	  as	  defined	  by	  expression	  of	  
CD64	  and	  CD16	  differ	  in	  phagocytic	  activity	  and	  generation	  of	  oxygen	  
intermediates.	  Immunobiology,	  2000.	  202(1):	  p.	  42-­‐50.	  450.	   Welch,	  G.R.,	  H.L.	  Wong,	  and	  S.M.	  Wahl,	  Selective	  induction	  of	  Fc	  gamma	  RIII	  
on	  human	  monocytes	  by	  transforming	  growth	  factor-­‐beta.	  J	  Immunol,	  1990.	  144(9):	  p.	  3444-­‐8.
	   263	  
451.	   Phillips,	  J.H.,	  C.W.	  Chang,	  and	  L.L.	  Lanier,	  Platelet-­‐induced	  expression	  of	  Fc	  
gamma	  RIII	  (CD16)	  on	  human	  monocytes.	  Eur	  J	  Immunol,	  1991.	  21(4):	  p.	  895-­‐9.	  452.	   Hirsh,	  M.,	  et	  al.,	  Overexpression	  of	  the	  high-­‐affinity	  Fcgamma	  receptor	  
(CD64)	  is	  associated	  with	  leukocyte	  dysfunction	  in	  sepsis.	  Shock,	  2001.	  
16(2):	  p.	  102-­‐8.	  453.	   Barth,	  E.,	  et	  al.,	  Differences	  in	  the	  expression	  of	  CD64	  and	  mCD14	  on	  
polymorphonuclear	  cells	  and	  on	  monocytes	  in	  patients	  with	  septic	  shock.	  Cytokine,	  2001.	  14(5):	  p.	  299-­‐302.	  454.	   Furutani,	  Y.,	  et	  al.,	  Cloning	  and	  sequencing	  of	  the	  cDNA	  for	  human	  
monocyte	  chemotactic	  and	  activating	  factor	  (MCAF).	  Biochem	  Biophys	  Res	  Commun,	  1989.	  159(1):	  p.	  249-­‐55.	  455.	   Carr,	  M.W.,	  et	  al.,	  Monocyte	  chemoattractant	  protein	  1	  acts	  as	  a	  T-­‐
lymphocyte	  chemoattractant.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  1994.	  91(9):	  p.	  3652-­‐6.	  456.	   Angus,	  D.C.,	  et	  al.,	  Epidemiology	  of	  severe	  sepsis	  in	  the	  United	  States:	  
analysis	  of	  incidence,	  outcome,	  and	  associated	  costs	  of	  care.	  Critical	  care	  medicine,	  2001.	  29(7):	  p.	  1303-­‐10.	  457.	   Wu,	  J.,	  et	  al.,	  Age-­‐dependent	  alterations	  of	  HLA-­‐DR	  expression	  and	  effect	  of	  
lipopolysaccharide	  on	  cytokine	  secretion	  of	  peripheral	  blood	  mononuclear	  
cells	  in	  the	  elderly	  population.	  Scand	  J	  Immunol,	  2011.	  74(6):	  p.	  603-­‐8.	  458.	   Richter,	  A.,	  et	  al.,	  HLA-­‐DR	  expression	  in	  acute	  pancreatitis.	  Eur	  J	  Surg,	  1999.	  
165(10):	  p.	  947-­‐51.	  459.	   Haveman,	  J.W.,	  et	  al.,	  HLA-­‐DR	  expression	  on	  monocytes	  and	  systemic	  
inflammation	  in	  patients	  with	  ruptured	  abdominal	  aortic	  aneurysms.	  Crit	  Care,	  2006.	  10(4):	  p.	  R119.	  460.	   van	  den	  Berk,	  J.M.,	  et	  al.,	  Low	  HLA-­‐DR	  expression	  on	  monocytes	  as	  a	  
prognostic	  marker	  for	  bacterial	  sepsis	  after	  liver	  transplantation.	  Transplantation,	  1997.	  63(12):	  p.	  1846-­‐8.	  461.	   Muehlstedt,	  S.G.,	  M.	  Lyte,	  and	  J.L.	  Rodriguez,	  Increased	  IL-­‐10	  production	  
and	  HLA-­‐DR	  suppression	  in	  the	  lungs	  of	  injured	  patients	  precede	  the	  
development	  of	  nosocomial	  pneumonia.	  Shock,	  2002.	  17(6):	  p.	  443-­‐50.	  462.	   Danikas,	  D.D.,	  et	  al.,	  Prognostic	  value	  of	  phagocytic	  activity	  of	  neutrophils	  
and	  monocytes	  in	  sepsis.	  Correlation	  to	  CD64	  and	  CD14	  antigen	  expression.	  Clin	  Exp	  Immunol,	  2008.	  154(1):	  p.	  87-­‐97.	  463.	   de	  Werra,	  I.,	  et	  al.,	  CD14	  expression	  on	  monocytes	  and	  TNF	  alpha	  
production	  in	  patients	  with	  septic	  shock,	  cardiogenic	  shock	  or	  bacterial	  
pneumonia.	  Swiss	  Med	  Wkly,	  2001.	  131(3-­‐4):	  p.	  35-­‐40.	  464.	   Rosengart,	  M.R.,	  et	  al.,	  Mitogen-­‐activated	  protein	  kinases	  in	  the	  intensive	  
care	  unit:	  prognostic	  potential.	  Ann	  Surg,	  2003.	  237(1):	  p.	  94-­‐100.	  465.	   Wesche,	  D.E.,	  et	  al.,	  Leukocyte	  apoptosis	  and	  its	  significance	  in	  sepsis	  and	  
shock.	  J	  Leukoc	  Biol,	  2005.	  78(2):	  p.	  325-­‐37.	  466.	   Murray,	  J.,	  et	  al.,	  Regulation	  of	  neutrophil	  apoptosis	  by	  tumor	  necrosis	  
factor-­‐alpha:	  requirement	  for	  TNFR55	  and	  TNFR75	  for	  induction	  of	  
apoptosis	  in	  vitro.	  Blood,	  1997.	  90(7):	  p.	  2772-­‐83.	  467.	   Janssen,	  W.J.,	  et	  al.,	  Fas	  determines	  differential	  fates	  of	  resident	  and	  
recruited	  macrophages	  during	  resolution	  of	  acute	  lung	  injury.	  Am	  J	  Respir	  Crit	  Care	  Med,	  2011.	  184(5):	  p.	  547-­‐60.	  
	   264	  
468.	   Giamarellos-­‐Bourboulis,	  E.J.,	  et	  al.,	  Early	  apoptosis	  of	  blood	  monocytes	  in	  
the	  septic	  host:	  is	  it	  a	  mechanism	  of	  protection	  in	  the	  event	  of	  septic	  shock?	  Crit	  Care,	  2006.	  10(3):	  p.	  R76.	  469.	   Brealey,	  D.,	  et	  al.,	  Mitochondrial	  dysfunction	  in	  a	  long-­‐term	  rodent	  model	  of	  
sepsis	  and	  organ	  failure.	  Am	  J	  Physiol	  Regul	  Integr	  Comp	  Physiol,	  2004.	  
286(3):	  p.	  R491-­‐7.	  470.	   Rowlands,	  D.J.,	  et	  al.,	  Activation	  of	  TNFR1	  ectodomain	  shedding	  by	  
mitochondrial	  Ca2+	  determines	  the	  severity	  of	  inflammation	  in	  mouse	  lung	  
microvessels.	  The	  Journal	  of	  clinical	  investigation,	  2011.	  121(5):	  p.	  1986-­‐99.	  471.	   Bain,	  J.,	  et	  al.,	  The	  selectivity	  of	  protein	  kinase	  inhibitors:	  a	  further	  update.	  Biochem	  J,	  2007.	  408(3):	  p.	  297-­‐315.	  472.	   Scott,	  A.J.,	  The	  regulation	  of	  tumour	  necrosis	  factor-­‐alpha	  converting	  
enzyme	  during	  acute	  inflammation.	  PhD	  thesis,	  2011.	  473.	   Walcheck,	  B.,	  et	  al.,	  Neutrophil	  rolling	  altered	  by	  inhibition	  of	  L-­‐selectin	  
shedding	  in	  vitro.	  Nature,	  1996.	  380(6576):	  p.	  720-­‐3.	  474.	   Allport,	  J.R.,	  et	  al.,	  L-­‐selectin	  shedding	  does	  not	  regulate	  human	  neutrophil	  
attachment,	  rolling,	  or	  transmigration	  across	  human	  vascular	  endothelium	  
in	  vitro.	  J	  Immunol,	  1997.	  158(9):	  p.	  4365-­‐72.	  475.	   Ingersoll,	  M.A.,	  et	  al.,	  Comparison	  of	  gene	  expression	  profiles	  between	  
human	  and	  mouse	  monocyte	  subsets.	  Blood,	  2010.	  115(3):	  p.	  e10-­‐9.	  476.	   Cavaillon,	  J.M.	  and	  M.	  Adib-­‐Conquy,	  Immune	  status	  in	  sepsis:	  the	  bug,	  the	  
site	  of	  infection	  and	  the	  severity	  can	  make	  the	  difference.	  Critical	  care,	  2010.	  14(3):	  p.	  167.	  477.	   Fan,	  J.,	  et	  al.,	  Role	  of	  neutrophil	  NADPH	  oxidase	  in	  the	  mechanism	  of	  tumor	  
necrosis	  factor-­‐alpha	  -­‐induced	  NF-­‐kappa	  B	  activation	  and	  intercellular	  
adhesion	  molecule-­‐1	  expression	  in	  endothelial	  cells.	  J	  Biol	  Chem,	  2002.	  
277(5):	  p.	  3404-­‐11.	  478.	   Piccini,	  A.,	  et	  al.,	  ATP	  is	  released	  by	  monocytes	  stimulated	  with	  pathogen-­‐
sensing	  receptor	  ligands	  and	  induces	  IL-­‐1beta	  and	  IL-­‐18	  secretion	  in	  an	  
autocrine	  way.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A,	  2008.	  105(23):	  p.	  8067-­‐72.	  479.	   Cruz,	  C.M.,	  et	  al.,	  ATP	  activates	  a	  reactive	  oxygen	  species-­‐dependent	  
oxidative	  stress	  response	  and	  secretion	  of	  proinflammatory	  cytokines	  in	  
macrophages.	  J	  Biol	  Chem,	  2007.	  282(5):	  p.	  2871-­‐9.	  480.	   Noguchi,	  T.,	  et	  al.,	  Requirement	  of	  reactive	  oxygen	  species-­‐dependent	  
activation	  of	  ASK1-­‐p38	  MAPK	  pathway	  for	  extracellular	  ATP-­‐induced	  
apoptosis	  in	  macrophage.	  J	  Biol	  Chem,	  2008.	  283(12):	  p.	  7657-­‐65.	  481.	   Yin,	  J.,	  et	  al.,	  Wound-­‐induced	  ATP	  release	  and	  EGF	  receptor	  activation	  in	  
epithelial	  cells.	  J	  Cell	  Sci,	  2007.	  120(Pt	  5):	  p.	  815-­‐25.	  482.	   Labasi,	  J.M.,	  et	  al.,	  Absence	  of	  the	  P2X7	  receptor	  alters	  leukocyte	  function	  
and	  attenuates	  an	  inflammatory	  response.	  J	  Immunol,	  2002.	  168(12):	  p.	  6436-­‐45.	  483.	   Koll,	  S.,	  et	  al.,	  Monocytic-­‐endothelial	  cell	  interaction:	  regulation	  of	  
prostanoid	  synthesis	  in	  human	  coculture.	  J	  Leukoc	  Biol,	  1997.	  61(6):	  p.	  679-­‐88.	  484.	   Lo,	  S.K.,	  et	  al.,	  Induction	  of	  tissue	  factor	  on	  monocytes	  by	  adhesion	  to	  
endothelial	  cells.	  J	  Immunol,	  1995.	  154(9):	  p.	  4768-­‐77.	  
	   265	  
485.	   Lukacs,	  N.W.,	  et	  al.,	  Production	  of	  chemokines,	  interleukin-­‐8	  and	  monocyte	  
chemoattractant	  protein-­‐1,	  during	  monocyte:	  endothelial	  cell	  interactions.	  Blood,	  1995.	  86(7):	  p.	  2767-­‐73.	  486.	   Bauer,	  G.J.,	  et	  al.,	  Adherence	  regulates	  macrophage	  signal	  transduction	  and	  
primes	  tumor	  necrosis	  factor	  production.	  Shock,	  2000.	  14(4):	  p.	  435-­‐40.	  487.	   Rajecky,	  M.,	  A.	  Lojek,	  and	  M.	  Ciz,	  Differentiating	  between	  intra-­‐	  and	  
extracellular	  chemiluminescence	  in	  diluted	  whole-­‐blood	  samples.	  Int	  J	  Lab	  Hematol,	  2012.	  34(2):	  p.	  136-­‐42.	  488.	   Biswas,	  D.,	  et	  al.,	  ATP-­‐induced	  autophagy	  is	  associated	  with	  rapid	  killing	  of	  
intracellular	  mycobacteria	  within	  human	  monocytes/macrophages.	  BMC	  Immunol,	  2008.	  9:	  p.	  35.	  489.	   Hanley,	  P.J.,	  et	  al.,	  Transient	  P2X7	  receptor	  activation	  triggers	  macrophage	  
death	  independent	  of	  Toll-­‐like	  receptors	  2	  and	  4,	  caspase-­‐1,	  and	  pannexin-­‐1	  
proteins.	  J	  Biol	  Chem,	  2012.	  287(13):	  p.	  10650-­‐63.	  490.	   Khakh,	  B.S.	  and	  R.A.	  North,	  P2X	  receptors	  as	  cell-­‐surface	  ATP	  sensors	  in	  
health	  and	  disease.	  Nature,	  2006.	  442(7102):	  p.	  527-­‐32.	  491.	   Aplin,	  A.E.,	  et	  al.,	  Cell	  adhesion	  differentially	  regulates	  the	  
nucleocytoplasmic	  distribution	  of	  active	  MAP	  kinases.	  J	  Cell	  Sci,	  2002.	  
115(Pt	  13):	  p.	  2781-­‐90.	  492.	   Detmers,	  P.A.,	  et	  al.,	  Role	  of	  stress-­‐activated	  mitogen-­‐activated	  protein	  
kinase	  (p38)	  in	  beta	  2-­‐integrin-­‐dependent	  neutrophil	  adhesion	  and	  the	  
adhesion-­‐dependent	  oxidative	  burst.	  J	  Immunol,	  1998.	  161(4):	  p.	  1921-­‐9.	  493.	   Weiss,	  S.J.,	  G.W.	  King,	  and	  A.F.	  LoBuglio,	  Evidence	  for	  hydroxyl	  radical	  
generation	  by	  human	  Monocytes.	  J	  Clin	  Invest,	  1977.	  60(2):	  p.	  370-­‐3.	  494.	   Britigan,	  B.E.,	  et	  al.,	  Mononuclear	  phagocytes	  have	  the	  potential	  for	  
sustained	  hydroxyl	  radical	  production.	  Use	  of	  spin-­‐trapping	  techniques	  to	  
investigate	  mononuclear	  phagocyte	  free	  radical	  production.	  J	  Exp	  Med,	  1988.	  168(6):	  p.	  2367-­‐72.	  495.	   Werner,	  E.	  and	  Z.	  Werb,	  Integrins	  engage	  mitochondrial	  function	  for	  signal	  
transduction	  by	  a	  mechanism	  dependent	  on	  Rho	  GTPases.	  J	  Cell	  Biol,	  2002.	  
158(2):	  p.	  357-­‐68.	  496.	   Husemann,	  J.,	  et	  al.,	  CD11b/CD18	  mediates	  production	  of	  reactive	  oxygen	  
species	  by	  mouse	  and	  human	  macrophages	  adherent	  to	  matrixes	  containing	  
oxidized	  LDL.	  Arterioscler	  Thromb	  Vasc	  Biol,	  2001.	  21(8):	  p.	  1301-­‐5.	  497.	   Chiarugi,	  P.,	  et	  al.,	  Reactive	  oxygen	  species	  as	  essential	  mediators	  of	  cell	  
adhesion:	  the	  oxidative	  inhibition	  of	  a	  FAK	  tyrosine	  phosphatase	  is	  required	  
for	  cell	  adhesion.	  J	  Cell	  Biol,	  2003.	  161(5):	  p.	  933-­‐44.	  498.	   Lorne,	  E.,	  et	  al.,	  Role	  of	  extracellular	  superoxide	  in	  neutrophil	  activation:	  
interactions	  between	  xanthine	  oxidase	  and	  TLR4	  induce	  proinflammatory	  
cytokine	  production.	  Am	  J	  Physiol	  Cell	  Physiol,	  2008.	  294(4):	  p.	  C985-­‐93.	  499.	   Borsellino,	  G.,	  et	  al.,	  Expression	  of	  ectonucleotidase	  CD39	  by	  Foxp3+	  Treg	  
cells:	  hydrolysis	  of	  extracellular	  ATP	  and	  immune	  suppression.	  Blood,	  2007.	  
110(4):	  p.	  1225-­‐32.	  500.	   Walzog,	  B.,	  et	  al.,	  Cross-­‐linking	  of	  CD18	  in	  human	  neutrophils	  induces	  an	  
increase	  of	  intracellular	  free	  Ca2+,	  exocytosis	  of	  azurophilic	  granules,	  
quantitative	  up-­‐regulation	  of	  CD18,	  shedding	  of	  L-­‐selectin,	  and	  actin	  
polymerization.	  J	  Leukoc	  Biol,	  1994.	  56(5):	  p.	  625-­‐35.	  501.	   Li,	  X.	  and	  H.	  Fan,	  Loss	  of	  ectodomain	  shedding	  due	  to	  mutations	  in	  the	  
metalloprotease	  and	  cysteine-­‐rich/disintegrin	  domains	  of	  the	  tumor	  
	   266	  
necrosis	  factor-­‐alpha	  converting	  enzyme	  (TACE).	  J	  Biol	  Chem,	  2004.	  
279(26):	  p.	  27365-­‐75.	  502.	   Smith,	  K.M.,	  et	  al.,	  The	  cysteine-­‐rich	  domain	  regulates	  ADAM	  protease	  
function	  in	  vivo.	  J	  Cell	  Biol,	  2002.	  159(5):	  p.	  893-­‐902.	  503.	   Rammelkamp	  CH,	  M.T.,	  Resistance	  of	  staphylococcus	  aureus	  to	  the	  action	  of	  
penecillin	  Proc	  Royal	  Soc	  Exper	  Biol	  Med,	  1942.	  51:	  p.	  386-­‐389.	  504.	   D'Costa,	  V.M.,	  et	  al.,	  Antibiotic	  resistance	  is	  ancient.	  Nature,	  2011.	  
477(7365):	  p.	  457-­‐61.	  505.	   Fauci,	  A.S.,	  Infectious	  diseases:	  considerations	  for	  the	  21st	  century.	  Clin	  Infect	  Dis,	  2001.	  32(5):	  p.	  675-­‐85.	  506.	   Pan,	  C.,	  et	  al.,	  Comparative	  proteomic	  phenotyping	  of	  cell	  lines	  and	  primary	  
cells	  to	  assess	  preservation	  of	  cell	  type-­‐specific	  functions.	  Mol	  Cell	  Proteomics,	  2009.	  8(3):	  p.	  443-­‐50.	  507.	   Eperon,	  S.	  and	  T.W.	  Jungi,	  The	  use	  of	  human	  monocytoid	  lines	  as	  indicators	  
of	  endotoxin.	  J	  Immunol	  Methods,	  1996.	  194(2):	  p.	  121-­‐9.	  508.	   Zhou,	  L.,	  et	  al.,	  Impact	  of	  human	  granulocyte	  and	  monocyte	  isolation	  
procedures	  on	  functional	  studies.	  Clin	  Vaccine	  Immunol,	  2012.	  19(7):	  p.	  1065-­‐74.	  509.	   Elkord,	  E.,	  et	  al.,	  Human	  monocyte	  isolation	  methods	  influence	  cytokine	  
production	  from	  in	  vitro	  generated	  dendritic	  cells.	  Immunology,	  2005.	  
114(2):	  p.	  204-­‐12.	  510.	   Schinkel,	  C.,	  et	  al.,	  Functional	  analysis	  of	  monocyte	  subsets	  in	  surgical	  
sepsis.	  J	  Trauma,	  1998.	  44(5):	  p.	  743-­‐8;	  discussion	  748-­‐9.	  511.	   Adib-­‐Conquy,	  M.,	  et	  al.,	  NF-­‐kappaB	  expression	  in	  mononuclear	  cells	  of	  
patients	  with	  sepsis	  resembles	  that	  observed	  in	  lipopolysaccharide	  
tolerance.	  Am	  J	  Respir	  Crit	  Care	  Med,	  2000.	  162(5):	  p.	  1877-­‐83.	  	  
	   	  
	   267	  
	  
Appendix	  1	  
	  Publications	  and	  presentations	  
	  
The	  data	  contained	  in	  Chapters	  4,	  5	  and	  6	  have	  been	  partially	  published	  in	  abstract	  form:	  
O’Callaghan	   DJP,	   O’Dea	   KP,	   Takata	   M,	   Gordon	   AC.	   Deactivated	   monocytes:	   not	   hypo-­‐
responsive	  but	  reprogrammed.	  Journal	  of	  the	  Intensive	  Care	  Society	  2012,	  13:1;	  69	  
O’Callaghan	  DJ,	  O’Dea	  KP,	  Gordon	  AC,	  Takata	  M.	  Monocyte	  TACE	  activity	  profiles	  are	  altered	  
by	  inflammatory	  stimuli.	  Intensive	  Care	  Medicine	  2011,	  37	  S1:	  A1010	  	  
O’Callaghan	  DJ,	  O’Dea	  KP,	  Gordon	  AC,	   Takata	  M.	  Monocyte	   TACE	   activity	  may	   respond	   to	  
environmental	  stimuli.	  Intensive	  Care	  Medicine	  2011,	  37	  S1:	  A1012	  
O’Callaghan	   DJP,	   O’Dea	   KP,	   Scott	   AJ,	   Takata	   M,	   Gordon	   AC.	   TACE	   activity	   -­‐	   a	   potential	  
indicator	   of	   monocyte	   inflammatory	   status	   during	   sepsis.	   Journal	   of	   the	   Intensive	   Care	  
Society	  2011,	  12:1;	  73	  
	  
The	   data	  within	   Chapter	   5	   has	   been	   presented	   in	   oral	   format	   and	   has	  won	   the	   following	  
prizes:	  
1st	  place,	  London	  Perioperative	  Research	  Meeting,	  2012	  
1st	  place,	  International	  Sepsis	  Forum,	  ICS	  State	  of	  the	  Art	  Meeting,	  2011	  
	   	  







	  Study	  documentation	  
	   	  




“Mechanisms	  of	  monocyte	  priming	  and	  tolerance	  in	  




























MAIN	  SPONSOR:	  Imperial	  College	  London	  	  
FUNDER:	  The	  Intensive	  Care	  Society	  







Protocol	  authorised	  by:	  
	  
Name	  &	  Role	   Date	   Signature	  
Dr	  D.	  O’Callaghan	  
Investigator	  
	   	  
Dr	  A.	  Gordon	  
Chief	  Investigator	  
	   	  
	   	  
	   271	  
Study	  Management	  Group	  
	  
Chief	  Investigator:	  Dr	  Anthony	  Gordon	  
	  
Co-­‐investigator:	  Dr	  David	  O’Callaghan	  	  
	  
	  
Study	  Coordination	  Centre	  	  
	  
For	  general	  queries,	  supply	  of	  study	  documentation,	  and	  collection	  of	  data,	  please	  contact:	  
	  
Study	  Coordinator:	  Dr	  David	  O’Callaghan	  
Address:	  Dept.	  of	  Critical	  Care,	  Charing	  Cross	  Hospital	  
E-­‐mail:	  d.ocallaghan@imperial.ac.uk	  
Tel:	  07968	  349928	  











	   272	  
Imperial	  College	  London	  is	  the	  main	  research	  sponsor	  for	  this	  study.	  	  For	  further	  information	  
regarding	  the	  sponsorship	  conditions,	  please	  contact	  the	  Research	  Governance	  Manager	  at:	  
	   	   	  
Joint	  Research	  Office	  
Sir	  Alexander	  Fleming	  Building	  
Imperial	  College	  
Exhibition	  Road	  
London	  SW7	  2AZ	  
Tel:	  020	  7594	  1188	  





This	  study	  is	  funded	  by	  the	  Intensive	  Care	  Society.	  
	  
This	   protocol	   describes	   the	  MEMOTACE	   study	   and	   provides	   information	   about	   procedures	  
for	   entering	   participants.	   Every	   care	   was	   taken	   in	   its	   drafting,	   but	   corrections	   or	  
amendments	   may	   be	   necessary.	   These	   will	   be	   circulated	   to	   investigators	   in	   the	   study.	  
Problems	   relating	   to	   this	   study	   should	   be	   referred,	   in	   the	   first	   instance,	   to	   the	   Chief	  
Investigator.	  	  
	  
This	  study	  will	  adhere	  to	  the	  principles	  outlined	  in	  the	  NHS	  Research	  Governance	  Framework	  
for	  Health	  and	  Social	  Care	  (2nd	  edition).	  It	  will	  be	  conducted	  in	  compliance	  with	  the	  protocol,	  
the	  Data	  Protection	  Act	  and	  other	  regulatory	  requirements	  as	  appropriate.	  
	   	  
	   273	  
Table	  of	  Contents	  
1.	   INTRODUCTION	   278	  
1.1	   BACKGROUND	  278	  
2.	  	  STUDY	  OBJECTIVES	   283	  
3.	  	  STUDY	  DESIGN	   283	  
3.1	   STUDY	  OUTCOME	  MEASURES	  285	  
4.	   Participant	  Entry	   286	  
4.1	   PRE-­‐REGISTRATION	  EVALUATIONS	   286	  
4.2	   INCLUSION	  CRITERIA	   286	  
4.3	   EXCLUSION	  CRITERIA	   287	  
4.4	   WITHDRAWAL	  CRITERIA	   287	  
5.	   adverse	  events	   288	  
5.1	   DEFINITIONS	   288	  
5.3	   REPORTING	  PROCEDURES	   288	  
6.	   ASSESSMENT	  AND	  FOLLOW-­‐UP	   289	  
7.	   STATISTICs	  and	  data	  analysis	   290	  
8.	   regulatory	  issues	   291	  
8.1	   ETHICS	  APPROVAL	   291	  
8.2	   CONSENT	   291	  
8.3	   CONFIDENTIALITY	   292	  
8.4	   INDEMNITY	   293	  
8.5	   SPONSOR	   293	  
8.6	   FUNDING	   293	  
9.	   Study	  Management	   293	  
10.	   Publication	  Policy	  293	  
11.	   References	   294	  
	   274	  
GLOSSARY	  OF	  ABBREVIATIONS	  
ALI	   Acute	  lung	  injury	  
APACHE	  II	   Acute	  Physiology	  and	  Chronic	  Health	  Evaluation	  II	  score	  
ARDS	   Acute	  respiratory	  distress	  syndrome	  
BALF	   Broncho-­‐alveolar	  lavage	  fluid	  
CAP	   Community	  acquired	  pneumonia	  
GCSF	   Granulocyte	  colony	  stimulating	  factor	  
ICP	   Intra-­‐cranial	  pressure	  
ICU	   Intensive	  care	  unit	  
LPS	   Lipopolysaccharide	  
LTA	   Lipoteichoic	  acid	  
memTNF	   Membrane	  bound	  TNF	  
PAMPs	   Pathogen	  associated	  molecular	  patterns	  
PEEP	   Positive	  end	  expiratory	  pressure	  
PRR’s	   Pattern	  recognition	  receptors	  
SIRS	   Systemic	  Inflammatory	  Response	  Syndrome	  
SOFA	   Sequential	  Organ	  Failure	  Assessment	  score	  
solTNF	   Soluble	  TNF	  
TACE	   Tumour	  necrosis	  factor	  converting	  enzyme	  
TNF	   Tumour	  necrosis	  factor	  
	  
	   	  




Acute	  lung	  injury	  
Acute	  respiratory	  distress	  syndrome	  
Monocytes	  
Tumour	  necrosis	  factor-­‐alpha	  converting	  enzyme	  
Tumour	  necrosis	  factor-­‐alpha	  
	   276	  
STUDY	  SUMMARY	  
	  
TITLE	   Mechanisms	  of	  monocyte	  priming	  and	  tolerance	  
DESIGN	   Observational	  study	  
AIMS	   To	  ascertain	  TACE	  activity	  in	  patients	  with	  direct	  &	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Patient	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  Risk	  of	  ALI	  
develops	  ALI	  Sampling	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  to	  t=0	  
Adult	  ICU	  patient	  with	  (or	  at	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  Medical	  /	  Nursing	  staff)	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  Collection:	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  &	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  and	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  data,	  length	  of	  ICU	  &	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1.	   INTRODUCTION	  	  
	  
1.1	   BACKGROUND	  
	  
Sepsis,	   the	   systemic	   inflammatory	   response	   syndrome,	   acute	   lung	   injury,	   the	   acute	  
respiratory	   distress	   syndrome	   and	   the	   compensatory	   anti-­‐inflammatory	   response	  
syndrome.	  
	  
Sepsis	   is	   the	   systemic	   inflammatory	   response	   (SIRS)	   due	   to	   infection.	   It	   remains	   a	   serious	  
problem	   placing	   a	   significant	   burden	   on	   healthcare	   resources	   despite	   efforts	   to	   reduce	  
morbidity	  and	  mortality.	  It	  accounts	  for	  9%	  of	  national	  mortality	  in	  the	  USA	  (Cavaiilon	  2009)	  
representing	  215,000	  deaths	  per	  year	  (Osuchowski	  et	  al	  2006).	  Outcome	  is	  related	  to	  illness	  
severity	  with	  the	  highest	  mortality	  occurring	   in	  severe	  sepsis	  (organ	  dysfunction	  secondary	  
to	  infection)	  and	  septic	  shock	  (severe	  sepsis	  plus	  hypotension	  refractory	  to	  fluids)	  (Dellinger	  
R.P.,	  et	  al	  2008).	  
	  
During	  sepsis	  pathogen	  associated	  molecular	  patterns	   (PAMPs),	   such	  as	   lipopolysaccharide	  
(LPS)	   or	   lipoteichoic	   acid	   (LTA),	   are	   recognised	   by	   pattern	   recognition	   receptors	   (PRR’s)	  
primarily	   the	   Toll-­‐like	   receptors.	   Receptor	   activation	   triggers	   an	   intracellular	   signalling	  
cascade	   which	   incorporates	   mitogen	   activated	   protein	   kinases	   (MAPK:	   p38;	   Extracellular	  
Signal-­‐Related	   Kinase	   and	   Jun	   N-­‐terminal	   Kinase)	   and	   produces	   the	   release	   of	   pro-­‐
inflammatory	  cytokines:	  tumour	  necrosis	  factor	  (TNF);	   Interleukin-­‐1	  (IL-­‐1),	   Interleukin-­‐6	  (IL-­‐
6)	   and	   Interferon	   γ	   (INFγ).	   The	   net	   result	   is	   tissue	   inflammation,	   destruction	   and	   loss	   of	  
function.	   This	   inflammatory	   cascade	   may	   be	   beneficial	   and	   produce	   destruction	   of	   the	  
pathogenic	  organism	  but,	  if	  uncontrolled,	  can	  be	  deleterious	  and	  result	  in	  the	  multiple	  organ	  
dysfunction	  syndrome	  (MODS).	  
	  
Within	  the	  lung	  organ	  dysfunction	  is	  manifest	  as	  acute	  lung	  injury	  (ALI)	  or,	  in	  its	  more	  severe	  
form,	   the	   acute	   respiratory	   distress	   syndrome	   (ARDS).	   These	   conditions	   can	   be	   caused	   by	  
pathologies/insults	  within	  the	  lung	  tissue	  (direct,	  eg	  pneumonia)	  or	  elsewhere	  (indirect).	   In	  
order	   to	   diagnose	   either	   condition	   the	   patient	   must	   have	   bilateral	   infiltrates	   on	   a	   chest	  
radiograph,	  in	  the	  absence	  of	  left	  atrial	  hypertension.	  In	  the	  presence	  of	  these	  prerequisites	  
a	   PaO2:FiO2	   of	   between	   27	   and	   40KPa	   represents	   ALI	   and,	   if	   less	   than	   27,	   ARDS.	   The	  
incidence	  of	  ARDS	  is	  between	  15-­‐34	  cases	  per	  100,000	  inhabitants	  per	  year	  (Frutos-­‐Vivar	  et	  
al	  2004)	  and	  the	  combined	  prevalence	  of	  ALI/ARDS	  amongst	  ventilated	  ICU	  patients	  is	  36.9%	  
(Roupie	  et	  al.1999).	  Both	  conditions	  place	  a	  significant	  burden	  on	  ICU	  resources,	  producing	  
an	  increase	  in	  ventilator	  dependence	  (Davidson	  et	  al.	  1999)	  and	  carrying	  a	  mortality	  of	  up	  to	  
40-­‐50%	  (Petrucci	  and	  Iacovelli	  2006).	  Current	  treatment	  is	  based	  around	  supportive	  therapy	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and	   employing	   a	   “lung	   protective”	   ventilation	   strategy	   (ARDSNET	   2000)	   that	   focuses	   on	  
minimising	  both	  atelectasis	  and	  plateau	  airway	  pressures	  by	  employing	  small	  tidal	  volumes	  
and	  high	  PEEP.	  A	  recent	  Cochrane	  review	  concluded	  that	  “effective	  pharmacotherapy	  for	  ALI	  
and	   ARDS	   is	   extremely	   limited,	   with	   insufficient	   evidence	   to	   support	   any	   specific	  
intervention”	   (Adhikari	   et	   al.	   2004).	   The	   identification	  of	   new	   therapeutic	   targets,	   such	   as	  
the	   enzyme	   whose	   regulation	   and	   activity	   we	   are	   investigating	   in	   this	   study	   (Tumour	  
necrosis	  factor	  converting	  enzyme:	  TACE),	  may	  result	  in	  the	  introduction	  of	  novel	  treatments	  
to	  reduce	  the	  mortality	  and	  morbidity	  associated	  with	  ALI/ARDS.	  
	  
The	   concept	   of	   a	   compensatory	   anti-­‐inflammatory	   response	   syndrome	   (CARS)	   was	  
introduced	   to	   explain	   the	   mechanism	   that	   prevents	   dissemination	   of	   the	   inflammatory	  
process	   (Bone	   1996).	   During	   CARS	   there	   is	   production	   of	   anti-­‐inflammatory	   mediators:	  
soluble	   tumour	   necrosis	   factor	   receptor	   (sTNFR);	   interleukin	   10	   (IL-­‐10);	   IL-­‐1	   receptor	  
antagonist	   (IL-­‐1Ra)	  and	  transforming	  growth	  factor	  β.	  There	  are	  two	  potential	  elements	  to	  
CARS,	   a	   temporal	   element	   where	   a	   pro-­‐inflammatory	   phase	   is	   followed	   by	   an	   anti-­‐
inflammatory	   one	   (Hotchkiss	   2003)	   and	   a	   localised	   element	   (Cavaillon	   2006).	   The	   latter	  
suggests	  a	  compartmentalised	  syndrome	  in	  which	  a	  pro-­‐inflammatory	  process	  occurs	  within	  
the	  affected	  tissue	  but	  an	  anti-­‐inflammatory	  process	  dominates	  within	  the	  plasma	  to	  avoid	  
promoting	  excessive	  systemic	  inflammation.	  
	  
There	   is	   evidence	   of	   further	   compartmentalisation	   of	   the	   SIRS/CARS	   response,	   this	   time	  
between	  the	  central	  circulation	  and	  the	  microcirculation.	  A	  key	  element	   in	  the	  progression	  
of	  ALI	  is	  margination	  of	  leukocytes	  to	  lung	  endothelium.	  Leukocytes	  roll	  along	  endothelium	  
until	   they	   bind	   to	   adhesion	   molecules	   (β-­‐2	   integrins,	   ICAM-­‐1,	   L-­‐selectin),	   stimulating	  
chemotaxis.	  Animal	  work	  (O’Dea	  2005)	  has	  demonstrated	  increased	  TNF	  production	  by	  lung	  
marginated	   monocytes	   compared	   to	   circulating	   monocytes	   in	   response	   to	   LPS	   challenge.	  
This	   may	   result	   in	   cell	   associated	   microvascular	   signalling	   via	   membrane	   bound	   TNF	  
(memTNF)	  or	  via	  locally	  released	  soluble	  TNF	  (solTNF).	  
	  
	  
Priming/immunosuppression	  in	  monocytes	  
	  
Endotoxin	   tolerance	   was	   first	   described	   in	   1946	   (Beeson	   1946)	   and	   refers	   to	   reduced	  
responsiveness	  to	  LPS	  challenge	  following	  a	  first	  encounter	  with	  the	  molecule	  (Cavaillon	  and	  
Adib-­‐Conquy	   2006).	   It	   is	   well	   recognised	   in	   monocytes	   and	   can	   be	   seen	   as	   a	   cytological	  
example	  of	  the	  immunosuppressive	  processes	  occurring	  during	  CARS.	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Priming	   refers	   to	   increased	   response	   to	   LPS	   challenge	   after	   previous	   low	   dose	   exposure.	  
Animal	  work	  (O’Dea	  2009)	  has	  demonstrated	  that	  that	  a	  “two	  hit”	  LPS	  model,	  where	  a	  sub-­‐
clinical	   dose	   of	   LPS	   is	   followed	   by	   a	   further	   dose	   at	   clinical	   levels,	   produces	   a	   substantial	  
increase	   in	   monocyte	   memTNF	   expression	   indicating	   priming.	   Priming	   can	   be	   seen	   as	   a	  
cytological	  example	  of	  the	  pro-­‐inflammatory	  state	  occurring	  within	  the	  affected	  tissue	  beds	  
in	  sepsis/SIRS.	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Tumour	  necrosis	  factor-­‐alpha	  converting	  enzyme	  
	  
TACE	   is	   a	   membrane	   bound	   enzyme	   and	   belongs	   to	   the	   ADAM	   (a	   disintegrin	   and	  
metalloprotease)	  family	  of	  proteases.	  It	  is	  fundamental	  to	  TNF	  regulation	  and	  cleaves	  up	  to	  
90%	  of	  memTNF	  to	  solTNF	  (Black	  2002).	  TACE	  is	  also	  responsible	  for	  the	  shedding	  of	  other	  
cell	   surface	   proteins	   including	   L-­‐selectin,	   a	   key	   adhesion	   molecule	   for	   leukocyte-­‐
endothelium	   interaction,	   TNF	   type	   I	   and	   II	   receptors,	   IL-­‐1	   type	   II	   receptor	   and	   the	   IL-­‐6	  
receptor.	  Its	  regulation	  remains	  incompletely	  understood	  but	  three	  key	  pathways	  appear	  to	  
converge	   on	   the	   enzyme:	   reactive	   oxygen	   species	   (ROS);	   the	   pro-­‐inflammatory	   cascade	  
involving	  TACE	  and	  its	  receptors	  and	  leukocyte	  adhesion/migration	  mediated	  via	  L-­‐selectin.	  
Work	  within	  our	   laboratory	  has	  demonstrated	   that	   rapid	  up	   regulation	  of	   TACE	   activity	   in	  
LPS	  stimulated	  monocytes	  is	  ROS	  dependent	  (Scott	  2007).	  
	  
Due	  to	  the	  potentially	  opposing	  effects	  of	  TACE	  activation,	  the	  enzyme	  could	  play	  a	  role	   in	  
determining	  the	  inflammatory/anti-­‐inflammatory	  balance	  of	  the	  cell.	  For	  example,	  release	  of	  
solTNF	   promotes	   an	   inflammatory	   process	   whereas	   the	   shedding	   of	   cell	   surface	   TNF	  
receptors	  reduces	  the	  number	  available	  to	  bind	  TNF	  thus	  reducing	  inflammation.	  
	  
	  




Is	  there	  evidence	  for	  compartmentalisation	  of	  the	   inflammatory	  response	  between	  
the	  lung	  tissue	  and	  central	  circulation	  in	  ALI?	  Does	  this	  compartmentalised	  process	  




“TACE	  regulation	  is	  a	  dynamic	  process,	  responding	  rapidly	  to	  environmental	  cues	  that	  place	  
it	  as	  a	  central	  orchestrator/regulator	  of	  the	  hyper	  and	  hypo-­‐responsive	  states	  that	  determine	  
sepsis	  pathophysiology.”	  
	  
If	   proved	   this	   may	   have	   implications	   for	   the	   treatment	   of	   sepsis.	   Increased	   TACE	   activity	  
within	  the	  tissue	  focus	  of	  sepsis/SIRS	  could	  be	  selectively	  targeted	  by	  inhibitory	  enzymes	  in	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order	  to	  reduce	  the	  inflammatory	  process.	  Those	  patients	  (e.g.	  meningococcemia)	  who	  have	  
high	   circulating	  pro-­‐inflammatory	   cytokines	  which	   correlate	  with	  mortality	   (Girardin	   1988)	  
may	  prove	  suitable	  for	  systemic	  therapy.	  
	  
In	  contrast	   it	   is	  known	  that	  septic	  plasma	  is	  an	   immunosuppressive	  milieu	  (Cavaillon	  2002)	  
and	   septic	   patients	   display	   both	   evidence	   of	   altered	   immune	   function	   and	   increased	  
susceptibility	   to	   nosocomial	   infections.	   In	   these	   patients	   therapy	   targeted	   at	   stimulating	  
TACE	  in	  an	  effort	  at	  countering	  their	  tolerant	  state	  may	  be	  appropriate.	  
	  
Additional	   data,	   generated	   by	   NMRS	   and	   GC-­‐MS	   analysis	   of	   gas	   and	   fluid	   samples,	   may	  
provide	  metabolic	  signatures	  to	  aid	  in	  the	  diagnosis	  of	  pneumonia	  and	  ALI.	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2.	  	  STUDY	  OBJECTIVES	  
	  
This	   study	   will	   investigate	   the	   physiological	   mechanisms	   that	   contribute	   to	   monocyte	  
priming	   and	   tolerance	   in	   relation	   to	   the	   activation	   of	   tumour	   necrosis	   factor	   converting	  
enzyme	  (TACE)	  and	  shedding	  of	  its	  substrates	  in	  acute	  inflammatory	  conditions	   in	  vivo.	  We	  
will	  utilise	  NMRS	  and	  GC-­‐MS	  to	  determine	  whether	  novel	  markers	  can	  be	  found	  to	  aid	  in	  the	  
diagnosis	  of	  pneumonia	  and	  ALI.	  
	  
Specifically	  we	  propose	  to	  answer	  the	  following	  questions:	  
	  
i. Do	  alveolar	  macrophages	  (AM’s)	  and	  circulating	  monocytes	  taken	  from	  patients	  
with	  ALI	  differ	  in	  terms	  of	  their	  TACE	  activity?	  
	  
ii. Are	  there	  differences	  in	  AM	  and	  plasma	  monocyte	  TACE	  activity	  between	  direct	  
and	  indirect	  lung	  injury?	  
	  
iii. How	   do	   these	   TACE	   activity	   levels	   compare	   to	   those	   obtained	   from	   in-­‐vitro	  




3.	  	  STUDY	  DESIGN	  
	  
This	   is	   an	   observational	   study	   in	  which	   serial	   blood	   samples	   and	   BALF	  will	   be	   taken	   from	  
patients	  who	  have	  established,	  or	  who	  are	  at	  risk	  of	  developing,	  ALI.	  The	  study	  will	  run	  for	  
36	  months	  and	  will	  recruit	  up	  to	  96	  patients	  in	  total,	  including	  12	  patients	  with	  direct	  ALI	  and	  
12	   with	   indirect	   ALI.	   The	   samples	   will	   be	   obtained	   from	   patients	   admitted	   to	   ICU	   within	  
Imperial	  College	  Healthcare	  NHS	  Trust.	  Patients	  will	  be	   recruited	  where	  possible	  within	  48	  
hours	  of	  intubation	  and	  ventilation.	  
	  
Samples	  will	  be	  taken	  from	  patients	  at	  the	  following	  time	  points:	  
	  
• Study	  entry	  (baseline)	  
• Day	  2	  
• Day	  4	  
• Day	  6	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If	  an	  “at	  risk”	  patient	  develops	  ALI	  after	  study	  entry,	  the	  sampling	  schedule	  will	  be	  reset	  to	  
“zero”	  at	  the	  time	  of	  ALI	  diagnosis	  and	  subsequent	  samples	  collected	  at	  the	  new	  time	  points.	  
	  
BALF	   will	   be	   collected	   for	   research	   purposes	   when	   bronchoscopy	   is	   being	   performed	   for	  
clinical	  purposes	  within	  48	  hours	  of	  onset	  of	  established	  acute	  lung	  injury/within	  48	  hours	  of	  
intubation	   and	   ventilation	   in	   those	   at	   risk	   of	   developing	   acute	   lung	   injury.	   During	  
bronchoscopy	   20-­‐120ml	   of	   saline	   will	   be	   instilled	   into	   the	   lungs	   and	   suctioned	   via	   the	  
bronchoscope.	  
	  
Blood	  (30ml	  EDTA)	  will	  be	  taken	  from	  15	  healthy	  volunteers	  recruited	  from	  Imperial	  College	  
London	   staff	   and	   used	   to	   construct	   in-­‐vitro	   models	   of	   priming	   and	   tolerance.	   Values	  
obtained	   from	   these	   models	   will	   be	   compared	   to	   those	   obtained	   from	   the	   adult	   ICU	  
population.	  Patients	  will	  have	  35ml	  of	  blood	  collected.	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3.1	   STUDY	  OUTCOME	  MEASURES	  
	  
Patients	   will	   be	   followed	   up	   daily	   whilst	   in	   ICU	   where	   demographic,	   physiological	   (to	  
calculate	   APACHE	   II	   and	   SOFA	   scores)	   and	   outcome	   data	   (length	   of	   ICU	   stay,	   duration	   of	  
organ	   support,	   nosocomial	   infection	   rates,	   outcome	   at	   ICU/hospital	   discharge)	   will	   be	  
recorded.	  
	  
All	  of	  this	  data	   is	  routinely	  collected	  for	  patients	  on	  the	  ICU	  at	   Imperial	  College	  Healthcare	  
NHS	  Trust.	  
	   	  
	   286	  
4.	   Participant	  Entry	  
	  
4.1 PRE-­‐REGISTRATION	  EVALUATIONS	  	  
Patients	  will	   need	   to	   have	   a	   full	   blood	   count,	   coagulation	   screen,	   chest	   X-­‐ray	   and	   arterial	  
blood	  gas	  analysis	  before	  they	  can	  meet	  the	  study	  inclusion	  criteria.	  These	  will	  be	  part	  of	  the	  
routine	  clinical	  management	  while	  in	  ICU.	  
	  
	  




Adult	  patients	   (≥	  16	  years)	  who	  fulfil	   the	  diagnostic	  criteria	   for	  ALI	  or	   judged	  to	  be	  at	  high	  
risk	  of	  developing	  ALI	  
ALI	  criteria	  
1.	  Patient	  intubated	  and	  ventilated	  
2.	  Within	  48	  hours	  of	  onset	  of	  ALI	  
3.	  ALI	  according	  to	  American/European	  consensus	  conference	  definition	  (Bernard	  et	  al)	  
a)	  Acute	  onset	  
b)	  Severe	  hypoxaemic	  respiratory	  failure	  (PaO2/FiO2	  ratio	  ≤	  40	  kPa)	  
c)	  Bilateral	  infiltrates	  on	  the	  chest	  radiograph	  in	  the	  absence	  of	  clinical	  evidence	  of	  left	  
atrial	  hypertension.	  
	  
High	  risk	  of	  developing	  ALI	  
1.	  Patient	  intubated	  and	  ventilated	  and	  expected	  to	  be	  ventilated	  for	  >48	  hours	  
2.	  Within	  48	  hours	  of	  intubation	  
3.	  Fulfil	  2/4	  of	  the	  criteria	  of	  the	  systemic	  inflammatory	  response	  syndrome	  (SIRS).	  The	  SIRS	  
criteria	  are:	  
(1) Fever	  (>380	  C)	  or	  hypothermia	  (<	  360	  C),	  	  
(2) Tachycardia	  (heart	  rate	  >	  90	  beats	  per	  minute),	  
(3) Tachypnoea	   (respiratory	   rate	   >	   20	   breaths	   per	  minute	   or	   PaCO2	   <	   4.3	   kPa)	   or	  
need	  for	  mechanical	  ventilation,	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(4) Abnormal	   leukocyte	   count	   (>	   12,000	   cells/mm3,	   <	   4000	   cells/mm3,	   or	   >	   10%	  




Adult	  (>16	  years)	  
Free	  from	  chronic	  pathology	  and	  inter-­‐current	  illness	  
	  




Refusal	  to	  consent/gain	  assent	  
Immunosuppression	  (Congenital	  or	  acquired)	  
Use	  of	  granulocyte	  colony	  stimulating	  factor	  




Refusal	  to	  consent	  
Venesection	  within	  last	  14	  days	  
Presence	  of	  chronic	  pathology/inter-­‐current	  illness	  
	  
4.4	   WITHDRAWAL	  CRITERIA	  (PATIENTS	  AND	  HEALTHY	  VOLUNTEERS)	  
	  
Withdrawal	  of	  consent/assent	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5.	   Adverse	  events	  
	  
5.1	   DEFINITIONS	  
Adverse	  Event	  (AE):	  any	  untoward	  medical	  occurrence	  in	  a	  patient	  or	  clinical	  study	  subject.	  
	  
Serious	   Adverse	   Event	   (SAE):	   any	  untoward	  and	  unexpected	  medical	  occurrence	  or	  effect	  
that:	  
• Results	  in	  death	  
• Is	  life-­‐threatening	  –	  refers	  to	  an	  event	  in	  which	  the	  subject	  was	  at	  risk	  of	  death	  
at	   the	   time	   of	   the	   event;	   it	   does	   not	   refer	   to	   an	   event	   which	   hypothetically	  
might	  have	  caused	  death	  if	  it	  were	  more	  severe	  
• Requires	   hospitalisation,	   or	   prolongation	   of	   existing	   inpatients’	  
hospitalisation	  
• Results	  in	  persistent	  or	  significant	  disability	  or	  incapacity	  
• Is	  a	  congenital	  anomaly	  or	  birth	  defect	  
	  
Medical	  judgement	  will	  be	  exercised	  in	  deciding	  whether	  an	  AE	  is	  serious	  in	  other	  situations.	  	  
Important	   AEs	   that	   are	   not	   immediately	   life-­‐threatening	   or	   do	   not	   result	   in	   death	   or	  
hospitalisation	  but	  may	  jeopardise	  the	  subject	  or	  may	  require	  intervention	  to	  prevent	  one	  of	  
the	  other	  outcomes	  listed	  in	  the	  definition	  above,	  will	  also	  be	  considered	  serious.	  
	  
Clinical	  outcomes.	  Clinical	  outcomes	  normally	  associated	  with	  ALI	  are	  exempt	  from	  adverse	  
event	   reporting,	   unless	   the	   investigator	   deems	   the	   event	   to	   be	   related	   to	   the	   research	  
procedure.	  The	  following	  events	  will	  be	  considered	  clinical	  outcomes:	  
	  
• Death	  related	  to	  ALI	  
• Cardiovascular	  failure,	  including	  the	  need	  vasopressors	  /	  inotropes	  
• Worsening	  respiratory	  failure	  
• Hepatic	  failure	  
• Renal	  failure,	  including	  the	  need	  for	  renal	  replacement	  therapy	  
• Haematological	  /	  Coagulation	  failure,	  including	  thrombocytopaenia	  
	  
Clinical	   details	   about	   these	   clinical	   outcomes	  will	   be	   routinely	   collected	   in	   the	   case	   report	  
form.	  
	  
5.3	   REPORTING	  PROCEDURES	  
All	   adverse	  events	  must	  be	   reported.	  Depending	  on	   the	  nature	  of	   the	  event	   the	   reporting	  
procedures	   below	   must	   be	   followed.	   Any	   questions	   concerning	   adverse	   event	   reporting	  
must	  be	  directed	  to	  the	  Chief	  Investigator	  in	  the	  first	  instance.	  
	  
	  
5.3.1	  Non	  serious	  AEs	  
All	  such	  events,	  whether	  expected	  or	  not,	  must	  be	  recorded.	  
	  
	  
5.3.2	  Serious	  AEs	  
An	   SAE	   form	   must	   be	   completed	   and	   faxed	   to	   the	   Chief	   Investigator	   within	   24	   hours.	  
However,	   relapse	   and	   death	   due	   to	   acute	   lung	   injury	   and	   its	   precipitating	   cause,	   and	  
	   289	  
hospitalisations	  for	  elective	  treatment	  of	  a	  pre-­‐existing	  condition	  do	  not	  need	  reporting	  as	  
SAEs.	  
	  
All	   SAEs	  must	   be	   reported	   to	   the	   North	   London	   REC	   3	  where	   in	   the	   opinion	   of	   the	   Chief	  
Investigator,	  the	  event	  was:	  
• ‘related’,	   i.e.	   resulted	   from	   the	   administration	   of	   any	   of	   the	   research	  
procedures;	  and	  
• ‘unexpected’,	   i.e.	   an	   event	   that	   is	   not	   listed	   in	   the	   protocol	   as	   an	   expected	  
occurrence	  
	  
Reports	   of	   related	   and	   unexpected	   SAEs	   must	   be	   submitted	   within	   15	   days	   of	   the	   Chief	  
Investigator	  becoming	  aware	  of	  the	  event,	  using	  the	  NRES	  SAE	  form	  for	  non-­‐IMP	  studies.	  	  	  
	  
Local	   investigators	   must	   report	   any	   SAEs	   as	   required	   by	   their	   Local	   Research	   Ethics	  
Committee	  and/or	  Research	  &	  Development	  Office.	  
	  
	  
Contact	  details	  for	  reporting	  SAEs	  
Fax:	  020	  3311	  1975,	  attention	  Dr	  A	  Gordon,	  Dr	  D	  O’Callaghan	  or	  Ms	  M	  Templeton	  
Please	  send	  SAE	  forms	  to:	  Dr	  A.	  Gordon	  
Tel:	  020	  3311	  7920	  (Mon	  to	  Fri	  09.00	  –	  17.00)	  
	  
	  
6.	   ASSESSMENT	  AND	  FOLLOW-­‐UP	  	  
	  
As	  no	  intervention	  is	  being	  made	  there	  will	  be	  no	  formal	  follow	  up	  arranged	  after	  discharge	  
from	  the	  ICU.	  
	  
The	   sampling	   period	   will	   end	   after	   the	   last	   blood	   sample	   is	   taken	   (6	   days	   post	  
enrolment/diagnosis	   of	   ALI/ARDS)	   but	  mortality	   data	   will	   be	   recorded	   so	   patients	   will	   be	  
followed	  up	  until	  the	  end	  of	  their	  hospital	  admission.	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7.	   STATISTICs	  and	  data	  analysis	  
	  
In	   order	   to	   detect	   a	   difference	   of	   50%	   in	   TACE	   activity,	   12	   patients	   with	   direct	   and	   12	  
patients	   with	   indirect	   ALI	   will	   be	   recruited	   to	   provide	   more	   than	   90%	   power	   at	   p=0.05.	  
Assuming	   a	   25%	   incidence	   of	   ALI	   amongst	   the	   at	   risk	   population	   (Rubenfeld	   2005)	   a	  
maximum	  of	  96	  “at	  risk”	  patients	  will	  be	  recruited.	  	  
	  
Using	   non-­‐parametric	   statistical	   analysis,	   data	   from	   patient	   samples	   will	   be	   compared	  
against	  acute	  physiology	  and	  chronic	  health	  evaluation	  II	  scores	  (APACHE	  II)	  as	  well	  as	  SOFA	  
and	  outcome	  markers	  (length	  of	  ICU	  stay,	  duration	  of	  organ	  support,	  mortality)	   in	  order	  to	  
determine	  the	  existence	  and	  degree	  of	  any	  correlation	  present.	  
	  
Data	  and	  all	  appropriate	  documentation	  will	  be	  stored	  for	  10	  years	  after	  the	  completion	  of	  
the	  study,	   including	  the	  follow-­‐up	  period	  (as	  per	   Imperial	  College	  London	  standard	  policy).	  
Data	   generated	   from	   this	   study	  will	   also	   be	   kept	   for	   10	   years	   and	  may	  be	  used	   in	   future,	  
ethically	  approved,	  studies.	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8.	   Regulatory	  issues	  
	  
8.1	   ETHICS	  APPROVAL	  
	  
The	  Chief	  Investigator	  has	  obtained	  approval	  from	  the	  North	  London	  REC	  3	  Research	  Ethics	  
Committee.	   The	   study	   must	   be	   submitted	   for	   Site	   Specific	   Assessment	   (SSA)	   at	   each	  
participating	  NHS	  Trust.	  The	  Chief	  Investigator	  will	  require	  a	  copy	  of	  the	  SSA	  approval	  letter	  
before	  accepting	  participants	  into	  the	  study.	  The	  study	  will	  be	  conducted	  in	  accordance	  with	  
the	  recommendations	  for	  physicians	  involved	  in	  research	  on	  human	  subjects	  adopted	  by	  the	  
18th	  World	  Medical	  Assembly,	  Helsinki	  1964	  and	  later	  revisions.	  
	  
	  
8.2	   CONSENT	  	  
	  
In	  most	  cases	   it	  will	  not	  be	  possible	   to	  obtain	  prospective	  consent	   from	  the	  patient	  at	   the	  
time	  of	  enrolment.	   This	   is	  due	   to	   the	   fact	   that	  many	  patients	  will	   have	  a	   reduced	   level	  of	  
consciousness	   due	   to	   their	   illness	   or	   due	   to	   sedative	   medication	   used	   as	   part	   of	   their	  
treatment.	  In	  these	  cases	  advice	  will	  be	  sought	  from	  a	  Personal	  Consultee	  (PerCon)	  or	  if	  no	  
PerCon	   can	   be	   located	   then	   advice	   will	   be	   sought	   from	   a	   Professional	   Consultee	   (ProLR).	  
Patients/consultees	  will	  be	  given	  up	  to	  24	  hours	  to	  give	  consent/	  advice.	  
	  
Patient	  Consent	  
If	  possible,	  informed	  consent	  will	  be	  obtained	  from	  the	  patient.	  The	  patient	  will	  be	  informed	  
about	   the	   trial	  by	   the	   responsible	  clinician	  or	  a	  member	  of	   the	   research	   team	  and	  given	  a	  
copy	   of	   the	   Patient	   Information	   Sheet	   (PIS).	   Informed	   patients	   will	   be	   given	   an	   adequate	  
amount	   of	   time	   to	   consider	   their	   participation	   in	   the	   trial.	   If	   the	   patient	   decides	   to	  
participate	  in	  the	  trial	  they	  will	  be	  asked	  to	  sign	  the	  Patient	  Consent	  Form	  which	  will	  then	  be	  
counter	   signed	  by	   the	   responsible	   clinician.	   The	  patient	  will	   retain	  one	   copy	  of	   the	   signed	  
Consent	   Form.	   Another	   copy	   will	   be	   placed	   in	   the	   patient’s	   medical	   records	   whilst	   the	  
original	  will	  be	  retained	  in	  the	  Trial	  Site	  File.	  
	  
Personal	  Consultee	  Advice	  (PerCon)	  
If	   the	   patient	   is	   unable	   to	   give	   consent,	   advice	  will	   be	   sought	   from	  a	   nominated	   Personal	  
Consultee	   (PerCon)	   who	   may	   be	   a	   relative,	   partner	   or	   close	   friend.	   The	   PerCon	   will	   be	  
informed	  about	  the	  trial	  by	  the	  responsible	  clinician	  or	  a	  member	  of	  the	  research	  team	  and	  
provided	  with	  a	  copy	  of	  the	  Covering	  Statement	  for	  the	  Personal	  Consultee	  with	  an	  attached	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Personal	   Consultee	   Information	   Sheet	   and	   asked	   to	   give	   advice	   as	   to	  whether	   the	  patient	  
wish	   to	  participate	   in	   such	  medical	   research.	   If	   the	  PerCon	  advises	   that	   the	  patient	  would	  
wish	   to	   participate	   they	  will	   be	   asked	   to	   sign	   the	   PerCon	  Assent	   Form	  which	  will	   then	   be	  
counter	  signed	  by	  the	  responsible	  clinician.	  The	  PerCon	  will	  retain	  a	  copy	  of	  the	  signed	  form.	  
A	   second	   copy	   will	   be	   placed	   in	   the	   patients’	   medical	   records	   whilst	   the	   original	   will	   be	  
retained	  in	  the	  Trial	  Site	  File.	  
	  
Professional	  Consultee	  Advice	  (ProCon)	  
If	  the	  patient	  is	  unable	  to	  give	  informed	  consent	  and	  no	  PerCon	  is	  available,	  a	  doctor	  who	  is	  
not	  connected	  with	   the	  conduct	  of	   the	   trial	  may	  act	  as	  a	  Professional	  Consultee	   (ProCon).	  
The	  doctor	  will	  be	  informed	  about	  the	  trial	  by	  the	  responsible	  clinician	  or	  a	  member	  of	  the	  
research	   team	   and	   given	   a	   copy	   of	   the	   Professional	   Consultee	   Information	   Sheet.	   If	   the	  
doctor	  advises	  that	  the	  patient	  would	  wish	  to	  participate	  then	  they	  will	  be	  asked	  to	  sign	  the	  
ProCon	  Assent	  Aorm.	  The	  doctor	  will	  retain	  one	  copy	  of	  the	  signed	  form.	  A	  second	  copy	  will	  
be	  placed	  in	  the	  patient’s	  medical	  records;	  the	  original	  will	  be	  retained	  in	  the	  Trial	  Site	  File.	  
	  
Retrospective	  Patient	  Information	  
Patients	   for	   whom	   assent	   is	   given	   by	   a	   PerCon	   or	   ProCon	   will	   be	   informed	   of	   their	  
participation	  in	  the	  trial	  by	  the	  responsible	  clinician	  or	  a	  member	  of	  the	  research	  team	  once	  
they	   regain	   capacity	   to	   understand	   the	   details	   of	   the	   study.	   The	   responsible	   clinician	  will	  
discuss	   the	   study	   with	   the	   patient	   and	   the	   patient	   will	   be	   given	   a	   copy	   of	   the	   Patient	  
Regaining	   Capacity	   Information	   Sheet	   to	   keep.	   The	   patient	  will	   be	   asked	   for	   retrospective	  
consent	  to	  remain	  in	  the	  study	  and	  to	  sign	  the	  Patient	  Regaining	  Capacity	  Consent	  Form.	  The	  
patient	  will	  retain	  one	  copy	  of	  the	  signed	  form.	  Another	  copy	  will	  be	  placed	  in	  the	  patient’s	  
medical	  records	  whilst	  the	  original	  will	  be	  retained	  in	  the	  Study	  Site	  File.	  
	  
The	   right	   of	   the	   participant	   to	   refuse	   to	   participate	   without	   giving	   reasons	   must	   be	  
respected.	  All	  participants	  are	   free	   to	  withdraw	  at	  any	   time	   from	  the	  study	  without	  giving	  
reasons	  and	  without	  prejudicing	  further	  treatment.	  
	  
	  
8.3	   CONFIDENTIALITY	  
The	   Chief	   Investigator	   will	   preserve	   the	   confidentiality	   of	   participants	   taking	   part	   in	   the	  
study	  and	  is	  registered	  under	  the	  Data	  Protection	  Act.	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8.4	   INDEMNITY	  
Imperial	   College	   London	   holds	   negligent	   harm	   and	   non-­‐negligent	   harm	   insurance	   policies	  
which	  apply	  to	  this	  study.	  
	  
	  
8.5	   SPONSOR	  
Imperial	   College	   London	   will	   act	   as	   the	   main	   sponsor	   for	   this	   study.	   	   Delegated	  
responsibilities	  will	  be	  assigned	  to	  the	  NHS	  trusts	  taking	  part	  in	  this	  study.	  	  	  
	  
	  
8.6	   FUNDING	  
The	  Intensive	  Care	  Society	  is	  funding	  this	  study.	  There	  will	  be	  no	  participant	  or	  investigator	  
payments.	  The	  work	  is	  being	  supported	  by	  the	  department	  of	  surgery	  and	  cancer	  at	  Imperial	  
College	  London	  who	  are	  allowing	  us	  to	  use	  their	  laboratory	  facilities.	  	  
	  
	  
8.7	   AUDITS	  
The	   study	  may	  be	   subject	   to	   inspection	   and	   audit	   by	   Imperial	   College	   London	  under	   their	  
remit	   as	   sponsor	   and	   other	   regulatory	   bodies	   to	   ensure	   adherence	   to	   GCP	   and	   the	   NHS	  
Research	  Governance	  Framework	  for	  Health	  and	  Social	  Care	  (2nd	  edition).	  	  
	  
	  
9.	   Study	  Management	  
	  




10.	   Publication	  Policy	  
	  
On	   completion	   the	   work	   will	   form	   part	   of	   a	   thesis	   which	   will	   be	   submitted	   for	   a	   higher	  
degree	  by	  Dr	  David	  O’Callaghan.	  The	  work	  will	  be	  submitted	  for	  peer	  review	  publication	  in	  
medical	  journals	  and	  presented	  at	  national	  and	  international	  medical	  and	  scientific	  meetings	  
in	  order	  that	  any	  findings	  can	  be	  fully	  disseminated.	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Name of Principal Investigator: Dr Anthony Gordon 
 Ethics	  committee:	  North	  London	  REC	  3	  REC	  reference:	  10/H0709/77	  
 
PATIENT REGAINING CAPACITY CONSENT FORM 
Please initial each box 
 
1. I confirm that I have read and understand the Patient Regaining Capacity Information 
Sheet dated November 2010 version 1.6 for the above study and have had the opportunity to 
ask questions which have been answered fully.      
             
 
2. I understand that my continued participation is voluntary and I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
             
 
3. I understand that sections of any of my medical notes may have been looked at by 
responsible individuals from Imperial College London/Imperial College Healthcare NHS Trust 
or from regulatory authorities where it is relevant to my taking part in this research. 
 
I give permission for these individuals to access/continue to access records that are relevant 
to this research.           
 
4. I agree to the use of my samples for future ethically approved research projects and for my 
blood to be used for DNA testing in inflammation research. I understand that this information 
will be kept confidential at all times.       
             
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5. The compensation arrangements have been discussed with me.     
6. I agree to my continued participation in the above study.      
 
7. I agree that data can be stored in anonymous form for up to 10 years & used in future, 






____________________ ________________________  ________________ 




____________________ _________________________  ________________ 
Name of Person  Signature     Date 
taking consent  
1 copy for subject; 1 copy for Principal Investigator; 1copy to be kept with hospital notes 
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Patient	  Regaining	  Capacity	  Information	  Sheet	  Whilst	  you	  have	  been	  on	  the	  Intensive	  Care	  Unit	  you	  have	  been	  unwell	  with	  or	  were	  at	  risk	  of	  a	  condition	  called	  acute	   lung	  injury	  (ALI)	  and	  have	  received	  life	  support	   from	  a	  breathing	  machine.	  In	  order	  to	  allow	  this	  to	  happen	  you	  have	  spent	  time	  sedated.	  We	  are	  currently	  studying	  patients	  with	  or	  at	  risk	  of	  ALI	  and	  whilst	  you	  were	  sedated	  we	  wished	   to	   recruit	   you	   into	   a	   study	   that	  we	  have	   organised	   in	   order	   to	   learn	  more	  about	  ALI.	  Because	  you	  were	  sedated	  we	  were	  unable	  to	   take	  consent	   from	  you	  so	  we	  approached	  someone	  to	  advise	  us	  on	  your	  behalf.	  Such	  a	  person	  is	  called	  a	  consultee	  and	  wherever	  possible	  it	  will	  have	  been	  someone	  who	  is	  interested	  in	  your	  well	  being	  or	  is	  taking	  part	   in	  unpaid	  care	  of	  you	  and	  was	  willing	  to	  act	  as	  a	  consultee	  on	  your	  behalf.	  Sometimes	  we	   are	   not	   able	   to	   identify	   such	   a	   person	   and	   in	   these	   cases	  we	  will	   have	  approached	   the	   doctor	   responsible	   for	   your	   care	   (who	   is	   unconnected	   with	   the	  research)	  to	  ask	  them	  to	  act	  as	  a	  nominated	  professional	  consultee.	  This	   consultee	   advised	  us	   on	  what	   they	   thought	   your	  wishes	   and	   feelings	  would	  be	   if	  you	  were	  able	  to	  consent,	  and	  on	  whether	  you	  should	  take	  part.	  Now	  that	  you	  are	  off	  sedation	  and	  able	  to	  consent	  for	  yourself	  we	  must	  ensure	  that	  you	  agree	  to	  continue	  in	  the	  study.	  Before	  you	  decide	  it	  is	  important	  for	  you	  to	  understand	  why	   the	   research	   is	   being	   done	   and	  what	   it	  will	   involve/has	   already	   involved.	   Please	  take	   time	   to	   read	   the	   following	   information	   carefully	   and	  discuss	   it	  with	  others	   if	   you	  wish.	  This	   sheet	   is	   designed	   to	   tell	   you	   the	   purpose	   of	   this	   study	   and	   give	   you	   detailed	  information	  about	  its	  conduct.	  Ask	  us	  if	  there	  is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  more	  information.	  Take	  time	  to	  decide	  whether	  or	  not	  you	  wish	  to	  give	  consent	  for	  your	  continued	  participation.	  Thank	  you	  for	  reading	  this.	  
What	  is	  the	  purpose	  of	  the	  study?	  White	  blood	  cells	  are	  a	  type	  of	  cell	  found	  throughout	  the	  body	  that	  help	  fight	  infection.	  Monocytes,	  the	  cells	  we	  are	  studying,	  are	  a	  specific	  type	  of	  white	  blood	  cell.	  In	  response	  to	   infection	   and	   inflammation	   these	   cells	   release	   chemicals	   that	   help	   determine	   the	  body’s	  immune	  response.	  In	  some	  circumstances	  it	  is	  thought	  that	  the	  immune	  response	  can	  be	  overactive,	  and	  in	  others	  that	  it	  can	  be	  underactive.	  We	  are	  studying	  monocytes	  to	  see	  if	  a	  protein	  inside	  them	  called	  TACE	  determines	  how	  they	  respond	  to	  infection.	  If	  we	  can	   find	  the	  answer	  to	  this	  question	   it	  would	  help	  our	  understanding	  of	   the	  way	  infection	  affects	  the	  body	  and	  perhaps	  help	  us	  identify	  new	  ways	  of	  treating	  it.	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Why	  have	  I	  been	  chosen?	  You	   have	   been	   asked	   to	   take	   part	   in	   this	   study	   as	   you	   developed,	   or	   were	   at	   risk	   of	  developing,	   a	   condition	   called	   acute	   lung	   injury	   (severely	   inflamed	   lungs).	   We	   are	  planning	   to	   study	   96	   patients	   in	   total	   admitted	   to	   Imperial	   College	   Healthcare	   NHS	  Trust.	  
Do	  I	  have	  to	  take	  part?	  No.	  Whilst	  you	  were	  sedated	  a	  consultee	  was	  approached	  and	  was	  asked	  for	  their	  advice	  about	  your	  wishes.	  Now	  that	  you	  are	  not	  sedated	  it	  is	  up	  to	  you	  to	  decide	  whether	  or	  not	  you	  give	  consent.	  	  If	   you	   do	   decide	   to	   take	   part	   you	  will	   be	   given	   this	   information	   sheet	   to	   keep	   and	   be	  asked	  to	  sign	  a	  consent	  form.	  If	  you	  decide	  to	  take	  part	  you	  are	  still	  free	  to	  withdraw	  at	  any	  time	  and	  without	  giving	  a	  reason.	  A	  decision	  to	  withdraw	  at	  any	  time,	  or	  a	  decision	  not	  to	  take	  part,	  will	  not	  affect	  the	  standard	  of	  care	  you	  receive.	  
What	  has	  the	  study	  involved	  and	  what	  will	  happen	  to	  me	  if	  I	  continue	  take	  part?	  Samples	  of	  lung	  secretions	  (phlegm)	  and	  blood	  that	  were	  taken	  from	  you	  as	  part	  of	  your	  routine	   ICU	   care	   have	   been	   analysed	   and	   the	   activity	   levels	   of	   this	   protein	   (TACE)	  measured.	  The	  lung	  secretions	  were	  taken	  from	  within	  the	  tubes	  that	  lead	  to	  your	  lungs	  and	  we	  used	  a	  camera	  to	  help	  guide	  us	  to	  the	  right	  area	  before	  we	  took	  the	  samples.	  This	  procedure	   is	   called	   a	   bronchoscopy	   and	   the	   samples	   that	   were	   taken	   are	   called	  bronchoscopic	   washings.	   Whilst	   the	   procedure	   was	   being	   performed	   you	   were	   given	  extra	  sedation	  and	  painkillers	  so	  you	  were	  not	  aware	  of	  what	  we	  were	  doing.	  This	  procedure	  is	  performed	  as	  part	  of	  the	  routine	  care	  of	  patients	  placed	  on	  a	  breathing	  machine	  whilst	   on	   the	   Intensive	   Care	   Unit	   and	  will	   only	   have	   been	   performed	   if	   you	  needed	  it	  to	  help	  you.	  Therefore	  you	  were	  not	  subjected	  to	  any	  extra	  procedure.	  If	  done	  it	  will	  have	  been	  to	  help	  clear	  the	  lungs	  of	  excess	  secretions	  and/or	  identify	  bacteria	  that	  may	  be	  causing	  infection	  there.	  	  We	   also	   needed	   to	   collect	   blood	   samples	   (30mls,	   around	   two	   tablespoons	   on	   four	  occasions)	  from	  you	  during	  your	  first	  six	  days	  on	  the	  Intensive	  Care	  Unit.	  These	  samples	  are	  normally	   collected	   from	  drips,	   lines	  and	  catheters	  already	   in	  place	  as	  part	  of	   your	  routine	  care.	  If	  you	  were	  at	  patient	  who	  was	  at	  risk	  of	  developing	  acute	  lung	  injury	  who	  went	  on	  to	  develop	  the	  condition	  we	  will	  have	  taken	  another	  four	  blood	  samples	  from	  you.	  The	  blood	  and	  lung	  secretion	  samples	  will	  be	  used	  to	  measure	  activity	  levels	  of	  the	  TACE	  protein	   found	   within	   the	   white	   blood	   cells	   that	   we	   think	   is	   important	   in	   producing	  inflammation.	  Once	  we	  have	  the	  samples	  we	  will	  process	  them	  and	  test	  how	  active	  the	  TACE	  protein	  is	  to	  help	  prove	  our	  theory.	  All	   samples	   will	   be	   coded	   and	   will	   not	   contain	   any	   personal	   identifying	   information.	  Samples	   will	   be	   stored	   in	   anonymous	   form	   and	   may	   be	   used	   in	   future,	   ethically	  approved,	  studies	  related	  to	  inflammation.	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What	  do	  I	  have	  to	  do?	  You	  will	  not	  have	   to	  do	  anything	  different	   if	  you	  decide	   to	  continue	   to	   take	  part.	  Your	  care	  on	  the	  ICU	  will	  continue	  as	  normal	  apart	  from	  having	  extra	  blood	  samples	  taken.	  Once	  you	  have	  left	  the	  ICU	  the	  only	  further	  information	  we	  will	  collect	  is	  related	  to	  your	  well-­‐being	  at	  the	  time	  you	  are	  discharged	  from	  hospital.	  
What	  is	  the	  drug	  or	  intervention	  that	  is	  being	  tested?	  There	  is	  no	  drug	  or	  intervention	  being	  tested.	  We	  are	  just	  collecting	  samples	  so	  that	  we	  can	  test	  these	  to	  see	  how	  the	  body	  responds	  to	  infection.	  We	  will	  extract	  DNA	  from	  these	  samples	  and,	  whilst	   this	  will	  not	  be	  used	   in	   this	   study,	   it	  will	  be	   stored	   in	  anonymous	  form	  and	  may	  be	  used	  in	  future,	  ethically	  approved,	  studies	  looking	  at	  inflammation.	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  As	  we	  are	  not	  testing	  a	  new	  drug	  or	  intervention	  there	  will	  be	  no	  direct	  benefit	  to	  you.	  However	   the	   information	   we	   get	   might	   help	   improve	   the	   treatment	   of	   people	   with	  severe	  infection	  and	  inflammation	  in	  the	  future.	  
What	  are	  the	  possible	  disadvantages	  and	  risks	  of	  taking	  part?	  The	  bronchoscopy	  can	  cause	  some	  bleeding	  in	  some	  people	  and	  can	  cause	  oxygen	  levels	  to	  drop	  temporarily.	  Every	  step	  will	  have	  been	  taken	  to	  prevent	  this	  and	  the	  procedure	  will	  only	  have	  been	  performed	  if	  it	  was	  required	  for	  non-­‐research	  purposes.	  Only	  very	  small	  quantities	  of	  extra	  blood	  samples	  have	  been	  collected	  from	  you,	  usually	  from	   existing	   lines,	   but	   it	  might	   have	   been	   necessary	   to	   collect	   a	   sample	   from	   a	   new	  needle	   which	   might	   have	   resulted	   in	   some	   minor	   discomfort	   during	   collection	   and	  possibly	  a	  small	  bruise.	  
What	  if	  something	  goes	  wrong?	  Imperial	   College	   London	   holds	   insurance	   policies	   which	   apply	   to	   this	   study.	   	   If	   you	  experience	  serious	  and	  enduring	  harm	  or	  injury	  as	  a	  result	  of	  taking	  part	  in	  this	  study,	  you	  may	  be	  eligible	  to	  claim	  compensation	  without	  having	  to	  prove	  that	  Imperial	  College	  is	  at	  fault.	  	  This	  does	  not	  affect	  your	  legal	  rights	  to	  seek	  compensation.	  If	  you	  are	  harmed	  due	  to	  someone’s	  negligence,	  then	  you	  may	  have	  grounds	  for	  a	  legal	  action.	   Regardless	   of	   this,	   if	   you	   wish	   to	   complain,	   or	   have	   any	   concerns	   about	   any	  aspect	  of	  the	  way	  you	  have	  been	  treated	  during	  the	  course	  of	  this	  study	  then	  you	  should	  immediately	   inform	   the	   Investigator	   (Dr	  Anthony	  Gordon,	   contact	  details	   at	   end).	  The	  normal	  National	  Health	  Service	  complaint	  complaints	  mechanisms	  are	  also	  available	  to	  you.	  If	  you	  are	  still	  not	  satisfied	  with	  the	  response,	  you	  may	  contact	  the	  Imperial	  AHSC	  Joint	  Research	  Office.	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Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  All	   information	  which	   is	   collected	  about	  you	  during	   the	  course	  of	   the	   research	  will	  be	  kept	  strictly	  confidential.	  Any	  information	  about	  you	  which	  leaves	  the	  hospital	  will	  have	  your	  name,	  address	  and	  date	  of	  birth	  removed	  so	  that	  you	  cannot	  be	  recognised	  from	  it.	  Other	  doctors	  in	  this	  hospital	  treating	  you	  will	  be	  told	  of	  your	  participation	  in	  this	  study.	  Information	  will	  be	  stored	  in	  anonymous	  form	  for	  up	  to	  3	  years	  after	  the	  study	  ends	  in	  order	   that	   further	  analysis	  can	  be	  performed	   if	   required.	  As	  you	  are	  not	  receiving	  any	  new	  treatments	  or	  anything	  other	  than	  normal	  ICU	  care	  your	  GP	  will	  not	  be	  informed	  of	  your	  participation.	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  The	   results	   of	   this	   study	   will	   be	   presented	   at	   medical	   meetings	   and	   published	   in	  scientific	   journals.	   Only	   group	   information	   and	   no	   personal	   information	   will	   be	  presented.	  If	  you	  wish	  a	  summary	  of	  the	  results	  of	  the	  study	  can	  be	  sent	  to	  you.	  
Who	  is	  organising	  the	  research?	  This	  study	  is	  being	  organised	  by	  doctors	  and	  scientists	  from	  Imperial	  College	  London.	  
Who	  has	  reviewed	  the	  study?	  All	  research	  in	  the	  NHS	  is	  looked	  at	  by	  an	  independent	  group	  of	  people	  called	  a	  Research	  Ethics	  Committee.	  This	  study	  has	  been	  reviewed	  and	  given	  a	  favourable	  opinion	  by	  the	  North	  London	  REC	  3	  committee.	  
Who can I contact for independent research information? 
If you have any questions about being in a research study, you can contact the Trust’s 
Patient Advice Liaison Service (PALS). They will give you advice about who you can 
talk to for independent advice. 
Thank you in advance for considering your continued participation in this study. If you 
have any questions about this research, the study staff will be more than happy to answer 
them. Their contact details are given below: 
Contact Name: Dr Anthony Gordon (Clinical Senior Lecturer, Consultant) 
Dr David O’Callaghan (Clinical Research Fellow) Address:	   Intensive	  Care	  Unit	  	  Charing	  Cross	  Hospital	  	  Fulham	  Palace	  Road	  	  London,	  W6	  8RF	  
Telephone Number: 020 3311 1964 	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  Ethics	  committee:	  North	  London	  REC	  3	  REC	  reference:	  10/H0709/77	  
	  
Name of Principal Investigator: Dr Anthony Gordon 
 
ASSENT FORM FOR PERSONAL CONSULTEES 
 
Please initial box 
 
1. I confirm that I have read and understood the Personal Consultee Information Sheet dated 
November 2010 version 1.6 for the above study and have had the opportunity to ask 
questions which have been answered fully.      
             
2. I understand that I am giving this assent based on what I believe would be my 
relative/friend/partner’s wishes. In my opinion they would wish to participate.    
 
3. I understand that my relative/friend/partner’s participation is voluntary and I am free to 
change my advice about their wish to participate and to withdraw assent at any time, without 
giving any reason and without their medical care or legal rights being affected.  
             
4. I understand that sections of any of my relative/friend/partner’s medical notes may be 
looked at by responsible individuals from Imperial College/Imperial College Healthcare NHS 
Trust or from regulatory authorities where it is relevant to my taking part in this research. 
I assent to these individuals accessing my relative/friend/partner’s records that are relevant to 
this research.            
5. I assent to the use of my relative/friend/partner’s samples for future ethically approved 
research projects and for their blood to be used for DNA testing in inflammation research. I 
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understand that this information will be kept confidential at all times.   
             
6. The compensation arrangements have been discussed with me.      
7. I assent to my relative/friend/partner taking part in the above study.      
8. I realise that my relative/friend/partner’s consent will override my assent when they are 
able to give informed consent.        
             
9. I assent to data being stored in anonymous form for up to 10 years & used in future, 
ethically approved, projects          
 
 
________________________  I am the patient’s 
________________________________ 




_______________________   ________________   ________________ 




________________________  ________________  ________________ 
Name of researcher taking assent Signature    Date   
 
 
1 copy for subject; 1 copy for Principal Investigator; 1copy to be kept with hospital notes 
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  &	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  Ethics	  committee:	  North	  London	  REC	  3	  REC	  reference:	  10/H0709/77	  
	  
Covering	  statement	  for	  Personal	  Consultee	  	  (to	  be	  given	  with	  the	  personal	  consultee	  information	  sheet)	  We	  would	  like	  to	  ask	  your	  relative	  /	  friend	  /	  partner	  whether	  they	  would	  be	  prepared	  to	  take	   part	   in	   a	   research	   study	   while	   they	   are	   a	   patient	   in	   this	   intensive	   care	   unit.	  Unfortunately,	  your	  relative	  /	  friend	  /	  partner	  is	  not	  well	  enough	  to	  be	  able	  to	  decide	  for	  themselves	   whether	   or	   not	   to	   participate.	   Therefore	   we	   ask	   if	   you	   would	   read	   the	  Personal	  Consultee	  Information	  Sheet	  carefully	  and	  give	  your	  advice	  as	  to	  your	  relative	  /	  friend	  /	  partners	  wishes	  about	  their	  participation	  in	  this	  medical	  research.	  When	  your	  relative	  /	  friend	  /	  partner	  has	  regained	  consciousness	  and	  has	  the	  ability	  to	  understand	  the	  purpose	  of	  this	  study,	  we	  will	  explain	  the	  study	  to	  them	  and	  seek	  their	  permission	   to	  continue	   to	  be	  a	  part	  of	   it.	  Your	   relative	  /	   friend	  /	  partner’s	  decision	   to	  continue	  in	  the	  study	  or	  withdraw	  will	  override	  the	  advice	  you	  have	  given.	  If	   you	   have	   any	   further	   questions	   now	   or	   any	   time	   in	   the	   future	   please	   feel	   free	   to	  contact	  the	  Principal	  Investigator.	  	  	  
Contact Name: Dr Anthony Gordon  Address:	   Intensive	  Care	  Unit	  	  Charing	  Cross	  Hospital	  	  Fulham	  Palace	  Road	  	  London,	  W6	  8RF	  	  
Telephone Number: 020 3311 1964 
 Thank	  you	  in	  advance	  for	  considering	  this	  request	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Personal	  Consultee	  Information	  Sheet	  We	  would	  like	  to	  ask	  your	  relative/friend/partner	  to	  take	  part	   in	  a	  research	  study	  but	  we	  are	  unable	  to	  as	  they	  are	  sedated.	  Because	  of	  this	  we	  would	  like	  to	  take	  your	  advice	  on	  what	   you	   feel	   your	   relative/friend/partners	  wishes	  would	   be	   if	   they	  were	   able	   to	  consent	  for	  themselves.	  You	  have	  been	  approached	  as	  a	  nominated	  consultee	  as	  you	  are	  someone	   who	   is	   interested	   in	   the	   welfare	   of	   your	   friend/relative/partner	   and	   have	  indicated	  that	  you	  are	  prepared	  to	  be	  consulted.	  As	  a	  nominated	  consultee	  you	  cannot	  give	  consent,	  only	  advice	  and	  the	  responsibility	  to	  decide	  whether	  your	  friend/relative/partner	  is	   included	  in	  the	  research	  lies	  ultimately	  with	  the	  research	  team.	  Before	  you	  give	  your	  advice	   it	   is	   important	   for	  you	   to	  understand	  why	   the	  research	   is	  being	  done	  and	  what	  it	  will	  involve.	  Please	  take	  time	  to	  read	  the	  following	  information	  carefully.	  This	   sheet	   tells	   you	   the	   purpose	   of	   this	   study	   and	   what	   will	   happen	   to	   your	  friend/relative/partner	  if	  they	  are	  entered	  into	  the	  study.	  It	  also	  contains	  more	  detailed	  information	   about	   the	   conduct	   of	   the	   research.	   Ask	   us	   if	   there	   is	   anything	   that	   is	   not	  clear	  or	  if	  you	  would	  like	  more	  information.	  Thank	  you	  for	  reading	  this.	  
What	  is	  the	  purpose	  of	  the	  study?	  White	  blood	  cells	  are	  a	  type	  of	  cell	  found	  throughout	  the	  body	  that	  help	  fight	  infection.	  Monocytes,	  the	  cells	  we	  are	  studying,	  are	  a	  specific	  type	  of	  white	  blood	  cell.	  In	  response	  to	   infection	   and	   inflammation	   these	   cells	   release	   chemicals	   that	   help	   determine	   the	  body’s	  immune	  response.	  In	  some	  circumstances	  it	  is	  thought	  that	  the	  immune	  response	  can	  be	  overactive,	  and	  in	  others	  that	  it	  can	  be	  underactive.	  We	  are	  studying	  monocytes	  to	  see	  if	  a	  protein	  inside	  them	  called	  TACE	  determines	  how	  they	  respond	  to	  infection.	  If	  we	  can	   find	  the	  answer	  to	   this	  question	   it	  would	  help	  our	  understanding	  of	   the	  way	  infection	  affects	  the	  body	  and	  perhaps	  help	  us	  identify	  new	  ways	  of	  treating	  it.	  
Why	  has	  my	  friend/relative/partner	  been	  chosen?	  We	  would	  like	  to	  ask	  them	  to	  take	  part	  in	  this	  study	  as	  their	  lungs	  have	  become,	  or	  are	  at	  risk	   of	   becoming,	   severely	   inflamed.	   We	   are	   planning	   to	   study	   96	   patients	   in	   total	  admitted	  to	  Imperial	  College	  Healthcare	  NHS	  Trust.	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Do	  they	  have	  to	  take	  part?	  No.	  We	  would	  like	  to	  take	  your	  advice	  about	  whether	  they	  would	  wish	  to	  participate.	  If	  you	  advise	  that	  they	  would	  want	  to	  take	  part	  you	  will	  be	  given	  this	  information	  sheet	  to	  keep	  and	  be	  asked	  to	  sign	  an	  assent	  form	  on	  behalf	  on	  your	  friend/relative/partner.	  You	  are	   free	   to	   change	   your	   advice	   at	   any	   time	   without	   giving	   a	   reason.	   Changing	   your	  advice,	  or	  if	  you	  advise	  that	  your	  friend/relative/partner	  would	  not	  wish	  to	  participate,	  will	  not	  affect	  the	  standard	  of	  care	  they	  receive.	  
What	  will	  happen	  to	  them	  if	  they	  do	  take	  part?	  If	  you	  advise	  that	  they	  would	  want	  to	  be	  included	  in	  the	  study	  then	  samples	  of	  sputum	  and	  blood	  that	  are	  taken	  from	  your	  friend/relative/partner	  as	  part	  of	  their	  routine	  ICU	  care	  will	  be	  analysed	  and	  the	  activity	  levels	  of	  the	  TACE	  protein	  measured.	  The	  sputum	  is	  taken	  from	  within	  the	  tubes	  that	  lead	  to	  the	  lungs	  and	  we	  use	  a	  camera	  to	  help	  guide	  us	  to	  the	  right	  area	  before	  we	  take	  the	  samples.	  This	  procedure	  is	  called	  a	  bronchoscopy	  and	  the	  samples	  that	  are	  taken	  are	  called	  bronchoscopic	  washings.	  This	   bronchoscopy	   will	   only	   be	   done	   if	   your	   friend/relative/partner	   is	   sufficiently	  unwell	   that	   they	   need	   life	   support	   to	   do	   the	   work	   of	   breathing	   for	   them	   (which	   will	  mean	  that	  they	  are	  asleep).	  Whilst	  the	  procedure	  is	  being	  performed	  they	  will	  be	  given	  extra	   sedation	   and	   painkillers	   so	   they	   are	   not	   aware	   of	   what	   we	   are	   doing.	   This	  procedure	   forms	   part	   of	   the	   routine	   care	   of	   patients	   placed	   on	   a	   breathing	   machine	  whilst	  on	  the	  Intensive	  Care	  Unit	  so	  they	  will	  not	  be	  subjected	  to	  any	  extra	  procedure.	  The	  bronchoscopy	  is	  done	  to	  help	  clear	  the	  lungs	  of	  excess	  sputum/secretions	  and	  to	  try	  and	   identify	   bacteria	   that	   may	   be	   causing	   infection	   there.	   This	   bronchoscopy	   will	   be	  performed	  once	  during	  their	  first	  48	  hours	  on	  the	  ICU	  if	  they	  develop,	  or	  are	  at	  risk	  of	  developing,	  a	  condition	  called	  acute	  lung	  injury	  and	  it	  is	  decided	  that	  it	  is	  necessary.	  We	   will	   also	   need	   to	   collect	   blood	   samples	   (30mls,	   around	   two	   tablespoons	   on	   four	  occasions	   in	   total)	   from	  your	   friend/relative/partner	  during	   their	   first	   six	  days	  on	   the	  Intensive	   Care	   Unit.	   These	   samples	   will	   normally	   be	   collected	   from	   drips,	   lines	   and	  catheters	  already	  in	  place	  as	  part	  of	  their	  routine	  care.	  If	  your	  friend/relative/partner	  is	  at	  risk	  of	  developing	  severely	  inflamed	  lungs	  and	  develops	  a	  condition	  called	  acute	  lung	  injury	  we	  will	  collect	  another	  four	  blood	  samples	  from	  them.	  The	   blood	   and	   sputum	   samples	   will	   be	   used	   to	   measure	   activity	   levels	   of	   the	   TACE	  protein	   found	   within	   the	   white	   blood	   cells	   that	   we	   think	   is	   important	   in	   producing	  inflammation.	  Once	  we	  have	  the	  samples	  we	  will	  process	  them	  and	  test	  how	  active	  the	  TACE	  protein	  is	  to	  help	  prove	  our	  theory.	  All	   samples	   will	   be	   coded	   and	   will	   not	   contain	   any	   personal	   identifying	   information.	  Samples	   will	   be	   stored	   in	   anonymous	   form	   and	   may	   be	   used	   in	   future,	   ethically	  approved,	  studies	  related	  to	  inflammation.	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What	  do	  I	  have	  to	  do?	  We	  are	  asking	  you	  to	  advise	  us	  whether	  your	  friend/relative/partner/would	  want	  to	  be	  involved	   in	   this	   study.	   If	   you	   advise	   that	   they	  would,	   you	  will	   be	   given	   a	   copy	   of	   this	  sheet	  to	  keep	  and	  be	  asked	  to	  sign	  an	  assent	  form	  on	  their	  behalf.	  Once	   your	   friend/relative/partner	   leaves	   the	   Intensive	   Care	   Unit	   the	   only	   further	  information	  we	  will	  collect	  is	  related	  to	  their	  well-­‐being	  at	  hospital	  discharge.	  As	  soon	  as	  they	  are	  conscious	  and	  able	  to	  consent	  for	  themselves	  we	  will	  approach	  them	  directly	  to	  ask	  for	  consent.	  If	  they	  say	  no	  they	  will	  be	  withdrawn.	  
What	  is	  the	  drug	  or	  intervention	  that	  is	  being	  tested?	  There	  is	  no	  drug	  or	  intervention	  being	  tested.	  We	  are	  just	  collecting	  samples	  so	  that	  we	  can	  test	  these	  to	  see	  how	  the	  body	  responds	  to	  infection.	  We	  will	  extract	  DNA	  from	  these	  samples	  and,	  whilst	   this	  will	  not	  be	  used	   in	   this	   study,	   it	  will	  be	   stored	   in	  anonymous	  form	  and	  may	  be	  used	  in	  future,	  ethically	  approved,	  studies	  looking	  at	  inflammation.	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  As	  we	  are	  not	  testing	  a	  new	  drug	  or	  intervention	  there	  will	  be	  no	  direct	  benefit	  to	  your	  friend/relative/partner.	   However	   the	   information	   we	   get	   might	   help	   improve	   the	  treatment	  of	  people	  with	  severe	  infection	  and	  inflammation	  in	  the	  future.	  
What	  are	  the	  possible	  disadvantages	  and	  risks	  of	  taking	  part?	  There	  is	  a	  risk	  that	  your	  friend/relatives/partners	  oxygen	  levels	  could	  drop	  during	  the	  bronchoscopy.	  If	  this	  happens	  the	  procedure	  will	  be	  stopped	  until	  these	  levels	  recover.	  They	  will	   be	   given	  100%	  oxygen	  before	   the	  bronchoscopy	   to	  minimise	   the	   chances	  of	  this	   happening.	   There	   is	   a	   chance	   of	   the	   procedure	   causing	   some	   bleeding	  within	   the	  lungs	   but	   the	   bronchoscopy	   will	   only	   be	   done	   if	   it	   is	   clinically	   indicated	   (i.e.	   part	   of	  routine	  ICU	  care)	  and	  as	  safe	  as	  possible.	  Only	   small	   quantities	   of	   extra	   blood	   samples	   will	   be	   collected	   from	   your	  friend/relative/partner,	  usually	  from	  existing	  lines,	  but	  it	  might	  be	  necessary	  to	  collect	  a	  sample	   from	   a	   new	   needle	   which	   might	   result	   in	   some	   minor	   discomfort	   during	  collection	  and	  possibly	  a	  small	  bruise.	  
What	  if	  something	  goes	  wrong?	  Imperial	   College	   London	   holds	   insurance	   policies	   which	   apply	   to	   this	   study.	   If	   your	  friend/relative/partner	  experiences	  serious	  and	  enduring	  harm	  or	  injury	  as	  a	  result	  of	  taking	  part	  in	  this	  study,	  they	  may	  be	  eligible	  to	  claim	  compensation	  without	  having	  to	  prove	   that	   Imperial	   College	   is	   at	   fault.	   This	   does	   not	   affect	   their	   legal	   rights	   to	   seek	  compensation.	  If	  your	   friend/relative/partner	   is	  harmed	  due	   to	  someone’s	  negligence,	   then	   they	  may	  have	  grounds	  for	  a	  legal	  action.	  Regardless	  of	  this,	  if	  you	  wish	  to	  complain,	  or	  have	  any	  concerns	   about	   any	   aspect	   of	   the	   way	   your	   friend/relative/partner	   has	   been	   treated	  during	   the	   course	   of	   this	   study	   then	   you	   should	   immediately	   inform	   the	   Chief	  Investigator	   (Dr	  Anthony	  Gordon,	   contact	   details	   at	   end).	   The	  normal	  National	  Health	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Service	  complaint	  complaints	  mechanisms	  are	  also	  available	  to	  you.	   If	  you	  are	  still	  not	  satisfied	  with	  the	  response,	  you	  may	  contact	  the	  Imperial	  AHSC	  Joint	  Research	  Office.	  
Will	  my	  friend/relative/partners	  participation	  in	  this	  study	  be	  kept	  confidential?	  All	  information	  which	  is	  collected	  about	  your	  friend/relative/partner	  during	  the	  course	  of	   the	   research	   will	   be	   kept	   strictly	   confidential.	   Any	   information	   about	   them	   which	  leaves	  the	  hospital	  will	  have	  their	  name,	  address	  and	  date	  of	  birth	  removed	  so	  that	  they	  cannot	  be	  recognised	  from	  it.	  Other	  doctors	  involved	  in	  your	  friend/relatives/partners	  treatment	   within	   this	   hospital	   will	   be	   told	   of	   their	   participation	   in	   this	   study.	  Information	  will	  be	  stored	  in	  anonymous	  form	  for	  up	  to	  three	  years	  after	  the	  study	  ends	  in	   order	   that	   further	   analysis	   can	   be	   performed	   if	   required.	   As	   your	  friend/relative/partner	   are	   not	   receiving	   any	   new	   treatments	   or	   anything	   other	   than	  normal	  ICU	  care	  their	  GP	  will	  not	  be	  informed	  of	  their	  participation.	  
What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  The	   results	   of	   this	   study	   will	   be	   presented	   at	   medical	   meetings	   and	   published	   in	  scientific	   journals.	   Only	   group	   information	   and	   no	   personal	   information	   will	   be	  presented.	  If	  you	  wish	  a	  summary	  of	  the	  results	  of	  the	  study	  can	  be	  sent	  to	  you	  and	  your	  friend/relative/partner.	  
Who	  is	  organising	  the	  research?	  This	  study	  is	  being	  organised	  by	  doctors	  and	  scientists	  from	  Imperial	  College,	  London.	  
Who	  has	  reviewed	  the	  study?	  All	  research	  in	  the	  NHS	  is	  looked	  at	  by	  an	  independent	  group	  of	  people	  called	  a	  Research	  Ethics	  Committee.	  This	  study	  has	  been	  reviewed	  and	  given	  a	  favourable	  opinion	  by	  the	  North	  London	  REC	  3	  ethics	  committee.	  
Who can I contact for independent research information? 
If you have any questions about being in a research study, you can contact the Trust’s 
Patient Advice Liaison Service (PALS). They will give you advice about who you can 
talk to for independent advice. 
Thank you in advance for considering your friend/relative/partners participation in this 
study. If you have any questions about this research, the study staff will be more than 
happy to answer them. Their contact details are given below: 
Contact Names: Dr Anthony Gordon (Clinical Senior Lecturer & Consultant) 
Dr David O’Callaghan (Clinical Research Fellow) Address:	   Intensive	  Care	  Unit	  	  Charing	  Cross	  Hospital	  	  Fulham	  Palace	  Road	  	  London,	  W6	  8RF	  
Telephone Number: 020 3311 1964  
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Mechanisms of Monocyte Priming & Tolerance 
Name of Principal Investigator:  Dr Anthony Gordon Ethics	  committee:	  North	  London	  REC	  3	  REC	  reference:	  10/H0709/77	  
PROFESSIONAL CONSULTEE ASSENT FORM 
 
Regarding patient _____________________________________________ 
 
This form should be completed by a doctor who is unconnected with the research study only 
in situations where the patient is temporarily unable to provide informed consent for 
themselves and if there is no relative / friend / partner willing and capable to act as the 
nominated personal consultee. The doctor primarily responsible for the medical treatment of 
the patient, or a person nominated by the relevant health care provider, can act as a 
professional consultee for the patient provided that they are not connected with the conduct of 
this study. 
I, Dr / Mr / Ms / Prof______________________________ as the clinician treating this patient 
declare by signing this form that I have read the Professional Consultee Information Sheet 
version -___ dated ___________ and have no objection for this patient to be entered into this 
research study. I also understand that should the patient regain consciousness they will be 
fully informed of the decision to enter them into this research study and consent will be sought 
from them for their continued participation. I agree that the patient’s consent will override my 
assent when the patient is able to give consent. 
 
 
_______________________  ________________  ________________ 




________________________  ________________  ________________ 
Name of researcher taking assent Signature    Date 
1 copy for ProCon; 1 copy for Principal Investigator; 1copy to be kept with hospital notes  
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Mechanisms	  of	  Monocyte	  Priming	  &	  Tolerance	  Ethics	  committee:	  North	  London	  REC	  3	  REC	  reference:	  10/H0709/77	  
Professional	  Consultee	  Information	  Sheet	  We	  would	  like	  to	  consent	  your	  patient	  to	  recruit	  them	  into	  a	  study	  but	  we	  are	  unable	  to	  as	  they	  are	  sedated	  and	  ventilated	  and	  therefore	  lack	  capacity.	  We	  have	  been	  unable	  to	  identify	   a	   suitable	   personal	   consultee	   and	   are	   approaching	   you	   as	   a	   nominated	  professional	   consultee	  because	  you	  are	   independent	  of	   the	   research	   team	  and	  are	   the doctor	  primarily	  responsible	  for	  the	  medical	  treatment	  of	  the	  patient.	  	  In	   your	   role	   as	   a	   consultee	   you	  must	   consider	   how	   the	   wishes	   and	   interests	   of	   your	  patient	   would	   incline	   them	   to	   decide	   if	   they	   had	   the	   capacity	   to	   make	   the	   decision.	  Before	   you	   give	   your	   advice	   it	   is	   important	   for	   you	   to	   understand	   the	   purpose	   of	   the	  research	  and	  its	  components.	  Please	   take	   time	   to	   read	   the	   following	   information	   carefully	   and	   ask	   us	   if	   there	   is	  anything	  that	  is	  not	  clear	  or	  if	  you	  would	  like	  more	  information.	  Thank	  you	  for	  reading	  this.	  
What	  is	  the	  purpose	  of	  the	  research?	  We	   are	   interested	   in	   the	   immune	   response	   that	   monocytes	   mount	   to	   inflammatory	  stimuli.	   Specifically	   we	   are	   measuring	   the	   activity	   of	   tumour	   necrosis	   factor-­‐alpha	  converting	   enzyme	   (TACE)	   which	   is	   responsible	   for	   cleaving	   the	   pro-­‐inflammatory	  cytokine	  TNF	  from	  its	  membrane	  bound	  to	  its	  soluble	  form.	  Because	  it	  also	  cleaves	  TNF	  receptors	  its	  activity	  can	  result	  in	  net	  pro	  or	  anti	  inflammatory	  effects.	  We	  hypothesise	  that	  TACE	  is	  key	  in	  dictating	  the	  inflammatory	  balance	  of	  the	  monocyte	  and	  that	  activity	  levels	   will	   differ	   in	   macrophages	   taken	   from	   infected	   tissue	   (inflammatory)	   when	  compared	  to	  circulating	  monocytes	  (anti-­‐inflammatory).	  The	   data	   generated	   will	   aid	   understanding	   of	   the	   relationship	   between	   the	   systemic	  inflammatory	  and	  compensatory	  anti-­‐inflammatory	  response	  syndromes	  and	  may	  help	  identify	  potential	  therapeutic	  targets.	  
Why	  has	  my	  patient	  been	  chosen?	  We	  are	  recruiting	  patients	  who	  have	  established,	  or	  are	  at	  risk	  of	  developing,	  acute	  lung	  injury.	   We	   are	   planning	   to	   study	   96	   patients	   in	   total	   admitted	   to	   Imperial	   College	  Healthcare	  NHS	  Trust.	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What	  will	  happen	  to	  them	  if	  they	  do	  take	  part?	  If	   you	   assent	   to	   their	   participation	   then	   alveolar	   macrophages	   and	   circulating	  monocytes	   obtained	   from	   samples	   that	   are	   taken	   from	   your	   patient	   as	   part	   of	   their	  routine	   ICU	   care	   will	   be	   analysed	   and	   cellular	   TACE	   activity	   levels	   measured.	   The	  alveolar	   macrophages	   will	   be	   obtained	   from	   broncho-­‐alveolar	   lavage	   fluid	   (BALF)	  obtained	  during	  bronchoscopy	  and	  the	  monocytes	  from	  blood	  samples.	  This	   bronchoscopy	   will	   only	   be	   done	   if	   it	   is	   clinically	   indicated	   (e.g.	   to	   aid	   sputum	  clearance	  or	  obtain	  microbiological	  data)	  so	  patients	  will	  not	  be	  subjected	  to	  any	  extra	  procedure	  as	  part	  of	  the	  study..	  The	  bronchoscopy	  will	  be	  performed	  once	  during	  their	  first	  48	  hours	  on	  the	  ICU	  if	  they	  develop,	  or	  are	  at	  risk	  of	  developing,	  acute	  lung	  injury,	  and	   it	   is	   clinically	   indicated.	  Whilst	   it’s	  performed	   their	   sedation	  and	  analgesia	  will	  be	  optimized.	  We	  will	  also	  collect	  blood	  samples	  (30mls	  on	  four	  occasions)	  from	  your	  patient	  during	  their	  first	  six	  days	  on	  the	  Intensive	  Care	  Unit.	  These	  samples	  will	  normally	  be	  collected	  from	   invasive	   lines	   placed	   as	   part	   of	   their	   routine	   care.	   If	   your	   patient	   is	   recruited	  because	   they	   are	   at	   risk	  of	   developing	   acute	   lung	   injury	   and	   then	  develop	   established	  acute	   lung	   injury	   the	   venesection	   timetable	   is	   reset,	   and	  we	  will	   collect	   another	   four	  blood	  samples	  from	  them.	  The	   blood	   and	   BALF	   samples	   will	   be	   processed	   and	   purified	   to	   obtain	   isolated	  monocytes	   and	   alveolar	  macrophages	  which	  will	   then	   have	   their	   TACE	   activity	   levels	  measured.	  We	  will	  also	  extract	  DNA	  from	  these	  samples	  and,	  whilst	  this	  will	  not	  be	  used	  in	  this	  study,	   it	  will	  be	  stored	   in	  anonymous	  form	  and	  may	  be	  used	   in	   future,	  ethically	  approved,	  studies	  looking	  at	   inflammation.	  The	  samples	  themselves	  will	  also	  be	  stored	  in	  anonymous	  form	  and	  again	  may	  be	  used	  in	  future,	  ethically	  approved,	  research.	  
What	  do	  I	  have	  to	  do?	  We	   are	   asking	   you	   to	   assent	   for	   your	   patient	   to	   be	   entered	   into	   the	   study.	   If	   you	   are	  happy	   to	   do	   this	   you	  will	   be	   given	   a	   copy	   of	   this	   sheet	   to	   keep	   and	   asked	   to	   sign	   an	  assent	  form	  on	  their	  behalf.	  Once	   your	  patient	   leaves	   the	   Intensive	  Care	  Unit	   the	   only	   further	   information	  we	  will	  collect	  is	  related	  to	  their	  status	  at	  hospital	  discharge.	  As	  soon	  as	  they	  are	  conscious	  and	  able	  to	  give	  informed	  consent	  for	  themselves	  we	  will	  approach	  them	  directly	  to	  ask	  for	  this.	   If	   they	   say	   no	   they	  will	   be	  withdrawn	   and	   their	   data	  will	   not	   be	   included	   in	   the	  analysis.	  
What	  are	  the	  compensation	  arrangements?	  Imperial	   College	   London	   holds	   insurance	   policies	   which	   apply	   to	   this	   study.	   If	   your	  patient	  experiences	  serious	  and	  enduring	  harm	  or	  injury	  as	  a	  result	  of	  taking	  part	  in	  this	  study,	  they	  may	  be	  eligible	  to	  claim	  compensation	  without	  having	  to	  prove	  that	  Imperial	  College	  is	  at	  fault.	  This	  does	  not	  affect	  their	  legal	  rights	  to	  seek	  compensation.	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If	  your	  patient	  is	  harmed	  due	  to	  someone’s	  negligence,	  then	  they	  may	  have	  grounds	  for	  a	  legal	  action.	  Regardless	  of	  this,	  if	  you	  wish	  to	  complain,	  or	  have	  any	  concerns	  about	  any	  aspect	  of	  the	  way	  your	  patient	  has	  been	  treated	  during	  the	  course	  of	  this	  study	  then	  you	  should	  immediately	  inform	  the	  Chief	  Investigator	  (Dr	  Anthony	  Gordon,	  contact	  details	  at	  end).	  If	  you	  are	  still	  not	  satisfied	  with	  the	  response,	  you	  may	  contact	  the	  Imperial	  AHSC	  Joint	  Research	  Office.	  
Will	  my	  patient’s	  participation	  in	  this	  study	  be	  kept	  confidential?	  All	  information	  which	  is	  collected	  about	  your	  patient	  during	  the	  course	  of	  the	  research	  will	  be	  kept	  strictly	  confidential.	  Any	  information	  about	  them	  which	  leaves	  the	  hospital	  will	  have	  their	  name,	  address	  and	  date	  of	  birth	  removed.	  Information	  will	  be	  stored	  in	  anonymous	  form	  for	  up	  to	  three	  years	  after	  the	  study	  ends	  in	   order	   that	   further	   analysis	   can	   be	   performed	   if	   required.	   As	   your	   patient	   is	   not	  receiving	  any	  novel	  treatment	  or	  anything	  other	  than	  normal	  ICU	  care	  their	  GP	  will	  not	  be	  informed	  of	  their	  participation.	  
Who	  is	  sponsoring	  the	  research?	  This	  study	  is	  sponsored	  by	  Imperial	  College	  London.	  
Who	  has	  reviewed	  the	  study?	  This	  study	  has	  been	  reviewed	  and	  given	  a	  favourable	  opinion	  by	  the	  North	  London	  REC	  3	  ethics	  committee.	  
If you have any questions about this research, the study staff will be more than happy to 
answer them. Their contact details are given below: 
 
Contact Names: Dr Anthony Gordon (Clinical Senior Lecturer & Consultant) 
Dr David O’Callaghan (Clinical Research Fellow) Address:	   Intensive	  Care	  Unit	  	  Charing	  Cross	  Hospital	  	  Fulham	  Palace	  Road	  	  London,	  W6	  8RF	  	  
Telephone Number: 020 3311 1964 	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Mechanisms	  of	  Monocyte	  Priming	  &	  Tolerance	  Ethics	  committee:	  North	  London	  REC	  3	  REC	  reference:	  10/H0709/77	  
Name of Principal Investigator: Dr Anthony Gordon 
HEALTHY VOLUNTEER CONSENT FORM 
Please initial each box 
1. I confirm that I have read and understand the Healthy Volunteer Information Sheet dated 
November 2010 version 1.6 for the above study and have had the opportunity to ask 
questions which have been answered fully.      
             
2. I understand that my participation is voluntary and I am free to withdraw at any time, 
without giving any reason.         
             
3. I understand that sections of any of my research records may be looked at by responsible 
individuals from Imperial College London or from regulatory authorities where it is relevant to 
my taking part in this research. 
I give permission for these individuals to access records that are relevant to this research.  
4. The compensation arrangements have been discussed with me.     
5. I agree to take part in the above study.         
6. I agree that data can be stored in anonymous form for up to 10 years & used in future, 
ethically approved projects        
             
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____________________ ________________________  ________________ 




____________________ _________________________  ________________ 
Name of person  Signature     Date 
taking consent  
 
1 copy for subject; 1 copy for Principal Investigator; 1copy to be kept in trial master file 	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Mechanisms	  of	  Monocyte	  Priming	  &	  Tolerance	  Ethics	  committee:	  North	  London	  REC	  3	  REC	  reference:	  10/H0709/77	  
Information	  Sheet:	  Healthy	  Volunteers	  You	  are	  being	  invited	  to	  take	  part	  in	  a	  research	  study.	  Before	  you	  decide	  it	  is	  important	  for	  you	   to	  understand	  why	   the	   research	   is	  being	  done	  and	  what	   it	  will	   involve.	  Please	  take	   time	   to	   read	   the	   following	   information	   carefully	   and	  discuss	   it	  with	  others	   if	   you	  wish.	  This	  sheet	   tells	  you	   the	  purpose	  of	   this	  study	  and	  what	  will	  happen	   to	  you	   if	  you	   take	  part.	  It	  also	  gives	  you	  more	  detailed	  information	  about	  the	  conduct	  of	  the	  study.	  Ask	  us	  if	  there	   is	  anything	   that	   is	  not	  clear	  or	   if	  you	  would	   like	  more	   information.	  Take	   time	   to	  decide	  whether	  or	  not	  you	  wish	  to	  take	  part.	  Thank	  you	  for	  reading	  this.	  
What	  is	  the	  purpose	  of	  the	  study?	  White	  blood	  cells	  are	  a	  type	  of	  cell	  found	  throughout	  the	  body	  that	  help	  fight	  infection.	  Monocytes,	  the	  cells	  we	  are	  studying,	  are	  a	  specific	  type	  of	  white	  blood	  cell.	  In	  response	  to	   infection	   and	   inflammation	   these	   cells	   release	   chemicals	   that	   help	   determine	   the	  body’s	  immune	  response.	  In	  some	  circumstances	  it	  is	  thought	  that	  the	  immune	  response	  can	  be	  overactive,	  and	  in	  others	  that	  it	  can	  be	  underactive.	  We	  are	  studying	  monocytes	  to	  see	  if	  a	  protein	  inside	  them	  called	  TACE	  determines	  how	  they	  respond	  to	  infection.	  If	  we	  can	   find	  the	  answer	  to	   this	  question	   it	  would	  help	  our	  understanding	  of	   the	  way	  infection	  affects	  the	  body	  and	  perhaps	  help	  us	  identify	  new	  ways	  of	  treating	  it.	  
Why	  have	  I	  been	  chosen?	  You	  have	  been	  asked	  to	  take	  part	  in	  this	  study	  as	  we	  need	  healthy	  volunteer	  blood.	  We	  are	   going	   to	   expose	  white	   blood	   cells	   from	   these	   samples	   to	   substances	  which	   cause	  infection/inflammation	  and	  compare	  these	  results	  to	  those	  we	  get	  from	  patient	  samples.	  We	  are	  planning	  to	  use	  blood	  from	  up	  to	  15	  healthy	  volunteers	  and	  96	  patients.	  
Do	  I	  have	  to	  take	  part?	  It	  is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	  If	  you	  do	  decide	  to	  take	  part	  you	  will	  be	   given	   this	   information	   sheet	   to	   keep	   and	   be	   asked	   to	   sign	   a	   consent	   form.	   If	   you	  decide	   to	   take	   part	   you	   are	   still	   free	   to	   withdraw	   at	   any	   time	   and	   without	   giving	   a	  reason.	  
What	  will	  happen	  to	  me	  if	  I	  take	  part?	  If	   you	   decide	   to	   take	   part	  we	  will	   take	   blood	   from	   you	   (30mls,	   around	   2	   tablespoons	  full).	  This	  blood	  will	  be	  used	   in	   the	   laboratory	  where	   it	  will	  be	  exposed	   to	   substances	  which	  cause	  infection/inflammation	  and	  we	  will	  measure	  how	  active	  the	  TACE	  protein	  is.	  If	  you	  agree	  to	  it,	  we	  may	  take	  more	  than	  one	  blood	  sample	  but	  this	  will	  not	  happen	  within	  two	  weeks	  of	  your	  previous	  blood	  sample	  being	  taken.	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What	  are	  the	  possible	  benefits	  of	  taking	  part?	  As	  we	  are	  not	  testing	  a	  new	  drug	  or	  intervention	  there	  will	  be	  no	  direct	  benefit	  to	  you.	  However	   the	   information	   we	   get	   might	   help	   improve	   the	   treatment	   of	   people	   with	  severe	  infection	  and	  inflammation	  in	  the	  future.	  
What	  are	  the	  possible	  disadvantages	  and	  risks	  of	  taking	  part?	  Only	  small	  quantities	  of	  blood	  samples	  will	  be	  collected	  from	  you	  but	  it	  will	  be	  necessary	  to	   use	   a	   needle	   which	   will	   result	   in	   some	   minor	   discomfort	   during	   collection	   and	  possibly	  a	  small	  bruise.	  
What	  if	  something	  goes	  wrong?	  Imperial	   College	   London	   holds	   insurance	   policies	   which	   apply	   to	   this	   study.	   If	   you	  experience	  serious	  and	  enduring	  harm	  or	  injury	  as	  a	  result	  of	  taking	  part	  in	  this	  study,	  you	  may	  be	  eligible	  to	  claim	  compensation	  without	  having	  to	  prove	  that	  Imperial	  College	  is	  at	  fault.	  This	  does	  not	  affect	  your	  legal	  rights	  to	  seek	  compensation.	  If	  you	  are	  harmed	  due	  to	  someone’s	  negligence,	  then	  you	  may	  have	  grounds	  for	  a	  legal	  action.	   Regardless	   of	   this,	   if	   you	   wish	   to	   complain,	   or	   have	   any	   concerns	   about	   any	  aspect	  of	  the	  way	  you	  have	  been	  treated	  during	  the	  course	  of	  this	  study	  then	  you	  should	  immediately	  inform	  the	  Investigator	  (Dr	  David	  O’Callaghan),	  contact	  details	  at	  end).	  The	  normal	  National	  Health	  Service	  complaint	  complaints	  mechanisms	  are	  also	  available	  to	  you.	  If	  you	  are	  still	  not	  satisfied	  with	  the	  response,	  you	  may	  contact	  the	  Imperial	  AHSC	  Joint	  Research	  Office.	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  All	   information	  which	   is	   collected	  about	  you	  during	   the	  course	  of	   the	   research	  will	  be	  kept	  strictly	  confidential.	  Any	  information	  about	  you	  which	  leaves	  the	  hospital	  will	  have	  your	  name,	  address	  and	  date	  of	  birth	  removed	  so	  that	  you	  cannot	  be	  recognised	  from	  it.	  Information	  will	  be	  stored	  in	  anonymous	  form	  for	  up	  to	  three	  years	  after	  the	  study	  ends	  in	  order	  that	  further	  analysis	  can	  be	  performed	  if	  required.	  As	  you	  are	  not	  receiving	  any	  new	  treatment	  your	  GP	  will	  not	  be	  informed	  of	  your	  participation.	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What	  will	  happen	  to	  the	  results	  of	  the	  research	  study?	  The	   results	   of	   this	   study	   will	   be	   presented	   at	   medical	   meetings	   and	   published	   in	  scientific	   journals.	   Only	   group	   information	   and	   no	   personal	   information	   will	   be	  presented.	  If	  you	  wish	  a	  summary	  of	  the	  results	  of	  the	  study	  can	  be	  sent	  to	  you.	  
Who	  is	  organising	  the	  research?	  This	  study	  is	  being	  organised	  by	  doctors	  and	  scientists	  from	  Imperial	  College,	  London.	  
Who	  has	  reviewed	  the	  study?	  All	  research	  in	  the	  NHS	  is	  looked	  at	  by	  an	  independent	  group	  of	  people	  called	  a	  Research	  Ethics	  Committee.	  This	  study	  has	  been	  reviewed	  and	  given	  a	  favourable	  opinion	  by	  the	  North	  London	  REC	  3	  committee.	  
Thank you in advance for considering participation in this study. If you have any 
questions about this research, the study staff will be more than happy to answer them. 
Their contact details are given below: 
 
Contact Name: Dr Anthony Gordon (Consultant & Clinical Senior Lecturer) 
Dr David O’Callaghan (Clinical Research Fellow) 
 Address:	   Intensive	  Care	  Unit	  	  Charing	  Cross	  Hospital	  	  Fulham	  Palace	  Road	  	  London,	  W6	  8RF	  	  
Telephone Number: 020 3311 1964  
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